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ABSTRACT 
 
The increased risk of cardiovascular disease (CVD) amongst South Asians (SAs) is unclear. This 
thesis examined potential biomarkers to address this. Cross-sectional data on SAs from 
community (n=1304) and hospital (n=148) populations was collected. Biomarkers were analysed 
by genotyping, mass spectrometry, automated-immuno-colourimetric-assays, ELISAs, and a new 
in-house assay for a novel marker, ferritin bound to apolipoprotein B. Diagnostic performance 
was assessed using receiver operating curves, logistic and linear regression models. C-reactive 
protein (CRP) was a comprehensive marker of CVD risk, where a range of 1.43-2.30 mg/L 
maximised sensitivity and specificity. CRP SNP (single nucleotide polymorphism) -390C>T/A 
contributed minimally to variation in CRP levels. Non-fasting triglycerides discriminated SAs at 
increased CVD risk, where APOA5 SNP -1131T>C was an independent predictor of triglycerides 
but APOC3 SNP -455T>C and -482C>T were not associated with triglycerides. The performance 
of IL-6, vWF, D-dimer and P-selectin were poor in comparison to CRP and triglycerides. BNP 
discriminated SAs with systolic heart failure with a cut off value of 36.4 pmol/l. Of the newly 
investigated biomarkers, a link between haemoglobin abnormalities and CVD was observed 
potentially through a mechanism involving iron transportation on lipoproteins. CRP and 
triglycerides should be considered in the routine CVD risk assessment of SAs.  
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Definitions used in the thesis 
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waist circumference
 
Men 
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The International Diabetes 
Federation (IDF) 
Body mass index  
 
≥ 27 kg/m2 
 
WHO (World Health Organisation) 
criteria 
Elevated triglycerides
 
 
≥ 1.7 mmol/l 
 
The National Cholesterol Education 
Program ATP III 
Low HDL cholesterol 
Men 
Women 
 
 
<0.9 mmol/l 
<1.0 mmol/l 
 
WHO (World Health Organisation) 
criteria 
Hypertension
 
 
≥130/≥ 85 mmHg and/or anti-
hypertensive therapy 
 
The National Cholesterol Education 
Program ATP III 
 
Diabetes mellitus 
 
HbA1c ≥ 6.5% and/or 
 anti-diabetic therapy 
 
American Diabetes Association 
 
Total cholesterol 
 
>5.18 mmol/l 
 
The National Cholesterol Education 
Program ATP III 
 
LDL cholesterol 
 
>4.14 mmol/l 
 
The National Cholesterol Education 
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following;  
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HDL-c < 1.0 mmol/L (men) & 
< 1.2 mmol/L (women) 
 
Blood pressure ≥ 130/85 mmHg 
 
Fasting plasma glucose ≥ 6.1 
mmol/L  
The National Cholesterol Education 
Program ATP III 
                   
10-year coronary heart disease 
risk score  
Existing atherosclerotic 
disease (yes/no), gender, age, 
systolic&diastolic blood 
pressure, smoker (yes/no), total 
cholesterol, HDL cholesterol, 
diabetic (yes/no) 
Derived from Framingham Heart 
Study 
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CHAPTER 1 INTRODUCTION 
1.1  Antecedents  of  cardiovascular  disease biomarkers  
Cardiovascular disease (CVD) is a complex disease caused by many lifestyle, environmental and 
genetic risk factors (Lusis et al., 2004). Epidemiological studies have established that family 
history is an independent risk factor for CVD (Colditz et al., 1986; Parikh et al., 2007). Further 
genetically determined atherosclerotic risk factors have been identified (Table 1) (Lusis, 2004). 
Heritability is the proportion of phenotypic variance attributable to genetic variance. For 
example, a heritability estimate of 0.25 for a specific risk factor indicates that levels of this factor 
within a population will differ, and that a quarter of this variability could be attributed to genetic 
individual differences.  
Table 1 Genetically determined risk factors for CVD 
Risk factors   Heritability estimates  
Risk factors with a significant genetic component 
 
LDL and VLDL cholesterol 
HDL-cholesterol 
Triglycerides 
Body mass index 
Systolic blood pressure 
Diastolic blood pressure 
Lipoprotein(a) 
Homocysteine  
Diabetes mellitus 
Fibrinogen 
C-reactive protein & Interleukin-6  
 
 
40-60% 
45-75% 
40-80% 
25-60% 
50-70% 
50-65% 
90% 
45% 
40-80% 
20-50% 
35-40% 
 
Gene polymorphism can alter proteins affecting their function, activity or expression. The impact 
of a polymorphism in a disease such as CVD may not manifest until it coexists with other genetic 
abnormalities or with specific environmental exposures (Hingorani et al., 2000). Dissecting the 
genetic basis for the intermediate phenotypes such as inflammatory and metabolic markers 
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involved in the development of atherosclerosis could reveal the underlying pathophysiology for 
increased CVD risk observed amongst the South Asian population. This section gives a brief 
overview of the candidate gene approach and the single nucleotide polymorphisms that contribute 
to the variation in inflammatory and metabolic phenotypes involved in the development of CVD.  
1.1.1  Candidate gene approach 
The completion of the human genome project in 2003 and the International HapMap project in 
2005 have allowed scientists to explore novel biomarkers and pathways associated with disease 
conditions. The two main approaches in genetic studies are the hypothesis driven candidate gene 
association studies, whereby the selection of the genetic marker is based on the understanding of 
the biological processes involved in the development of the disease and the unbiased approach 
which includes genome-wide association scans (GWAS). In GWAS, single nucleotide 
polymorphisms (SNPs) which may not necessarily be involved in the expression of the disease 
are used as markers to identify individual or clusters of disease-associated alleles (Vasan, 2006, 
Iles, 2008).  
In this thesis, candidate gene approach will be employed to establish genotype-phenotype 
relationship. Candidate gene association studies allow a selection of SNPs with known biological 
function including rare variants to be explored. Even SNPs that do not reach significance  
(P ≤ 10-7) in genome wide association studies can still reach significance levels for a candidate 
gene study (p ≤ 10-3-10-4). Candidate gene approach is required in the post-GWAS stage mainly 
to identify the genuine causative variants and to determine the effect of genetic variants in a 
particular population. Moreover, in the absence of a detailed GWAS data in a given disease it is 
cost-effective to conduct a candidate gene study (Wilkening et al., 2008).  
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1.1.2  Candidate genes in inflammation 
Inflammation plays a prominent role in the development of atherosclerosis (Ross, 1999) and so 
genes related to the inflammatory pathway have been the main focus for genomic studies in 
CVD. The variations in the inflammatory phenotypes and genotypes could contribute to the 
increased susceptibility for CVD observed amongst subjects of South Asian origin. This section 
will discuss genetic markers that contributed to intraindividual variations in C-reactive protein 
(CRP) and interleukin-6 (IL-6) levels in non-Asian population. Both the inflammatory markers 
have been associated with CVD. CRP is the widest in use inflammatory biomarker and elevated 
levels have been associated with increased risk of type 2 diabetes mellitus (T2DM), hypertension 
(Pradhan et al., 2001), and CVD (Ridker et al., 1997).  
1.1 .2 .1  C-react ive  protein  
There are many confounding factors that contribute to the interindividual variation in CRP levels, 
but the use of genetic variants that regulate the levels of CRP is a form of natural randomised trial 
or otherwise termed as Mendelian Randomization. This is achieved by random assortment of 
alleles from parents to offspring during gamete formation and conception. Thus minimizing the 
effect of non-genetic factors and providing an unbiased approach to assess the role of CRP in 
CVD (Hingorani et al., 2006; Thanassoulis and O’Donnell, 2009).  
The mendelian randomization approach was used in the Rotterdam study (C reactive Protein 
Coronary Heart Disease Genetics Collaboration (CCGC), 2011), where established CVD risk 
factors increased significantly across increasing quartiles of CRP levels in European subjects but 
none differed across the four common gene variants of the CRP gene. The study showed a 
significant genotype-phenotype association and highlighted the unbiased approach of studying 
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the effect of CRP on disease risk though its gene. The notion behind this approach is if high 
levels of CRP contribute to disease risk, then subjects with common genetic variants of the CRP 
gene that raise CRP levels should have an increased risk of CVD (Kardys et al., 2006; Hingorani, 
2006).  
1 .1 .2 .1 .1  Structure  of  C-react ive  gene   
The human CRP gene is located on chromosome 1 and the promoter region of the gene is 
considered to be highly polymorphic that affect blood CRP levels (Lei et al., 1985 and Woo et al., 
1985) and subsequently CVD risk. Family and twin studies suggest that about 35%-40% 
variation in the plasma CRP level is heritable (Pankow et  al., 2001; Retterstol et al., 2003; 
MacGregor et al., 2004) 
figure 1 Structure of C-reactive gene 
 
 
Both Lei, 1985 and Woo, 1985 reported that CRP protein contains an 18 amino acid signal sequence and a mature 
protein of 206 amino acids. The CRP gene is composed of 1 intron which includes a GT repeat sequence that 
separates 2 exons (red boxes). The first exon encodes an 18 amino acid signal sequence (green box) and the first 2 
amino acids of the mature protein whilst the second exon encodes the remaining 204 amino acids.   
Reproduced from Hage et al., 2007, p.1116 
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1.1.2.1.1.1 Common single nucleotide polymorphisms of the C-reactive protein gene and phenotypic 
variation  
Carlson et al., (2005) conducted a unique study with three experimental stages; initially the 
pattern of genetic variation across the CRP gene locus on chromosome 1q21-q23 was identified 
by resequencing the region in a multi-ethnic variation discovery panel. A set of 8 common 
haplotypes from seven TagSNPs were then defined in a population of European descent and 
African descent and studied in a much larger population (The Coronary Artery Risk Development 
in Young Adults-CARDIA study). The CRP gene haplotypes were significantly associated with 
variation in CRP levels (p< 10
-6
), whereby haplotypes associated with low levels of CRP reduced 
the plasma levels of CRP by 1.5 mg/L per copy and vice versa. Similar results were reported in 
European descent in the Rotterdam study (Kardys, 2006), and in the third National Health and 
Nutrition Examination Survey (Crawford et al, 2006), where CRP gene haplotypes were 
associated with CRP levels.  
Several genetic association studies of CRP have assessed the link between genotype and plasma 
CRP levels (Zee and Ridker, 2002: Brull et al., 2003; D’Aiuto et al., 2005). The majority of these 
association studies have investigated  a small number of genetic polymorphisms, found in the 
promoter region (Kovacs et al., 2005) and 3'-untranslated region (UTR) (Brull, 2003) of the CRP 
locus. Hage (2007) identified two SNPs at the promoter region of the CRP gene which are 
functional, -409G>A (490 indicate the position of the SNP on the gene, here G is the wild 
type/major allele and A is the minor allele, the same format will be used throughout this thesis) 
(dbSNP ID-rs3093062) and -390C>T>A (rs3091244). These polymorphisms directly contributed 
to the interindividual variation of blood CRP levels. Higher CRP levels were observed in carriers 
of -409GG and -390TT. The two SNPs were reported to reside within the E box elements E-box 
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1 and E-box -2, which are functional since transcription factors bind to them and is altered in the 
presence of -409GG and -390TT SNPs.  
Carlson (2005) and Szalai et al., (2005) confirmed that the rs3091244 triallelic SNP in the 
promoter region alters the affinity for transcription factors and affects the transcription of the 
gene which results in variation of blood CRP levels. In vitro study using CRP promoter-firefly 
luciferase reporters showed that individuals with -409G/-390T haplotype had a highest promoter 
activity, with high transcription factor binding version of E-box 1 and E-box 2 and high levels of 
CRP when compared to -409A/-390T individuals who showed weak promoter activity and hence 
lowest CRP levels (Szalai, 2005). 
In the Women’s Health Initiative Observational study (Lee et al., 2009); the genetic variants in 
the CRP gene were significantly associated with plasma CRP concentrations in a large multi-
ethnic case control study of 3782 postmenopausal women. The minor allele frequencies for 13 
SNPs in the CRP gene varied across the 4 ethnic groups (Whites, Blacks, Hispanics, 
Asians/Pacific Islanders, P < 0.0001). The minor alleles of SNPs rs3093068, rs1130864, and 
rs1417938 were associated with higher levels of CRP (geometric-mean increase per minor-allele 
change, 1.20 -1.25 mg/L) whilst the minor alleles of rs1205 and rs1800947 were associated with 
lower levels of CRP (decrease of 1.28 – 1.48 mg/L) in Whites. In Asians/Pacific Islanders the 
minor alleles at rs3093068 and rs1205 had a stronger association with higher levels of CRP than 
that seen in Whites (geometric- mean increase, 1.65 mg/L vs. 1.25 mg/L). 
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1 .1 .2 .1 .2  Genet i c  var iants  of  C-react ive  prote in  and  d isease  
as socia t ions  
Prospective studies have shown that plasma levels of CRP predict incident CVD (Ridker, 1997; 
Ridker et al., 2002; Danesh et al., 1998) and recurrent CVD events (Haverkate et al., 1997; Speidl 
et al., 2002) and CVD mortality (Harris et al., 1999; Lindahl et al., 2000). Genetic variation of the 
CRP gene contributes to the CRP level in plasma. Hence, subjects with common genetic variants 
of the CRP gene that raise CRP levels may have an increased risk of CVD. This section 
summarizes the genetic disease association studies conducted on the inflammatory marker CRP.  
1.1.2.1.2.1 Cardiovascular disease 
In the Framingham heart study (Kathiresan et al., 2006), out of 13 common CRP SNPs the 
functional triallelic - rs3091244 SNP remained associated with plasma CRP levels even after 
adjustment for clinical covariates and accounting for correlation among SNPs in 1640 
participants (stepwise P<0.0001). The triallelic SNP explained 1.4% of the variation in CRP 
levels. Subjects homozygous for CC genotype had the lowest level of CRP compared to 
heterozygotes (CT or CA genotypes) who had intermediate level of CRP and minor allele 
homozygotes (TT or AA) showed the highest level of CRP. The triallelic SNP rs3091244 was not 
associated with prevalent CVD (n=210, P =0.62 in multivariable adjusted model). The odds ratio 
for the group that included major allele heterozygotes
 
(CT and CA) was 0.96 (95% CI 0.67 to 
1.37), and for the group
 
with both minor alleles (TA, TT, and AA), was 0.79 (95% CI
 
0.48 to 
1.29) when compared with the major allele homozygotes (CC) as reference
 
genotype. The SNP 
rs3091244 was also not associated with incident CVD (n=52, P=0.18 in multivariable adjusted 
model).  
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Suk Danik et al., (2006) assessed the relationship between seven common genetic variants within 
the CRP gene and the rise in plasma CRP levels after an acute coronary syndrome (ACS) in 
European American patients. The triallelic rs3091244 SNP was associated with the highest level 
of CRP. Kovacs (2005) associated the triallelic SNP with baseline CRP levels in patients with 
CHD. However this finding was not replicated in AIRGENE study (Kolz et al., 2008), which 
assessed the influence of genetic variants involved in the inflammatory pathway on the variability 
of CRP in patients with prior myocardial infarction (MI). Two minor alleles of the SNPs, 
rs1800947 and rs1205 within the CRP gene were associated with low CRP levels and 
demonstrated a dose dependent effect.   
In a large study to establish the relationship between genetically elevated CRP levels and the risk 
of ischemic heart disease (IHD), the four CRP polymorphisms (rs3091244, rs1130864, rs1205, 
rs3093077) accounted for 64% increase in CRP levels, despite equal distribution of CVD risk 
factors across the genetic variants. However, the genotypes were not associated with increased 
risk of IHD (Zacho et al., 2008). Similarly, studies by Zee and Ridker (2002) and Kardy (2006) 
also failed to associate CRP genotypes with the risk of arterial thrombosis and the risk of 
coronary heart disease (CHD) respectively, despite showing a substantial genetic influence on 
CRP levels.  
In the third National Health and Nutrition Examination Survey, the functional rs3091244 SNP 
was associated with CRP levels and with prevalent CHD in the non-Hispanic population (Lee, 
2009). Since the functional significance of this triallelic SNP in the promoter region of CRP gene 
has been demonstrated in vitro, this association could be a true causal relationship (Crawford, 
2006).  
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1.1 .2 .2  Inter leukin  6  
1 .1 .2 .2 .1  Structure  of  in terleukin  6  gene   
Bowcock et al., (1988) localized the IL-6 gene to chromosome 7p21 using linkage studies. IL-6 
gene consists of four introns and five exons and encodes a 212 amino acid protein.  
1.1.2.2.1.1 Common single nucleotide polymorphisms of interleukin 6 gene and plasma levels of 
interleukin -6  
Fishman et al., (1998) identified a G>C polymorphism at position -174 within the promoter 
region of the IL-6 gene on chromosome 7. This site involves a DNA binding site for the NF-IL-6 
transcription factor, which is responsible for gene expression. In 102 healthy subjects, the G 
allele was associated with higher plasma levels of IL-6 compared to subjects with the C allele 
(GG: 274 pg/ml (95% CI, 2.43 -3.10); GC: 2.64 (2.35-2.97); CC: 1.63 (1.44-1.86), P=0.02). The 
study demonstrated that the 174G>C promoter polymorphism is functional, in that genetic 
variation influences the protein levels of IL-6, i.e. phenotypic expression.  The functional activity 
of the 174G>C promoter polymorphism was detected by luciferase assay and demonstrated that 
G allele gene contruct showed higher expression of IL-6 compared to the C allele construct. The 
minor allele C had a reduced promoter activity which led to reduced expression of IL-6.  
Fishman (1998) demonstrated the interethnic variation in the prevalence of this polymorphism in 
383 Caucasians, 115 Gujarati Indians and 101 Afro Caribbean’s. The frequency of the C allele 
was particularly rarer in Gujarati Indians and Afro Caribbean’s 0.150 (95% CI, 0.094-0.184) and 
0.05 (0.016-0.072) compared to Caucasians 0.403 (0.37-0.44).  
Several studies have investigated the relationship between this promoter polymorphisms of IL-6 
and plasma levels of IL-6 but the results are conflicting. (Burzotta et al., 2001; Jerrard-Dunne et 
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al., 2003). Rauramaa et al., (2000) studied the effect of the 174G>C IL-6 polymorphism in 87 
asymptomatic Finnish men (aged 50 -60 years). Levels of IL-6 in those with GG genotype were 
comparable to those with the C allele.  
1.1.2.2.1.2 Single nucleotide polymorphisms of interleukin-6 gene and plasma levels of C-reactive 
protein  
 
Since IL-6 is a major inducer of CRP gene expression, and the -174G>C IL-6 promoter 
polymorphism is directly responsible for the phenotypic expression of IL-6. Studies have 
investigated the relationship between this polymorphism and plasma levels of CRP. Vicker et al., 
(2002) conducted a study of 588 members from 98 nuclear families. The strength of such 
‘family’ studies is in the genetic homogeneity of the study subjects. The baseline CRP levels 
were highly heritable (h
2
 =0.39, P<0.0000001), the results were similar to those reported by 
Pankow (2001). The -174 C allele was associated with high baseline CRP levels (P=0.01).  
Humphries et al., (2001) showed in 494 middle-aged healthy UK men that carriers of the -174C 
allele had higher levels of CRP compared to non-carriers but the results were not significant 
(P=0.13).  
1 .1 .2 .2 .2  Genet i c  var iants  of  in ter l eukin -  6  and  d isease  assoc ia t ions  
Prospective studies have shown that plasma levels of IL-6 predict incident CVD (Ridker et al., 
2000a; Ridker et al., 2000b) and recurrent CVD events (Biasucci et al., 1996; Biasucci et al., 
1999b) as well as mortality (Harris et al., 1999). The genetic variation in the IL-6 gene contribute 
to the variability of IL-6 in plasma, so ideally subjects with common genetic variants of the IL-6 
gene that raise IL-6 levels should have an increased risk of CVD. This section summarizes the 
genetic disease association studies conducted on the inflammatory marker IL-6.  
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1.1.2.2.2.1 Cardiovascular disease   
Humphries (2001) showed that the 174G>C IL-6 promoter polymorphism is associated with the 
increased risk of CHD in 2751 middle-aged healthy UK men, followed up for 6 years. The -174 
C allele was significantly associated with higher systolic blood pressure (mean mmHg (95% CI); 
CC = 138.0 (136.3 -139.8); GC = 137.9 (136.9 – 138.9) compared to the G allele; GG = 135.5 
(134.3 – 136.7), P =0.007) irrespective of their smoking status. This relationship between 
genotype and systolic blood pressure was greater in men with body mass index (BMI) >24.86 
kg/m
2 
(CC had 2.9 mmHg and GC 2.6 mmHg higher than GG, P=0.05) compared to men in the 
lowest tertile of BMI (CC + GC, 1.4 mmHg higher than GG, P=0.29). Carriers of the -174C 
allele had a relative risk (RR) of CHD of 1.54 (95% CI 1.0-2.23, P=0.048) compared to those 
with the G allele, this relationship was greatest in smokers (compared to GG non-smokers, RR 
2.66, CI 1.64-4.32) and remained statistical significant after adjustment for CVD risk factors 
(P=0.04).  
In 466 patients of the U.K. Small Aneurysm Trial (Jones et al., 2001), the -174C allele was 
associated with higher plasma levels of IL-6 (CC (median) 15.6 pg/ml; GC 4.8 pg/ml) compared 
to patients with GG genotype (1.9 pg/ml, P=0.047). Patients with small aneurysms who were 
carriers of the C allele had a higher risk of future CVD events and all cause mortalities compared 
to patients with the GG genotype: hazard ratios 0.51 (95% CI, 0.25-1.00), P=0.05 and  0.32 (95% 
CI, 0.12 -0.93), P=0.036 respectively.  
The relationship between the -174G>C promoter polymorphism of IL-6 gene, plasma levels of 
IL-6 and the length of hospital stay after coronary revascularization was demonstrated by 
Burzotta (2001) in 111 patients with multivessel CHD. The plasma levels of IL-6 were measured 
before surgery, after surgery and at discharge and showed a mean 17-fold increase with peak 
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values at 24 hours (P<0.0001). The levels of IL-6 were significantly different across the 
genotypic groups irrespective of comparable clinical and surgical characteristics. Sixty two 
patients homozygous for GG genotype had higher concentrations of IL-6 (mean ± SD, 69 ± 83 
pg/ml at 48 hour after surgery) compared to thirty nine patients heterozygous for CG (49 ± 26 
pg/ml) and ten homozygous for CC (33 ± 17 pg/ml), (P = 0.015). Patients who had GG 
homozygous stayed longer in the intensive care unit (2.5 ± 3.4 vs. 1.4 ± 0.9 days, P=0.02) and in 
the hospital (6.7 ± 4.0 vs. 5.3 ± 1.4 days, P=0.02) compared to patients who were carriers for C 
allele.  
There are studies that have reported conflicting results on the -174G>C promoter polymorphism 
of IL-6 gene, whereby high levels of IL-6 has been associated with the CC genotype. In the 
carotid atherosclerosis progression study (CAPS) (Jerrard-Dunne, 2003), the CC genotype was 
associated significantly with higher levels of IL-6  compared to GG/GC genotypes, despite 
comparable distribution of CVD risk factors across the genotype groups. The median (IQR) were 
GG, 1.51 (1.46) pg/ml; GC, 1.56 (1.30) pg/ml; and CC, 1.87 (1.86) pg/ml. Amongst those with 
IL-6 -174 CC genotype, the odds ratio (OR) for elevated IL-6 was 1.68 (95% CI, 1.00 -2.82, 
p=0.049) after age and gender adjustment and 2.07 (1.16-3.72, p=0.014) after adjustment for 
confounding factors. Moreover, the CC genotype was associated with elevated carotid artery 
intima-media thickness (P=0.001) and increased risk of carotid plaque (OR, 3.64 (95% CI, 1.15-
11.54, P=0.028) in patients who were heavy alcohol drinkers.   
1.1.2.2.2.2 Diabetes mellitus, insulin resistance and obesity 
Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the destruction of 
the insulin producing islet beta cells. The genetic variants within the cytokine genes mainly IL-6 
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have been implicated in the genetic susceptibility to T1DM. Jahromi et al., (2000) demonstrated 
in a case control study that the IL-6-174G>C promoter polymorphism was associated with 
susceptibility to T1DM. The prevalence of the homozygous GG genotype was greater in patients 
compared to control subjects (50.6% vs. 33.3%, p<0.002). The CC genotype was less prevalent in 
the patient group compared to healthy subjects (12.5% vs. 24.2%, p<0.004). 
The 174G>C promoter polymorphism of IL-6 has also been implicated in the pathogenesis of 
T2DM. In the European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam 
cohort, Mohlig et al., (2004) studied 188 T2DM cases and 186 controls. Cases were disease free 
at baseline and have developed the disease during the follow up of 2.3 years. The distribution of 
baseline characteristics including IL-6 concentrations was comparable in all genotypes except for 
age. The main finding was that the 174G>C IL-6 promoter polymorphism modified the 
association between BMI and the risk of T2DM. Amongst subjects with the CC genotype, the 
correlation between BMI and IL-6 levels was higher (0.52; 95 CI, 0.366–0.650; n = 103) 
compared to subjects with the GG genotype (0.2; 95%
 
CI, 0.036–0.344; n = 150) and GC 
genotype (0.31; 95% CI, 0.209–0.410; n = 311). Amongst those with BMI greater than or equal to 
28 kg/m
2
, the risk of T2DM was estimated to be 17.68 (95% CI, 3.57–87.66) for the CC 
genotype, 3.44 (95% CI, 1.34–8.24) for the GG genotype and 2.94 (95% CI, 1.56–5.56) for the 
GC genotype.  
Increased levels of IL-6 observed in T2DM and obesity have been associated with indices of 
adiposity and insulin resistance. Berthier et al., (2003) studied the association between the -
174G>C promoter polymorphism of IL-6 and indices of adiposity in 270 healthy French- 
Canadian men. The G allele was more prevalent amongst lean subjects (BMI <25 kg/m
2
, P=-
0.007 and waist <100 cm, P=0.01). The G allele was also common amongst subjects with low 
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concentrations of insulin (<160pmol/l) and glucose (<4.6 mmol/l), P=0.03 and P=0.01 
respectively. Across all genotypes, men who had CC and GC genotype showed a larger waist 
girth (102.76 ± 11.19 cm and 101.85 ± 10.62 cm) compared to those who were GG homozygous 
(97.98 ± 11.36 cm, P=0.02).  
1.1.2.2.2.3 Lipid abnormalities  
Fernandez-Real et al., (2000) studied the influence of the -174G>C IL6 promoter polymorphism 
on plasma lipids in 32 Caucasian healthy subjects (17 women). Age, sex, BMI, waist to hip ratio 
was comparable across all genotypes (CC vs. GC and GG). Healthy subjects with the G allele 
showed higher levels of plasma triglycerides (1.5 ± 0.9 vs. 0.90 ± 0.37 mmol/L; p=0.01), VLDL 
triglycerides (0.97 ± 0.69 vs. 0.42 ± 0.2 mmol/L; p=0.002), fasting (881vs 458 µmol/L, p=0.01) 
and post glucose load free fatty acids (229 vs. 90.5 µmoll/L, p=0.03), lower levels of HDL 
cholesterol (0.25 ± 0.14 vs. 0.39 ± 0.26 moll/L, p=0.058) but similar cholesterol and LDL 
cholesterol levels compared to those with the C allele. In univariate analysis, serum levels of IL-6 
correlated positively with fasting triglycerides, VLDL triglycerides and post load free fatty acids 
(correlation coefficient, r=0.61, 0.65 and 0.60 respectively, p<0.001) and negatively with HDL 
cholesterol (r=-0.42, p<0.05). Subjects with the G allele showed the expected trend of higher 
serum IL-6 levels (9.9 ± 6.9 vs. 6.85 ± 1.7 pg/ml. p=0.09).  
1.1.3  Candidate genes in lipid metabolism 
Genetic studies so far have identified several loci that influence lipid metabolism and thereby 
increase the risk of CVD. Some of the major proteins that play a role in the generation of an 
atherogenic lipid profile are LDL receptor, apolipoprotein B-100, apolipoprotein E, lipoprotein 
(a), lipoprotein lipase, apolipoprotein CIII, cholesteryl ester transfer protein, apolipoprotein AI, 
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lecithin cholesterol acyl transferase and microsomal triglyceride transfer protein (Milewicz et al., 
2000). Genetic variations within the genes involved in lipid metabolism have been proposed to 
explain the interindividual differences in plasma levels of total cholesterol, triglycerides and 
HDL-c and associated risk of CVD. Table 2 summarises the genes that are involved in the lipid 
metabolism that affect the overall lipoprotein integrity in the circulation. 
Table 2    Genes involved in the lipid metabolism that affect the overall lipoprotein integrity in the circulation 
Genes Role in lipid metabolism 
LDL receptor  
Microsomal triglyceride transfer protein 
(MTP) 
ATP binding cassette protein A1 (ABCA1) 
 
Apolipoprotein A1(apoA-1) 
Lecithin cholesterol acyl transferase (LCAT) 
Cholesteryl ester transfer protein (CETP) 
 
Apolipoprotein E (apoE) 
 
Hepatic lipase (HL) 
 
Apolipoprotein CIII (ApoCIII) 
 
Apolipoprotein AV (ApoAV) 
Lipoprotein lipase (LPL) 
Uptake of cholesterol rich LDL  
Assembly of plasma VLDL, precursor for ApoB 
containing lipoproteins in plasma 
Cholesterol efflux pump in reverse cholesterol transport 
 
Protein component of HDL 
Etherification of HDL-C and maturation of HDL particle  
Transfer of cholesteryl esters from HDL to ApoB 
containing lipoprotein in exchange for triglycerides 
LDR/ApoE receptor mediated uptake of atherogenic 
lipoproteins 
HDL metabolism, clearance of ApoB containing 
lipoproteins 
Mediate clearance of triglyceride rich lipoproteins via 
ApoE mediated receptor 
Regulator of triglycerides 
Catabolism of triglycerides    
Information taken from Lusis, 2004 
It is beyond the scope of this thesis to mention all the candidate genes that contribute to 
interindividual differences in lipid levels in circulation and risk of CVD. The excess burden of 
CHD in South Asians is partly attributed to dyslipidaemia defined as having high levels of 
triglyceride, low levels of HDL-c and high levels of Lp (a) (Bhatnagar et al., 1995; Patel et al., 
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2006). This section mainly summarizes the candidate genes that contribute to low HDL-c and 
high triglyceride levels and those that have been associated with an increased risk of CVD.  
1.1 .3 .1  Candidate genes  that  contr ibute  to  low HDL and 
high trig lycer ide leve ls  
1 .1 .3 .1 .1  Apol ip oprotein  C 3 gene  and Apol ipoprotein  A5  gene  
1.1.3.1.1.1 Structure and function of Apolipoprotein C3 
ApoCIII is a 79-residue glycoprotein and is synthesised in the liver and intestine as the protein 
component of VLDL and HDL particles (Ooi et al., 2008). Over expression of ApoCIII delays the 
catabolism of triglycerides by down regulating LPL and impairs the apoE mediated clearance of 
triglyceride-rich lipoprotein by the liver, resulting in hypertriglyceridemia (Li et al., 1995). The 
protein is encoded by the APOC3 gene and is located within A1/CIII/AIV/AV gene cluster on 
chromosome 11q23-q24 (Protter et al., 1984). Figure 2 shows the AI-CIII-AIV gene region.  
figure 2 A1-CIII-AIV gene region 
 
 
 
 
 
 
 
 
 
 
 
 
APOC3 gene consists of 4 exons which encodes a 79 amino acid protein. Common APOC3 gene polymorphisms 
are C3238G (Sstl) in the 3’ UTR (untranslated region), C1100T in exon 3, -482C>T & - 
455T>C (not shown here) in the promoter insulin-response element (IRE)  
Reproduced from Waterworth et al., 1999, p.1873 
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Two common APOC3 promoter polymorphisms –482C>T, -455T>C within the insulin response 
element are associated with hypertriglyceridemia (Dammerman et al., 1993) and susceptibility to 
T1DM. The expression of ApoCIII is down regulated by insulin (Waterworth et al., 2003); the 
mutant allele of the APOC3 promoter polymorphisms inhibits the ability of insulin to regulate 
ApoCIII expression. Increased plasma levels of ApoCIII promote β-cell destruction; reduce 
insulin secretion henceforth triggers the pathophysiological pathway to the onset of T1DM 
(Hokanson et al., 2006).  
1.1.3.1.1.2 Single nucleotide polymorphisms of Apolipoprotein CIII gene and levels of triglycerides  
In the multi-ethnic population based study, the Dallas Heart study and the Atherosclerosis Risk in 
Communities study, Kozlitina et al., 2011 demonstrated that the APOC3 -482C>T and -455T>C 
polymorphisms were not related to triglyceride levels. Olivieri et al., (2003) demonstrated in 
subjects with metabolic syndrome that the C-allele of APOC3 -455T>C polymorphism was 
associated with high triglycerides and increased ApoCIII activity. Waterworth et al., (1999) 
investigated the response of APOC3 gene variants to oral glucose and fat tolerance tests in 405 
young, healthy male offspring who had a family history of early MI and 415 age matched 
controls. The -482C>T polymorphism did not regulate postprandial changes in triglycerides but 
regulated response to oral glucose tolerance test whereby subjects with the rare allele had 
elevated levels of glucose (28.7% area under the curve (AUC), P=0.013) and insulin (20.5% 
AUC, p<0.01). 
In the Second Northwick Park Heart Study (NPHSII), Waterworth et al., (2000) showed in a 
cohort of 2745 healthy men that −482T allele was associated with elevated triglycerides but was 
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dependent on smoking status (increase of 13.7% in triglycerides −482T allele in current smokers, 
8.6% in exsmokers, and - 7.4% in those who never smoked).  
1 .1 .3 .1 .2  Apol ipoprot ein  A5 gene  
1.1.3.1.2.1 Structure and function of Apolipoprotein A5 
Pennacchio and colleagues (2001) discovered the APOA5 gene by sequencing of the APOA1-
CIII-AIV gene region in mice and humans. The gene is located 27kb distal to apoA-IV in 
apoA1/C3/A4/A5 gene cluster on chromosome 11q23. The function of APOA5 gene was 
determined in APOA5 transgenic mice and APOA5 knockout mice. The human APOA5 
transgenic mice (overexpression of APOAV) had low levels of plasma triglyceride (0.32 ± (SD) 
0.11 mg/ml) compared to APOA5 knockout mice (1.53 ± 0.77 mg/ml). Figure 3 presents the 
structure of APOA5 gene and location of SNPs within the gene (Pennacchio et al., 2002). 
figure 3 Structure of APOA5 gene 
 
The gene consists of 4 exons (black boxes) which encode a 366 amino acid protein. Position of the most common 
SNPs within APOA5 gene are shown here. The SNP of interest for this thesis is -1131T>C located within the 
promoter region of APOA5 gene. 
Reproduced from Pennacchio, 2002, p.3033 
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1.1.3.1.2.2 Single nucleotide polymorphisms of Apolipoprotein A5  gene and levels of triglycerides 
and high density lipoprotein cholesterol 
Chandak et al., (2006) investigated the prevalence of APOA5 genetic variations and its 
association to triglyceride levels in 557 Indian adults from Pune, India and 237 White adults in 
the UK.  The minor allele frequency for APOA5 -1131C allele was more common amongst 
Indians from Pune compared to UK White subjects (20% vs. 4%, p =0.00001). The percentage 
increase in triglyceride levels in subjects with -1131C allele was 19%, p = 0.0003. In 2808 
healthy middle aged men, subjects with CC genotype of APOA5 -1131T>C polymorphism had 
40% higher triglyceride compared to those with TT genotype (Talmud et al., 2002). 
Jiang et al., (2010) demonstrated in two Chinese populations that APOA5 -1131 T>C was 
strongly related to triglyceride levels in Hong Kong subjects (β =0.192, p=2.6 × 10(-13) and 
Gangzhou subjects (β = 0.159, p = 1.3 × 10 (-12). The levels of triglyceride were 36.1% higher in 
CC compared to TT genotype. The odds for elevated triglycerides (≥ 1.7 mmol/l) in subjects with 
TC and CC genotypes respectively were 1.81 (1.37-2.39) and 2.22 (1.44-3.43) in Hong Kong 
subjects and 1.27 (1.05-1.54) and 1.97 (1.42-2.73) in Guangzhou subjects. In the study by 
Aouizerat et al., (2003), the C allele of the APOA5 -1131 T>C had elevated triglyceride by 
21mg/dl, p=0.009, VLDL cholesterol by 8 mg/dl, p=0.0001 and reduced HDL cholesterol by 2 
mg/dl, p=0.017.  
Pennacchio (2001) showed in 500 Caucasian men and women that a minor haplotype of 
APOA5*2 defined by three polymorphisms, 1259T>C, IVS3+ 476G>A and -1131T>C was 
associated with a 20-30% elevation in triglyceride levels. In 2002, the same group showed that a 
minor haplotype of APOA5*3 containing a rare allele of the 56C>G is associated with high 
plasma triglyceride levels. The  APOA5*3 haplotype was almost three fold more prevalent in 
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Caucasian men and women with plasma triglyceride concentrations above the 90
th
 percentile 
compared to those with levels below the 10
th
 percentile (Pennacchio, 2002).     
Dorfmeister et al., (2007) examined the association of APOA5 -1131 T>C with lipids and diabetic 
parameters in 931 Europeans and 610 Indian Asians with T2DM. Carriers of the minor allele, C 
allele had higher triglyceride levels in both groups but was significant only in Europeans 
(p=0.04) and was not associated with parameters of diabetes.  
1 .1 .3 .1 .3  Genet i c  var iants  of  Apol ipoprote in  C3  and Apol ipopro te in  A 5  
and  d isease  associa t ions  
1.1.3.1.3.1 Cardiovascular disease and metabolic syndrome 
Oliviero et al., (2002) investigated the link between APOC3 455T>C genetic polymorphisms and 
CHD in 549 patients who had angiographically documented CHD and 252 CHD free patients. 
The prevalence of CC genotype was higher in CHD patients compared to CHD-free subjects, 
18.6% vs. 9.2% (P<0.001). The odds for increased risk of CHD in patients with CC genotype 
after adjusted for all major risk factors were 2.18. In 2003, Olivier investigated in the same cohort 
a possible link between APOC3 455T>C polymorphism and the metabolic syndrome. Metabolic 
syndrome was more prevalent amongst CHD patients compared to CHD free patients (38.1% vs. 
15.3%) and the odds for CHD in patients with metabolic syndrome was 3.39 (95% CI, 2.35-
4.90).  
Bhaskar et al., (2011) investigated the association of APOA5 -1131T>C in a cohort of 520 South 
Indians of whom 250 were CHD patients (160 with T2DM and 90 without diabetes), 150 T2DM 
subjects and 120 age and sex matched healthy subjects. The  frequency of APOA5 -1131 CC 
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genotypes and C allele was higher in CHD patients with T2DM compared to CHD patients 
without diabetes and healthy controls (OR =1.71: 95% CI 1.0-2.67, p = 0.012).  
In the Italian study of early-onset MI which comprised of 1864 patients with first MI above 45 
years and 1864 age and sex matched controls, APOA5 -1131T>C was associated with risk of 
early-onset MI after adjustment for triglyceride (p= 0.006). The odds of having early MI in 
subjects with C allele was 1.44 (95% CI 1.23 – 1.69). APOA5 -1131 T>C was significantly 
associated with raised plasma triglyceride levels in healthy subjects compared to non-carriers. 
The percentage increase per C allele was 11.4% (95% CI 4 -19%) equivalent to 0.15 mmol/l 
(95% CI 0.11-0.20 mmol/l) (De Caterina et al., 2011). Evans et al., (2011) investigated the 
development of atherosclerosis and genetic variations in the APOA5 gene in 60 patients with type 
III hyperlipidaemia. The odds for the development of atherosclerosis in patients with type III 
hyperlipidaemia with the C allele was 3.69. 
1 .1 .3 .1 .4  Common genet i c  var iants  that  contri bute  to  c i rcu la t ing  l ip id  
l eve ls  and  r i sk  of  coronary  artery  d isease   
It is beyond the scope of this thesis to mention all the genetic markers that are related to 
triglycerides and low HDL-c levels. However, this section summarises a genome wide 
association study conducted by Waterworth et al., (2010) to identify novel/known genetic 
determinants of triglycerides, low HDL-c and LDL-c. The genome wide association study was 
performed in three stages initially on 17 723 participant from 8 studies (stage 1), then replicated 
in 37 774 participants from 8 populations and in a population of Indian Asian descent (stage 2), 
and association studies between SNPs at lipid loci and risk of CHD in 9633 cases and 38 684 
controls (stage 3).  
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In the genome wide association meta-analysis, the following genes showed strong association 
with LDL-c, APOB, the APOE-C1-C4-C2 cluster, CELSR2, EGF LAG seven-pass G-type 
receptor 2), HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), LDLR, PCSK9 (proprotein 
convertase subtilisin/kexin type 9) and CILP2 (cartilage intermediate layer protein 2). The genes 
that showed strong association with HDL-c were CETP, LIPC (lipase hepatic), LIPG (lipase 
endothelial), LPL, ABCA1, LCAT, GALNT2 (UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 2) and MMAB/MVK  
(methylmalonic aciduria (cobalamin deficiency) cblB type/mevalonate kinase). Whilst the genes 
that were strongly associated with triglyceride levels were ZNF259-APOA5-A4-C3-A1 cluster, 
LPL, ANGPTL3 (angiopoietin-like 3), GCKR (glucokinase (hexokinase 4) regulator), TRIB1 
(tribbles homolog 1) and MLXIPL (MLX interacting protein-like). A SNP in APOE-C1-C4-C2 
cluster showed strong association with all 3 lipid traits (Waterworth, 2010).  
In the Indian Asian population, the following loci were associated with lipid traits, PPP1R3B 
(SNP associated was rs2126259, β-coefficient –0.023, p = 9.6×10-4) for circulating LDL-c levels, 
FADSI (SNP associated was rs174548, β-coefficient -0.017, p=1.1×10-4) for circulating HDL-c 
and (β-coefficient 0.041, p=2.6×10-5) triglyceride levels and AFF1 (SNP associated was 
rs442177, β-coefficient 0.027, p=2.9×10-4) for circulating triglyceride levels (Waterworth, 2010).  
Positive association with CHD risk were found within genetic variations in CELSR2, APOB and 
APOE-C1-C4-C2 cluster genes that influenced LDL-c levels. SNPs at APOA5-A4-C3-A1 cluster 
which contributed strongly to triglyceride levels in stage 1 were also associated with risk of CHD 
(Waterworth, 2010). Figure 4 shows the association between SNPs that contributed to lipid traits 
and risk of coronary heart disease.  
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figure 4 Association between SNPs that contributed to lipid traits and risk of coronary heart disease  
 
 
Meta-analysis included 8 studies comprising 7,018 cases and 20 765 controls 
A- Shows SNPs that contributed to LDL-c levels that were associated with the risk of CHD 
B- Shows SNPs that contributed to triglycerides and HDL-c levels that were associated with the risk of CHD. 
Reproduced from Waterworth, 2010, p.2273 
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1.2  Characterisat ion and val idi ty  of  cardiovascular  biomarkers  
Biomarkers are an efficient tool for identifying vulnerable subjects at the risk of developing 
CVD, where these signature molecules could aid clinicians in the diagnosis, evaluation or 
monitoring of patients with CVD effectively and efficiently. According to the NIH working 
group on definitions, 2001 (Biomarkers Definitions Working Group, 2001), biomarker is “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
process, pathogenic processes, or pharmacologic response to a therapeutic intervention”. 
Definitions for different types of biomarkers are shown in Table 3 (Vasan, 2006; Shorr et al., 
2008).  
Table 3  Type of Biomarkers  
 Type 0 biomarker: ‘A marker of the natural history of a disease and correlates longitudinally with known clinical 
indices’. 
Type 1 biomarker: ‘A marker that captures the effects of a therapeutic intervention in accordance with its mechanism 
of action’. 
Type 2 biomarker (Surrogate end-point): ‘A marker that is intended to substitute for a clinical endpoint; a surrogate 
endpoint is expected to predict clinical benefit on the basis of epidemiological, therapeutic, pathophysiological, or 
other scientific evidence’.  
Definitions taken from Shorr, 2008 
A biomarker can be any measurement or test obtained from a patient, it can be measured on a 
biological substance such as blood, urine, tissue, it can be a recording obtained from patient such 
as blood pressure, ECG, arterial stiffness or can be an imaging test such as echocardiogram, 
angiography. Biomarkers can be broadly classified as antecedent biomarkers –those risk factors 
or risk markers that identifies the risk of developing a disease, screening biomarkers –those 
markers that identifies the presence of clinical or preclinical disease, diagnostic biomarkers- those 
markers that identifies overt disease, staging or prognostic biomarkers –those markers that 
categorise disease severity or evaluate responses to therapeutic intervention (Biomarkers 
Definitions Working Group, 2001; Vasan, 2006). 
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Biomarkers can serve as surrogate end points but only a few biomarkers achieve the surrogate 
endpoint status. A surrogate marker is a marker that is intended to substitute for a clinical 
endpoint; a surrogate endpoint is expected to predict clinical benefit on the basis of 
epidemiological, therapeutic, pathophysiological, or other scientific evidence. It is extremely 
useful when it can be easily measured and highly correlated with true clinical endpoints for 
example ejection fraction being surrogate marker for heart failure (HF). One of the benefits of 
surrogate endpoints is; it can be evaluated for safety and efficacy of a particular therapy within a 
short time frame in small studies rather than distant clinical events such as mortality or clinical 
outcomes, which requires larger clinical trials. The utility of surrogate endpoint in clinical 
settings requires demonstration of accuracy- highly significant correlation with the true endpoint, 
reproducibility, easily measurable and cost effective. However, if numerous factors affect the 
clinical outcome of interest along with the surrogate endpoint then its validity is drastically 
reduced (Wittes et al., 1989; Vasan, 2006).  
1.2.1  Characteristics  of an ideal biomarker  
A biomarker can be applied in a clinical setting when it is accurate, reproduceable, easy to 
measure, has high sensitivity and specificity for the endpoint and can be easily interpreted by 
clinicians. Examples for such biomarkers that have enabled clinicians in CV disease management 
are troponin T which indicates the extent of myocardial damage and identifies patients who had a 
MI from those who had an unstable angina, BNP (brain natriuretic peptide) which indicates 
progression of HF, D-dimer which identifies patients with pulmonary embolism and coronary 
angiography which evaluates the severity of CHD (Vasan, 2006). The desirable properties of 
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CVD biomarkers of screening, diagnosis and prognosis are shown in Table 4 (reproduced from 
Vasan, 2006, p.2337).  
Table 4 Desirable properties of CVD biomarkers    
All biomarkers Screening biomarkers to 
identify vulnerable 
patients 
Diagnostic biomarkers to 
identify ischemia or injury 
Prognostic biomarkers 
General features 
 
 
Measure a specific 
pathology 
 
Add to clinical 
assessment 
 
Acceptable to patient 
 
Linear relation 
between change in 
marker and change in 
pathology 
 
Stable product 
 
 
 
Single measure 
representative 
 
 
Applicable to men and 
women, different ages, 
different ethnicities 
 
Replication in multiple 
studies 
 
 
 
 
 
 
 
 
 
Assay/measurement 
features 
Internationally   
 standardised  
 
Known reference limits 
 
 
Add to known CHD index 
such as the FHS risk score 
 
Change in c statistic or 
AUC (discrimination) 
 
Acceptable calibration 
 
High specificity to avoid 
mislabelling asymptomatic 
individuals 
 
 
Account for a moderate or 
greater proportion of CHD 
in the community 
 
Change management 
 
 
 
Reclassify risk in patients 
at intermediate risk 
 
 
Target individuals with 
increased levels of 
biomarker superior to 
conventional risk factors 
for reducing risk 
 
Cost-benefit ratio 
favourable 
 
 
 
 
High myocardial 
specificity 
 
Not present in normal 
serum/ non-cardiac tissue 
 
Zero baseline, immediate 
release (early detection) 
 
Long half life 
 
Permit long time window 
for diagnosis 
 
 
 
But <24 h to permit 
diagnosis of recurrent 
ischemia 
 
Release proportional to 
injury size or ischemic 
burden 
 
Convenience for point-of-
care testing 
 
 
Rapid test available in <1 
h 
 
 
 
 
No special sample 
preparation needed 
 
 
 
Inexpensive 
 
Readily available 
 
 
Known reference limits 
 
 
Add to known 
prognostic index 
 
Change in marker alters 
management 
 
Affect choice of drug 
 
Change dose of drug 
 
 
 
 
Indicate tolerance 
 
 
 
Indicate safety margin 
 
 
 
Used for monitoring 
progression of disease 
 
 
Trajectory of marker 
correlates with disease 
progression 
 
 
 
High specificity to 
avoid mislabelling 
asymptomatic 
individuals 
 
Cost effective 
 
  REMARK guidelines 
  (McShane et al;  
   2005) 
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Accuracy  
 
 
Precision 
 
 
 
 
Assay application 
features  
 
Tested in a spectrum 
of people with  
varying degrees of  
pathology 
 
High sensitivity and  
 Specificity 
 
Laboratory features 
 
Automation   
  
High throughput/short  
 turnaround time  
 
 Connectivity to  
laboratory information  
 management systems 
 
 Compatibility with 
existing laboratory  
processes  
 
Desirable features for 
in vitro diagnostic 
industry    
 
Address unmet patient 
needs  
  
Return on  investments  
       
Requirements for  
research and 
development phases  
         
Manufacturability      
 
Marketability  
including barriers to 
entry    
 
Diagnostic cut-off well  
defined and accepted 
  
Known discrimination 
 limits or action thresholds 
Change management, 
triage or specific treatment 
 
“Rule out” strategy 
 
   
With high sensitivity; 
more important to avoid 
 missing disease 
 
 
Cost-effective 
 
 
STARD guidelines 
(Bossuyt et al, 2003) 
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Post sales customer 
support   
  
 Other market  
 features (acceptance,  
competition,    
regulatory issues, 
reimbursement, third 
party patent rights) 
 
 
 
Reproduced from Vasan, 2006, p.2337 
 
1.2.2  Development of biomarkers in cardiovascular disease   
There are mainly two approaches for the development of biomarkers in CVD i) “knowledge 
based” approach depends on the understanding of the biological processes involved in the 
development of the disease ii) “unbiased” approach uses current technologies such as genomics, 
proteomics bioinformatics to study tens of thousands of molecules to identify biomarkers that 
relates to different stages of the disease (Vasan, 2006).  
The various stages involved from the discovery of a biomarker to its application in clinical 
practice are shown in figure 5. Before considering a biomarker in clinical practice, clinician 
should consider some key questions relating to its measurement, validation, whether the new 
biomarker adds new information diagnostically or prognostically and its cost is justifiable to the 
healthcare system. Table 5 shows some key questions before considering a new biomarker in 
practice.  
Table 5 Some key questions that need to be considered before using a new biomarker in practice 
Has the assay been standardized?  
Is the assay reproducible, accurate, and available?  
Is the distribution of biomarker values in the general population and in select demographic subsets well 
known?  
What are abnormal levels (reference limits and discrimination limits)?  
Do biomarker levels correlate with known CVD risk factors?  
Does a new biomarker reveal novel mechanisms of CVD initiation or progression?  
Does the biomarker predict the outcome of interest?  
Has residual confounding been excluded as an explanation for the observed association of a marker with CVD 
risk?  
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Is the new biomarker better than or does it have incremental utility over currently established biomarkers 
considered together?  
Will the use of a multimarker strategy using a new biomarker in combination with known biomarkers 
improve overall testing for CVD?  
Do the biomarkers add to the established risk prediction algorithms?  
Can a therapeutic course of action or the likelihood of response to an agent be determined with the use of a 
new biomarker?  
Will clinical practice change as a result of use of a new biomarker for screening, diagnosis, prognostication, 
or treatment?  
Is use of the biomarker shown to be cost-effective? 
Reproduced from Vasan, 2006, p.2349 
 
figure 5 Five phases of biomarker development: from discovery to application in clinical practice 
Reproduced from Vasan, 2006, p.2348 
RCT- randomized controlled trial, ROC –receiver operating curves 
 
1.2 .2 .1   Def in ing  abnormal  b iomarker  levels   
In order to apply a biomarker in a clinical setting, it is important to characterise the distribution of 
the biomarker initially in a healthy population free of the disease of interest and then in patient 
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population. There are 3 approaches for defining abnormal biomarker levels (Vasan, 2006). Figure 
6 shows the approaches for defining abnormal biomarker levels.  
figure 6 Approaches for defining abnormal biomarker levels 
  
 
 
 
 
 
 
 
 
 
 
In approach 1, reference limits are generated in a healthy sample free of the disease of interest in cross-sectional 
studies and a percentile cut point mostly between the 95th or 97.5th percentile is chosen to define abnormality. In 
approach II, discrimination limits are generated by evaluating the degree of overlap between patients with and 
without disease in cross sectional studies. Finally in approach III, threshold defining risk is generated in prospective 
cohort studies and relates levels of biomarkers to the incidence of disease and establishes a threshold beyond which 
risk escalates (Definitions taken from Vasan, 2006).  
 
Reproduced from Vasan, 2006, p.2338 
FN- false-negative, FP-false positive, TN- true negative, TP- true positive, Pts-patients, F/U- follow-up 
 
1.2 .2 .2   Evaluation of  the  performance  of  b iomarkers  
There are several factors that lead to variability in biomarkers and this should be considered in 
the early phases of biomarker development. Table 6 shows sources of biomarker variability and 
recommended steps to reduce variability.  
 
 55 
Table 6 Sources of biomarker variability 
Preanalytical Variability  Analytical Variability  Steps to Reduce Variability 
Sample and assay related  
     
Type of specimen              
 
 
Type of sample 
 
24-h vs. single morning void  
            
Sample processing 
 
Anticoagulant 
 
Stabilizing agent 
             
Temperature  
                
Endogenous degrading enzymes 
 
Freeze-thaw cycles 
          
Sample storage  
             
Assay related  
 
Minimal detection limit 
 
 
 
 
Image acquisition 
            
Interobserver  
            
Intraobserver  
 
Biological (subject related) 
 
Intraindividual  
 
Diurnal 
Day-to-day 
Seasonal 
Menstrual 
Fasting state 
Beat-to-beat (for imaging studies) 
 
Interindividual 
Age 
Gender 
Interlaboratory variability  
 
Analytical platforms  
 
 
Lot-lot variability  
 
Reagents 
 
Calibration functions  
 
 
 
Intralaboratory variability  
 
Personnel-related  
 
Interreader and intrareader      
 
Temporal drifts   
 
Lot-lot variability  
 
 
For clinical chemistry laboratory 
 
Use of a reference lab and reference 
standard  
 
Replicate measurements  
 
Add phantoms (dummy Ids) to 
samples  
Limit multiple lots  
 
Freeze samples immediately 
 
Avoid repeated freeze and thaw 
cycles  
Regular calibration of instruments  
 
Assess interassay and intra-assay 
precision at low and high levels
 
Optimal is <1/4 (CVI; within-subject 
variability)     
 
Desirable is <1/2 CVI
 
 
Minimal acceptable is <3/4 CVI
 
 
Assess bias (based on CVI and CVG 
where CVG is between-subject 
variability) 
Optimal is <0.125 (CVI+CVG)
1/2 
 
Desirable is <0.25 (CVI+CVG)
1/2
  
 
 
Minimal acceptable is <0.375 
(CVI+CVG)
1/2
 
 
Regular laboratory supervision and 
assessment of drifts
 
Develop reference ranges 
 
Assess impact of covariates on 
analyte values 
 
For imaging studies 
Standardized reading protocol 
Centralized reading 
Multiple beats measured 
Blind duplicate readings to  
evaluate interobserver and  
intraobserver variability  
Periodic recertification of  
Observers 
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Race 
Pregnancy 
Menopausal status 
Drugs 
Diet 
Exercise  
 
 
For genotyping studies 
Check for mendelian consistent and 
inconsistent errors (spurious excess of 
recombinants)              
Hardy-Weinberg equilibrium checks             
Analyses of repeats 
 
For microarray data 
Minimum Information About a 
Microarray Experiment (MIAME) 
standards      
Includes use of normalization 
controls (housekeeping genes, RNA 
spiking) 
Metrics of analytical variability 
Accuracy: The degree of agreement of a test result with an accepted reference standard or true value.      
Bias: A quantitative measure of inaccuracy or departure from accuracy. A signed difference between 2 values, 
T, usually expressed as the difference between 2 values, X−T, or the difference as a percentage of the 
reference or true value, 100 (X−T)/T.  
Precision: Closeness of agreement between independent test results obtained under stipulated conditions; 
indicates freedom from inconsistency or random error.      
Coefficient of variation (CV): A measure of precision calculated as the standard deviation of a set of values 
divided by the average. It is usually multiplied by 100, to be expressed as a percentage.          
Repeatability relates to essentially unchanged conditions and is often termed within-series precision or within-
run precision.          
Intermediate precision refers to conditions in which there is variation in 1 or more of the factors time, 
calibration, operator, and equipment, usually within a  laboratory.         Reproducibility 
relates to change in conditions, i.e., different laboratories, operators, and measuring systems (including 
different calibrations and reagent batches) and is often termed interlaboratory precision.  
Limit of detection (LoD): Smallest amount or concentration of analyte that can be distinguished from 
background at a stated confidence level.  
Limit of quantitation (LoQ): Lowest amount of analyte in a sample that can be quantitatively determined 
with (stated) acceptable precision and (stated, acceptable) accuracy, under stated experimental conditions.  
Reference method: A thoroughly investigated measurement procedure, clearly and exactly describing the 
necessary conditions and procedures, for the measurement of 1 or more property values that has been shown 
to have trueness of measurement and precision of measurement commensurate with its intended use.  
Reference materials: Substances with properties that are established for the use as standards, calibrators, 
controls, the verification of a measurement method, or the assignation of values. 
Reproduced from Vasan, 2006, p.2343 
 
In this thesis, the performances of blood biomarkers that have been extensively studied in the 
general population were evaluated in South Asian population. Receiver operating characteristics 
(ROC) curves were used to evaluate the accuracy of the biomarkers in terms of its sensitivity and 
its specificity. Table 7 shows evaluation of the performance of biomarkers by receiver operating 
characteristics curves.  
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Table 7 Evaluation of the performance of biomarkers by receiver operating characteristics curves 
Reproduced from Vasan, 2006, p.2338 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
An ROC curve is a plot of the sensitivity versus (1−specificity) of a diagnostic test, in which the different 
points on the curve correspond to different cut points used to determine whether the test results are positive.  
 
Sensitivity is defined as the ability of a test to detect disease (condition of interest) when it is truly present, 
i.e., it is the probability of a positive test result given that the patient has the disease.       
 
Specificity is the ability of a test to exclude the disease (condition of interest) in patients, who do not have 
disease, i.e., it is the probability of a negative test result given that the patient does not have the disease. 
 
Predictive value tells us how good the test is at predicting the true positives or true negatives, i.e., the 
probability that the test will give the correct diagnosis.       
     
The positive predictive value is the probability that a patient has the disease given that the test results are 
positive.    
       
The negative predictive value is the probability that a patient does not have the disease or condition given that 
the test results are indeed negative.  
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1.3  Biomarkers  of  cardiovascular  disease  
Blood borne biomarkers in CVD are developed based on the understanding of their role in the 
pathogenesis of CVD. Atherosclerosis has been implicated in the pathogenesis of ischemic 
cardiovascular and cerebrovascular diseases (Ross, 1999; Libby et al., 2002). Clinical 
manifestations of atherosclerosis comprise of CHD, ACS, peripheral artery disease (PAD) and 
stroke (Lusis, 2004). Figure 7 summarises the pathobiology of cardiovascular disease (Watkins 
and Farral, 2006). 
It is beyond the context of this thesis to list all the biomarkers of CVD, this section mainly 
concentrates on biomarkers of inflammation and haemostasis which will be measured in our 
study cohort. Table 8 presents potential blood borne biomarkers of cardiovascular disease.  
figure 7 Pathophysiology of cardiovascular disease 
 
 
 
Low density lipoprotein (LDL) cholesterol enters dysfunctional endothelium (which is damaged by smoking or 
diabetes, for example and this is reflected by decreased nitric oxide (NO) production) and is oxidized by macrophage 
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and smooth muscle cells. Release of growth factors and cytokines, and upregulation of adhesion molecules, attract 
further monocytes. Foam cells (arising from lipid-laden macrophages) accumulate and smooth muscle cells 
proliferate, which results in the growth of the plaque. Inflammatory cell infiltrate, smooth muscle cell death through 
apoptosis, and matrix degradation through proteolysis (by matrix metalloproteinases- MMPs) generate a vulnerable 
plaque with a thin fibrous cap and a lipid-rich necrotic core. Plaque rupture can cause thrombosis which might be 
sufficient to cause vessel occlusion.  
Reproduced from Watkins and Farral, 2006, p.164 
Inflammatory mechanisms play a key role in all stages of the disease from the initial recruitment of  
circulating leucocytes to the arterial wall to the eventual rupture of the unstable plaque. (Blake and Ridker,  
2002; Paffen and DeMaat, 2006). The onset of inflammation within the arterial wall begins with the  
accumulation of lipids which creates a diseased endothelium (Blake and Ridker, 2002; Ridker, 2005).  
Adhesion molecules such as P-selectin, vascular cell adhesion molecule –1(VCAM-1) induced by CRP mediates the  
process of endothelial attachment resulting in the migration of inflammatory cells into the sub endothelial space. 
 Accumulation of foam cells and proliferation of smooth muscle cells results in the growth of the plaque. Apoptosis of  
smooth muscle cells and infiltration of inflammatory cytokines results in vulnerable plaque with a thin fibrous cap  
and a lipid-rich necrotic core, rupture of which can cause thrombus or blood clot (Watkins and Farral, 2006).  
 
 
Table 8 Blood borne biomarkers of cardiovascular disease 
 
 
Biomarker 
 
CVD 
pathophysiological 
process 
 
Acute coronary syndrome and silent myocardial ischemia/injury 
 
Ischemia-modified albumin 
Glyocogen phosphorylase isoenzyme BB 
Choline 
Unbound free fatty acids 
Cytokines and chemokines  
Heat shock proteins 
Autacoid mediators: adenosine, nitric oxide, angiotensin-II, prostanoids, neuro-
peptides 
Vasoactive peptides: endothelin (vasoconstrictor), adrenomedullin, kinins, Nt-pro-
BNP/BNP, ANP, calcitonin gene-related peptide, substance P (vasodilator peptides) 
Myocardial ischemia 
Serum glutamate oxaloacetate transferase 
Myoglobin 
CK-MB 
cTns T and I 
Glyocogen phosphorylase isoenzyme BB 
Heart fatty-acid binding protein 
Heat shock proteins 
Myocyte necrosis / 
irreversible injury 
Pregnancy-associated plasma protein A  
Exracellular matrix molecules (versican), matrix metalloproteinases 
Myeloperoxidase, other reactive oxygen species (ROS) 
Cytokines (ICAM-1, VCAM-1, sCD40L, interferon-γ, TNF-α, IL-1; chemokines: 
MCP-1, MIP-1, IL-8) 
Platelet-endothelial cell adhesion molecule (PECAM) 
Placental growth factor  
Plaque destabilization 
Atherosclerosis (plaque formation and progression) 
Oxidized LDL-C, apoA, apoB, particle size, particle density 
CRP 
Inflammation 
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Cytokines (IL-6, IL-1β, -10, -12- 18, TNF-, transforming growth factor-β (TGF-β), 
sCD40L) and their receptors 
Chemokines (MCP-1, IL-8) and their receptors 
Lp-PLA2 
Serum amyloid A  
PECAM 
Heat shock proteins 
Adiponectin 
 
 
Growth factors (fibroblast growth factor, platelet-derived growth factor, TGF-β) 
ROS 
Smooth muscle cell 
proliferation, migration 
and differentiation 
Cell adhesion molecules (E-, P-, L-selectins, P-selectin glycoprotein ligand-1, 
ICAM-1, VCAM-1) 
Fibrinogen, t-PA, PAI-1, tissue factor, D-dimer, vWF, TAFI 
sCD40L 
Homocysteine 
Lp(a) 
Thrombogenesis/lysis 
LDL-C, oxidized LDL-C 
Cell adhesion molecules  
ROS 
Endothelial 
dysfunction/damage 
Oxidized LDL-C 
Heat shock proteins 
Microbe antigens 
Neopterin 
Interferon-γ 
Inflammatory cytokines 
Immune activation 
Oxidized LDL-C 
ROS: myeloperoxidase, glutatione peroxidase,  superoxide dismutase 
Oxidative stress 
Endopeptidases (matrix metalloproteinase) Elastin and collagen 
breakdown 
Haemodynamic stress and left ventricular remodelling 
B-type natriuretic peptide (BNP), pro-BNP peptide Stretch of ventricular 
myocardium 
Atrial natriuretic peptide Atrial stretch 
NT-proBNP – N-terminal pro- B-type natriuretic peptide; BNP – B-type natriuretic peptide; ANP – atrial natriuretic 
peptide;  CK-MB – creatine kinase MB fraction; cTns – cardiac troponins; ROS - reactive oxygen species;  ICAM-1 
– intercellular adhesion molecule 1; VCAM – vascular cell adhesion molecule 1; sCD40L – soluble CD40 ligand; 
TNF-α – tumor necrosis factor α; IL-1, -6, -8, -10, -12, -18 – interleukin –1, -6, -8, -10, -12, -18; MCP-1 - monocyte 
chemoattractant protein-1; MIP-1 - fractalkine macrophage inflammatory protein; PECAM - platelet-endothelial 
cell adhesion molecule; LDL-C – low density lipoprotein cholesterol; CRP – C-reactive protein; TGF-β - 
transforming growth factor-β; lipoprotein-associated phospholipase A2 – Lp-PLA2; t-PA – tissue type plasminogen 
activator; PAI-1 – plasminogen activator inhibitor 1; vWf – von Willebrand factor; TAFI – thrombin activatable 
fibrinolysis inhibitor; Lp(a) – lipoprotein (a) 
Reproduced from Dotsenko et al., 2008 
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1.3.1  Markers of Inflammation 
Inflammation plays a major role in all stages of atherosclerosis i.e., initiation, progression and 
thrombotic complication of the atherosclerotic plaque. Table 9 shows the inflammatory markers 
considered as predictors of prevalent or incident CVD by The Centers for Disease Control and 
Prevention and The American Heart Association (AHA) (Pearson et al., 2003). 
Table 9 Inflammatory markers considered as predictors of incident or prevalent cardiovascular disease  
Adhesion molecules  
Cytokines 
Acute phase reactants- Fibrinogen, Serum amyloid A, C-reactive protein 
White Blood Cell count 
Erythrocyte sedimentation rate 
Adapted from Pearson, Circulation 2003, p.501 
The following sections summarize some of the prominent inflammatory biomarkers in clinical 
practice and evidences from epidemiological and clinical studies.  
1.3 .1 .1  C-react ive  protein   
C reactive protein is the widest in use inflammatory biomarker. Healthy subjects have serum CRP 
levels of <5 mg/L and levels above these are considered abnormal. Plasma concentration of CRP 
can raise 10000 fold in 24 hours in an event of tissue injury. For the purpose of CVD screening, it 
is recommended to use high sensitivity assay for CRP (Hs-CRP). The assay can detect very low 
levels of CRP in blood down to 0.3 mg/L in apparent healthy subjects and was introduced after a 
standardization program at the Centers for Disease Control and Prevention. In recent years, the 
acute phase reactants such as CRP have been studied as potential markers of more subtle and 
persistent systemic variables loosely termed as low grade inflammation. The detection of this 
biomarker is easy and cost effective with commercially available Hs-CRP assay kits. The 
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coefficient variation of this assay is generally <10%. There is a considerable intraindividual 
variability in the levels of CRP even in the absence of underlying inflammatory conditions 
(Pearson, 2003). Table 10 shows the biological states that are associated with variation in CRP 
levels.  
Ridker et al., (2001a) showed in the AFCAPS/TexCAPS trial that the levels of CRP could remain 
stable over a long period of time in 2834 metabolically stable subjects; there was no difference in 
the median levels of CRP at baseline and follow up at 1 year. Similarly Meier-Ewert et al., (2001) 
and Ockene et al., (2001) showed that CRP levels were not subjected to circadian variations and 
exhibited high reproducibility.  
Table 10 Biological states associated with variations in CRP levels 
Increased levels of CRP Age  
Elevated blood pressure 
Elevated body mass index 
Cigarette smoking 
Metabolic syndrome/ diabetes mellitus 
Low HDL and high triglycerides  
Estrogen/progesterone hormone use  
Decreased levels of CRP Moderate alcohol consumption 
Physical activity 
Weight loss 
Adapted from Pearson 2003, p.503 
According to the recommendations of American Heart Association, Hs-CRP assay should be 
performed on metabolically stable subjects without obvious inflammatory conditions and 
expressed as mg/L only. The cut-off values for low risk (<1.0 mg/L), average risk (1.0 to 3.0 
mg/L), and high risk (>3.0 mg/L) are based on the distribution of hs -CRP in the adult population 
(Pearson, 2003; Fortmann et al., 2004; Myers et al., 2004). 
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1 .3 .1 .1 .1  Associa t ion  of  C -react ive  protein  wi th  cardiovascu lar  d i sease  
Prospective studies have demonstrated the role of CRP in primary and secondary prevention of 
CVD. This section summarizes the findings from major epidemiological and clinical studies that 
associated CRP with incident CVD events, recurrent events and mortality rates.   
1.3.1.1.1.1 C-reactive protein and prediction of incident cardiovascular events  
Prospective studies conducted in healthy subjects showed a dose-response relationship between 
the levels of CRP and the risk of incident or first CVD event. Ridker (1997) showed that healthy 
men with high CRP levels had three times the risk of MI (relative risk, 2.9; 95% confidence 
interval, (1.8-4.6); P<0.001) and twice the risk of stroke (relative risk, 1.9; 95% confidence 
interval, (1.1-3.3); P=0.02) compared to men with low CRP levels.  
A similar nested case control study in 28,263 healthy women showed that the relative risk for 
cardiovascular events in women in the highest quartile to be 1.5; (95% confidence interval, (1.1 -
2.1); P<0.001) compared to those in the
 
lowest quartile of hs- CRP. In this study, Ridker (2000a) 
demonstrated that prediction models  that incorporated both hs- CRP and lipid levels were better 
at predicting the risk of CVD compared to the model based on lipid levels alone (P<0.001). In the 
ROC analysis, the addition of CRP levels to total cholesterol improved the area under the curve 
(AUC) from 0.59 to 0.66 (P<0.001) and the addition to the ratio of total cholesterol to HDL- c 
from 0.64 to 0.68 (P<0.001). The risk of CVD was significantly higher among women who had 
high levels of CRP and targeted low levels of LDL cholesterol. These findings suggest that 
incorporation of CRP can significantly improve
 
models for the prediction of cardiovascular risk 
and may lead to
 
better clinical identification of patients who might benefit
 
from primary 
prevention.  
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Later Ridker (2002) demonstrated in 27,939  healthy women followed up for a mean of 8 years, 
that plasma levels of CRP are a better predictor of future CVD events at all levels of estimated 
10-year risk for events according to
 
the Framingham risk score and LDL-c. Figure 8 shows 
multivariable-adjusted Relative Risks of Cardiovascular Disease based on the levels of C - 
reactive protein (AHA guild lines) and the Estimated 10-Year Risk Based on the Framingham 
Risk Score; and levels of C - reactive protein and categories of LDL Cholesterol.  
figure 8 Multivariable-adjusted Relative Risks of Cardiovascular Disease based on the levels of C-Reactive 
Protein (AHA guildlines) and the estimated 10-Year Risk Based on the Framingham Risk Score; and levels of C-
Reactive Protein and categories of LDL Cholesterol.  
 
 
 
 
 
 
 
 
Reproduced from Ridker, 2002, p.1564 
A number of prospective studies have demonstrated the ability of CRP to predict incident CVD 
events in diverse populations which included the women’s health study (Ridker et al., 1998a; 
Ridker, 2000a; Ridker, 2002), the Honolulu Heart study (Curb et al., 2003), the MONICA 
(Multinational MONInitoring of trends and determinants in CArdiovascular disease)- Ausberg 
cohort, the ARIC (Atherosclerosis Risk in Communities) study. Meta analyses of prospective 
population studies (Danesh, 1998) compared individuals with CRP values in the upper tertile 
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with those in
 
the lower tertile at baseline showed a combined risk ratio 1.7 (95% CI, 1.4-2.1) for 
CVD. These prospective studies recorded CVD events some years after baseline blood collection, 
thus CRP measurement preceded the onset of disease. The study design allows to estimate 
relative risk across various strata of hs- CRP (Pearson, 2003). The relative risk of future 
cardiovascular events in 14 healthy populations with baseline CRP levels of <1 mg/L, 1 to 3 
mg/L and >3 mg/L after adjustment for traditional risk factors (Figure 9). The findings of these 
studies are highly consistent with no evidence of heterogeneity.  
figure 9 Relative risk of future cardiovascular events in 14 healthy populations with baseline Hs-CRP 
levels of <1 mg/L, 1 to 3 mg/L and >3 mg/L after adjustment for traditional risk factors.  
 
 
Reproduced from Ridker, 2007a,  
In the Cardiovascular Health Study, Tracy et al., (1997) reported higher levels of CRP in subjects 
with subclinical disease at baseline in 5201 healthy elderly men and women. The presence of 
subclinical disease was defined based on the resting electrocardiogram,
 
echocardiogram, carotid 
artery duplex scanning, ankle-brachial
 
blood pressure, history of CVD, Rose questionnaire, 
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cardiovascular
 
surgery, and use of selected medications consistent with the
 
diagnosis of angina or 
congestive HF. Mean baseline levels of CRP in women with subclinical disease compared to 
control subjects were 3.33 and 1.90mg/L respectively (p=<0.05). There was a 2.3 fold (95% CI, 
0.9-6.1) increase in the risk of incident MI among women with subclinical disease with CRP 
levels in the upper quartile (2.79 -46.04 mg/L). The overall odds ratio (OR) for incident MI in 
both men and women was 2.67
 
(95% confidence interval [CI], 1.04-6.81), with a stronger 
relationship in women (4.50 [0.97 to 20.8]) than in men
 
(1.75 [0.51 to 5.98]).  
Epidemiological studies have also demonstrated a link between inflammatory markers and 
incident HF. In the Framingham Heart Study, 732 patients (mean age 78 years, 67% women) free 
of prior MI and HF were followed up for a mean of 5.2 years. There was a 2.8-fold increase in 
the risk of HF amongst those with a serum CRP level
 
5 mg/dL (95% CI, 1.22 -6.50, P=0.02) 
(Vasan et al., 2003).  
CRP has not been a good measure for the extent of atherosclerosis in studies by Redberg et al., 
(2000); Folsom et al., (2001) and Hunt et al., (2001). The marker showed poor association with 
tests that measure the extent of atherosclerosis such as Doppler ultrasound scans of carotid 
arteries and electron beam computerized tomography for coronary calcium. On the contrary, 
some studies have shown positive association between CRP and atherosclerotic burden, further 
research is required to establish this relationship (Tataru et al., 2000; Gronholdt et al., 2000). 
1.3.1.1.1.2 C reactive protein and prediction of cardiovascular disease risk factors 
Apart from prediction of incident CVD events, CRP has shown to predict incident T2DM, 
hypertension and modify risk associated with metabolic syndrome. In the women’s health study, 
the relative risks of T2DM for women in the highest vs. lowest quartiles of CRP were 4.2 (95% 
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CI, 1.5-12.0; P=0.001) independent of BMI and insulin (Pradhan, 2001). Similar findings were 
reported in middle aged men in the West of Scotland Coronary Prevention study, whereby men in 
the upper quintile of CRP (>4.18 mg/L) had threefold risk for T2DM compared to those in the 
lower quintile (<0.66 mg/L) after adjustment for established CVD risk factors including blood 
pressure and lipid levels (Freeman et al., 2002).   
In the nondiabetic population of the Insulin Resistance Atherosclerosis Study (IRAS), 1008 
participants aged 40 -69 years, of whom 33% had impaired glucose tolerance were studied (Festa 
et al., 2000). A linear relationship between the CRP levels and an increase in the number of 
metabolic disorders (dyslipidaemia, body adiposity, insulin resistance and hypertension) was 
observed, in the presence of 0, 1, 2, 3, or 4 metabolic disorders, the mean log of CRP levels 
(±SE) were 0.075 ± 0.06, 0.511 ± 0.06, 0.845 ± 0.07, 1.34 ± 0.10 and 1.39 ± 0.17 respectively. 
CRP was strongly associated with BMI, waist circumference, insulin sensitivity, fasting insulin 
and proinsulin (all correlation coefficients > 0.3, P<0.0001).  
Sesso et al., (2003) showed CRP to predict incident hypertension in women, the relative risks of 
developing hypertension from the lowest to the highest levels of CRP were 1.00, 1.07 (95% CI, 
0.95-1.20), 1.17 (95% CI, 1.04-1.31), 1.30 (95% CI, 1.17-1.45), and 1.52 (95% CI, 1.36-1.69) 
(P<.001) respectively after adjustment for established CVD risk factors. Studies have also 
reported an association between elevated CRP levels and incident ischemic stroke (Rost et al., 
2001), PAD (Ridker et al., 2001b) and sudden death (Albert et al., 2002).  
1.3.1.1.1.3 Utility of c-reactive protein in clinical practice over established cardiovascular disease risk 
factors 
Although prospective studies have demonstrated independent predictive power of CRP (Ridker, 
2002; Cushman et al., 2005; Folsom et al., 2006), there is a growing concern regarding the 
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usefulness of CRP measurement to improve CVD risk prediction beyond those provided by 
classical risk factors. Prospective studies conducted to determine the role of CRP in everyday 
clinical practice suggest that CRP measurements may have limited clinical utility as a biomarker 
for CVD risk assessment. (van der Meer et al., 2003; Miller et al., 2005; Wang et al., 2006). In 
the third National Health and Nutrition Examination Survey, the elevated levels of CRP in the 
general population were attributed to the presence of traditional CVD risk factors mainly measure 
of adiposity and high levels of CRP rarely occurred in their absence (Miller, 2005).   
The incorporation of CRP to global CVD model to assess future CVD events in a cohort of 24 
558 healthy women, followed up for more than 10 years resulted in the reclassification of 40% -
50% of women at intermediate risk based on Adult Treatment Panel III (ATP-III) score to higher 
or lower risk categories (Ridker et al., 2007b). This finding is in conflict with the Framingham 
heart study by Wang, (2006) which showed a minimal contribution of CRP to CVD risk 
assessment.  
1.3.1.1.1.4 C-reactive protein and prediction of recurrent cardiovascular events and deaths   
 
Prospective studies suggest that CRP may have a role in the risk stratification of patients with 
already established CVD. In the European Concerted Action of Thrombosis and Disabilities 
(ECAT) Angina Pectoris study, hs- CRP was a predictor of coronary events in 2121 patients with 
angina, followed up for two years. The risk of coronary event in patients whose CRP levels were 
>3.6mg/L was almost doubled compared to those with lower levels of CRP (Haverkate, 1997).  
Speidl (2002) studied a group of 125 patients with premature CHD for 54 months. Clinical end 
points were defined as death, MI, need for coronary revascularization, or admission to hospital 
with angina pectoris. There was a 3.8-fold  (risk ratio 3.82, 95% CI 1.19-12.17) increased risk of 
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future CVD events in patients in the highest tertile of CRP levels compared to the patients in the 
lowest tertile.  
Similarly in patients with unstable CHD, followed up for almost 36 months, CRP was a predictor 
of mortality. The mortality rates were 5.7% among 314 patients with CRP  levels of <2 mg/L,  
7.8% among  294 patients with CRP levels of
 
2 -10 mg/L  and 16.5% among  309 patients with 
CRP levels >10 mg/L (P= 0.29 and P=0.001, respectively) (Lindahl, 2000). In the lowa 65+ 
Rural Health study, higher CRP levels (≥ 2.78 mg/L) were associated with  increased risk of 
death (RR=1.6; 95% CI, 1.0-2.6) in 1293 elderly subjects (mean age of 77.8 (3.2) years) (Harris, 
1999).  
Biasucci et al., (1999a) showed in 53 patients with unstable angina who were followed up for 1 
year that those who had elevated CRP ≥ 3 mg/L were at increased risk of recurrent CVD events. 
At discharge, 27 patients had normal CRP levels and 26 patients had elevated CRP levels, median 
CRP levels were 2.4 mg/L (range, 0.6-2.9 mg/L) and 9.9 mg/L (3.3-9 mg/L), (p<0.001) 
respectively. During the follow up, only 15% (4 patients) with discharge CRP levels of <3mg/L 
but 69% (18 patients) with elevated CRP had coronary events, 4 had MI and 14 showed phases of 
instability. The odds ratio for recurrent instability at 1 year in those with elevated CRP levels 
>3mg/L was 8.57 (95% CI, 1.66-44.2) p=<0.01. New phases of instability occurred
 
in 13% of 
patients in the lower tertile of CRP (≤2.5 mg/L), in 42% of those in the intermediate tertile (2.6 to 
8.6 mg/L),
 
and in 67% of those in the upper tertile (≥8.7 mg/L, ). During follow up, the 
recurrence of coronary events were significantly higher in patients in upper tertile of CRP (≥8.7 
mg/L) compared to patients in intermediate (2.6 to 8.6 mg/L) and lower (≤2.5 mg/L) tertiles 
(P<0.001).  
 70 
A similar study in 32 patients with
 
chronic stable angina, 31 with severe unstable angina, and 
29
 
with acute MI showed that elevated CRP levels at the time of hospital admission predicts poor 
outcomes in patients with unstable angina. Twenty patients with unstable angina had elevated 
levels of CRP ≥ 0.3 mg per decilitre and experienced more ischemic episodes in the hospital than 
those with levels <0.3 mg per
 
deciliter (mean [±SD] number of episodes per patient,
 
4.8 ±2.5 vs. 
1.8 ±2.4; P = 0.004). Moreover, 22 patients with MI who had levels of CRP ≥ 0.3 mg per decilitre 
had unstable angina (Liuzzo et al., 1994).  
1.3 .1 .2  Inter leukin  6  
IL-6 is considered to be less superior to CRP in the assessment of inflammatory response and the 
risk of CVD. IL-6 is subjected to diurnal variations and is a less stable when compared to CRP. 
The expression of CRP is directly regulated by IL-6 while the synthesis of IL-6 is by diverse 
stimuli (Vickers et al., 2002).  
1 .3 .1 .2 .1  Associa t ion  of  in ter l euk in  6  wi th  card iovascular  d i sease  
This section summarizes the findings from major epidemiological and clinical studies that 
associated IL-6 with incident CVD events, recurrent events and mortality.   
1.3.1.2.1.1 Interleukin 6 and prediction of incident cardiovascular events  
A prospective study conducted by Ridker (2000a) in 28,263 healthy women showed that the 
baseline levels of IL-6 were significantly higher in women with CVD events (median (IQR), 1.65 
(1.14-2.62) pg/ml) compared to women free of CVD events (1.30 (1.00-2.03) pg/ml, P=0.003). 
The relative risk for future cardiovascular events in women in the highest quartile compared to 
those in the
 
lowest quartile of IL-6 was 2.2; (95% confidence interval, (1.1 -4.3); P=0.02). The 
prediction models that incorporated IL-6 along with lipid levels were better at predicting the risk 
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of CVD compared to the model based on lipid levels alone (P<0.01). The addition of IL-6 to the 
lipid measurements in the ROC analysis increased the AUC from 0.59 to 0.64 (P<0.003).  
In the same year again, Ridker (2000b) showed in the Physician’s health study that plasma levels 
of IL-6 predicts the risk of future MI in 14,916 healthy men who were followed up for 6 years. 
During the follow up, 202 men developed MI and had higher levels of IL-6 compared to those 
who were free of CVD (1.81 versus
 
1.46 pg/mL; P=0.002). The relative risk of MI in men in the 
highest quartile compared to those in the lowest quartile was 2.3 (95%
 
CI 1.3 to 4.3, P=0.005). 
There was a 38% increase in the risk of MI for each quartile increase of IL-6 (95% CI, 15% - 
66%,
 
P=0.001).The association between plasma levels of IL-6 and the risk of future MI remained 
significant after adjustment for CVD
 
risk factors and CRP (P<0.001). 
Epidemiological studies have demonstrated a link between IL-6 and incident HF. Vasan (2003) 
demonstrated IL-6 to be a  predictor of HF in the Framingham heart study, where there was a 
68% increase in the risk of HF across the increasing tertiles of serum IL-6 levels (P=0.03). In the 
Multi-Ethnic study of Atherosclerosis, levels of IL-6 showed a strong independent inverse 
association with prognostic measure of HF (regional left-ventricular (LV) function) in 894 
healthy individuals without documented evidence of CVD. In this prospective community based 
study, 44.6% were women and the median age was 67 (IQR, 59-74), the participants were 
assessed for the presence of subclinical atherosclerosis and CVD risk factors. High levels of IL-6 
were independently associated with reduced systolic function after adjustment for demographic 
factors, CVD risk factors and measures of subclinical atherosclerosis, in the LV septum 
[regression coefficient = 1.03, 95% CI, 0.26-1.79, P = 0.008] and inferior wall (regression 
coefficient = 1.65, 95% CI 0.74-2.56, P < 0.001). Here regression coefficient of 1.03 means that 
1.03 variation in the dependent variable is predicted by one unit increase in IL-6 levels. Elevated 
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levels of IL-6 showed a stronger independent association with reduced regional systolic function 
compared to CRP (Yan et al., 2010).  
IL-6 has shown to predict incident T2DM. In the women’s health study, the relative risks of 
T2DM for women in the highest vs. lowest quartiles of IL-6 were 2.3 (95% CI, 0.9 -5.6; P for 
trend =0.07) independent of BMI and insulin. Overall the RR for future diabetes increased by 
28% per quartile increase in baseline IL-6 levels (P=0.07) (Pradhan, 2001). 
1.3.1.2.1.2 Interleukin 6 and prediction of recurrent cardiovascular events and deaths   
Prospective studies have reported elevated levels of plasma IL-6 in patients with ACS. Biasucci 
(1996) provided evidence for the role of IL-6 in unstable angina in a case control study. The 
levels of IL-6 were undetectable (<3pg/mL) in healthy subjects, were determined in only 6 (21%) 
out of 29 patients with stable angina but were detectable in 23 (61%) of 38 patients with unstable 
angina (P<0.01). The plasma levels of IL-6 were significantly different in both patient groups, 
median levels 5.25 pg/ml (range, 0-90pg/ml) in patients with unstable angina and below detection 
limit (0-7pg/ml) in patients with stable angina (p<0.005). Moreover, 19 (83%) of 23 patients with 
unstable angina who had detectable levels of IL-6 had a complicated in hospital outcome. IL-6 
was positively correlated with CRP (r=0.4, p=0.013), that means the levels of IL-6 were directly 
related to levels of CRP. A better positive correlation between IL-6 and CRP (r=0.96, p=0.002) 
was shown by Sturk et al., (1992).  
Biasucci (1999b) again showed higher levels of cytokines in patients with unstable angina who 
had an in-hospital CVD event after 48 hours. In 43 patients aged 62±8 years admitted with 
unstable angina who were given the same medical therapy, 26 patients had a CVD event. In 
patients who were free of any in-hospital event, the levels of IL-6 decreased at 48 hours from 
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(median (IQR)) 4.7 pg/ml (0.1-12.6) to 0.94 pg/ml (0.05-10.4). In patients with a CVD event, the 
levels of IL-6 increased from 7.3 pg/ml (0.1-22.9) to 9.5pg/ml (0.1-47.5), p<0.01. The levels of 
IL-6 were significantly different between the two groups at admission (p=0.018).  
Miyao et al., (1993) reported elevated levels of IL-6 in 23 patients with MI in a case control 
study. The subjects were followed for 4 weeks. The plasma levels of IL-6 in patients with MI 
were significantly higher (ranging from mean (SD), 28.5 (6.6) pg/ml at admission to 46.5 (7.8) 
pg/ml at discharge) compared to control subjects (11.4 (2.9) pg/ml, p<0.01).   
In the lowa 65+ Rural Health study, 1293 healthy subjects were followed up for a mean of 4.6 
years. The relative risk of death for the highest quartile of IL-6 (≥ 3.19 pg/ml) compared with the 
lowest quartile of IL-6 was 1.9 (95% CI, 1.2-3.1). During follow up, subjects with both elevated 
IL-6 and CRP had almost a threefold greater risk of mortality compared to those with low levels 
of inflammatory markers. These findings were independent of age, sex, BMI, smoking status, 
diabetes and CVD (Harris, 1999).  
1.3.2  Lipids and lipoproteins 
In the 1940’s the “lipid hypothesis” was a target of swirling controversy and it was only after the 
discovery of statin in the late 1980’s that the causal relationship between cholesterol 
accumulation in the arterial wall and atherosclerosis was proven (Steinberg, 2004). The 
‘Atherogenic lipid triad’ of high serum triglyceride levels, low serum HDL-c levels and high 
levels of LDL-c particles along with insulin resistance, visceral adiposity and a low grade 
inflammation are strong predictors of T2DM and cardiovascular complications (Reilly and Rader, 
2003). 
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In plasma, lipoproteins mainly transport water-insoluble lipids such as triglycerides, cholesterol 
and cholesteryl esters. Apolipoprotein B containing lipoproteins are of two forms –apoB48, 
expressed in mammalian intestine and apoB100, expressed in mammalian liver. ApoB containing 
lipoproteins, VLDL, LDL and lipoprotein (a).  (Lp (a)) are atherogenic and an elevated level of 
these lipoproteins in the plasma are associated with  increased risk of CHD (Gusarova et al., 
2003).On the contrary, apolipoprotein A1 (ApoA1), main protein of HDL particle is anti 
atherogenic and plays a major role in reverse cholesterol transport. This section briefly 
summarise the epidemiological studies that have investigated the association between lipids and 
lipoproteins with CVD.   
1.3 .2 .1  Triglycer ides  and cardiovascular  di sease  
The role of triglycerides in CVD is controversial (Hulley et al., 1980); however case control 
studies have demonstrated triglycerides as an independent risk factor for CVD (Brunner et al., 
1977; Castelli et al., 1977; Reardon et al., 1985). Austin et al., (1988) examined the association 
between LDL subclass phenotypes and the risk of MI in 109 cases and 121 controls. Patients had 
more small dense LDL particles which were associated with 3 fold increase risk of MI. 
Triglycerides and low HDL-c were independent predictors for the increased risk of MI associated 
with small dense LDL phenotypes.  
In a meta-analysis of population based cohort studies (Hokanson and Austin, 1996), the evidence 
for the association between triglycerides and CVD was weakened after adjustment for total 
cholesterol, LDL-c or HDL-c. The meta analysis was performed on 17 studies that involved 
46413 men and 10864 women, the univariate relative risk per 1 mmol/l increase in triglyceride  
were 1.32 (95% CI, 1.26-1.39) and 1.76 (95% CI, 1.50-2.07) for men and women respectively. 
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After adjustment for HDL-c, the relative risk was reduced to 1.14 (95% CI, 1.05-1.28) and 1.37 
(95% CI, 1.13-1.66) in men and women respectively, all p<0.05.  
Sarwar et al., 2007 performed a meta-analysis consisting of 29 Western prospective studies 
involving 262,525 participants who were followed up for 12.1 years. The odds ratio for increased 
risk of CVD was 1.72 (95% CI, 1.56-1.90) in subjects in the upper tertile of triglycerides 
compared to the lower tertile. In 2009, the Emerging Risk factors Collaboration conducted meta-
analyses of 68 prospective studies involving 302,430 participants. After adjustment for age and 
sex, the hazard ratio for CHD with triglyceride was 1.37 (95% CI, 1.31-1.42), however after 
adjustment for HDL-c and non-HDL-c, this was reduced to 0.99 (95% CI, 0.94-1.05).  
1.3 .2 .2  Low dens ity  l ipoprote in  cholesterol ,  total  
cholesterol ,  h igh dens i ty  l ipoprote in  cholesterol  and 
cardiovascular  d isease  
A prospective meta-analysis of 14 randomized trials of statins involving 90,056 participants 
demonstrated that a 1.0 mmol/l reduction in LDL-c over 1 year reduced coronary mortality by 
19% (rate ratio, RR 0.81 (95% CI, 0.76-0.85), p<0.0001, all-cause mortality by 12% (RR 0.88 
(95% CI, 0.84-0.91), p<0.0001, major vascular events by 21% (RR 0.79, 95% CI, 0.74-0.80), 
p<0.0001 (Baigent, et al., 2005). Further reduction in CV events was demonstrated by Cannon et 
al., (2006) with intensive statin therapy. In the Prospective Studies collaborative meta-analysis of 
61 prospective observational studies, a 1mmol/l reduction in total cholesterol was associated with 
lower CHD mortality at all age groups (hazard ratio of 0·44 (95% CI, 0·42—0·48), 0·66 (0·65—
0·68) and 0·83 (0·81—0·85) at ages 40—49, 50—69, and 70—89 years respectively) 
(Prospective Studies Collaboration, 2007).  
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HDL-c is inversely associated with the risk of CVD (Gordon, 1977; Gordon  et al., 1989). 
Castelli et al., (1986) demonstrated in participants of the Framingham study who were followed 
up for 12 years that HDL-c is an independent determinant of CHD risk. Figure 10 shows the 
incidence of CHD by HDL-c and total cholesterol levels.   
figure 10 Incidence of coronary heart disease by high density cholesterol and total cholesterol level in the 
Framingham Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dashed lines indicate two bars that are hidden from view:  CHD rate for HDL-C less than 40 mg/dL (<1.03mmol/L), 
total cholesterol 230 to 259 mg/dL (5.95 to 6.70 mmol/L) is 10.7%; 
 CHD rate for HDL-C 40 to 49mg/dL (1.03 to 1.27 mmol/L), total cholesterol greater than or equal to 260 mg/dL 
(6.72 mmol/L) is 6.6%. CHD rate for those with HDL-C levels < 40 mg/dL (<1.03mmol/l) and normal Total-C < 200 
mg/dL (<5.17 mmol/l) is 11.24%   Reproduced from Castelli, 1986, p.2837 
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1.3 .2 .3  Apol ipoprote ins  and cardiovascular  d isease  
In the INTERHEART case-control study, McQueen et al., (2008) demonstrated in 9,345 MI 
patients and 12,120 age and gender matched controls that ApoB/ApoA1 ratio was a better 
discriminator than any of the lipid measures for the risk of MI. The odds ratio for MI per 1 SD 
(standard deviation) change in ApoB/ApoA1 ratio was 1.59 (95% CI, 1.52-1.64), in 
ApoA1 0.67 (95% CI, 0.65-0.70), ApoB 1.32 (95% 1.28-1.36), in total cholesterol 1.16 (95% CI, 
1.13-1.19), in HDL-c 0.85 (95% CI, 0.83-0.88), in total cholesterol/HDL-c 1.17 (95% CI, 1.13-
1.20). Parish et al., (2009) demonstrated in a case-control study consisting of 3510 MI patients 
and 9805 controls that ApoA1 and Apo B were predictive of risk of MI. The relative risk of MI 
with ApoA1/ApoB ratio was 7.3 (95% CI, 5.8-9.2) when comparing those in the top with bottom 
decile of this ratio.   
In the AMORIS (Apolipoprotein-related mortality risk) study, apolipoproteins were better 
predictors of fatal MI compared to normal lipid measures. The age adjusted risk ratios (RR) for 
fatal MI per 1SD change in ApoB was 1.43 (95% CI, 1.28-1.60) in men and 1.34 (95% CI, 1.10-
1.62) in women whilst in ApoB/ApoA1 ratio, RR was 1.23 (1.18-1.27) in men and 1.38 (1.25-
1.52) in women, all p<0.05.  
1.3.3  Circulating cytokines, adhesion mo lecules and immune 
regulation molecules  
Atherosclerosis is a chronic inflammatory disease and a complex network of factors: cytokines, 
chemokines, cell adhesion molecules, reactive oxygen species, immune regulation molecules, 
acute phase reactants to name a few mediate the underlying immunologic and inflammatory 
process. These mediators function as potential targets for monitoring the different stages of 
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atherosclerosis or the underlying inflammatory process and in providing prognostic information 
towards CVD risk. There is limited data on the predictive value of markers such as IL-8, IL-18, 
TNF-α, MCP-1, P-selectin, E-selectin, ICAM-1 and VCAM-1 in CVD. Most of the published 
research on these markers has been done in prospective nested case-control studies (Dotsenko, 
2008).  
1.3 .3 .1  Adhes ion molecules  
In a nested case-control study, Ridker et al., (1998b) measured soluble intercellular adhesion 
molecule 1 (sICAM-1) in 474 patients who developed their first MI and 474 controls after 9 years 
of follow up. The relative risk of future MI was 80% higher in subjects whose baseline sICAM-
1concentration were in the highest quartile >260ng/ml (RR 1.8 [1.1-2.8], p=0.02). Luc et al., 
(2003) conducted a case-control study nested in the PRIME study where ICAM-1 was associated 
with the risk of future coronary events. The relative risk of future coronary events in patients who 
had high levels of ICAM-1 (>625 ng/ml) compared to those with low levels (<505 ng/ml) was 
1.90 (95% CI, 1.21-2.96), p=0.005 after adjustment for major risk factors.  
Pradhan et al., (2002) demonstrated in the Physician’s Health Study, a nested case-control study 
consisting of 14,916 middle-aged men that levels of ICAM-1 at baseline predicted the 
development of PAD. After adjustment for lipid and non-lipid risk factors, the odds for the 
development of PAD in men in the top quartile of ICAM-1 levels compared to those in the 
bottom quartile was 3.9 (95% CI, 1.7-8.6), p=0.001. In the ARIC study (Hwang et al., 1997), 
CHD subjects were identified after a 5 year follow up period. Subjects in the highest quartile of 
baseline ICAM-1 levels had 5.53 times increased risk of developing incident CHD and 2.64 times 
greater chance of having carotid artery atherosclerosis compared to those in the lowest quartile 
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(95% CI, 2.51-12.21) and (95% CI, 1.40-5.01) respectively. Similarly the odds for carotid artery 
atherosclerosis amongst those in the highest quartile of E-selectin compared to those in the lowest 
quartile were 2.03 (95% CI, 1.14-3.62). However sVCAM-1 levels were not associated with CV 
risk in the same cohort (de Lemos et al., 2000).  
In a prospective cohort of 1246 patients with angiographically documented CHD, there was a 
2.8-fold increase in the risk of future fatal CV events amongst patients in the top quartile of 
baseline sVCAM-1 levels compared to the bottom quartile (95% CI, 1.4-5.4), p=0.003 after 
controlling for all major inflammatory markers (Blankenberg et al., 2001).  
Malik et al., (2001) conducted a meta-analysis of prospective studies of soluble adhesion 
molecules and CHD. The odds for CHD after adjustment for major risk factors in men in the top 
third of baseline measurements of adhesion molecules compared to the bottom thirds were as 
follows for VCAM-1: 0.96 (0.66-1.40); E-selectin: 1.13 (0.78-1.62); and P-selectin: 1.20 (0.81-
1.76) respectively. The study concluded that adhesion molecules do not add much predictive 
value compared to existing established risk factors. Figure 11 shows the prospective studies that 
were included in the meta-analysis and odds ratio for CHD in individual studies in comparison to 
men in the top thirds of baseline measurements of adhesion molecules with those in bottom thirds 
of measurements. 
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figure 11 Meta-analysis of prospective studies of adhesion molecules and risk of coronary heart disease 
 
Reproduced from Malik, 2001, p.972 
 
1.3.4  Markers of thrombosis, haemostasis and coagulation 
pathway 
1.3 .4 .1  Thrombot ic ,  haemostat ic  and coagulat ion 
markers  and inc ident  cardiovascular  d isease  
1 .3 .4 .1 .1  Thrombot i c  markers  
In the study by Danesh et al., (2001) which involved 630 cases and 1269 controls nested in a 
prospective cohort of 5661 men followed up for 16 years. The odds for CHD in men with 
baseline fibrin D-dimer in the top third compared to those in the bottom third was 1.79 (95% CI 
1.36 -2.36) after adjustment for conventional risk factors. In a meta-analysis of seven prospective 
studies including the above mentioned study involving a total of 1535 CHD cases who were 
followed up for a mean of 5 years. The combined odds ratio in participants with baseline D-dimer 
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values in the top third compared to those in the bottom third was 1.7 (95% CI 1.3-2.2).Figure 12 
shows the meta-analysis of prospective studies of D-dimer and coronary heart disease 
figure 12 Prospective studies of D-dimer and coronary heart disease   
 
 
 
 
 
 
 
 
 
Reproduced from Danesh, 2001, p.2326 
 
1 .3 .4 .1 .2  Markers  of  endothe l ia l  dysf unct ion  
In a prospective incident case-control study from Sweden, von willebrand factor (vWF) was 
strongly associated with first MI, with an odds ratio of 2.52 (95% CI, 1.72-3.67) in patients with 
high levels of vWF at baseline (Wennberg et al., 2011).  
Whincup et al., (2002a) investigated the relation between vWF and risk of CHD in 625 men with 
coronary events and 1226 controls nested in a prospective study of 5661 men aged 40-49 years, 
who were followed up for 16 years and conducted a meta-analysis of relevant studies at that time. 
Men who had baseline vWF concentration above 126 IU.dl had an increased risk of CHD, odds 
ratio 1.82 (95% CI, 1.37 -2.41) compared to those who had less than 90 IU.dl (-1), odds ratio, 
1.53 (95% CI, 1.10 -2.12), p <0.001. In five prospective studies (Meade et al., 1994; Folsom et 
al., 1997; Smith et al., 1997; Rumley et al., 1999; Thorgersen et al., 1998) involving a total of 
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899 cases of MI and 18 553 controls with a mean follow up of 7 years. The combined odds ratio 
for CHD was 1.2 (95% CI 0.8-1.9) in subjects with vWF levels in the top third compared to those 
in the bottom third. Figure 13 summarises the prospective studies of vWF and CHD published 
before mid-2001.  
figure 13 Prospective studies of von Willebrand factor and coronary heart disease published before mid-
2001  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Risk 
ratios 
compare top and bottom thirds of baseline measurements. Black squares indicate the risk ratio in each study, with the 
square size proportional to the number of cases and the horizontal lines representing 
 99% confidence intervals.—, no adjustment reported for possible confounders; +, adjustment for age and sex only; 
++ for these plus smoking; +++, for these plus some other classical vascular risk factors. 
Reproduced from Whincup, 2002a, p.1765  
  
A meta-analysis of all prospective studies before mid-2000 involved a total of 1524 CHD cases 
and 19 830 controls which yielded a combined odds ratio of 1.5 (95% CI 1.1 -2.0). By including 
in the meta analysis, prospective studies with pre-existing vascular disease (studies shown in 
figure 12) yielded an additional 723 CHD cases and 5720 controls. The combined odds ratio for 
CHD was similar 1.6 (1.0 -2.5) (figure 14). 
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figure 14 A meta-analysis of prospective studies of von Willebrand factor and coronary heart disease    
 
 
 
 
  
 
 
Risk ratios compare top and bottom thirds of baseline measurements. Black squares indicate the risk ratio in 
each study, with the square size proportional to the number of cases and the horizontal lines representing 95% 
confidence intervals. 
Reproduced from Whincup, 2002a, .p.1768 
 
1.3.5  Cardiac natriuretic peptides 
Groenning et al., (2004) evaluated the efficacy of N-terminal pro-brain natriuretic peptide (NT-
proBNP) concentrations as a diagnostic and prognostic marker for left ventricular systolic 
dysfunction (LVSD) in the general population who were followed up for a median 805 days. NT- 
proBNP successfully discriminated patients with symptoms of HF and left ventricular ejection 
fraction (LVEF) ≤40% with an area under the curve of 0.94. NT-proBNP was the strongest 
independent predictor of mortality (hazard ratio, 5.7, p<0.0001) and hospital admissions for HF 
(13.83, p<0.0001). In the Breathing Not Properly study which involved 1586 patients admitted to 
emergency department with acute dyspnoea and without severe renal failure, the diagnostic 
accuracy of BNP as a marker of HF at a cut-off value of 100pg/ml was 83.4% (Maisel et al., 
2002).  In the same cohort, McCullough et al., (2002) demonstrated that the addition of BNP to 
clinical setting improved the diagnostic accuracy of chronic HF from 74% to 81%. The ESC 
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guidelines for the diagnosis and treatment of acute and chronic HF recommends the following in 
patients with acute dyspnoea, BNP values <100ng/L rules out HF, for values between 100-500 
ng/L and above, diagnosis of HF should be confirmed by imaging (Task Force Members, 2010).    
Berger et al., (2002) demonstrated in patients with chronic HF that BNP alone was the predictor 
of sudden death (p=0.0006). Furthermore, survival rates were significantly higher in patients with 
levels below 130 pg/ml compared to patients with values above 130 pg/ml (91% vs. 81%, 
p=0.0001). Harrison et al., (2002) evaluated the performance of BNP as a predictor of future 
cardiac events in patients with dyspnoea. A BNP value of 480 pg/ml significantly predicted HF 
endpoints –HF death or hospital admission with the AUC of 0.870 (95% CI 0.826-0.915). The 
incidence of HF endpoints in patients with BNP levels >480 pg/ml was 51% compared to 2.5% in 
patients with BNP levels less than 230 pg/ml. In patients with BNP levels > 230 pg/ml, the 
relative risk of 6 month HF death was 24.1 and 6 month non-cardiac death was 1.1.  
Wallen et al., (1997) performed a similar study evaluating BNP in 85 years old from the general 
population in Sweden who were followed up for five years. Circulating BNP levels predicted five 
year mortality in the elderly population (p<0.001). BNP levels were associated with mortality 
independent of confounding factors such as IHD, HF, hypertension, atrial fibrillation in this 
elderly population (risk ratio 1.259 (95% CI 1.088 – 1.457), P=0.0020.  
In the Framingham heart study (Wang, 2004), a 1 SD increase in log BNP levels was associated 
with a 27 percent increase in mortality (p=0.009), a 28 percent increase in the risk of first CVD 
event (p=0.03) and a 77 percent increase in the risk of HF (p<0.001). Hazard ratios for death, first 
CVD event and HF were 1.62, 1.76 and 3.07 respectively in subjects with BNP levels above the 
80
th
 percentile (20.0 pg per millilitre for men and 23.3 pg per millilitre for women), all p<0.05.  
In 2006, Wang and colleagues evaluated multiple biomarkers in the prediction of CVD events in 
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the Framingham Heart Study. BNP levels best predicted mortality and major CV events; hazard 
ratios were 1.40 and 1.25 respectively. BNP levels alone provided valuable information for CV 
risk stratification compared to the additional 10 biomarkers to conventional risk factors.  
In a population-based prospective study of 658 older Dutch adults, NT-proBNP predicted 
mortality and first major CVD events. Adjusted Hazard ratio for mortality and first major CVD 
events were 1.96 (95% CI, 1,21 -3.19) and 3.24 (1.80-5.79)  respectively in subjects with NT-
proBNP values above the 80
th
 percentile compared to those with values below the 80
th
 percentile 
(Kistorp  et al., 2005). In the LIFE sub study (Olsen et al., 2006); the incidence of CV events was 
11.5 in participants with median NT-proBNP above 170pg/ml compared to 5.4% in those with 
low levels. NT-proBNP was superior to CRP as a predictor of composite endpoints and CVD 
mortality, (HR 1.9 [1.6–2.4] per SD 0.49 log (pg/ml and HR 2.5 [1.9–3.3] per SD, both P < 
0.001). NT-proBNP added significantly to CVD risk stratification along with conventional risk 
factors in the prediction of composite CV events with an AUC of 0.75 and CVD mortality with 
an AUC of 0.83.  
The utility of BNP levels in therapeutic interventions were evaluated in the STARS-BNP 
multicenter study where plasma BNP guided therapy was compared to medical treatment in 220 
New York Heart Association functional classes II to III patients. During the follow up period of 
median 15 months, the HF end points- HF related death or hospital stay was fewer in the BNP 
guided therapy group compared to the clinical group (24% vs. 52%, p<0.001) (Jourdain et al., 
2007). 
The prognostic value of BNP has also been evaluated in patients with CHD. In the A to Z trial 
(Morrow et al., 2005), a prospective observational study of 4497 patients with non-ST elevation 
or ST-elevation ACS, BNP levels were evaluated at hospital discharge for ACS and during 
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follow up for up to 12 months. Patients who had BNP levels >80 pg/ml at baseline were 
associated with subsequent death or new HF (adjusted HR 2.5, 95% CI 2.0 -3.3), at 4 months 
(adjusted HR 3.9, 95% CI 2.6-6.0) and at 12 months (adjusted HR 4.7, 95% CI 2.5-8.9).The 
hazard ratio for patients who had newly elevated BNP levels at month 4 was higher 4.5 (95% CI 
2.3 -8.6) compared to those who had elevated BNP levels both at baseline and 4 months.   
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1.4  Cardiovascular  disease in  South  Asians  in  the  United  
Kingdom: potent ial  problems with  cardiovascular  disease r isk  
assessment  in  South  Asians         
1.4.1  South Asians in the UK 
South Asians generally refers to people originating from India, Pakistan, Bangladesh and Sri 
Lanka with distinct languages, religions and customs. The early settlement of South Asians in the 
UK started during the mass migration in the 1970’s. According to the 2001 census, the total 
ethnic minority population in the UK was 7.9% (4.6 million) and South Asians accounted for 
3.5% (2 million) of this population  In Britain, the areas where the ethnic minorities are mainly 
concentrated are Greater London, West Midlands, West Yorkshire and Greater Manchester 
(Office for National Statistics, census 2001).  In 2008, the ethnic minority population in the West 
Midlands was 12.3% Table 138 in appendix A 9.1.1 shows the proportion of ethnic minority 
population in the West Midlands. Table 139 shows the ethnic minority population in Birmingham 
(Race for opportunity, regional factsheet, 2010). 
1.4.2  Cardiovascular disease in South Asians in the UK 
The burden of CVD is most prominent amongst South Asians in the United Kingdom compared 
to the general population. The prevalence of CVD is reported to be 40% or higher in UK South 
Asians compared to White Europeans (Balarajan, 1996; Wild and McKeigue, 1997). The onset of 
the disease is also much earlier in life, where CVD mortality is at least 2-fold higher in young 
South Asian males than their counterparts (Balarajan, 1996).  This section highlights the burden 
of CVD, factors that contribute to excess risk of CVD in South Asians and its consequences.  
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1.4 .2 .1  Inc idence  of  cardiovascular  disease  amongst  UK South 
Asians 
Pedoe et al., (1975) studied 42,200 residents of the London Borough of Tower Hamlets below the 
age of 65 for nearly 3 years (1970-1972), of whom 3380 were South Asians. The number of 
coronary events observed amongst South Asian men mostly Bangladeshi was 40 and the expected 
rate for Asian born men in the Borough was 31.  
Khattar et al., (2000) performed a longitudinal comparison of CV morbidity and mortality in 528 
whites, 106 South Asians and 54 Afro-Caribbean’s with essential hypertension who were 
followed up for 9.2 years. All cause event rate was highest among South Asians, 3.46 compared 
to 2.50 (ns) and 0.90 (p=0.002) events/100 patient-years for whites and Afro-Caribbean’s 
respectively. Moreover, South Asians showed an excess of coronary events compared to whites, 
2.86 vs. 1.32 events/100 patient-years, p=0.002. In this study, South Asian ethnicity was an 
independent predictor of CV outcomes, hazard ratio 1.79, p=0.008 compared to whites.  
In the UK Prospective Diabetes Study, the incidence of MI was examined in 4974 patients (82% 
white, 10% South Asians and 8% Afro-Caribbean’s) with newly diagnosed T2DM aged 25-65 
years between 1977 and 1991. The age standardised rate per 1000 person years for MI was 14.6 
(95% CI, 13.3 -15.9), 4.3 (2.5 -7.0) and 15.4 (10.6-21.4) for whites, Afro Caribbeans and South 
Asians respectively. On cox regression, the hazard ratio associated with Afro-Caribbean ethnicity 
for MI compared to whites was 0.3 (95% CI, 0.2-0.6) after adjusting for conventional risk factors, 
whilst for South Asians was 1.2 (95% CI, 0.9-1.7). In this study South Asians and whites showed 
a similar risk of MI (UK Prospective Diabetes Study group, 1998).  
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Patel et al., (2008a) investigated the incidence of CV events in 350 Caucasian and 104 South 
Asian patients with hypertension over a 5 year period.  The MI event rate was 6.4 per 1000 
patient years in Caucasians and 17.8 per 1000 patient years in South Asians. South Asians also 
had a lower event-free survival rate for MI compared to Caucasians, log rank chi square =4.12, 
p=0.04.  
Fischbacher et al., (2007) conducted a retrospective cohort study (2001 to 2003) using linkage 
techniques that combined health and census data so that ethnicity is recorded accurately for the 
population of Scotland. The incidence rate ratio for MI was 1.45 (95% CI, 1.17 -1.78) for South 
Asian men and 1.80 (95% CI, 1.31 -2.48) for South Asian women compared to non-South Asians 
in Scotland. However, the study reported a better survival rate following incident MI in South 
Asians, hazard ratio for death was 0.59 (95% CI 0.43 -0.81). This is contrary to prior studies that 
have reported poorer survival rates in South Asians (Hughes, 1989; Wilkinson et al., 1996). 
1.4 .2 .2  Prevalence  of  cardiovascular  disease  amongst  UK 
South Asians  
William et al., (1993) conducted a cross sectional survey amongst 159 South Asians and 319 
White Europeans, mean age of 35 years in the city of Glasgow. CVD events were self-reported 
and a significant ethnic difference in the prevalence of CVD was reported in Asian women, not 
men compared to White European women (14% versus 6%, P<0.0005). Rudat (1994) conducted 
a similar survey in 1017 Indians, 927 Pakistanis and 665 Bangladeshis living in inner cities in the 
UK. Self-reported CVD events were 2%, 3% and 5% (percentage-standardized for age and sex) 
amongst Indians, Pakistanis and Bangladeshis respectively. Nazroo (1997) conducted a similar 
survey in 1273 Indians, 1185 Pakistanis, 591 Bangladeshis and 2867 White European who 
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provided self-reported data on heart disease. Adjusted prevalence ratios accounting for standard 
of living in Indian and African Asian groups combined and Pakistani and Bangladeshis combined 
were 0.67 and 1.24 respectively compared to the White population.  
Bhopal et al., (1999) performed a cross sectional survey to investigate the prevalence of CVD in 
South Asians compared to the general population in Newcastle upon Tyne. Self-reported details 
on CVD and ECG were obtained from 259 Indian, 305 Pakistani, 120 Bangladeshi and 825 
European men and women aged 25-74 years. South Asians showed a higher prevalence of CVD 
compared to the general population, age adjusted prevalence of CVD based on ECG was 6% in 
South Asians and 2% in Europeans.    
McKeigue et al., (1993) conducted a similar survey in 1421 South Asian men and 1515 European 
men aged 40-69 years in Southall, London. Age-standardized prevalence rate for CVD based on 
ECG reports was 16.6% in South Asians compared to 12.1% in Europeans. Hughes et al., (1989) 
evaluated presentation of first MI in immigrant Asians and Whites in Britain. The relative rate of 
MI in immigrant Asians was 4.9% (95% CI 3.4-6.9) compared to White population. Moreover, 
the mean age of first MI in immigrant Asians was much lesser in 50.2 years compared to 55.5 
years in Whites (mean difference 5.5 years (95% CI 2.5-7.1).  
In 2004, the prevalence of CVD at all ages irrespective of gender was highest in the Irish 
population and the general population in the UK at around 15%. The next highest rates were 
observed amongst Indian men and Pakistani men at 11% and 12% respectively. The prevalence 
of CVD in Indian women and Pakistani women were 7%.  The prevalence of CHD was similar in 
men of Irish origin (6%), Indian origin (6%) and of English descent (6%). Pakistani men had the 
highest prevalence rates of CHD at 8%. A similar trend but lower rates of CHD were observed in 
women compared to men (Ethnic differences in cardiovascular disease, 2010 online resource).     
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1.4 .2 .3  Cardiovascular morta l i ty  rates  in  UK South Asians  
The population-based studies, the Southall study and Brent study in West London examined the 
risk of CHD mortality in 1420 South Asian and 1787 European men aged 40 to 69 years. On 
multivariable analysis after adjustment for age, smoking, and cholesterol, the CHD mortality rate 
almost doubled in South Asians compared to Europeans (hazard ratio, HR 2.14, 95% CI 1.56 -
2.94, P<0.001). South Asian men showed higher CHD mortality in all models after adjustment 
for conventional risk factors (Forouhi et al., 2006).  
Balarajan et al., (1984) performed a proportional mortality analysis on immigrants of Indian 
subcontinent origin and English descent who died in England and Wales in 1975-77. A total of 
3657 immigrants died in England and Wales, of whom 1667 died of circulatory diseases mainly 
IHD and cerebrovascular disease. A proportional mortality ratio of 100 meant that the proportion 
of total mortality for a specified condition in immigrants was equal to that of the reference 
population in England and Wales. The proportional mortality ratios for circulatory disease in 
immigrants of Indian subcontinent was calculated separately for men and women, 120 (number 
of deaths, 1341) and 117 (number of deaths, 326) respectively with deaths in English descent as 
standard.  
Marmot et al., (1984) also performed mortality analysis on immigrants of Indian subcontinent 
based on the 1971 census in England and Wales and deaths in 1970-72. Standardised mortality 
ratios (SMR) for IHD in immigrants born in the Indian subcontinent were calculated separately 
for men and women, SMR (number of deaths) 115 (1533) and 115 (739) respectively, with deaths 
in England and Wales as standard. Mortality from CHD was 20% higher in men and women of 
South Asian origin compared to the general population in England and Wales in 1970-72. Wild 
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and McKeigue (1997) analysed mortality in adults aged 20-69 years in 1970-72 and 1989-92 
using 1971 and 1991 censuses. SMR and number of deaths from IHD in South Asian men and 
women for the period 1989-92 were 146 (3348) and 151 (882) respectively. Young South Asian 
men aged 20-44 years showed a higher SMR of 169 compared to other age groups.  
McKeigue and Marmot (1988a) examined CHD mortality in South Asians aged 20-64 years in 
four London Borough between 1979-1983. SMR for CHD amongst different Asian groups in four 
London Borough between 1979-83 are shown in table 11. The study concluded that mortality 
from CHD in South Asians has increased by 25% compared to the general population since 1970-
72.  
Table 11 Mortality from coronary heart disease among Asians aged 20-64 in different London boroughs during 
1979-83 
 
 
 
 
 
 
 
Adapted from McKeigue and Marmot, 1988a, p.903 
Balarajan (1991) examined ethnic differences in mortality from IHD in England and Wales by 
country of birth of the deceased in 1979-83 and 1970-72. SMR were calculated for each ethnic 
group for IHD for the two periods with the five year age-sex specific rates for England and Wales 
for 1979-83 as standard. In 1979-83, SMR for IHD in men and women aged 20-69 years from the 
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Indian subcontinent was 136 and 146 respectively. The mortality ratio for IHD in young Indian 
men aged 20-29 and 30-39 years were 313 (21 deaths) and 210 (123 deaths) respectively. 
Compared to 1970-72, mortality rates from IHD increased in Indian men and women by 6% and 
13% respectively. 
Harding and Maxwell (1997) examined mortality by social class in migrants aged 20-64 years by 
country of birth in England and Wales based on 1991-93 mortality data. Men from the Indian 
subcontinent showed higher mortality rates from IHD, SMR 150 (number of deaths 1736) 
compared to the reference population. Wild et al., (2007) examined IHD mortality for people 
aged 20 years and over in England and Wales by country of birth based on the 2001 census and 
mortality data for 2001-2003. SMR for IHD (number of deaths) in men born in Bangladesh, India 
and Pakistan were 409 (175), 2528 (131) and 1044 (162) respectively and in women born in 
Bangladesh, India and Pakistan were 167 (97), 149 (1672), 174 (454) respectively. Excess 
mortality from IHD was found in young Pakistani adults aged 20-44 years, SMR 261 (95% CI 
203-330) based on 70 deaths.  
Bellary et al., (2010) investigated the effect of ethnicity on the risk of CV events and mortality in 
1486 South Asian and 492 white Europeans with T2DM  over a 2 year period. The adjusted odds 
ratio for CVD event or death from CVD was 1.4 (95% CI, 0.9-2.2) in South Asian compared to 
white European (p value-NS). The mean age of death was much younger for South Asian 66.8 
years. (11.8) compared to 74.2 years. (12.1) in white Europeans, a mean difference of 7.4 years 
(95% CI 1.0-13.7), p=0.023.   
The mortality rates for CHD fell by 29% in men and 17% in women in the general population 
(aged 20-69) from 1971 to 1991. A similar but slow pattern was observed amongst South Asian 
immigrants, whose rates fell by 20% in men and 7% in women (Wild and McKeigue, 1997). 
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Recent data from 1979 to 2003 also showed a steady decline in CHD mortality rates in South 
Asians (aged 39-69). However rate ratios for CHD mortality are still high amongst South Asians 
(Harding et al., 2008).  
1.4.3  Heart failure in South Asians  
South Asians have a higher prevalence of CHD and diabetes mellitus compared to the general 
population in the UK and hence a greater prevalence of HF is anticipated in this ethnic group. 
Prior epidemiological studies showed a threefold higher risk of hospitalization with HF amongst 
South Asians compared to white population. Moreover the onset of HF was much younger in 
South Asians and mostly in men compared to the White population in the UK (Lip et al., 1997; 
Davis et al., 2000; Blackledge et al., 2003; Newton et al., 2005; Gill et al., 2009). 
Blackledge (2003) compared 5057 white patients and 336 South Asian patients aged 40 or over 
with newly diagnosed HF in Leicestershire between 1 April 1998 and 31 March 2001. The 
hospital incidence rates for HF in South Asian men and women were 2.2 and 2.9 respectively 
compared to the white population. Moreover South Asian HF patients were much younger, had a 
high prevalence of concomitant MI and diabetes mellitus compared to white HF patients (18.8% 
vs.10.7%) and (45.8% vs. 16.2%), all p<0.001 respectively. Despite an adverse risk profile, the 
hazard ratio for all-cause mortality was lower in South Asians compared to White HF patients 
(HR 0.82, 95% CI 0.68-0.99). Similarly findings were reported by Lip (1997) where South Asian 
HF patients had lower inpatient mortality compared to white European patients (13.2% vs. 
20.7%). Davis (2000) followed up these patients for 8 years and the total mortality was 87.0% 
amongst South Asians and 90.5% amongst White European patients.  
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Bhopal and Fischbacher (2003) suggested that the young age of South Asian patients admitted 
with HF is an artefact and simply display the age distribution of the South Asian population in 
the UK. Newton (2005) used the same population in Leicestershire but this time age and gender 
matched South Asian and White patients hospitalized for the first time for HF and compared 
prognosis. South Asian HF patients showed a higher prevalence of prior hypertension and 
diabetes mellitus, (45% vs. 33%) and (46% vs. 18%), both p<0.05. South Asian HF patients 
showed more preserved left ventricular function (38% vs. 23%, p=0.002) and less advanced HF 
(18% vs. 28%, p=0.025) compared to white HF patients. The odds ratio for all-cause mortality 
amongst South Asian HF patients was 0.71 (95% CI 0.53-0.96), p=0.02.   
In the study by Galasko et al., (2005) in Harrow, UK between January 2000 and May 2001, the 
prevalence of LVSD was similar in White and South Asian patients but a significant difference 
was observed in the underlying aetiology. South Asian patients had a higher prevalence of prior 
CHD, findings similar to those reported by Blackledge (2003) and Gill et al., (2011). Bhopal et 
al., (2012) conducted a retrospective cohort study in Scotland comprising of 4.65 million subjects 
to examine the ethnic variations in the incidence of HF between May 2001 and April 2008. The 
incidence of first hospitalization for HF was modestly higher amongst Pakistani men (RR 134.9) 
compared to white British men (RR 86.4) and Chinese men (RR 54.2). Similar findings were 
observed amongst women with higher incidence rates among Pakistani women compared to 
white British women (RR 86.0) and Chinese women (RR 62.9). In the E-ECHOES, the 
prevalence of HF amongst South Asians and Afro-Caribbeans groups was 1.1%, similar to those 
reported in the general population (Gill, 2011; Davies et al., 2001)  
The prevalence of HF is more likely to be similar in South Asians and Whites in the UK (Gill, 
2011). South Asians with HF are more likely to have concomitant MI, hypertension and diabetes 
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mellitus which might predispose this group to diastolic HF with preserved LV function hence the 
lower prevalence of LVSD (Galasko, 2005). Better survival in South Asian HF patients are 
mainly due to preserved left ventricular function, less advanced HF and younger age at first 
presentation (Blackledge, 2003; Newton, 2005; Sosin et al., 2004).  
1.4.4  Traditional Cardiovascular risk factors in South Asians  
Several hypotheses exist relating to ethnic differences and the excess of CHD in South Asians. 
Table 12 shows some of the plausible hypotheses that have been suggested (Kuppuswamy and 
Gupta, 2005; Patel and Bhopal, 2004). 
Table 12 Hypotheses relating to excess coronary heart disease in South Asians 
1. Cardiovascular risk profiles amongst South Asians living abroad are likely to have 
deteriorated with migration from countries of origin to Western Countries, specifically 
from changes in dietary exposures. 
2. The prevalence of non-conventional risk factors such as high levels of lipoprotein a and 
homocysteine amongst South Asians 
3. South Asians are more susceptible to cardiovascular disease due to genetic reasons 
4. The increased prevalence of traditional risk factors comprising of insulin resistance, 
diabetes mellitus, hypertension, central obesity, hyperlipidaemia, lack of physical 
activity and smoking amongst South Asians.  
5. The classic risk factors may interact differently and hence cause more adverse events in 
South Asians 
6. People with ancestral origins in hostile tropical environments such as people from the 
Indian subcontinent exhibit increased pro-inflammatory responses compared to those 
living in a temperate environment. However, when migrating to temperate environment 
the balance between the benefit and the risk of these increased pro inflammatory 
responses is altered, resulting in an increased incidence of inflammatory related 
diseases. 
7. South Asians show elevated subclinical inflammation and endothelial dysfunction and 
the manifestations of these factors are much earlier in life 
 
Of all the above mentioned hypotheses, the higher prevalence of metabolic syndrome is the most 
convincing one and this has been proven in research in South Asians so far. This section will 
summarise studies that have examined traditional and non-traditional cardiovascular risk profiles 
in South Asians.  
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1.4 .4 .1  Insul in  res i stance and diabetes  mel l i tus  
Whincup et al., (2002b) conducted a cross sectional study to examine insulin resistance in 73 
British South Asian and 1287 White children aged 8-11 years. Mean glucose concentrations were 
similar in both groups. However, insulin concentrations were higher in South Asian children 
compared to White children, percentage difference 53% (95% CI, 14-106) after fasting and 54% 
(95% CI, 19-99) after glucose load, and differences remained after adjustment for adiposity and 
other confounders. Cruickshank et al., (1991) compared 107 Indian Gujaratis and 101 White 
Europeans in West London and found the prevalence rate for diabetes was 30% and 3% 
respectively.   
Mckeigue et al., (1988b) compared the prevalence of diabetes mellitus and hyperinsulineamia in 
253 men and women aged 35-69 in East London, UK. The prevalence of diabetes was three times 
higher in Bangladeshis men and women, 22% and 23% compared to European men and women, 
10% and 4% respectively. Again serum insulin concentrations measured after a glucose load 
were higher amongst Bangladeshis men and women 65 mU/l and 57mU/l compared to European 
men and women 32mU/l and 27 mU/l respectively, p<0.05. Insulin levels were associated with 
high triglyceride levels and low HDL cholesterol levels in Bangladeshis.  
In the cross sectional study by Bhopal (1999) in Newcastle upon Tyne, the prevalence of diabetes 
was higher amongst Pakistani and Bangladeshi men 22.4% and 26.6 % respectively compared to 
15.2% in Indians. In the Whitehall II study, the prevalence of diabetes mellitus was higher in 
South Asians, the odds of being diabetic was 4.2 (95% CI 3.0-5.8) compared to the White 
population (Whitty et al., 1999). In the Wandsworth Health Authority population based study in 
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South London between 1994 to 1996, age and sex adjusted prevalence ratio for diabetes mellitus 
was 3.8 (95% CI 2.6 -5.6) in South Asians compared to Whites (Cappuccio et al., 1997).  
Mckeigue et al., (1991) examined metabolic disturbances related to insulin resistance in a 
population survey of 3193 men and 561 women aged 40-69 years in London. South Asians 
showed a higher prevalence of diabetes mellitus compared to the European group (19% vs. 4%). 
The prevalence of diabetes mellitus in European men and women were 4.8% (95% CI 3.7-5.8) 
and 2.3% respectively compared to 19.6 (17.5-21.7) and 16.1 (11.7-20.5) in South Asian men and 
women. Compared to the European men, mean serum insulin levels were 1.4 higher in the fasting 
state and 2.1 times higher 2h after a glucose load in South Asian men, this remained after 
adjustment by plasma glucose levels. South Asians also had elevated blood pressure, higher 
triglyceride levels and lower HDL-c compared to Europeans.   
Dhawan et al., (1994) performed a case-control study to compare the prevalence of diabetes and 
hyperinsulinaemia in 83 British Asians, 30 Indian Asians and 87 White men, all with 
angiographically proven CHD with age matched controls. British Asians and Indian Asians 
exhibited a higher prevalence of diabetes and impaired glucose tolerance compared to White 
British men. Amongst British Asian patients and Indian patients, only 52% and 43% were 
normoglycaemic whilst 75% of White patients were normoglycaemic. Table 13 summarises the 
prevalence of diabetes, impaired glucose and normoglycaemia for this study. Fasting insulin 
concentrations were higher in patients of all ethnic groups compared to controls (p<0.001) with 
British Asian patients having higher levels compared to white patients (28.2µ/ml vs. 12.7µ/ml). 
Again at one hour of glucose challenge, insulin concentrations were higher in all patients 
compared to controls (p<0.001), with British Asian patients showing a high level of 122.0µ/ml 
compared to 72.7µ/ml in White patients.   
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Table 13 Prevalence of diabetes, impaired glucose and normoglycaemia 
 
Adapted from Dhawan, 1994, p.416. Values are number (%) 
In a longitudinal study, Patel, (2008a) showed that the prevalence of diabetes was 22.9% higher 
in hypertensive South Asians compared to hypertensive Caucasians. Diabetic hypertensive 
patients showed a lower event-free survival rate for MI compared to non-diabetic hypertensive 
patients (log rank =12.2, p=<0.001). Of all the conventional risk factors, the onset of MI was 
associated only with diabetes in South Asians, odds ratio 3.77 (95% CI, 1.55-9.15, p=0.003). In 
South Asians, the onset of diabetes mellitus is much earlier in life and the disease is more 
progressive resulting in higher rates of nephropathy and retinopathy compared to European 
diabetic patients (Burden et al., 1992; Chandie Shaw et al., 2006; Stolk et al., 2008; Raymond et 
al., 2009).  
1.4 .4 .2  Obesi ty  
Population studies in the United Kingdom have shown central adiposity reported as waist to hip 
ratio and insulin resistance to be the underlying factors that predispose South Asians to increased 
risk of CVD (McKeigue, 1991; Dhawan, 1994). A pro inflammatory state has been associated 
with these factors and the increased risk of CVD, but the precise mechanisms in South Asians is 
unclear. South Asians have a greater waist-to-hip ratio compared to whites which has been 
associated with atherogenic lipid profile and dysglycemia despite having similar BMI. This is 
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mainly due to under development of the superficial subcutaneous adipose tissue in South Asians 
which results in fat deposition in the visceral adipose tissue (Patel et al., 2012a).  
The Southall and Brent studies in West London (Forouhi, 2006) showed that South Asians were 
younger (51.2 years versus 52.9 years, p<0.001)), had low BMI (25.9 kg/m
2
 versus 26.2 kg/m
2
) 
and lower cholesterol (5.8 mmol/l versus 5.9 mmol/l), p<0.001) than European men. The 
components of metabolic syndrome were more prevalent among South Asians compared to 
Europeans, waist circumference (93.3 cm versus 92.0 cm), fasting glucose (6.0 mmol/l versus 5.6 
mmol/l), low HDL-c (1.1 mmol/l versus 1.2 mmol/l), high triglyceride (1.7 mmol/l versus 1.4 
mmol/l) and more hypertensive (52% versus 39.9%), all p<0.001.  
In the study by Mckeigue (1991) mean waist-hip circumference ratio was higher in South Asians 
compared to Europeans in the UK. Waist hip circumference ratio in South Asian men and women 
were 0.98 (95% CI 0.97-0.98) and 0.85 (0.84-0.86) compared to 0.94 (0.93-0.94) and 0.76 (0.75-
0.77) in European men and women respectively. In South Asians, waist-hip girth ratio positively 
correlated with insulin, glucose tolerance, blood pressure and triglyceride. The study concluded 
that the higher prevalence of insulin resistance syndrome along with central obesity amongst 
South Asians in the UK might predisposes this group to diabetes and excess risk of CHD. 
Dhawan (1994) showed similar results in their study cohort. Waist to hip ratio was positively 
correlated to insulin and triglyceride levels and negatively to low HDL- c. Waist to hip ratio was 
the strongest independent predictor of  CHD in British Asians, relative risk 4.1 (95% CI 2.2 -7.7), 
p<0.0001. 
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1.4 .4 .3  Hypertens ion  
Cruickshank et al., (1983) investigated ethnic differences in blood pressure by studying factory 
workers aged 15-64 years in Birmingham, England. The prevalence of hypertension was 22% in 
Whites and 17% in South Asians. South Asian men had lower systolic (128.7 mmHg vs. 134.2 
mmHg) and higher diastolic blood pressure (79.9mmHg vs. 78.7mmHg) compared to Whites. In 
the Birmingham factory screening survey conducted by Lane et al., (2002), the prevalence of 
hypertension was similar in South Asian men and Whites (16% vs. 19.4%).  
In the study by Mckeigue (1988b) mean blood pressure were lower in Bangladeshis 119/78 
mmHg compared to 129/81 mmHg in Whites. Cruickshank (1991) compared 107 Indian 
Gujaratis and 101 White Europeans in West London and found the prevalence rate for 
hypertension was 32% and 20% respectively.   
Bhopal (1999) conducted a cross sectional study, the Health Survey of England to examine the 
prevalence of hypertension in 259 Indian, 305 Pakistani, 120 Bangladeshi and 825 European men 
and women aged 25-74 years in Newcastle upon Tyne. The prevalence of hypertension was lower 
in South Asians, 10% compared to 18% in Europeans. Amongst South Asians, Indians were more 
hypertensive compared to Pakistanis and Bangladeshis, 14% vs. 9% and 6% respectively. In the 
Whitehall II study (Whitty, 1999), the prevalence of hypertension was higher in South Asians, the 
odds of being hypertensive was 2.3 (95% CI 1.6-3.3) compared to the White population.  
In the Health Surveys for England study (Primatesta et al., 2000); between 1991-1996 the 
prevalence of hypertension amongst South Asians 40 years and above was 51% compared to 36% 
in Whites. The odds of being hypertensive was 1.9 (95%CI 1.4-2.4), p<0.001 in South Asian men 
compared to their White counterparts. In the Wandsworth Health Authority study (Cappuccio, 
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1997) in South London between 1994 to 1996, age and sex adjusted prevalence ratio for 
hypertension was 2.5 (95% CI 2.1 -3.2) in South Asians compared to Whites. The prevalence rate 
for hypertension in South Asians was 44% compared to 28% in Whites (Cappuccio et al., 1998).  
There are inconsistency in blood pressure and prevalence rates of hypertension in UK studies that 
have compared South Asians to White population. This is mainly attributed to the differences in 
age, sex of the samples, method of measuring blood pressure and definition of South Asians. The 
Health Survey of England study 1999 clearly showed the difference in hypertension within the 
South Asian group, with Indians having higher blood pressure compared to Pakistanis, and 
Bangladeshis having the lowest blood pressure (Bhopal, 1999; Agyemang and Bhopal, 2002).  
1.4 .4 .4  Smoking  
In the UK, smoking is more common amongst Bangladeshi men (49%) compared to Whites 
(29%), Pakistani (28%) and Indian (19%). In the community based qualitative study conducted 
by Bush et al., (2003) in 87 Bangladeshi and 54 Pakistani aged 18-80 years in Newcastle, 60% of 
Bangladeshi men and 51% of Pakistani men smoked. Smoking is considered to be socially 
acceptable in these groups.  
1.4 .4 .5  Abnormal  l ip id  prof i les  
The ‘Atherogenic lipid triad’ of high serum triglyceride levels and low serum HDL-c levels occur 
commonly in South Asians compared to Whites. More than half of the HDL in South Asians 
consist of dysfunctional pro-inflammatory HDL and have been associated with sub-clinical CHD 
(Dodani et al., 2008). 
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In the Whitehall II cohort study (Whitty, 1999) , the odds for being in the adverse quartile of risk 
for lipids amongst South Asian men were 0.89 (95% CI 0.71-1.0) for cholesterol, 2.1 (95% CI 
1.7-2.8) for HDL-c, 1.55 (95% CI 1.3 -1.9) for triglycerides and amongst South Asian women 
were 0.60 (95% CI 0.4-0.9) for cholesterol, 2.73 (95% CI 1.8-4.3) for HDL-c, 1.55 (95% CI 1.0- 
2.3) compared to White subjects. The levels of ApoB were also higher in South Asians compared 
to Whites, odds ratio being 1.33 (95% CI 1.1-1.7) in South Asian men and 1.26 (95% CI 0.8-1.9) 
in South Asian women.  
In the Child Heart and Health Study in England (CHASE), Donin et al., (2010) assessed blood 
lipid patterns in 2026 UK children who consisted of 285 black Africans, 188 black Caribbeans, 
534 South Asians and 512 white Europeans children. Compared to white Europeans, South Asian 
children had lower HDL-c, -0.7 mmol/l (95% CI, -0.11 - -0.03 mmol/l) and elevated triglyceride 
levels (proportional difference 0.14 mmol/l (95%CI, 0.09 – 0.20 mmol/l) and similar total and 
LDL cholesterol levels.  
Palaniappan et al., 2007 demonstrated in South Asian women that a highly atherogenic lipid 
profile was associated with insulin resistance. Insulin resistant women had higher levels of 
triglycerides (mean (SD) 151 (70) mg/dL vs. 93(42) mg/dL), lower HDL-c (44 (9) mg/dL vs. 53 
(9) mg/dL), lower HDL-c classes and smaller and dense LDL particle size compared to insulin 
sensitive women with no differences in total cholesterol and LDL-c between the two groups. 
Gasevic et al., (2012) investigated the clinical utility of triglyceride to HDL-c ratio (TG/HDL-C) 
in predicting insulin resistance in 4 ethnic groups – Aboriginals, Chinese, Europeans and South 
Asians. The performance of TG/HDL-C as a discriminator of insulin resistance on ROC analysis 
was area under curve (95% CI) 0.777 (0.707 -0.847) in Aboriginals, 0.723 (0.647-0.798) in 
Chinese, 0.752 (0.675-0.828) in Europeans and 0.676 (0.590-0.762) in South Asians. The 
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TG/HDL-C ratio was not a good marker for the identification of insulin resistance in South 
Asians compared to the other groups.  
Patel et al., (2010) demonstrated that fasting serum triglycerides were the best discriminator of 
metabolic and CHD risk in South Asians of all lipid and lipoprotein variables. Fasting 
triglycerides discriminated South Asians with obesity, raised blood pressure, fasting glycaemia, 
hyperinsulinaemia, metabolic syndrome and raised CHD risk score from healthy subjects with a 
mean area under curve of 0.683 (0.564-0.879), all p≤0.001. 
1.4 .4 .6  Lack of  phys ica l  act iv ity   
Williams et al., (2011a) compared physical activity levels on the Health Survey for England 
(1999-2004) participants, 5421 South Asians and 8974 Whites aged 18-55 years. The total 
physical activity metabolic equivalents of task scores were lower in South Asians compared to 
White participants in the UK, 973 vs.1465 –min/week, p<0.001, this was irrespective of 
individual sociodemographic factors. The same group then performed a longitudinal 
observational study with follow up mortality data on 13,293 Whites and 2120 South Asians aged 
≥ 35 years who participated in the Health Survey for England study. South Asians were more 
physically inactive compared to White participants (28.1% vs. 47%). Mortality data showed 
deaths from CHD occurred more in UK South Asians, mainly in those of Pakistani and 
Bangladeshi origin compared to UK Whites (HR 2.87, 95% CI 1.74 - 4.73). Lack of physical 
activity explained >20% of the excess CHD mortality observed amongst UK South Asians even 
after adjustment for potential confounding factors (William et al., 2011b)      
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1.4.5  Problems and challenges for cardiovascular disease risk 
assessment in South Asians  
The burden of CVD is more prominent amongst South Asians compared to the general 
population in the UK where the rates of CVD mortality is 40% higher in South Asians compared 
to the indigenous white population (Gill et al., 2007). The underlying pathophysiology for this 
increased risk of CVD is not clear. The higher prevalence of diabetes mellitus and elevated levels 
of triglycerides do reflect an increased risk of CVD in South Asians (Patel, 2008a; Patel, 2010). 
However the onset of CVD events is much earlier in life amongst South Asians and is often 
accompanied by the absence of traditional CVD risk factors such as hypertension and elevated 
serum lipids (Patel, 2008a; Patel, 2012a). Karthikeyan et al., (2009) demonstrated in the 
INTERHEART study that the risk of MI is higher in South Asians despite optimal levels of LDL-
c and suggested a lower threshold for LDL-c for this ethnic group. In this study apolipoproteins 
which are not included in the CVD risk assessment showed strongest association with the risk of 
MI in South Asians.  
The primary prevention of CV events using established risk estimation strategies based on the 
Framingham equation underestimates risk in South Asians. Cappuccio et al., (2002) demonstrated 
in a population based cross sectional study in the UK that the 10 year CHD risk score based on 
Framingham equation underestimated CVD risk in South Asians when compared to the general 
population and suggested a lower threshold for the CHD risk score in South Asians. In the 
Newcastle Heart Project, Bhopal et al., (2005) explored the predictive ability of the Framingham 
and FINRISK risk prediction scores in South Asians where their performance were similar and 
agreed with the observed CHD SMR  in South Asians as a combined group but with substantial 
heterogeneity in sub groups. The risk prediction models overestimated CHD mortality rates in 
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Indian men and underestimated CHD mortality rates in Pakistani and Bangladeshi women 
suggesting the need to address heterogeneity of the South Asian population in cardiovascular 
healthcare.  
The Framingham based risk score has been recalibrated in order to extend its application to ethnic 
minority groups for instance ETHRISK, a web based risk score was proposed by Brindle et al., 
(2006) but it requires further validation in South Asians. The QRISK2 score has been 
recommended in South Asians where CVD risk estimated is multiplied by a factor of 1.4 
(National Institute for Health and Clinical Excellence, 2008). However CV events occur in South 
Asians at clinically insignificant levels of CVD risk scores and adjustment of CVD risk 
prediction scores based on ethnicity can lead to identifying high risk South Asians. Health 
inequalities in cardiovascular healthcare are further widened by cultural and social barriers faced 
by South Asians in the UK (Patel, 2012a). There is a need for exploring biomarkers that can 
identify South Asians at increased risk of CVD early. 
1.4.6  Haemoglobinopathies in South Asians 
Haemoglobin is an iron containing protein in red blood cells that delivers oxygen from the lungs 
to peripheral tissues and is a tetramer made up of two pairs of alpha and non-alpha globin chains 
(β, δ, γ). The globin chain is coded by the HBA1 and HBA2 genes on chromosome 16p13.3 while 
the non-alpha globin chains are coded by the HBB gene on chromosome 11p15.5 (Trent, 2006). 
Figure 15 shows the structure of haemoglobin and figure 16 shows the globin gene loci. In a 
normal adult, ~95% of the haemoglobin is HbA (α2β2), 2-3% is HbA2 (α2δ2) and less than 1% is 
HbF (α2γ2) (Ryan et al., 2010). 
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figure 15 Structure of haemoglobin 
 
Haemoglobin consists of two pairs of α and β globin chains made of 141 and 146 amino acid residues 
respectively (in red and blue). The globin chains are coordinated to four oxygen binding iron containing haem 
groups (in green). Reproduced from Protein database ID- 1GZX  
 
 
figure 16 The globin gene loci 
 
Beta globin locus-The two gamma genes produces Hb F & is active only during fetal growth, after birth beta 
gene is activated. Alpha globin locus- All four genes contribute to the production of alpha globin chains. 
      Reproduced from http://sickle.bwh.harvard.edu/hbsynthesis.html 
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Haemoglobinopathies are inherited autosomal recessive disorders and are due to mutations in 
genes coding for the globin proteins which either results in the underproduction of normal globin 
chains known as the thalassemia syndromes or synthesis of structurally abnormal globin chain 
known as variant Hbs. In very few cases haemoglobin disorders can be characterized by both 
phenotypes for example Hb E. (Old et al., 2003). 
Thalassemias are further classified based on the genes involved into α and β thalassemias and sub 
divided based on whether some or no globin proteins are produced (α+, β+ or αo, βo) (Trent, 
2006). In beta thalassmia, reduced or no synthesis of beta globin chains leads to excess synthesis 
of alpha chains (Marengo-Rowe, 2007). Beta thalassemia is particularly common in subjects 
from the Indian subcontinent with a carrier rate of 3-17% while alpha thalassemia is less 
prevalent in this region (Panigrahi and Marwaha, 2007).  
1.4 .6 .1  Common haemoglobinopathies  in South Asian s 
It is beyond the scope of this thesis to go into details on all the haemoglobin disorders found in 
the Indian subcontinent. Common clinically significant variants Hbs and beta thalassemia 
mutations are shown in table 14.  
Table 14 Common  haemoglobinopathies in the Indian subcontinent  
Variants Hb 
Hb S 
Hb C 
Hb D-Punjab 
Hb E 
Hb J 
Hb H 
Hb O-Arab 
Hb Lepore (αδ) 
Beta thalassemia mutations  
IVS1-5 (G-C) (frequency 63.17%) 
619 base pair deletion (3.75%) 
IVS 1-1 (G-T) (2.71%) 
CD 41/42 (-CTTT) (3.49%) 
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CD 15 (G-A) (7.83%) 
CD 16 (-C) (A-T) 
CD 17 
CD 30 (G-C) (4.33%) 
CD 8/9 (+G) (1.42%) 
Capsite + (A-C) 
Poly A (T-C) (3.55%) 
(Old, 2003; Edison et al., 2008; Sachdev et al., 2010) 
1.4 .6 .2  Diagnos is  o f  haemoglobinopathies   
Various tests involved in the diagnosis of haemoglobinopathies are shown in table 15.  
Table 15 Diagnosis of haemoglobinopathies 
Full blood count 
 
Thalasssemias reflected by low MCV (mean corpuscular volume) and 
MCH <27pg (mean corpuscular haemoglobin). 
Variants Hb normally have normal MCV and MCH for e.g. Hb S 
which will require a blood film. 
Note: Iron deficiency anaemia should be excluded. Abnormal FBC 
and/or  family history should be further investigated 
Haematological tests  HbEPG test involves electrophoresis of globin proteins on 
gel, membrane based kits or HPLC. Abnormal bands help to 
identify variants Hb. 
 HbA2 test involves globin electrophoresis and quantitation 
of HbA2 peak on HPLC. Elevated HbA2 indicate β 
thalassemia 
 HbF test involves globin electrophoresis and quantitation of 
HbF peak on HPLC. Slightly raised HbF indicate silent β 
thalassemia.  
 Mass spectrometry is ideal for population screening and 
characterise various variant Hbs.  
 
DNA testing  This is done when haematological tests fail to identify 
haemoglobinopathies or to confirm a diagnosis by identifying 
specific mutation.  
Chan and colleagues (2010) described a two stage DNA based test for 
the identification of the most prevalent β thalassemia mutations.  
Trent, 2006 
1.4 .6 .3  Evolut ion of  haemoglobinopathies  in  South 
Asians 
The prevalence of haemoglobinopathies is mostly concentrated in malarial and tropical regions 
such as the Indian subcontinent and has been associated with an evolutionary benefit of 
protection against malaria in carriers or heterozygotes. According to the “malaria hypothesis” 
‘this could result in a “balanced polymorphism” where the homozygote’s haematological 
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disadvantage is balanced by the resistance to malaria displayed by the heterozygote’ (Haldane, 
1949: Lopez et al., 2010). Resistance to malaria is mainly due to enhanced immune response to 
parasite infected erythrocytes and erythrocyte abnormalities provide poor environment for 
parasite invasion and growth (Pasvol et al., 1978; Ayi et al., 2004).    
On the other hand, carriers of beta thalassemia trait exhibit aberrant erythropoiesis and 
haemolysis which leads to mild anaemia and iron loading (Weatherall, 2000) which could 
potentially increase the risk of CVD in this group (Sullivan, 1981). However, studies by Maioli et 
al., (1989 & 1997) demonstrated that carriers of beta thalassemia trait exhibit lower total 
cholesterol, LDL-c and ApoB levels and hence lower risk of CVD. Case-control studies in non-
Asian populations (Wang and Schilling, 1985; Crowley et al., 1987) have demonstrated a lower 
prevalence of beta thalassemia trait in patient with MI compared to controls. However the link 
between haemoglobinopathies such as Hb variants, beta thalassemia trait and risk of CVD has not 
been explored in South Asian population.    
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CHAPTER 2 AIMS AND HYPOTHESIS 
2.1  General  aims and hypothesis    
CVD is the leading cause of death in Britain, but compared to the general population, the burden 
is more prominent amongst the country’s ethnic minorities (Gill, 2007). The classic 
cardiovascular risk factors – hypertension, diabetes and smoking play a central role in the 
prevention of CVD, however many individuals susceptible to heart disease exhibit one or none of 
the above mentioned risk factors (Gerszten and Wang, 2008). On-going Government initiatives 
highlight an urgent need to have targeted CVD risk management for these groups. Even though 
we can diagnose CVD using clinical tools, our prediction of CVD risk remains poor (Raleigh et 
al., 1997; Vasan, 2006) and is likely to be underestimated in high-risk groups such as South 
Asians (McEwan et al., 2004; Brindle et al., 2005: Patel et al., 2007). In recent years, there has 
been a surge in the evaluation of the prognostic value of circulating biological markers or 
‘biomarkers’–measurable and quantifiable biological parameters that can aid clinicians in CVD 
disease management, risk stratification and prevention. The main aim of this thesis is to evaluate 
the performance of such blood biomarkers and genetic based markers in identifying South Asians 
with an increased risk of CVD from those who are asymptomatic for CVD. Secondly, to 
determine if haemoglobinopathies which are highly prevalent amongst the South Asian 
population contribute to increased risk of CVD.  
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2.1.1  Hypothesis 1- The blood biomarker study   
The study hypothesis is that South Asians with CVD risk factors and existing CVD events will 
have high levels of biomarkers of inflammation (CRP, IL-6), endothelial dysfunction (vWF), 
thrombosis (D-dimer) and coagulation (P-selectin) compared to healthy South Asians. The study 
also hypothesized that South Asians with HF will have abnormal levels of biomarker of cardiac 
function (BNP) compared to healthy South Asians. The performance of each biomarker will be 
evaluated using ROC analysis. ROC curve analysis will be performed initially in South Asians 
asymptomatic for CVD and then will be validated in a group of South Asians with CVD risk 
factors (on medication for anti-hypertensive, anti –diabetic or lipid lowering therapy) and existing 
CVD events.  
2.1.2  Hypothesis 2 -The genetic study 
This study investigates the genetic susceptibility of South Asians towards phenotypic markers of 
inflammation and metabolic disorders and also to increased risk of CVD. The study hypothesis is 
that abnormal levels of biomarkers of inflammation (CRP, IL-6) and metabolic disorder (lipid 
profiles) are associated with specific genetic polymorphisms -390C>T>A (rs3091244) within the 
promoter region of CRPgene, -174G>C (rs1800795) within the promoter region of IL-6 gene,  -
455T>C (rs2854116) and -482C>T (rs2854117) within the insulin response element on APOC3 
gene and -1131T>C (rs662799) on APOA5 gene. The prevalence of these genetic polymorphisms 
is different from those reported in other ethnic groups.  
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CHAPTER 3 METHODS 
3.1  Study populat ion  
This section gives an overview of the study population for the two main studies in this thesis –the 
blood biomarker study and the genetic study.  
3.1.1  The blood biomarker study 
The study population for the blood biomarker study consisted of subjects of South Asian origin in 
the UK originating from India, Pakistan and Bangladesh. A total of 1222 South Asians aged 45 
years and over were recruited through the Ethnic-Echocardiographic Heart of England Screening 
Study (E-ECHOES) (Gill, 2009).  
3.1 .1 .1  The Ethnic -Echocardiographic Heart  of  England 
Screening Study  (E -ECHOES)-  The  blood biomarker  
s tudy  
The E-ECHOES (Gill, 2009) is a population based epidemiology study which was conducted 
within the West Midlands in the UK from September 2006 to August 2009. The aim of the study 
was to establish the prevalence and severity of LVSD and HF amongst South Asian and Black 
African-Caribbean ethnic groups within the West Midlands. This study was purely observational. 
A sub study –blood biomarkers was conducted to explore 2 aspects of HF physiology, which 
have pathophysiological and prognostic implications. Firstly, BNP testing has been proposed as a 
screening test for cardiac and HF and a risk marker for CVD, but there are no substantial 
population-based data relating to South Asians. Secondly, abnormal inflammatory indices (IL-6 
and CRP), endothelial dysfunction (vWF), coagulation (P-selectin) and thrombosis (D-dimer) are 
present in HF, and have prognostic implications. Again, there are no substantial population-based 
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data relating to non-white ethnic groups, nor any exploration of the inflammatory stimuli of the 
endothelium and thrombogenesis or the genetic susceptibility to these disorders (British Heart 
Foundation grant application, PG/05/036). The study protocol (05/Q2708/45) was approved by 
the Walsall Local Research Ethics Committee and a written consent was obtained from all study 
participants. 
Note: The study protocol and all study related documents were prepared by the Principal and 
Chief investigators for the E-ECHOES.  
Detailed description of the E-ECHOES including subject recruitment, study protocol, subject 
characteristics: demographic details, clinical and medication history are shown in section 
3.1.1.1.1.   
In the total of 1222 subjects, 505 were South Asians asymptomatic for CVD (this included high 
risk subjects but who were unaware of it until the assessment), 519 South Asians were 
symptomatic for CVD risk (on medication for modifiable CVD risk factors namely for high 
blood pressure, diabetes mellitus and abnormal lipid profiles) and 198 subjects were with existing 
CVD events (figure 17).  
figure 17 Subjects in the blood biomarker study 
 
                                                           South Asians asymptomatic for CVD, n =276 
 
Men, n = 702                                                   South Asians with  CVD risk factors, n =294 
  
                                                           Existing CVD, n =132 
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                                                            South Asians asymptomatic for CVD, n =229 
 
Female, n=520                                               South Asians with CVD risk factors, n =225 
                                                  
                                                            Existing CVD, n = 66         
South Asians asymptomatic for CVD were South Asians who were not on any medication for modifiable CVD risk 
factors at recruitment. South Asians with CVD risk factors were South Asians on medication for modifiable CVD risk 
factors such as on anti hypertensive, anti-diabetic and lipid lowering therapies.  
3 .1 .1 .1 .1  Subject  recru i tment   
General practices within Birmingham with a high proportion of ethnic minority patients were 
identified and eligible subjects were selected by sex and aged 45 years and over from the practice 
age-sex registers. South Asian subjects were identified from the practice list using the Nam 
Pechan software which screens for South Asian names. The general practitioner then reviewed 
the list to ensure the ethnicity of the selected subjects and excluded anyone whom they consider 
inappropriate for the study. Invitation letters were then sent to potential subjects inviting them to 
attend their practice. The ethnicity of the selected subject was again confirmed before booking an 
appointment with the help of an interpreter where required (Gill, 2009). Figure 18 shows the 
recruitment process for the E-ECHOES. 
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figure 18 Recruitment process for the E-ECHOES 
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 Invitation letters                               Telephone reminder                                                                                                  
 
 
  
                                  Arrange screening 
 
 
  
 Screening                        Analysis and write up 
 
 
 
 Send reports to GP 
 
Adapted from Gill, 2009 
3 .1 .1 .1 .2  Study  Protocol  
Subjects were invited to participate in the study at their local general practice and written 
informed consent was obtained. At the clinic, the research team collected data using a 
standardised protocol comprised of a questionnaire which incorporated details on demography 
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and clinical history, physical examination, and electrocardiography and echocardiography 
examination. Blood sampling was done for those who gave consent for the blood sub-study.  
Note: Clinical research fellows were actively involved in the recruitment for this study and 
provided me the samples for my thesis. 
 
Table 16 Study protocol  
 Details obtained 
Patient information sheet and consent form Trained research fellows obtained written consent 
from all study subjects 
Questionnaire Included details on age, date of birth, address,  
post-code, self-determined ethnicity, religion, place 
of birth, migration history, languages spoken, level 
of education, alcohol consumption, cigarette 
smoking, tobacco use, exercise assessment, history 
of illness/ co-morbidity (myocardial infarction,  
angina, hypertension, heart failure, stroke, diabetes) 
in self and family and current medication 
Physical examination Standardised anthropometric measurement–Height & 
weight (Seca Ltd, Birmingham UK), body mass 
index and waist measurement.  
Blood pressure were undertaken three times using  
the OMRON 705CP (Omron Healthcare Europe, 
Mannheim, Germany). 
Electrocardiography (ECG) and echocardiography  
Examination 
Performed by trained research fellows  
For ECG investigation, a resting 12 lead ECG  
(Mortara ELI 150) was recorded & coded  
independently by two cardiologist using the 
Minnesota criteria. 
Measurement of left ventricular ejection fraction and 
function by echocardiography  using a portable 
VIVID I machine (GE Healthcare, Chalfont St Giles, 
UK). The presence and degree of left ventricular 
hypertrophy was assessed from chamber dimensions. 
Left ventricular function was measured objectively 
using an area-length method from the apical four- 
chamber view. In cases where an objective 
measurement of left ventricular ejection fraction is 
not possible, a qualitative assessment was made, that 
is, definite impairment (LVEF <40%), borderline 
(40-50%) and preserved (>50%), consistent with the 
investigators' normal clinical practice 
Blood sampling with consent Samples were collected in EDTA treated, citrate 
treated and serum blood tubes and were  transported  
to Centre for Cardiovascular sciences, City Hospital  
for processing and storage at -70
o
c for batch analysis. 
(HbA1c & full blood count  analysis were done on  
the same day of sampling.  
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Plasma and serum samples for lipid profiles, liver 
enzymes, blood biomarkers and genetic analysis 
were stored at -70
o
c for batch analysis)  
 
 
3 .1 .1 .1 .3  Response  ra te   
The overall response rate to the E-Echoes was 56% and response rate to blood sampling was 
50%.  
3 .1 .1 .1 .4  Subject  character i s t i cs :demograph ic  deta i l s ,  c l in i ca l  and 
med icat ion  h i s tory   
3.1.1.1.4.1 Demographic details 
A total of 1222 subjects were randomly selected from a large sample of 3441 South Asian  for 
my thesis, of them 702 were men (mean age 58.0 years) and 520 were women (mean age 57.0 
years). Details of their ethnicity (self-determined) are shown in table 17. There were six ethnic 
groups, namely Indian or British Indian, Pakistani or British Pakistani, Bangladeshi or British 
Bangladeshi, East African Asian, Sri Lankan and other Asian background. The mean age for the 
study subjects when they migrated to the UK was mean (SD), 21.3 (12.0) years for men (n=688) 
and 25.0 (12.1) for women (n=507). The mean age for subjects when they left school was mean 
(SD), 15.3 (2.4) years for men (n=615) and 14.2 (3.0) years for women (n =352). Details on 
alcohol consumption and smoking are shown in table 18.  
Table 17 Ethnic groups of  the study participants 
Male, n = 702 (mean age 58 years) 
Ethnic groups Number of subjects (%) 
Indian/British Indian 328 (46.7) 
Pakistani/British Pakistani 257 (36.6) 
Bangladeshi/British Bangladeshi 67 (9.5) 
East African Asian 43 (6.1) 
Other Asian background 7 (0.9) 
Female, n = 520 (mean age 57 years) 
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Indian/British Indian 270 (51.9) 
Pakistani/British Pakistani 166 (31.9) 
Bangladeshi/British Bangladeshi 52 (10) 
East African Asian 28 (5.4) 
Sri Lankan 1 (0.2) 
Other Asian background 3 (0.6) 
 
Table 18 Alcohol consumption and smoking for the study cohort 
Male, n = 702 (mean age 58 years) 
No, always a non-drinker 351 (28.7) 
No, used to drink but stopped (over 12 months ago) 105 (8.6) 
Yes, but very occasionally 175 (14.3) 
Yes 71 (5.8) 
Current smokers 116 (16.5) 
Female, n = 520 (mean age 57 years) 
No, always a non-drinker 471 (38.5) 
No, used to drink but stopped (over 12 months ago) 7 (0.6) 
Yes, but very occasionally 39 (3.2) 
Yes 3 (0.2) 
Current smokers 8 (1.5) 
 
3.1.1.1.4.2 Details on Medication   
The questionnaire used during the screening process included details on current medication. The 
medication were broadly categorised into diuretics, beta blockers, ACE inhibitors, anti-
arrhythmic drugs, positive inotropic drugs, lipid lowering drugs, calcium channel blockers, anti 
thrombotic agents, anti-coagulants, angiotensin-II receptor antagonists, alpha-adrenoceptor 
blocking drugs, nitrates and anti-diabetic drugs.  
Table 19 Medication history for the study population 
Male, n = 702 (mean age 58 years) 
Drug category Number of subjects (%) 
Diuretics 94 (13.4) 
Beta blockers 95 (13.5) 
ACE inhibitors 180 (25.6) 
Anti-arrhythmic drugs 1 (0.14) 
Positive inotropic drugs 1 (0.14) 
Lipid lowering drugs 301 (43.0) 
Calcium channel blockers 119 (17.0) 
Anti thrombotic agents 118 (16.8) 
Anti-coagulants 0 
Angiotensin-II receptor antagonists 55 (7.8) 
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Alpha-adrenoceptor blocking drugs 22 (3.1) 
Nitrates 31 (4.4) 
Anti-diabetic drugs 159 (23.0) 
Female, n = 520 (mean age 57 years) 
Diuretics 85 (16.3) 
Beta blockers 60 (11.5) 
ACE inhibitors 85 (16.3) 
Anti-arrhythmic drugs 0 
Positive inotropic drugs 2 (0.4) 
Lipid lowering drugs 180 (34.6) 
Calcium channel blockers 64 (12.3) 
Anti thrombotic agents 53 (10.2) 
Anti-coagulants 1 (0.2) 
Angiotensin-II receptor antagonists 52 (10) 
Alpha-adrenoceptor blocking drugs 6 (1.2) 
Nitrates 11 (2.1) 
Anti-diabetic drugs 100 (19.2) 
3.1.1.1.4.3 Clinical History  
The history of co-morbidity in self and family was recorded. The number of subjects with co-
morbidities namely hypertension (130/85 mmHg and/or anti-hypertensive drugs), arrhythmias, 
angina, MI, HF, diabetes mellitus (HbA1c >6.5% and/or anti-diabetic drugs), peripheral artery 
disease, stroke and TIA (self-reported) are shown in figure 19.  
figure 19 Details on co-morbidities-(E-ECHOES -The Biomarker study) 
 
                                                                                Hypertension, n=606 
                                                                                    Arrythmias, n =11 
                          Angina, n =79                            
                                                                                   Myocardial infarction, n =67     
                                                                                   
Male, n = 702                                                             Heart failure, n =6        
                                                                                   Diabetes mellitus, n =427       
 
                                                   Peripheral artery disease, n =2 
                     Stroke, n =24  
                TIA, n =10 
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                                                                                Hypertension, n=421 
                                                                                    Arrythmias, n =4 
                          Angina, n =37                     
                                                                                   Myocardial infarction, n =24 
                                                                                   
Female, n = 520                                                                Heart failure, n =6      
                                                                                   Diabetes mellitus, n =295   
 
                                                   Peripheral artery disease, n =1 
                     Stroke, n =10 
                TIA, n =11 
 
3.1 .1 .2  Power ca lculat ion  
Sample sizes for ROC analysis were estimated from published tables (Obuchowski, 2000). At a 
5% type I error rate, and 80% power, we estimated that 229 patients would be sufficient to detect 
moderate differences [10% difference in area under the curve (AUC)] in the performance of 
blood biomarkers at discriminating those with increased risk of CVD, assuming the curves to 
have a moderate accuracy (sensitivity of 0.60 and at a false-positive rate of 0.10).  
                                           
3.1.2  The genetic study 
The study population for the genetic study were from two main studies involving South Asian 
population in the department, namely E-ECHOES and Niaspan: Indo-Asian Stroke patient 
Atherosclerotic Regression trial (NIASTAR). Detailed description of the Niastar trial and subject 
characteristics from each study: demographic details, clinical and medication history are shown 
in section 3.1.2.1.  
A total of 1053 were included in the genetic study, 804 were South Asians asymptomatic for 
CVD (this included high CVD risk subjects on medication for modifiable CVD risk factors 
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namely for high blood pressure, diabetes mellitus and abnormal lipid profiles) and 247 South 
Asians were with existing CVD events (figure 20).  
figure 20 Subjects in the genetic  study 
 
                                                           South Asians asymptomatic for CVD, n =434 
 
Men, n = 602                                                  
  
                                                           Existing CVD, n =168 
                                                            South Asians asymptomatic for CVD, n =370 
 
Female, n=449                                               
                                                  
                                                            Existing CVD, n = 79  
South Asians asymptomatic for CVD where South Asians who were not on any medication for modifiable CVD risk 
factors at recruitment. 
3.1 .2 .1  Subject  character is t ics :demographic  deta i l s ,  
c l in ical  and medicat ion his tory -  E-ECHOES study 
3 .1 .2 .1 .1  Demographic  deta i l s  
A total of 954 subjects were randomly selected for the genetic study, of them 532 were men 
(mean age 58.0 years) and 419 were women (mean age 57.0 years). Details of their ethnicity 
(self-determined) are shown in table 20. There were six ethnic groups, namely Indian or British 
Indian, Pakistani or British Pakistani, Bangladeshi or British Bangladeshi, East African Asian, Sri 
Lankan and other Asian background.  
Table 20 Ethnic groups of  the study participants 
Male, n = 532 (mean age 58.0 years) 
Ethnic groups Number of subjects (%) 
Indian/British Indian 253 (48.0) 
Pakistani/British Pakistani 190 (36.0) 
Bangladeshi/British Bangladeshi 53 (10.0) 
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East African Asian 32  (6.0) 
Other Asian background 4  (0.8) 
Female, n = 419 (mean age 57.0  years) 
Indian/British Indian 213 (51.0) 
Pakistani/British Pakistani 143 (34.1) 
Bangladeshi/British Bangladeshi 39 (9.3) 
East African Asian 21 (5.0) 
Sri Lankan 1 (0.2) 
Other Asian background 1 (0.5) 
 
3 .1 .2 .1 .2  Deta i l s  on  Medicat ion  
The questionnaire used during the screening process included details on current medication. The 
medication were broadly categorised into diuretics, beta blockers, ACE inhibitors, anti-
arrhythmic drugs, positive inotropic drugs, lipid lowering drugs, calcium channel blockers, anti 
thrombotic agents, anti-coagulants, angiotensin-II receptor antagonists, alpha-adrenoceptor 
blocking drugs, nitrates, anti-hyprtensive and anti-diabetic drugs.  
Table 21 Medication history for the study population 
Male, n = 532 (mean age 58.0 years) 
Drug category Number of subjects (%) 
Diuretics 67 (13.0) 
Beta blockers 71 (13.3) 
ACE inhibitors 131 (24.6) 
Anti-arrhythmic drugs 0 
Positive inotropic drugs 0 
Lipid lowering drugs 175 (33.0) 
Calcium channel blockers 84 (16.0) 
Anti -platelet agents 83 (16.0) 
Anti-coagulants 0 
Angiotensin-II receptor antagonists 39 (7.3) 
Alpha-adrenoceptor blocking drugs 20 (4.0) 
Nitrates 23 (4.3) 
Anti-diabetic drugs  93 (18.0.) 
Female, n = 419 (mean age 57.0 years) 
Diuretics 64 (15.3) 
Beta blockers 43 (10.3) 
ACE inhibitors 65 (16.0) 
Anti-arrhythmic drugs 0 
Positive inotropic drugs 2 (0.5) 
Lipid lowering drugs 121 (29.0) 
Calcium channel blockers 55 (13.1) 
Anti platelet agents 39  (9.3) 
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Anti-coagulants 1 (0.2) 
Angiotensin-II receptor antagonists 44 (11.0) 
Alpha-adrenoceptor blocking drugs 5  (1.2) 
Nitrates  7 (2.0) 
Anti-diabetic drugs 63 (15.0) 
3 .1 .2 .1 .3  Cl in ica l  Hi s tory  
The history of co-morbidity in self and family was recorded. The number of subjects with co-
morbidities namely hypertension (blood pressure 130/85mmHg and/or on anti-hypertensive 
medications), arrhythmias, angina, MI, HF, diabetes mellitus (HbA1c >6.5% and/or on anti-
diabetic medications), peripheral artery disease, stroke and TIA (self-reported) are shown in 
figure 21.  
figure 21 Details on co-morbidities (E-ECHOES -The Genetic study) 
 
                                                                                Hypertension, n=441 
                                                                                    Arrythmias, n =7 
                          Angina, n = 61                  
                                                                                   Myocardial infarction, n = 51   
                                                                                   
Male, n = 532                                                             Heart failure, n =2 
                                                                                   Diabetes mellitus, n =  325 
 
                                                   Peripheral artery disease, n =1 
                     Stroke, n = 14 
                TIA, n =7 
 
 
 
                                                                                Hypertension, n=337 
                                                                                    Arrythmias, n =3 
                          Angina, n =27                     
                                                                                   Myocardial infarction, n =17 
                                                                                   
Female, n = 419                                                                Heart failure, n =3      
                                                                                   Diabetes mellitus, n = 236 
 
                                                   Peripheral artery disease, n =0 
                     Stroke, n =7 
                TIA, n =10 
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3.1 .2 .2  NIASTAR TRIAL:  Eff icacy  and Safety  of  
Niaspan in  South Asian Stroke  Survivors   
 
The NIASTAR trial was a randomised, double blind, placebo-controlled study comparing the 
efficacy and safety of co-administration of Niaspan (1000-2000 mg) with Simvastatin (10-40 mg) 
versus placebo with Simvastatin (10-40 mg) amongst 280 stroke patients of South Asian origin.  
The study was authorised by Medicines and Healthcare products Regulatory Agency (MHRA) 
(Eudract no. 2005-004080-28). The protocol was approved by the Oxfordshire Research Ethics 
Committee and written informed consent was obtained from all study participants. All 
participants were of South Asian origin in the UK originating from India, Pakistan and 
Bangladesh with a prior history of stroke or TIA. The participants were recruited from the stroke 
unit at Sandwell and West Birmingham Hospitals, NHS trust.  
Note: The study participants for the NIASTAR trial were recruited by the research team at 
Sandwell Medical Research Unit 
3 .1 .2 .2 .1  Subject  characteri s t i cs :  demographic  deta i l s ,  c l in i ca l  and 
med icat ion  h i s tory -  NIASTAR TRIAL  
3.1.2.2.1.1 Demographic details 
A total of 102 South Asian subjects with stroke were selected from the NIASTAR trial for the 
genetic study, of them 71 were men (mean age 62.0 years) and 30 were women (mean age 66.0 
years). Details of their ethnicity (self-determined) are shown in table 22. 
Table 22 Ethnic groups of  the study participants 
Male, n = 71 (mean age 62.0 years) 
Ethnic groups Number of subjects (%) 
Indian/British Indian 43 (69.4) 
Pakistani/British Pakistani 17 (27.4) 
Bangladeshi/British Bangladeshi 2 (3.23) 
Female, n = 30 (mean age 66.0 years) 
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Indian/British Indian 17 (71.0) 
Pakistani/British Pakistani 5 (21.0) 
Bangladeshi/British Bangladeshi 2 (8.33) 
Ethnicity - Self reported or based on names, was available only for 62 men and 24 women  
3.1.2.2.1.2 Details on Medication  
All participants provided details on their current medications as per the study protocol. The 
medication were broadly categorised into diuretics, beta blockers, ACE inhibitors, anti-
arrhythmic drugs, positive inotropic drugs, lipid lowering drugs, calcium channel blockers, anti 
thrombotic agents, anti-coagulants, angiotensin-II receptor antagonists, alpha-adrenoceptor 
blocking drugs, nitrates, anti-hypertensive and anti-diabetic drugs. Table 23 shows the 
medication history for the study population. 
Table 23 Medication history for the study population 
Male, n = 71 (mean age 62.0 years) 
Drug category Number of subjects (%) 
Diuretics 13 (19.0) 
Beta blockers 13 (19.0) 
ACE inhibitors 43 (61.4) 
Anti-arrhythmic drugs 1 (1.4) 
Positive inotropic drugs 0 
Lipid lowering drugs 48 (70.0) 
Calcium channel blockers 15 (21.4) 
Anti -platelet agents 61 (87.1) 
Anti-coagulants 4 (6.0) 
Angiotensin-II receptor antagonists 0 
Alpha-adrenoceptor blocking drugs 5 (7.2) 
Nitrates  4 (6.0) 
Anti-diabetic drugs 28 (41.0) 
Female, n = 30 (mean age 66.0 years) 
Diuretics 12 (40.0) 
Beta blockers 10 (33.3) 
ACE inhibitors 18 (60.0) 
Anti-arrhythmic drugs 0 
Positive inotropic drugs 0 
Lipid lowering drugs 24 (80.0) 
Calcium channel blockers 10 (33.3) 
Anti platelet agents 26 (87.0) 
Anti-coagulants 4 (13.3) 
Angiotensin-II receptor antagonists 0 
Alpha-adrenoceptor blocking drugs 2 (7.0) 
Nitrates 3 (10.3) 
Anti-diabetic drugs 18 (60.0) 
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3.1.2.2.1.3 Clinical History  
The history of co-morbidity in self was recorded. The number of stroke subjects with co-
morbidities namely hypertension (blood pressure 130/85mmHg and/or on anti-hypertensive 
medications), MI, HF, diabetes mellitus (HbA1c >6.5% and/or on anti-diabetic medications) and 
peripheral artery disease are shown in figure 22. 
figure 22 Details on co-morbidities-(Niastar trial- The Genetic study) 
 
                                                                                Hypertension, n=64 
                                                                                                      
                                                                                   Myocardial infarction, n =  14 
                                                                                   
Male, n = 71                                                              Heart failure, n =3 
                                                                                    
                                                                                   Diabetes mellitus, n = 29                                                 
                                          
                                       
                                                         
                                                                                Hypertension, n=29 
                                                                                                      
                                                                                   Myocardial infarction, n = 5 
                                                                                   
Female, n = 30                                                              Heart failure, n =1 
                                                                                    
                                                                                   Diabetes mellitus, n =  18                                                 
                                            
3.1.3  Pilot data on abnormalities of beta globin gene and 
cardiovascular disease 
3.1 .3 .1  Subjects  character is t ics :  demographic  deta i ls ,   
medicat ion and c l in ica l  h is tory  
3 .1 .3 .1 .1  Demographic  deta i l s  
A total of 156 South Asian subjects were included in this pilot study, of whom 84 control 
subjects were selected from E-ECHOES and 72 ischaemic stroke patients from NIASTAR trial 
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for this thesis, of them 98 were men (mean age 59.2 years) and 57 were women (mean age 58.1 
years).  Details of their ethnicity (self-determined) are shown in table 24. 
Table 24 Ethnic groups of the study population 
Ethnicity was missing for8 female subjects and 2 male subjects 
3 .1 .3 .1 .2  Deta i l s  on  Medicat ion   
The medication were broadly categorised into diuretics, beta blockers, ACE inhibitors, anti-
arrhythmic drugs, lipid lowering drugs, calcium channel blockers, anti-platelet therapy and anti-
diabetic drugs.  
Table 25 Medication history for the study population 
Male, n = 98 (mean age 59.2 years) 
Drug category Number of subjects (%) 
Diuretics 54 (55.1) 
Beta blockers 17 (17.3) 
ACE inhibitors 20 (20.4) 
Anti-arrhythmic drugs 26 (26.5) 
Lipid lowering drugs 72 (73.5) 
Calcium channel blockers 45 (46.0) 
Anti platelet drugs 59 (60.2) 
Anti-diabetic drugs 17 (17.3) 
Female, n = 57 (mean age 58.1years) 
Diuretics 26 (45.6) 
Beta blockers 16 (28.1) 
ACE inhibitors 19 (33.3) 
Anti-arrhythmic drugs 10 (17.5) 
Lipid lowering drugs 28 (49.1) 
Calcium channel blockers 23 (40.3) 
Anti-platelet drugs  26 (46.0) 
Anti-diabetic drugs 9 (15.8) 
 
Male, n = 98 (mean age 59.2 years) 
Ethnic groups Number of subjects (%) 
Indian/British Indian 49 (51.0) 
Pakistani/British Pakistani 32 (33.3) 
Bangladeshi/British Bangladeshi 9 (9.4) 
East African Asian 6 (6.3) 
Female, n = 57(mean age 58.1 years) 
Indian/British Indian 26 (53.1)) 
Pakistani/British Pakistani  14 (29.0) 
Bangladeshi/British Bangladeshi 7 (14.3) 
East African Asian  2 (4.1) 
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3.2  Preparation  of  p lasma and serum from whole  blood  
Blood samples were obtained from patients who gave written informed consent for E-ECHOES 
sub-study –blood biomarkers. Blood were collected in EDTA treated, citrate treated and serum 
tubes (Sarstedt, Germany) and were stored at 4
o
C prior to transportation from the General 
Practices within West Midlands to the laboratory at the Centre for Cardiovascular Sciences, City 
Hospital by the research team at the end of each day. The blood tubes were spun at 3000 rpm for 
15 minutes in a refrigerated centrifuge at 4
o
C. Serum and plasma were then aliquoted into 
eppendorfs, labelled appropriately with patient’s unique study ID, date of collection and nature of 
sample i.e. serum, EDTA treated plasma, citrated plasma. The serum and plasma samples were 
then stored at -70
o
C freezer at the Centre for Cardiovascular sciences, City Hospital until batch 
analysis for blood biomarkers. Full blood count was analysed on fresh EDTA treated whole blood 
samples before storage at -70
0
C for DNA extraction.    
3.3  Measurement  of  biochemical  measures ,  l ipid prof i les  and 
plasma biomarkers  on automated systems  
3.3.1  Basic biochemical  tests  
All biochemical measures which included liver enzymes (alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), γ-glutamyltransferase (GGT) & alkaline phosphatise), kidney 
function test (creatinine), lipid profiles (ApoAI, ApoB, total cholesterol, HDL-c, LDL-c & 
triglycerides), iron and glycated haemoglobin (HbA1c) were determined in serum samples batch 
wise on automated auto-analyser (COBAS Integra 400 plus, Roche Diagnostics, UK) as per 
manufacturer’s intructions. Full blood count was measured on fresh EDTA treated whole blood 
samples on ADVIA 120 Haematology system (Siemens, UK).  
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3.3 .1 .1  Calculated  Trig lycer ides  
Calculated triglyceride was determined using the Friedwald formula (Friedewald, 1972); 
Triglycerides = 2.2 × (CHOL-HDL-C-LDL-C) 
3.3.2  Plasma biomarkers   
3.3 .2 .1  High sensi t iv i ty  C-reacyive  protein  
The acute phase reactant was determined by particle enhanced turbidimetric assay (COBAS Integra 
400 plus, Roche Diagnostics, UK). The assay quantitatively determines human CRP concentration in 
serum, human CRP agglutinates with latex particles coated with monoclonal anti-CRP antibodies. 
The precipitate is determined turbidmetrically at 552 nm. The lower detection limit for this assay is 
0.71 mg/L. The test was calibrated with Calibrator f.a.s. proteins (Roche Diagnostics, UK) and CRP 
T- control (Roche Diagnostics, UK) was used as QC, the inter assay CV was 5.0%.  
3.3 .2 .2  D-dimer  
The biomarker was determined by particle enhanced immunoturbidimetric assay (COBAS 
Integra 400 plus, Roche Diagnostics, UK) in citrated plasma. The assay quantitatively determines 
D-dimer epitopes in plasma, D-dimer agglutinates with latex particles coated with monoclonal 
antibodies to the D-dimer epitope. The precipitate is determined turbidmetrically at 659 nm. The 
lower detection limit for this assay is <0.08 μg FEU/ml. The test was calibrated with D-dimer 
calibrator (Roche Diagnostics, UK), D-dimer control I/II (Roche Diagnostics, UK) were used as 
QC, the inter-assay CV were 1.2% and 2.1% respectively.  
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3.3 .2 .3  Brain  natr iuret ic  pept ide  
Brain natriuretic peptide was determined in EDTA treated plasma samples on ADVIA Centaur 
automated system (Bayer Diagnostics, Germany). The priniciple behind the assay is two site 
sandwich immunoassay using direct chemiluminescent technology. The analyser detects relative light 
units produced by chemiluminescence reactions using acridinium ester as the substrate. Two 
antibodies, an acridinium ester labelled monoclonal mouse anti-human BNP F (ab’) 2 fragment 
specific to the ring structure of BNP and a biotinylated monoclonal mouse anti-human antibody 
specific to the C-terminal portion of BNP which is coupled to streptavidin paramagnetic beads reacts 
with the analyte in the sample to form immune-complex, the chemiluminescent reaction is started by 
addition of acid and base. Unbound acridinium labelled antibody is removed. The amount of relative 
light units detected by the system is directly proportional to the amount of analyte present in the 
sample. Bayer BNP Calibrator and Control material was used in each run. The manufacturer’s overall 
(including inter- and intra-assay variability) coefficient of variation was <5% at all tested BNP 
concentrations. 
3.4  Measurement  of  plasma biomarkers  by  enzyme l inked 
immunoassay  
Plasma biomarkers IL-6, P-selectin and vWF were measured by sandwich enzyme linked 
immunoassay (ELISA) technique. ELISA technique for each assay are described in this section.  
3.4.1  Interleukin 6 
Interleukin 6 was determined in EDTA plasma. The Duoset ELISA development kit (R & D 
systems, UK) used two antibodies, one a mouse anti-human IL-6 as the capture antibody and the 
other biotinylated goat anti-human IL-6 linked to a peroxidase conjugate as a detection antibody. 
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Microtitre plates were coated with 100µl of capture antibody (working concentration-2µg/ml), 
incubated overnight at room temperature. After washing the plates with PBS buffer, 100µl of neat 
EDTA samples and standards were added to the plates and incubated for 2 hours at room 
temperature. Again after washing the plates with PBS buffer, 100µl of detection antibody 
(working concentration -200ng/ml) was added and incubated for 2 hours. After washing the 
microtitre plates with PBS buffer, 100µl streptavidin-HRP conjugate was added for 20 minutes. 
The addition of substrate (hydrogen peroxide and tetramethylbenzidine) promoted the 
colorimetric reaction which was stopped with 50µl stop solution and plates were read at 492nm 
(Dynatec 500). The lower detection limit for this assay is 9.375 pg/ml. The inter assay CV was 
13.0% and intra assay CV based on standards was 11.0% (Table 26).  
Table 26 Inter-assay coefficient of variation for Interleukin-6  
No:  Concentration of  
controls 1 (pg/ml) 
Concentration of  
controls 2 (pg/ml) 
Concentration of  
controls 3 (pg/ml) 
Concentration of  
controls 4 (pg/ml) 
1 55.69 635.18 1415.71 1529.85 
2 45.22 588.08 1460.71 1553.32 
3 56.83 497.85 1172.71 1281.03 
4 46.19 455.71 1545.30 1631.44 
5 - - 1177.629 1320.28 
6 - - 1499.94 1759.62 
 CV -12.0% CV – 15.0% CV -12.0% CV -12.1% 
Plasma samples of different IL-6 concentrations were used as quality control for IL-6 assays(in singlets) because 
IL-6 levels were undetectable in 174 healthy subjects and wanted to make sure the assay was working at various 
concentrations. 
3.4 .1 .1  Inter leukin  6 ELISA assay  reagents  and buffers  
3 .4 .1 .1 .1  Phosphate  buf f er   
Phosphate buffer saline tablets (5 tablets) and 0.5 ml Tween were dissolved in one litre of water 
(pH-7.4).  
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3 .4 .1 .1 .2  Ant ibodies   
The capture antibody for the IL-6 ELISA assay was prepared by reconstituting the vial with 1ml 
PBS which gave a stock of 360µg/ml. A working concentration of 2µg/ml was obtained by 
adding 10ml of PBS to 55µl (i.e. 20µg) of stock.  
The detection antibody was prepared by reconstituting the vial with 1ml PBS which gave a stock 
of 36µg/ml. A working concentration of 200ng/ml was obtained by adding 10ml of PBS to 55µl 
(i.e. 20 µg) of stock.  
3 .4 .1 .1 .3  Standards  
The standards were prepared by adding 500μl of PBS into the vial to give a stock of 35ng/ml (or 
35000pg in 500μl). A working top standard concentration of 600pg/ml was obtained by adding 
1961μl of PBS-T to 39.29 μl of stock (1200 pg or 1.2 ng/2ml). This is enough for 4 plates.  
3 .4 .1 .1 .4  Preparat ion  of  samples  
100µl of neat EDTA plasma was added to each well. 
3 .4 .1 .1 .5  Conjugate  and  subs tra te  so lu t ion  
The conjugate, streptavidin-HRP was prepared by adding 10ml of PBS-T to 50µl.  
Substrate solution was prepared by mixing equal volumes of colour reagent A, hydrogen 
peroxide and colour reagent B, tetramethylbenzidine (R & D systems, UK) (5 ml of each is 
enough for one 96-well plate).  
3 .4 .1 .1 .6  Stop  so lu t ion  
To obtain 1mol/L of hydrochloric acid, 913.8ml of deionised water was mixed with 86.2 ml of 
HCl (11.6(M).    
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3.4.2  P-selectin 
The Duoset ELISA development kit (R & D systems, UK) was used to determine the levels of P 
selectin in EDTA plasma. The kit used two antibodies, one a mouse anti-human P-selectin as the 
capture antibody and the other a biotinylated sheep anti-human P-selectin linked to a peroxidase 
conjugate as a detection antibody. Microtitre plates were coated with 100µl of the capture 
antibody (working concentration 2µg/ml), incubated at room temperature overnight. Plates were 
washed with PBS buffer (pH-7.4) and 100µl of 1:5 diluted EDTA plasma and standards were 
added to the microtitre plates for 2 hour at room temperature. Plates were again washed with PBS 
buffer and 100µl detection antibody (working concentration 20µg/ml) was added and incubated 
at room temperature for 2 hours. After washing the microtitre plates with PBS buffer, 100µl 
streptavidin-HRP conjugate was added for 20 minutes. The addition of substrate (hydrogen 
peroxide and tetramethylbenzidine) promoted the colorimetric reaction which was stopped with 
50µl stop solution and plates were read at 492nm (Dynatec 500). The lower detection limit for 
this assay is 125.0 pg/ml. Precinorm U (Roche Diagnostics,UK) were used as QC, the inter assay 
CV was 13.0% and intra assay CV was 8% based on standards (Table 27).  
Table 27 Inter assay coefficient of variation for P-selectin assay 
No: Concentration of Precinorm U (ng/ml) 
1 35.85 
2 35.82 
3 35.77 
4 28.17 
5 281.4 
6 35.92 
7 31.00 
8 35.54 
9 35.60 
10 27.82 
11 22.07 
12 29.66 
13 31.77 
CV = 13.0% 
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Quality controls and samples were analysed in singlets 
3.4 .2 .1  P-se lect in  ELISA assay  reagents  and buffers  
3 .4 .2 .1 .1  Phosphate  buf f er  
Phosphate buffer saline tablets (5 tablets) and 0.5 ml Tween were dissolved in one litre of water 
(pH 7.4).  
3 .4 .2 .1 .2  Ant ibodies  
The capture antibody was prepared by reconstituting the vial with 1ml PBS which gave a stock of 
concentration 360µg/ml. A working concentration of 2µg/ml was obtained by adding 10ml of 
PBS to 55µl (i.e. 20µg) of stock.  
The detection antibody  was prepared by reconstituting the vial with 1ml PBS which gave a stock 
of 3.6µg/ml. A working concentration of 20µg/ml was obtained by adding 10ml of PBS to 55µl 
(i.e. 20 µg) of stock.  
3 .4 .2 .1 .3  Standards  
The standards were prepared by adding 500μl of PBS into the vial to give a stock of 130ng/ml (or 
130,000pg in 500μl). A working top standard concentration of 8000pg/ml was obtained by 
adding 1877μl of PBS-T to 123 μl of stock (16000pg/2ml). This is enough for 4 plates.  
3 .4 .2 .1 .4  Preparat ion  of  samples  
EDTA plasma was diluted by mixing 50µl to 200µl of PBS to obtain a 1:5 dilution and 100µl 
was then added to each well. 
3 .4 .2 .1 .5  Conjugate  and  subs tra te  so lu t ion  
The conjugate, streptavidin-HRP was prepared by adding 10ml of PBS-T to 50µl. Substrate 
solution was prepared by mixing equal volumes of colour reagent A, hydrogen peroxide and 
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colour reagent B, tetramethylbenzidine (R & D systems, UK) (5 ml of each is enough for one 96-
well plate).  
3 .4 .2 .1 .6  Stop  so lu t ion  
To obtain 1mol/L of hydrochloric acid, 913.8ml of deionised water was mixed with 86.2 ml of 
HCl (11.6(M).    
3.4.3  Von willebrand factor 
vWF was determined in citrated plasma using an in house ELISA developed by Dr Andrew 
Blann (Research Scientist, Centre of Cardiovascular sciences, City Hospital, Birmingham, UK). 
The ELISA used rabbit anti-human vWF polyclonal antiserum as the capture antibody and rabbit 
anti-human vWF polyclonal antiserum conjugated to horse radish peroxidase as the  detection 
antibody. Microtitre plates were coated with 100µl of the primary antiserum (30µl in 20.5ml 
coating buffer, pH-9.6), incubated at room temperature overnight. Plates were washed with PBS 
buffer (pH-7.4) and 100µl of 1/40 diluted citrated plasma and standards were added to the 
microtitre plates for 1 hour at room temperature. Plates were again washed with PBS buffer and 
100µl secondary antiserum-the peroxidise-labelled conjugate (30µl in 20.5 ml PBS buffer) was 
added and incubated at room temperature for 45 minutes. After washing the microtitre plates with 
PBS buffer, 100µl substrate (OPD, hydrogen peroxide, pH 5.3 citrate buffer) was added. The 
colorimetric reaction was stopped immediately with 50µl stop solution and plates were read at 
492nm (Dynatec 500). The lower detection limit for this assay is 65 IU/dL. Universal controls 
were used as QC, the inter assay CV was 9.5% and intra assay CV was 3.0% (Table 28). 
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Table 28 Coefficient of variation for von willebrand factor assay 
No: Concentration of universal 
controls (IU/dL) 
Concentration of universal 
controls (IU/dL) 
Mean concentration of universal 
controls (IU/dL) 
1 114.00 105.00 110.00 
2 100.00 95.00 98.00 
3 89.00 95.00 92.00 
4 86.00 83.00 85.00 
5 87.00 86.00 86.00 
6 76.00 74.00 75.00 
7 77.00 81.00 79.00 
8 99.00 104.50 102.00 
9 89.60 85.70 87.65 
10 95.00 88.00 91.50 
11 80.50 78.50 79.50 
12 82.90 82.40 82.65 
13 81.00 82.30 81.65 
14 83.95 81.95 82.95 
15 82.36 82.08 82.22 
16 83.17 83.98 83.57 
17 77.23 69.63 73.43 
18 78.42 79.29 78.85 
19 81.66 81.38 81.52 
20 79.99 79.17 79.58 
21 81.70 79.68 80.69 
22 81.05 80.0 80.48 
23 80.10 80.79 80.44 
24 83.28 82.40 82.83 
25 81.02 81.13 81.08 
26 82.11 81.65 81.88 
27 82.15 81.10 81.62 
3.4 .3 .1  Von wi l lebrand factor ELISA assay  re agents  and 
buffers  
3 .4 .3 .1 .1  Coat ing buf f er  
Coating buffer was prepared by dissolving 0.795g of sodium carbonate and 1.465g of sodium 
hydrogen carbonate in 500ml of distilled water (pH-9.6). The buffer was stored at 4
0
C. 
3 .4 .3 .1 .2  Phosphate  buf f er  
Wash buffer was prepared by dissolving phosphate buffer saline tablets (5 tablets) and 0.5 ml 
Tween in one litre of water (pH 7.4). 
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3 .4 .3 .1 .3  Ant ibodies   
The capture antibody was prepared by adding 30 μL of rabbit anti-human vWF polyclonal 
antiserum to 20.5 mls coating buffer and the detection antibody by adding 35 μL anti-human 
vWF polyclonal antiserum conjugated to horse radish peroxidase to 20 ml of wash buffer. Both 
antibodies were commercially available from Danish company Dako.  
3 .4 .3 .1 .4  Standards  
The standards are referenced against a WHO standard from the National Institute for Biological 
Standards and Controls (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 
3QH.  Tel 01707 646 399, fax 01707 646 977. They provided a lyophilised ampoule of plasma 
with a defined mass of vWF which was made up in water to a desired concentration. The 
standards were prepared as follows; 
The top standard was created by adding 80 μL of plasma to 780 μL of dilution buffer. This gave a 
result of 180 IU/dL. The second standard was prepared by adding 60 μL of plasma to 780 μL of 
dilution buffer which gave a concentration of 130 IU/dL. The middle standard was obtained by 
adding 30 μL of plasma to 780 μL of dilution buffer which gave a concentration of 90 IU/dL. 
Finally the bottom standard was obtained by adding 10 μL of plasma to 780 μL of dilution buffer 
and this this gave a concentration of 65 IU/dL. Blank of concentration 0 IU/dL was made up of 
780 μL of dilution buffer.  
3 .4 .3 .1 .5  Substrate  so lu t ion  
Substrate solution was prepared by adding one OPD tablet and 10 µl hydrogen peroxide to 20ml 
of citrate phosphate buffer. Citrate phosphate buffer was prepared by adding 3.65 g citric acid 
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and 4.73 g sodium hydrogen phosphate to 500 ml distilled water, pH was about 5.3. If not, the pH 
was adjusted with concentrated acid or concentrated sodium hydroxide solution.  
3 .4 .3 .1 .6  Stop  so lu t ion  
To obtain 1mol/L of hydrochloric acid, 913.8ml of deionised water was mixed with 86.2 ml of 
HCl (11.6(M).    
3.5  Isolat ion  of  deoxyribonucleic  acid  from human whole  blood/  
serum and taqman single nucleot ide  polymorphism genotyping  
To study the genetic markers in this thesis, deoxyribonucleic acid (DNA) was extracted from 
whole blood or serum samples using Agencourt genfind blood & serum genomic isolation kit 
(Beckman Coulter, High Wycombe, UK) or QIAamp DNA blood mini kits (Qiagen, West 
Sussex, UK). Wet DNA was then used in taqman single nucleotide polymorphism genotying on 
StepOne real time and 7500 PCR systems (Applied Biosytems, UK).  
3.5.1   Isolation of  deoxyribonucleic acid  
Whole blood treated with EDTA and serum samples were stored at -70C at the Centre for 
Cardiovascular Sciences, City Hospital until the performance of DNA extraction. Genomic DNA 
was isolated from frozen whole blood or serum samples by Agencourt’s SPRI paramagnetic bead 
technology or Qiagen’s silica membrane technology. Both protocols involved the addition of 
lysis buffer to rupture cell membranes and proteinase k to remove any enzymes that might break 
apart DNA. In one of the protocols, DNA is immobilized on magnetic particles by the addition of 
a magnetic binding reagent. This differential binding allows the DNA to be easily separated from 
contaminants using a magnetic field, whilst in the second protocol DNA is adsorbed onto the 
QIAamp silica membrane. Contaminants which can inhibit polymerase chain reaction (PCR) 
 140 
were then rinsed away using a simple washing procedure, and the genomic DNA was eluted from 
the magnetic particles and the silica membrane in sterile water.  
NOTE: The DNA isolation for 60% of the samples was performed using QIAamp DNA blood 
mini kits. The extraction was completed by Dr Jonathan James at Functional Genomic and 
Proteomic services, School of Biosciences, University of Birmingham. The rest of the DNA was 
extracted using taqman sample to SNP kit (Applied Biosystems, UK). Details of the taqman 
sample to SNP kit are shown in appendix B 9.2.1. 
3.5.2  Taqman single nucleo tide polymorphism genotyping  
The taqman is a hybridisation based assay and utilizes taqman probes which incorporate minor 
groove binder (MGB) at the 3’ end which confers a superior allelic discrimination. The goal of 
the MGB molecule is to bind to the minor groove of the DNA helix and thus stabilise the MGB-
probe/template complex. The probe can be as short as 13 bases which ensure specificity and 
stabilisation. Furthermore, primers are used in the assay for PCR specificity.  
The detection of SNP is achieved by 5’ nuclease chemistry, where exonuclease cleavage of a 5’ 
allele-specific dye label generates the permanent assay signal. All MGB probes include a 
nonfluorescent quencher (NFQ) that virtually eliminates the background fluorescence associated 
with traditional quenchers and provides a greater signal-to-noise ratio for superior assay 
sensitivity (Taqman Probe-based assay chemistry, www.appliedbiosystems.com). 
All the SNP assays were designed according to the standard PCR conditions set on the StepOne 
real time PCR and 7500 fast PCR (Applied Biosystems, UK). 
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figure 23  Taqman Probe-based assay chemistry 
 
Reproduced from Applied Biosystems website- 
 http://www.appliedbiosystems.com/absite/us/en/home/applications-technologies/real-time-pcr/taqman-and-sybr-
green-chemistries.html (accessed on December 2009) 
 
 
3.5 .2 .1  Genotyping of  tr ia l le l ic  s ingle  nucleot ide 
polymorphism,  rs3091244 us ing  Taqman PCR  
Taqman SNP assays for the triallelic SNP rs3091244 was custom designed using bioinformatics 
tools. Figure 24 shows an overview of the steps involved in the custom designed taqman SNP 
assays for rs3091244.  
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figure 24  Overview of the custom designed Taqman SNP assays for rs3091244 
 
 
                                                     
 
 
                                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target sequence was obtained from the dbSNP database at 
http://www.ncbi.nlm.nih.gov/SNP  
 
 
 
 
 
 
 
 
                                        Assessing the quality of the sequence  
1) The uniqueness of the sequences was established by BLAST (Basic Local Alignment Search Tool) at 
http://www.ncbi.nlm.nih.gov/BLAST  assessed on 27.10.2009 
                   
 
 
 
 
2) There were no repetitive elements detected in this sequence after analysing the sequence through the 
program Repeat masker. (http://repeatmasker.genome.washington.edu) 
 
3) Specialized BLAST was performed to identify SNPs not of interest and was masked with a N. 
 
         
    
 
 
 
 
4) The masked sequence with SNP of our interest was then submitted to Applied Biosytems for taqman 
SNP genotyping assay 
 
dbSNP-rs3091244 
GTCCATGGCTCTGGGAGGAGCATGTTTGTTTTCCTCATTTCCCAGTCTGTAAATAAGCA
AATTGAAAGGGGTTAGTGATAATGTCCATCTCCAGAAGCTGTCAGATTTCCTTTGTCAA
ACTCTATGATTTGGGCTGAAGTAGGTGTTGGAGAGGCAGCTACCACGTGCACCCAGAT
GGCCACT[A/C/T]GTTTAATATGTTACCATTTCCCATTATTTTCGCAGGATAGATAGCCAA
AGTGGAGCCCTGAGAGATTTCTTCATTTTTCCTGTCATAAAGAATTGGTAATTCAGTAG
TCATAGGAGTTTGTAATAAATAACTCACATTGATTTCTCTGTTCTGAAATAATTTTGCTT
CCCCTCTTCCCGAAGCTCTGACACCTGCCCCAA 
Sequence producing significant alignment;  
Locus- NT 004487 -Homo sapiens chromosome 1 genomic contig, score -599, E-value =9.4e-169 
GTCCATGGCTCTGGGAGGAGCATGTTTGTTTTCCTCATTTCCCAGTCTGTAAATAAGCA
AATTGAAAGGGGTTAGTGATAATGTCCATCTCCAGAAGCTGTCAGATTTCCTTTGTCA
AACTCTATGATTTGGGCTGAAGTAGGTGTTGGAGAGGCAGCTACCACNTGCACCNAGA
TGGCCACT[c/t]GTTTAATATGTTACCATTTCCCATTATTTTCGCAGGATAGATAGCCAA
AGTGGAGCCCTNAGAGATTTCTTNATTTTTCCTGTCATAAAGAATTGGTAATTCAGTAG
TCATAGGAGTTTGTAATAAATAACTCACATTGATTTCTCTGTT 
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Since the SNP was triallelic (A/C/T), two paired conventional Taqman SNP assays were 
designed to detect all three alleles of the triallelic SNP. One for C/A and one for C/T genotyping. 
The C allele was labelled with FAM, and the minor alleles A and T were labelled with VIC, both 
the genotyping assays were performed in separate tubes. 
Table 29 show the details of the two biallelic assay used to detect rs3091244 and table 30  
shows the Taqman primer and probe sequences used for the genotyping of rs3091244.  
Genomic wet DNA was used for all genotyping experiments. Negative controls (sterile water) 
and two positive controls for the triallelic CRP SNPs were analysed on all plates to ensure there 
was no contamination. The reaction volume for each well was set to 20 µl (Table 31) and number 
of cycles to 50 (Table 32). The reaction volume and cycling stages for the PCR were similar for 
all taqman SNP assays. 
Table 29 Taqman SNP assays to detect the  triallelic SNP rs3091244 
Assay name Gene name  Gene symbol rs ID Alleles tested  Major allele to 
minor allele  
AHO9VY8 
AHN1ECS 
C-reactive protein 
 C-reactive protein 
CRP 
CRP 
rs3091244 
rs3091244 
C>T 
C>A 
C-T 
C-A 
 144 
Table 30 Taqman primer and probe sequences used for the genotyping of rs3091244  
Genotype  Primer (5’-3’) Allele  Allelic probe  
Forward Reverse  
C/T 
 
 
C/A 
AGGTGTTGGAGAGGCAGCTA 
 
 
GTTGGAGAGGCAGCTACCA 
 
TCCTGCGAAAATAATGGGAAATGGT  
 
 
TCCTGCGAAAATAATGGGAAATGGT 
C 
T 
 
C 
A 
VIC*  ATGGCCACTCGTTTAA MGBNFQ 
FAM* ATGGCCACTTGTTTAA MGBNFQ 
 
VIC*
   
AGATGGCCACTCGTTTA MGBNFQ 
FAM*AGATGGCCACTAGTTTA MGBNFQ 
The positions of SNPs in the allelic probes are underlined.   
*reporter dye used for allelic discrimination 
 
 
Table 31 Reaction mix 
Reagents  Volume (µl/ 96 well plate) 
2 × Taqman SNP genotyping mastermix  
40 × Taqman SNP genotyping assay 
DNAse-free water 
Genomic DNA template 
Total volume 
1008.0 
50.40 
756.0 
2.0 (per well) 
20.0 (per well) 
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Table 32 Cycling stage for the PCR  
 Pre-PCR read Thermal cycling Post-PCR read 
Stage Holding stage Holding stage Cycling (50 cycles)  Holding stage 
Denature Anneal/ extend 
Temperature 60
0
C 95
0
C 92
0
C 60
0
C 60
0
C 
Time (mm:ss) 00:30 10:00 00:15 01:00 00:30 
 
In the experiment for C/T genotyping, three genotypes will be identified: CC, CT and TT. The 
CA genotype may be included in the samples identified as the CC genotype and the AT 
genotype may be included in the samples identified as the TT genotype. The  
AA genotype will not be amplified. Similarly in the C/A genotyping experiment, three 
genotypes will be identified: CC, CA and AA. The CT genotype and the AT genotype may be 
included in the samples identified as the CC genotype and the AA genotype respectively. The 
TT genotype will not be amplified (Morita et al., 2007).  
figure 25 Scatter diagram of the data for the genotyped single nucleotide polymorphism (rs3091244) 
 
C allele labelled with FAM on the horizontal axis and the minor alleles A and T labelled with VIC on the vertical 
axis. Each genotype group is depicted in different colours and negative control is plotted as black squares 
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The genotyping results from 2 experiments, C/T and C/A Taqman assays will be combined to 
obtain all the results. 
3.5 .2 .2  Genotyping of  s ingle  nucleot ide  polymorphism 
rs1800795  using  Taqman PCR  
The -174G/C IL-6 promoter polymorphism is a biallelic SNP and figure 43 in appendix B 
9.2.1.2 gives an overview of the custom designed taqman SNP assay for rs1800795. Table 33 
show the details of the biallelic assay used to detect rs1800795 and table 34 shows the 
Taqman primer and probe sequences used for the genotyping of rs1800795.  
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Table 33 Taqman SNP assays for the biallelic SNP rs1800795 
Assay name Gene name  Gene 
symbol 
rs ID Alleles 
tested  
Major allele to 
minor allele  
AHY9ICB Interleukin-6  IL-6  rs1800795 
 
 
G>C 
 
 
G-C 
 
 
 
Table 34 Taqman primer and probe sequences used for the genotyping of rs1800795 
Genotype  Primer (5’-3’) Allele  Allelic probe  
Forward Reverse  
G/C 
 
 
 
TGACGACCTAAGCTGCACTTTT
  
AGATTGTGCAATGTGACGTCCTT G 
C 
VIC*  TTGTGTCTTGCGATGCTA MGBNFQ 
FAM* TTGTGTCTTGCCATGCTA MGBNFQ 
  
The positions of SNPs in the allelic probes are underlined.   
*reporter dye used for allelic discrimination 
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3.5 .2 .3  Genotyping of  s ingle  nucleo t ide  polymorphism 
rs2854116  using  Taqman PCR  
The T455C (rs2854116) promoter polymorphism of APOC3 gene is a biallelic SNP. An 
overview of the custom designed taqman SNP assay for rs2854116 is shown in figure 44 in 
appendix. B 9.2.1.2. Table 35 show the details of the biallelic assay used to detect rs2854116 
and table 36 shows the Taqman primer and probe sequences used for the genotyping of 
rs2854116.  
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Table 35 SNP assays for the biallelic SNP rs2854116  
Assay name Gene name  Gene 
symbol 
rs ID Alleles tested  Major allele to minor 
allele  
AHBJG2W Apolipoprotein C3 APOC3 rs2854116 T/C T-C 
 
 
 
Table 36 Taqman primer and probe sequences used for the genotyping of rs2854116  
Genotype  Primer (5’-3’) Allele  Allelic probe  
Forward Reverse  
T/C 
 
 
 
CTGAACACAGCCTGGAGTAGAG TGCCGGAGCCACTGATG T 
C 
VIC*  ACTCCAAACATCCCCC MGBNFQ 
FAM*   CTCCAAACACCCCCC MGBNFQ 
  
The positions of SNPs in the allelic probes are underlined.   
*reporter dye used for allelic discrimination 
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3.5 .2 .4  Genotyping of  s ingle  nucleot ide  polymorphism 
rs2854117  using  Taqman PCR  
 
The C482T (rs2854117) promoter polymorphism of APOC3 gene is a biallelic SNP. An 
overview of the custom designed taqman SNP assay for rs2854117 is shown in figure 45 in 
appendix B 9.2.1.2. Table 37 shows the details of the biallelic assay used to detect rs2854117 
and table 38 shows the Taqman primer and probe sequences used for the genotyping of 
rs2854117.  
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Table 37 Taqman SNP assays for the biallelic SNP rs2854117 
Assay name Gene name  Gene 
symbol 
rs ID Alleles tested  Major allele to minor 
allele  
AHQJAN9 Apolipoprotein C3 APOC3 Rs C/T C-T 
 
 
Table 38 Taqman primer and probe sequences used for the genotyping of rs2854117 
Genotype  Primer (5’-3’) Allele  Allelic probe  
Forward Reverse  
C/T 
 
 
 
CTGAACACAGCCTGGAGTAGAG AGAGCTCAGCCCTGTAACCA C 
T 
VIC*   CAGAAGACCGGGCATC MGBNFQ 
FAM* CAGAAGACCAGGCATC MGBNFQ 
  
The positions of SNPs in the allelic probes are underlined.   
*reporter dye used for allelic discrimination 
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3.5 .2 .5   Genotyping of  s ingle  nucleot ide  polymorphism 
rs662799 us ing Taqman PCR  
Taqman SNP genotyping assay for APOA5 polymorphism was a pre designed assay supplied by 
Applied Biosytem. Table 39 shows the sequence used for designing Taqman SNP genotyping for 
rs662799.  
Table 39 Sequence for Taqman SNP genotyping assay for rs662799 
Assay ID Reference 
SNP 
number 
Sequence used for Taqman SNP assay 
C_2310403_10 rs662799 GAGCCCCAGGAACTGGAGCGAAAGT[A/G]AGATTTGCCCCA 
TGAGGAAAAGCTG 
 
3.6   Zonal  densi ty  gradient  u l tracentri fugation  
Zonal ultracentrifugation is a technique used to separate lipid sub fractions in plasma based on 
their size, shape and density. Zonal separations are obtained by placing layer after layer of 
density gradient solutions based on the densities of different lipid sub fractions. During 
ultracentrifugation lipid sub fractions based on their size and density migrate to their respective 
gradient layer and form discreet bands (Wilcox and Heimberg, 1970). Detailed description is 
shown in appendix B 9.2.3. 
3.7  Mass spectrometry for  identi f icat ion  of  haemoglobin  variants  
by  ESI-MS   
Note: A total of 174 whole blood EDTA treated samples were analysed by electrospray ionization 
mass spectrometry (ESI-MS) for the identification of haemoglobin disorders. The analysis was 
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carried out by Charlotte Scarff under the supervision of Prof Jim Scrivens at Centre for 
biomedical mass spectrometry and proteomics, Department of Biological Sciences, University of 
Warwick. Detailed description is shown in appendix B 9.2.4. 
3.8  Development  of  a  novel  enzyme l inked immunoassay -Ferri t in 
bound to  Apolipoprote in  B 
3.8.1  Background 
In the United Kingdom, the burden of CVD is more prominent amongst the country’s ethnic 
minorities (Barnett et al., 2006; Gill, 2007), and this is mainly due to the preponderance of CVD 
risk factors, such as diabetes mellitus which are most evident amongst South Asians compared to 
the general population (Nicholl et al., 1986; Mckeigue, 1991; Patel, 2008a; Patel, 2012a).
 
Increased body iron stores have been implicated in the pathogenesis of diabetes mellitus (Jiang et 
al., 2004); moreover increased circulating levels of ferritin have been associated with ApoB 
concentrations (Fernandez-Real et al., 1998). Studies have identified ferritin heavy and light 
chains to directly bind ApoB (Rashid et al., 2002; Seki et al., 2008) and that ferritin regulates the 
secretion of ApoB (Hevi and Chuck, 2003). The physiological or the clinical implications of 
ferritin bound to ApoB have not been explored. In this thesis an ELISA method was developed to 
determine the levels of ferritin bound to ApoB. The study also hypothesised an ethnic difference 
in the levels of ferritin and ferritin bound to ApoB among non-diabetic South Asian and 
European subjects.  
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3.8.2   Research design and methods  
Subjects consisted of healthy volunteers recruited for research at the Centre for Cardiovascular 
Sciences, City Hospital, Birmingham. Diabetes status was determined by evidence within 
hospital case notes or by measurement of fasting plasma glucose. All subjects provided written 
informed consent. Ethical approval for this study was obtained from the local ethics committee.  
Serum cholesterol (CHOD-PAP method), HDL (direct method) and ApoB were determined using 
routine auto analyser assays (Cobas Integra 400, Roche Diagnostics, UK) Separated EDTA 
plasma were stored at -70
0
C for batch analysis.  
3.8.3  Enzyme l inked immunoassay for ferrit in  and ferrit in  bound to 
apol ipoprotein B  
3.8 .3 .1  Princ iple  of  the  tes t   
An in-house sandwich ELISA was developed for the measurement of ferritin levels and ferritin 
bound to ApoB on EDTA plasma using commercially available antibodies (Rockland, 
Gilbertsville, PA USA and R& D systems, Abingdon, UK). The assay utilizes two capture 
antibodies IgG fraction of anti-human ferritin antibodies and anti-human apolipoprotein B 
antibody for solid phase i.e. microtiter wells.  The assay was performed on 96-well micro titre 
plates, divided into two sections, the first half was coated with IgG fraction of anti-human ferritin 
antibodies that were highly specific for human ferritin and the second half was coated with anti-
human apolipoprotein B antibody. Calibrators, controls and serum samples were incubated for 2 
hours and allowed to react with the capture antibodies. The detection antibody, biotin conjugated 
IgG fraction of anti-ferritin was then added  and was incubated for 2 hours. This resulted in 
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ferritin molecules and ferritin bound to ApoB molecules  in the sample being sandwiched 
between the solid phase and the enzyme linked detection antibody.  
After washing off excess secondary antibody, conjugate streptavidin-horseradish peroxidase 
(HRP) and chromogenic substrates were used to determine the concentration of ferritin and 
ferritin bound to ApoB. The lower limit of detection using this ELISA assay for ferritin was 
78.12 pg/ml.  
3.8 .3 .2  Ferri t in  bound to  apol ipopr ote in  B-ELISA assay  
reagents  and buffers  
3 .8 .3 .2 .1  Phosphate  buf f er  
Phosphate buffer saline tablets (5 tablets) and 0.5 ml Tween were dissolved in one litre of water.  
3 .8 .3 .2 .2  Ant ibodies  
The capture antibodies for this assay were IgG fraction of anti-ferritin Ab [human spleen] [rabbit] 
(Rockland, USA) and anti-human apolipoprotein B (ApoB) (R&D systems, UK). The capture 
antibody, IgG fraction of anti-ferritin Ab was prepared by reconstituting the vial with 5.0ml of 
sterile water which gave a stock solution of 10.0 mg/ml. A working concentration of 250 ng/ml 
was obtained by adding 2.5µl stock to 10mls of PBS. The second capture antibody, anti-human 
ApoB antibody was prepared by reconstituting the vial 0.5ml PBS which gave a stock solution of 
0.2 mg/ml. A working concentration of 1000 ng/ml was obtained by adding 25µl stock to 10ml 
PBS.  
The detection antibody was biotin conjugated IgG fraction of anti-ferritin [human spleen] [rabbit] 
antibody and was prepared by reconstituting the vial with 1ml of sterile water which gave a stock 
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solution of 10.0mg/ml. A working concentration of 2000ng/ml was obtained by adding 1µl to 
50ml of PBS.  
3 .8 .3 .2 .3  Standards  
The standards for this assay were the quality control for ferritin assay for COBAS Integra 400 
plus (Roche Diagnostics, UK). The top standared of 5000pg/ml was obtained by adding 33.3μl of 
stock to 966.7μl of PBS). This was diluted 6 times to obtain a 7-point serial dilution standard 
curve as shown in table 24.  
Table 40 Preparation of standards for ferritin bound to ApoB ELISA assay 
Ferritin Volume from preceding standard 
 
Volume of PBS 
5000pg/ml (1) 
 
Stock  
2500pg/ml (2) 
 
500μl from (1) 500μl 
1250pg/ml (3) 
 
500μl from (2) 500μl 
625pg/ml (4) 
 
500μl from (3) 500μl 
312.5pg/ml (5) 
 
500μl from (4) 500μl 
156.25pg/ml (6) 
 
500μl from (5) 500μl 
 78.12pg/ml 
 
500μl from (6) 
 
500μl 
 
 
 
3 .8 .3 .2 .4  Preparat ion  of  samples  and  qua l i ty  control s  
Serum samples were used for this assay, 5µl of serum on anti-ferritin primary antibody coated 
side (1:20) and 25µl on anti-human ApoB coated side (1:4). Universal controls were used as 
quality controls for this assay. 
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3 .8 .3 .2 .5  Substrate  so lu t ion  
The conjugate, streptavidin-HRP was prepared by adding 10ml of PBS-T to 50µl. Substrate 
solution was prepared by mixing equal volumes of colour reagent A, hydrogen peroxide and 
colour reagent B, tetramethylbenzidine (R & D systems, UK) (5 ml of each is enough for one 96-
well plate).  
3 .8 .3 .2 .6  Stop  so lu t ion  
To obtain 1mol/L of hydrochloric acid, 913.8ml of deionised water was mixed with 86.2 ml of 
HCl (11.6(M)).    
3.8.4  Statistical analysis  
To detect a ½ a standard deviation in ferritin means with a power of 80% (P <0.05 using a 2-
tailed test) 42 subjects in each group were needed. Data were analysed in SPSS v14 (SPSS Inc., 
Chicago, IL) using standard and non-parametric tests.    
3.8.5  Results  
3.8 .5 .1  Intra-assay  and Inter-assay  coef f ic ients  of   
var iat ion  for  ferri t in  b ound to  apol ipoprote in  B assay  
 
The intra-assay coefficient of variation (CV) for ferritin bound to ApoB assay was determined by 
replicates of 8 different serum samples. The intra-assay coefficient of variation for the assay is 
shown in table 25. The inter-assay coefficient of variation for the assay is shown in table 26. 
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Table 41 Intra-assay coefficient of variation for ferritin  
Sample  OD 1 OD 2 Mean OD Concentration of 
ferritin (pg/ml) 
1 0.767 0.790 0.7785 7901.596 
2 0.734 0.710 0.722 6431.198 
3 0.739 0.730 0.7345 6744.144 
4 0.760 0.724 0.742 6925.563 
5 0.732 0.736 0.734 6722.107 
6 0.725 0.759 0.742 6924.374 
7 0.725 0.694 0.7095 6159.382 
8 0.770 0.766 0.768 7602.516 
Mean CV-2.0% (For a good assay CV should be <5%) 
OD- optical density, raw data from ELISA plate reader 
 
Table 42 Inter-assay coefficient of variation for ferritin  
Sample  Concentration of ferritin 1 
(pg/ml) 
Concentration of ferritin 2 
(pg/ml) 
Mean concentration of ferritin 
(pg/ml) 
1 2051.563 2055.051 2053.307 
2 2925.662 3273.29 3099.476 
3 4507.394 4541.473 4524.434 
4 2662.656 2299.913 2481.285 
5 4265.547 4188.92 4227.234 
6 970.372 949.61 959.991 
7 5840.194 6046.832 5943.513 
8 2662.656 2299.913 2481.285 
Mean CV -5.0% (For a good assay CV should be <10%) 
Raw data from ELISA plate reader 
3.8 .5 .2  Ethnic  d i f ference  in  the  leve ls  of  ferr it in  and 
ferr i t in  bound to  ApoB  
 
Age, gender and CVD risk were comparable for 41 South Asian and 41 Caucasian subjects.  
Table 27 shows the demographic and cardiovascular risk profiles. Ferritin levels for South Asians 
were median (IQR) 62.48 (34.56-90.26) ng/ml and for Caucasians were 75.52 (42.03-103.98) 
ng/ml (P=0.112). ApoB levels for South Asians were 0.63 (0.18) g/L and for Caucasians were 
0.70 (0.16) g/L (P=0.680). The percentage of ferritin bound to ApoB for non-diabetic South 
Asians were 1.27 (0.69-2.52) % and for non-diabetic Caucasians were 0.68 (0.21-1.30) % 
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(P=0.004). Amongst all subjects, five South Asians and four Caucasians had a CRP level of 
>5mg/L.    
Table 43   Ethnic differences in cardiovascular risk profiles amongst non-diabetic subjects  
Variables South Asians (n=41) Caucasians (n=41) P value  
Age (years) 
 
59.4 (13.14) 
 
60.4 (12.62) 
 
0.788 
 
Gender (% male) 
 
29 (70.7) 
 
27 (65.9) 
 
0.205 
Body mass index (kg/m
2
) 
 
25.4 (4.28) 
 
27.2 (3.90) 
 
0.583 
 
Systolic blood pressure (mmHg)  
 
140.06 (22.97) 
 
140.88 (23.37) 
 
0.642 
 
Diastolic blood pressure (mmHg) 
 
84.17 (12.05) 
 
83.39 (13.68) 
 
0.610 
 
Total cholesterol (mmol/L) 
 
4.41 (1.08) 
 
4.91 (0.93) 
 
0.807 
 
High density lipoprotein (mmol/L)  
 
1.34 (0.32) 
 
1.38 (0.41) 
 
0.215 
 
Apolipoprotein B (g/L) 
 
0.63 (0.18) 0.70 (0.16) 
 
0.680 
 
Ferritin (ng/ml) 
 
62.5 (34.6-90.3)  
 
75.5 (42.0-104.0) 
 
0.112 
 
Ferritin bound to ApoB (%) 1.27 (0.69-2.52) 0.68 (0.21-1.30) 0.004 
 
3.8.6  Discussion  
The findings of this study suggest an ethnic difference in the ferritin bound to ApoB among non-
diabetic subjects, with South Asians showing a higher percentage of ferritin-ApoB compared to 
Caucasians despite having comparable levels of ferritin and ApoB. The physiological role of 
ferritin binding proteins such as ApoB is not clear. ApoB forms a complex with circulating 
ferritin and is involved in its clearance from the circulation (Sakamoto
 
et al., 2009; Orino and 
Watanabe, 2008).  
One of the possible explanations for higher percentage of ferritin-ApoB in South Asians could be 
aberrant erythropoiesis and increased iron availability in the circulation (Patel et al., 2008b; 
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Camejo et al., 1998) due to haemolytic disease such as beta thalassemia. We showed in a 
previous study that in South Asian women with iron deficiency anemia, the prevalence of 
diabetes mellitus is exceptionally raised (Chackathayil et al., 2012), but this concept needs further 
investigation. 
Sullivan (1981) proposed a link between body iron stores and heart disease, but the results from 
epidemiological studies to prove this hypothesis has been conflicting (Danesh and Appleby, 
1999). Elevated body iron stores have been implicated in the pathogenesis of diabetes mellitus 
(Jiang, 2004), metabolic syndrome and insulin resistance (Tuomainen et al., 1997; Jehn et al., 
2004). Elevated levels of ferritin have been associated with increased risk of diabetes mellitus in 
healthy subjects (Jehn et al., 2007). In our study, ferritin levels were within normal ranges and 
comparable in both non diabetic South Asian and Caucasian subjects.  
In diabetes, in vitro studies have demonstrated that accumulation of amino acetone generates 
reactive oxygen species that could affect the ferroxidase and iron uptake ability of ferritin 
resulting in iron induced oxidative stress (Dutra et al., 2003). Elevated circulating levels of 
ferritin have been associated with plasma triglycerides, and ApoB concentrations (Fernandez-
Real, 1998). However, whether high levels of ferritin bound to ApoB could be potentially toxic 
under normal physiological condition or pathophysiological condition such as diabetes mellitus 
requires further investigation.  
Ferritin is a 450 kDa multimeric protein which consists of 24 units of two types - heavy and light 
chains. Ferritin has the capacity to store 4500mol of iron/mol of ferritin and is up regulated 
during oxidative stress. The ferroxidase activity of the heavy chain catalyses the oxidation of 
ferrous iron to ferric iron for intracellular iron storage (Balla et al., 2003). ApoB is a hydrophobic 
protein with molecular mass of 512 kDa and is the main constituent of chylomicrons, very low-
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density lipoproteins (VLDL) and LDL.  Seki (2008) demonstrated in vitro studies that ApoB 
binds ferritin via hemin (iron containing porphyrin) and suggested a link between iron 
metabolism and lipid metabolism. Proteomic studies have also identified ferritin heavy and light 
chains to directly bind ApoB (Rashid, 2002; Seki, 2008).  
Camejo (1998) suggested a model for the binding of hemin to ApoB. There is a high affinity 
between the carboxylic groups of the hemin and positively charged segments of apoB rich in 
lysine and arginine on the surface of LDL monolayer whereby the porphyrin ring is interacting 
with fatty acid chains of phospholipids and free cholesterol and the tetrapyrrole ring is embedded 
in the hydrophobic core of LDL. The alteration in the charge and structure of the LDL particle 
after hemin oxidation leads to increase uptake and degradation of oxidised LDL by macrophages. 
The binding of ferritin bound to ApoB can be of pathological significance and further work is 
warranted as to whether high levels of ferritin bound to ApoB could be an indicative of onset of 
diabetes and increased risk of CVD in South Asians. 
3.9  Stat is t ical  analysis  
All statistical analysis performed for this thesis is detailed in appendix C 9.3.7 (9.3.7.1-9.3.7.4). 
3.9.1  Statistical analysis  
3.9 .1 .1  Descr ipt ive  s tat i st ics   
All statistical analysis was performed using a computer based statistical package called ‘SPSS’ 
(version 18, SPSS Inc., USA) using standard and non-parametric tests and Kolmogorov-Smirnov 
normality plots. Central tendencies and variation for parametric data (normally distributed data) 
are presented as mean (standard deviation (SD)) or medians (interquartile range (IQR)) for non-
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parametric data (skewed distribution). Comparisons were made by independent samples t-test or 
Mann-Whitney test, as appropriate.  
Differences in genotype frequencies in the study population were assessed using ‘chi-square’ test. 
A probability level of p<0.05 was considered statistical significance. The significance of 
differences in characteristics such as demographic details were compared between the different 
genotypes using the One-Way ANOVA test for parametric test and Kruskal-Wallis test for non-
parametric test.   
figure 26 Flow chart for descriptive statistics 
 
 
 
3.9 .1 .2  Correlat ion analys is  
Bivariate correlation analysis was used to interpret the relationship between two variables 
assuming that such relationships were linear. The ‘Pearson Rank Test’ was used where variables 
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followed a normal distribution. The Pearson Test gave a correlation coefficient, r ranging from -1 
to 1 based on the strength of the association and a probability level of p<0.05 was considered to 
be significant. The alternative to the Pearson Test is the ‘Spearman Rank Test’ and was used on 
non-parametric data. A similar score for correlation and probability was used. 
Where a variable was thought to correlate with more than one variable, partial correlation 
analysis was used to calculate multiple correlation coefficients. For example the correlation 
between two variables could be influenced by a third variable.  
3.9 .1 .3  Regression analys is  
3 .9 .1 .3 .1  Linear  Regress ion  
Linear regression analysis was used to test relationships between normally distributed data (those 
assuming to have a linear relationship). It is the straight line that best describes the linear 
relationship between the two variables. Multivariable linear regression analysis was used to 
identify for instance clinical covariates associated with CRP levels and to predict the score of the 
dependent variable from a list of confounding factors or independent variables that were assumed 
to interact with the particular outcome.  
For genotype phenotype association, multivariable linear regression model was used to test the 
null hypothesis that CRP levels did not differ by SNP genotype. The ‘step’ method on multiple 
regression analysis was used to determine correlation that was significant (p<0.05), the strength 
of which was determined using the beta coefficient. The beta coefficient represents how strongly 
the independent variable influences the dependent variable. For categorical variables, the 
regression coefficient indicates the average difference in the dependent variable between the two 
groups, adjusted for any difference between the groups with respect to other variables in the 
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model. This is equivalent to analysis of covariance. For quantitative independent variables, it is 
measured in standard deviation units. In a linear regression model to determine the independent 
predictors of CRP, a beta coefficient of 5 means that a one standard deviation change in the 
independent variable results in a 5 standard deviation change in CRP levels. R- square indicates 
percentage of variation in dependent variable explained by the independent variable. 
3 .9 .1 .3 .2  Logi s t i c  Regress ion   
To determine the probability of an event (reported as odds ratio) occurring in the presence of a 
particular genotype, multivariate logistic regression models were developed with various 
independent confounding factors included in all models.  
For instance from previous studies, body mass index, smoking status, total/HDL cholesterol ratio, 
hypertension, CVD, and triglycerides have been identified as predictors of CRP levels which 
were considered when the genotypes for the CRP triallelic SNP (wild type were coded as 0 and 
homozygous for mutant allele and heterozygous were coded as 1) were used as dependent 
variable in the model. A step-wise logististic regression analysis was performed to test the null 
hypothesis that the marker genotype is not associated with increased CVD risk or CVD event in 
this population. For all analyses, a p<0.05 will be considered significant.   
3.9 .1 .4  Receiver  operat ing  characteris t ics  c urve  analys is  
The ability of each blood biomarkers to discriminate between the presence of CVD risk in South 
Asians were analysed on ROC graph, the area under the ROC curves (AUC) and cut off values 
were calculated. ROC is a graphical plot in which sensitivity or true positive rate is plotted on the 
Y-axis and false positive rate or 1-specificity is plotted on the X- axis. 
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Figure 27 shows a ROC graph with five different predictions. The perfect classification is 
represented by 0.1 point in the upper left corner, where there is 100% sensitivity and 100% 
specificity. A point on the diagonal line or otherwise called the line of no discrimination from the 
left bottom to the top right corners represents random guessing, the accuracy of B in the figure is 
50%. Any points below the diagonal line represent poor classification while any points above the 
diagonal line represent good classification. Any classifiers on the left-hand side of an ROC graph 
closer to the X-axis make positive classification with strong evidence of few false positive errors 
but also low true positive rates. On the other hand, classifiers on the upper right-hand side of an 
ROC graph make positive classification with weak evidence of predicting all positive rates 
correctly but also have high false positive rates. In figure 48, C is a better predictor than A 
(Fawcett, 2006). 
figure 27 ROC graph showing four different prediction 
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CHAPTER 4 RESULTS 1 
4.1  The performance of  inf lammatory markers  as  discriminators  o f  
cardiovascular  disease r isk in South  Asia ns  in  the  UK 
4.1.1  Aims and hypothesis 
The aim of this section was to evaluate the diagnostic validity of blood biomarkers of 
inflammation, CRP and IL-6 in the prediction of CVD risk amongst South Asians asymptomatic 
for CVD in the UK. The hypothesis was that biomarkers of inflammation would be able to 
discriminate South Asians with CVD risk factors such as hypertension, obesity, diabetes mellitus, 
abnormal lipid profiles, metabolic syndrome and 10 year CHD risk score.  
4.1.2  The validity of inflammatory markers as discriminators 
of cardiovascular disease risk in South Asian populations 
in the UK 
4 .1 .2 .1  Characteri s t i cs  of  the  s tudy cohort   
The biomarker study cohort consisted of 505 South Asians asymptomatic for CVD and not on 
any therapies for modifiable CVD risk factors; of who 276 were men (mean age (SD), 55.0 years 
(8.3) and 229 were women (54.1 years (8.3). The characteristics of the study population are 
shown in Table 44. There were more male smokers than women, 14.1% versus 2%, p<0.001. The 
prevalence of hypertension was higher in South Asian men compared to South Asian women, 
p=0.04. The prevalence of diabetes mellitus was similar in South Asian men and women. The 
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prevalence of obesity was higher amongst South Asian women compared to South Asian men, 
60.4% versus 42.4%, p<0.001. South Asian men showed a higher prevalence of metabolic 
syndrome and increased risk for CVD compared to South Asian women, prevalence rate for 
metabolic syndrome 53% versus 42.4%, 10 year CHD risk score 13% versus 6.5% respectively, 
all p<0.05.  
There were no gender differences in mean systolic blood pressure, serum cholesterol and LDL-c. 
South Asian women showed higher levels of HDL-c and ApoAI compared to South Asian men 
(both p<0.001). South Asian men showed higher levels of ApoB and triglyceride compared to 
South Asian women, p=0.04 & p=0.005 respectively. There were significant gender differences 
in the prevalence of low HDL-c and raised triglycerides with South Asian men having higher 
rates compared to South Asian women, all p<0.05. There were significant gender differences in 
the levels of liver enzymes, with South Asian men having high levels of ALT, AST and GGT 
compared to South Asian women, all p<0.05. Similarly South Asian men had high levels of 
creatinine, a marker of renal function compared to South Asian women, p<0.05.   
There were significant gender differences in the levels of inflammatory markers with South Asian 
women asymptomatic for CVD showing higher levels of CRP (p<0.001) and IL-6 (p=0.121, NS) 
compared to South Asian men. Distributions of all lipid measures, inflammatory markers and 
other biochemical measures for the study cohort are shown in Table 45.  
Table 44 Characteristics of the study population  
Characteristics Men (n=276) Women (n = 229) P value 
Age (years)
* 
55.0 (8.3) 54.1 (8.3) 0.441 
Current smokers, n (%) 39 (14.1) 2 (2.0) <0.001 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
190 (69.0) 138 (60.3) 0.044 
Diabetes mellitus (HbA1c ≥ 6.5%), n (%)  32 (12.4) 28 (13.0) 0.870 
Obesity (BMI≥27 kg/m2), n (%)  117 (42.4) 137 (60.4) <0.001 
Increased waist Circumference  
(≥ 90 cm in men and ≥ 80 cm in women), n (%)  
201 (73.0) 199 (87.3) NS 
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Systolic blood pressure (mmHg)
*
 137.0 (16.1) 135.4 (20.1) 0.384 
Diastolic blood pressure (mmHg)
*
 84.0 (10.0) 82.0 (11.0) 0.011 
Waist circumference (cm)
*
 96.2 (11.1) 93.0 (12.3) 0.001 
Body mass index (kg/m2)
* 
27.0 (4.0) 28.4 (5.0) <0.001 
Metabolic syndrome (%) 146 (53.0) 97 (42.4) 0.018 
10 year coronary heart disease 
risk score (%)
 + 
13.0 (8.3-18.0) 6.5 (3.9 -11.0) <0.001 
*
Parametric data reported as mean (SD)-Independent sample T-test,
+
Non-parametric data reported as median 
(IQR)- Mann-Whitney test 
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
 
Table 45 Distribution of lipids, inflammatory markers and other biochemical measures in the study population  
Characteristics Men (n=276) Women (n=229) P value 
Apolipoprotein AI (g/l)
+
 1.25 (1.11 -1.37) 1.37 (1.18 -1.53) <0.001 
Apolipoprotein B (g/l)
*
 0.80 (0.3) 0.72 (0.2) 0.041 
Serum cholesterol (mmol/l)
* 
5.0 (1.3) 5.0 (1.3) 0.562 
HDL cholesterol (mmol/l)
* 
1.00 (0.3) 1.20 (0.4) <0.001 
Low HDL cholesterol, n (%) 104 (39.2) 67 (31.0) 0.050 
LDL cholesterol (mmol/l)
* 
3.0 (1.0) 3.0 (1.0) 0.950 
Triglycerides (mmol/l)
+
 2.22 (1.51-3.05) 1.84 (1.30-2.64) 0.005 
Raised triglyceride, n (%) 180 (67.2) 128 (57.4) 0.030 
Calculated triglycerides
+ 
2.07 (1.30-2.90) 1.85 (1.21-2.52) 0.042 
Alkaline phosphatase (U/L)
+
  71.2 (59.0-88.0) 74.4(61.3-89.0) 0.299 
Alanine transaminase (U/L)
+ 
21.7 (17.0-30.0) 16.1 (13.0-21.1) <0.001 
Aspartate transaminase (U/L)
+ 
20.0 (17.0-25.0) 19.0 (15.2-22.4) 0.006 
Creatinine (µmol/l)
+ 
69.0 (57.1-78.0) 52.0 (46.0-61.0) <0.001 
Gamma glutamyl transpeptidase (U/L)
+ 
26.4 (18.0-40.0) 19.2 (13.0 -28.0) <0.001 
C-reactive  protein (mg/L)
+
 1.67 (0.80-3.25) 2.80 (1.05-4.80) <0.001 
Interleukin 6
+
 (pg/ml) 11.0 (0.0-83.4) 20.0 (0.0-86.0) 0.121 
*
Parametric data reported as mean (SD)-Independent sample T-test 
,
+
Non-parametric data reported as median (IQR)- Mann-Whitney test 
 
4.1 .2 .2  Levels  of  C-react ive  protein  across  cardiovascular  r isk 
factor in  South Asians asymptomatic  for  cardiovascula r 
d isease  
The purpose of this section was to estimate CRP levels across each cardiovascular risk factor in 
South Asians asymptomatic for CVD. In the entire cohort, levels of CRP were higher in South 
Asians with greater obesity, diabetes mellitus, low HDL-c, metabolic syndrome and raised 10 
year CHD risk score compared to healthy South Asian subjects. Differences in the levels of CRP 
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across CVD risk factors are shown in Table 46, figure 28-33. Levels of CRP were comparable in 
hypertensive and non-hypertensive subjects and in subjects with normal and elevated 
triglycerides in this cohort.  
Table 46 Differences in the levels of C-reactive protein across  cardiovascular risk factors in South Asians 
asymptomatic for cardiovascular disease 
Risk factors CRP levels (mg/L) P value (mann-whitney test) 
Hypertensive (>130 mmHg or 85 mmHg) 
Not hypertensive 
2.00 (0.90 – 4.43) 
2.03 (0.92 – 4.04) 
0.826 
Obesity (BMI≥27 kg/m2) 
Not obese 
2.69 (1.23-4.68) 
1.39 (0.77-3.08) 
<0.001 
Central obesity (≥ 90 cm in men and ≥ 80 cm in 
women) 
Not obese 
2.26 (1.02-4.49) 
 
1.10 (0.50-2.20) 
<0.001 
With diabetes mellitus (HbA1c ≥ 6.5%) 
Without diabetes mellitus 
2.73 (1.45-4.66)  
1.87 (0.83-3.98) 
0.003 
Low HDL cholesterol (<0.9 mmol/l in men & <1.0 
mmol/l in women) 
Normal HDL Cholesterol  
2.44 (1.02-5.66)  
 
1.90 (0.85-3.63) 
0.008 
Elevated triglycerides (≥ 1.7 mmol/l) 
Normal triglycerides 
2.13 (1.00 – 4.45) 
1.82 (0.83 – 4.25) 
0.136 
With metabolic syndrome
* 
Without metabolic syndrome 
2.27 (1.06-4.67)  
1.65 (0.80-3.63) 
0.004 
10 year CHD risk score (>20%) 
10 year CHD risk score (<20%) 
2.58 (1.26-5.90) 
1.98 (0.89-4.02) 
0.011 
Reported as median and interquartile range  
*
 Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
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figure 28 Levels of C-reactive proteins and obesity  in South Asians asymptomatic for cardiovascular 
disease 
 
       Mann-Whitney test 
                             
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
 
figure 29 Levels of C-reactive protein and central obesity in South Asians asymptomatic for 
cardiovascular disease  
 
Mann-Whitney test 
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
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figure 30 Levels of C-reactive protein and diabetes mellitus in South Asians asymptomatic for 
cardiovascular disease 
 
Mann-Whitney test 
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines  
 
figure 31 Levels of  C-reactive protein and low HDL cholesterol in South Asians asymptomatic for 
cardiovascular disease  
 
     Mann-Whitney test 
   
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
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figure 32 Levels of  C- reactive protein and metabolic syndrome in South Asians asymptomatic for 
cardiovascular disease 
 
Mann-Whitney test 
 
 
 
 
 
   
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines.  
figure 33 Levels of  C-reactive protein and Framingham 10 year coronary heart disease risk score in 
South Asians asymptomatic for cardiovascular disease 
 
     Mann-Whitney test 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
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4 .1 .2 .3  The assoc ia t ion  betw een  C -  react ive  protein  and  cardiovascu lar  
r i sk  f ac tors  in  South  As ian  men  and w omen   
Correlation analysis was performed to identify clinical variables that were associated with CRP 
levels in South Asian men and women.  
CRP levels were positively associated with waist circumference, BMI, HbA1c, triglycerides, 
alkaline phosphatase, GGT and 10 year CHD risk score and negatively with HDL-c in South 
Asian men and women. Details are shown in Table 47. 
Table 47 Correlation analysis for  CRP in South Asian men and women 
Variables South Asian men 
 
South Asian women 
Spearman’s 
correlation 
coefficient, 
r 
P value Spearman’s 
correlation 
coefficient, r 
P value 
Waist circumference (cm) 0.147 0.014 0.333 <0.001 
Body mass index (kg/m
2
) 0.147 0.014 0.369 <0.001 
HbA1c (%) 0.170 0.006 0.198 0.003 
Haemoglobin (g/dL) 0.241 0.003 NS 
White blood cell count 0.275 0.001 0.232 0.008 
HDL cholesterol -0.166 0.007 -0.186 0.006 
Calculated fasting triglycerides 0.175 0.004 0.231 0.001 
Triglycerides (mmol/l) NS 0.199 0.003 
Alkaline phosphatase (U/L) 0.356 <0.001 0.213 0.002 
Creatinine (µmol/l) NS -0.140 0.040 
Gamma glutamyl transpeptidase  
(U/L) 
0.147 0.017 0.319 <0.001 
CHD risk score 0.227 <0.001 0.232 0.001 
Other variables that were included in the bivariate correlation analysis were age, mean 
 systolic blood pressure, mean diastolic blood pressure, red blood cell count, ALT, AST,  
ApoA, ApoB, LDL-c, cholesterol, all p-NS. 
 
Since CRP was positively associated with both waist circumference and BMI, partial correlation 
analysis was performed. On partial correlation analysis, BMI and waist circumference did not 
associate independently with CRP in South Asian men after controlling for each other. In South 
Asian women, BMI was positively and independently associated with CRP after controlling for 
waist circumference, correlation coefficient r = 0.179, p =0.00. Details are shown in Table 48.  
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Table 48 Partial correlation for CRP and obesity in South Asian men and women   
Control variables South Asian men South Asian women 
Body mass index (kg/m
2
) Waist circumference,  
r =0.016, p=0.792 
Waist circumference,  
r= 0.99, p=0.136 
Waist circumference (cm) Body mass index, 
r= 0.015, p=0.799 
Body mass index, 
r=0.179, p=0.007 
 
 
On simple linear regression, the strongest association was observed between CRP and BMI 
amongst South Asian women, adjusted R
2
 = 0.125, beta coefficient =0.032, p<0.001 (figure 34) 
whilst in South Asian men, alkaline phosphatase showed the strongest association with CRP, 
adjusted R
2
 = 0.119, beta coefficient (β) = 0.006, p<0.001 (figure 35).   
figure 34 Association between log transformed  C-reactive protein and body mass index amongst South 
Asian women 
                                                                                                                        Simple linear regression 
 
 
 
 
 
R
2
 =0.125 
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figure 35 Association between log transformed  C-reactive protein and alkaline phosphatase amongst 
South Asian men 
                                                                                                                           Simple linear regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.1 .2 .4  Clinical  corre lates  of  C -  react ive  prote in  in  South Asian 
men and w omen:  mult ip le  regress ion models  
The purpose of multiple regression models was to identify clinical correlates that independently 
explained variations in CRP levels in South Asian men and women. Multiple regression models 
were developed with variables associated with CRP levels on correlation analysis. 
Using multiple linear regression, 10 year CHD risk score, alkaline phosphatase and BMI 
explained 16.0% of the variability in CRP levels amongst South Asian men asymptomatic for 
CVD, overall R
2 
= 0.157, p<0.001(Table 49).  
Table 49 Clinical correlates of  C-reactive protein in South Asian men: multiple linear regression model1 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Alkaline phosphatase (U/L) 
10 year CHD risk score (%) 
Body mass index (kg/m2) 
 
0.006 
0.009 
0.018 
 
0.003 – 0.008 
0.002 – .016 
0.004 – 0.032 
 
<0.001 
0.008 
0.013 
0.116 
0.054 
0.024 
Overall adjusted R
2
 for the model 0.157, p<0.001 
R
2
 =0.119 
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Variables included in the model- BMI, HbA1c, white blood cell count, calculated triglyceride levels, alkaline 
phosphatase and 10 year CHD risk score.  
Please note, the overall adjusted R
2
 for a similar model using non-fasted triglycerides instead of calculated 
triglycerides was 0.235, p<0.001 
 
Amongst asymptomatic women, BMI, creatinine, alkaline phosphatase and calculated 
triglycerides explained 23.3% of the variations in CRP levels, overall R
2 
= 0.233, p<0.001. BMI 
alone explained 12.1% of the variation in CRP levels in South Asian women. 
Table 50 Clinical correlates of  C-reactive protein in South Asian women: multiple linear regression model 1 
Predictor variables Beta 
coefficients 
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Body mass index (kg/m2) 
Creatinine (µmol/l) 
Alkaline phosphatase (U/L) 
Calculated fasting triglyceride 
0.033 
-0.007 
0.003 
0.040 
0.021 - 0.044 
-0.011 - (-0.003) 
0.001 - 0.005 
0.007 - 0.073 
<0.001 
<0.001 
0.004 
0.018 
0.121 
0.040 
0.041 
0.040 
Overall adjusted R
2
 for the model 0.233, p<0.001 
Variables included in the model- BMI, HbA1c, HDL cholesterol, calculated fasting triglycerides, alkaline  
phosphatase, creatinine and gamma glutamyl transpeptidase  
Please note the overall adjusted R
2
 for a similar model using non-fasted triglycerides instead of calculated 
triglycerides was 0.241, p<0.001 
 
4.1 .2 .5  The performance  of  C -react ive  prote in  as  a  d iscr iminator  of  
cardiovascular  r i sk  in  South Asians  asymptomatic  for 
cardiovascular  d i sease:  ROC analys is  
The purpose of this section was to evaluate the discriminative value for CRP in the identification 
of South Asians at an increased risk of CVD amongst South Asians asymptomatic for CVD. The 
discriminative measure was assessed by sensitivity and specificity and the area under the ROC 
curves.  
On ROC analysis, CRP significantly discriminated those with greater obesity, diabetes mellitus, 
raised calculated fasting triglycerides, low HDL-c, raised 10 year CHD risk score and metabolic 
syndrome from healthy South Asians, all AUC- 0.573 - 0.658, p<0.05, (Table 51).  
Validity of CRP was not evaluated in South Asians symptomatic for CVD risk factors (n=519) 
and CVD (n=198), this was due to the effect of lipid lowering therapy on CRP levels. 
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Table 51 C-reactive protein as a discriminator of metabolic and cardiovascular disease risk amongst South Asian 
men and women asymptomatic for cardiovascular disease 
 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 AUC- area under curve, 95% CI –confidence interval 
 
 Raised blood pressure (>130 mmHg or 
85 mmHg)  
(328, 65.0% had hypertension) 
 
Body mass index (> 27kg/m
2
) 
(254, 50.1% were obese) 
P value  AUC 95% CI P value  AUC 95% CI 
C-reactive protein 
(mg/L) 
0.826 0.506 0.454-0.558 <0.001 0.630 0.581-0.679 
Cut-off value for CRP 
(mg/L)  
NS 1.985 mg/L 
 Central obesity (≥ 90 cm in men and ≥ 
80 cm in women)  
(400, 79.3% were obese) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
(60, 13.0% were diabetic)
 
P value AUC 95% CI P value AUC 95% CI 
C-reactive protein 
(mg/L)  
<0.001 0.658 0.596-0.720 0.003 0.618 0.549-0.688 
Cut-off value for CRP 
(mg/L)  
1.555 mg/L 2.255mg/L 
 Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Elevated calculated triglycerides (≥ 
1.7 mmol/l) (286, 61.0% had raised 
triglycerides) 
P value AUC 95% CI P value AUC 95% CI 
C-reactive protein (mg/L 0.136 0.540 0.487-0.594 0.003  0.582 0.531 - 0.633 
Cut-off value for CRP 
(mg/L) 
NS 2.05 mg/L 
 Low HDL cholesterol (<0.9 mmol/l in 
men & <1.0 mmol/l in women, non-
smokers) (171, 35.3% had low HDL-c) 
10 years CHD risk         score (>20%) 
(61, 13.0% had high CVD risk) 
P value AUC 95% CI P value AUC 95% CI 
C-reactive protein 
(mg/L)  
0.008 0.573 0.518-0.627 0.011 0.601 0.528-0.674 
Cut-off value for CRP 
(mg/L)  
2.065 mg/L 2.265 mg/L 
 Metabolic syndrome
*
 (ATP III defined) 
(243, 48.1% had metabolic syndrome) 
 
P value  AUC 95% CI 
C-reactive protein 
(mg/L)  
0.004 0.575 0.525-0.625 
Cut-off value for CRP 
(mg/L) 
1.995 mg/L 
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4.1.3  The performance of interleukin-6 as a discriminator of 
cardiovascular disease risk in South Asians 
asymptomatic for cardiovascular disease  
4 .1 .3 .1  The associa t ion  betw een  in terl eukin -6  and  ca rdiovascu lar  r i sk  
f ac tors  in  South  As ian  men  and  women   
Correlation analysis was performed to identify clinical correlates that were associated with IL-6 
levels but none of the clinical variables were associated with IL-6 in this cohort. All variables 
included in the spearman correlation analysis are shown in Table 52.   
Table 52 Correlation analysis for interleukin -6  in South Asian men and women 
None of the following variables were associated with IL-6 levels on spearman correlation analysis; 
         Age, gender, mean systolic blood pressure, mean diastolic blood pressure, waist measurement, body 
mass index, glycated haemoglobin, haemoglobin, red blood cell count, white blood cell count, 
ApoB, ApoAI, total cholesterol, LDL-c, HDL-c, triglycerides, ALT, AST, creatinine, gamma 
glutamyl transpeptidase and 10 years CHD risk score. 
 
With regards to the relation between IL-6 levels and prevalence of CVD risk factors 
(hypertension, greater obesity, diabetes mellitus, elevated triglycerides, low HDL-c, metabolic 
syndrome and raised 10 year CHD risk score), only South Asian women with low HDL- c (<1.0 
mmol/l in women) showed a significantly higher levels of IL-6 compared to women with normal 
HDL cholesterol, median (IQR) 42.5 (0.00 – 236.0) vs. 16.1 (0.00-61.0), p=0.05.  
4.1 .3 .2  The performance of  inter leukin -6  as  a  discr iminator  of  
cardiovascular  r i sk  in  South Asians  asymptomatic  for 
cardiovascular  d isease:  ROC analys is  
ROC analysis was done to evaluate the performance of IL-6 in the identification of South Asians 
at an increased risk of CVD amongst South Asians asymptomatic for CVD. On ROC analysis, 
IL-6 did not discriminate between South Asians with CVD risk factors (hypertension, greater 
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obesity, diabetes mellitus, elevated triglycerides, low HDL-c and metabolic syndrome) and raised 
10 year  CHD risk score from healthy South Asians (Table 53). 
Table 53 Interleukin 6 as discriminator of metabolic and cardiovascular disease risk amongst South Asian men and 
women asymptomatic for cardiovascular disease 
 
4.1.4  Discussion 
Our aim was to evaluate the diagnostic validity of CRP and IL-6 in the discrimination of CVD 
risk in South Asians asymptomatic for CVD in the UK. Our findings suggest a lower 
discriminative range for CRP in South Asians than that determined by the current guidelines in 
the general population. The findings were replicated in two other South Asian cohorts i) a 
homogeneous Indian community in the UK ii) a homogeneous Indian community in India 
(Description of study population -Patel; 2006), results are shown in appendix C 9.3.1 table 145 & 
146. Levels of CRP in the range of 1.43 –2.30  mg/L significantly discriminated South Asians 
with increased risk of CVD. IL-6 levels failed to discriminate South Asians with increased risk of 
CVD in our cohort. Prospective studies have shown that elevated levels of IL-6 predict incident 
CVD in Europeans (Ridker, 2000a; Ridker, 2000b; Danesh et al., 2008). In our cohort, the levels 
 
 
 
 
 
 
Interleukin-6 (pg/ml) 
 
Raised blood pressure (>130 mmHg or 
85 mmHg) 
Body mass index (> 27kg/m
2
) 
 
P value  AUC 95% CI P value  AUC 95% CI 
0.332 0.527 0.473-0.580 0.569 0.485 0.434-0.536 
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
P value AUC 95% CI P value AUC 95% CI 
0.591 0.517 0.453-0.581 0.425 0.467 0.387-0.547 
Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Low HDL cholesterol (<0.9 mmol/l 
in men & <1.0 mmol/l in women, 
non-smokers) 
P value AUC 95% CI P value AUC 95% CI 
0.893 0.504 0.450-0.558 0.094 0.549 0.491-0.608 
Metabolic syndrome
*
 (ATP III defined) 10 years CHD risk score (>20%) 
P value AUC 95% CI P value AUC 95% CI 
0.277 0.528 0.477-0.580 0.181 0.444 0.364-0.525 
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of IL-6 were undetectable (<9.375 pg/ml) in 34.5% (174) of healthy subjects and hence maybe 
was unable to determine its association with CVD risk.    
The performance of CRP was not evaluated in a White population but was compared to already 
established guidelines in the general population. CRP was measured in this cohort using 
commercially available Hs-CRP assay kits. The coefficient variation of this assay is generally 
<10%. The assay can detect very low levels of CRP in blood down to 0.3 mg/L in apparent 
healthy subjects and was introduced after a standardization program at the Centers for Disease 
Control and Prevention (Pearson, 2003; Fortmann, 2004; Myers, 2004). White blood cell count 
was available for only 279 South Asians in this cohort hence was unable to determine the effect 
of infection on CRP levels. Out of these 279 South Asians, only 6 subjects had mild leucocytosis 
which was reflected by high CRP levels. Another limitation for our study is the cross sectional 
study design and hence is unable to answer questions regarding the causal role of inflammatory 
markers in this population. The study was purely designed to determine the performance of 
inflammatory marker and its association with conventional CVD risk factors in South Asians.  
There is a growing concern regarding surrogate markers such as CRP and its usefulness of to 
improve CVD risk prediction beyond those provided by classical risk factors (Danesh, 2004). 
Genetic studies so far argue against a causal relationship between CRP and CVD and show this 
marker as a mere bystander with no active role in the development of CVD (Kardys, 2006; Elliot 
et al., 2009;). Studies have shown that elevated levels of CRP in the general population are linked 
to the presence of conventional CVD risk factors. Current guidelines do not recommend CRP as 
an independent predictor of CVD but it is essential to define patient groups where it could be 
applicable (Miller, 2005; Emerging risk factor collaboration, 2010).   
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Consistent with previous studies, CRP levels were higher in women compared to men in our 
cohort. In the study by Forouhi et al., (2001) elevated CRP levels were correlated with central 
obesity after adjustment for BMI in South Asian women which reflected the higher prevalence of 
metabolic syndrome. This study suggested visceral adipose tissue as a key promoter of low-grade 
chronic inflammation in South Asian women. The main source for interleukin-6 (IL6), an inducer 
of hepatic CRP synthesis is the visceral adipose tissue. However in our cohort, central obesity 
was significantly lower in South Asian women compared to South Asian men while BMI was 
higher amongst South Asian women. The likely explanation is ectopic fat being stored in sites 
other than the visceral adipose tissue like in liver, skeletal and cardiac muscle cells which could 
contribute to pro inflammatory state and stimulate the production of CRP in liver (Smith, 2008).  
The performance of obesity and central obesity as discriminators of CVD risk factors and 
increased risk of CVD was evaluated in this population (results are shown in appendix C 9.3.2 
table 147). These findings are consistent with previous prospective studies which have 
highlighted measures of central obesity as cost effective, accurate in predicting CVD risk and 
should be incorporated in established CVD risk assessment tools (de Koning et al., 2007; 
Czernichow et al., 2011).  
The study also examined the clinical correlates of CRP, which included traditional cardiovascular 
risk factors which have been demonstrated in prior studies (Kathiresan, 2006). In this cohort of 
South Asians asymptomatic for CVD, liver function test, alkaline phosphatase and kidney 
function test, creatinine levels were found to be correlates of CRP. In South Asian men, alkaline 
phosphatase alone explained 11.6% of the total variance in CRP levels while in South Asian 
women, BMI alone explained 12.1% of the total variance in CRP levels.    
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4.1 .4 .1  Conclus ion 
Our findings suggest that CRP levels in the range of 1.43-2.30 mg/L discriminates South Asians 
at increased risk of CVD. This level is lower than that seen in white populations. Our findings 
were replicated in two cohorts i) a homogeneous Indian community in the UK ii) a homogeneous 
Indian community in India. IL-6 levels did not discriminate South Asians at increased risk of 
CVD. 
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4.2  Genotype-  phenotype and genotype -disease associat ion  of  
inf lammatory markers   
4.2.1  Aims and hypothesis  
There is increasing evidence supporting the use of CRP as a biomarker of CVD. South Asians 
have an increased risk of CVD, and this is reflected by higher circulating levels of CRP. Genetic 
association studies in Europeans have identified -390C>T>A (rs3091244) within the promoter 
region of C-reactive protein gene on chromosome 1q21-q23 and -174G>C (rs1800795) within 
the promoter region of Interleukin-6 gene on chromosome 7 to be associated with levels of C-
reactive protein and CVD, yet genetic association studies amongst South Asians are scarce. The 
aim of this section was to determine the allelic frequency of rs3091244 and rs1800795 and the 
contribution of these SNPs to inter-individual variability in CRP & IL-6 levels and CVD in South 
Asians.  
4.2.2  Genotype-phenotype and genotype-disease association of 
inflammatory markers in South Asians  
4 .2 .2 .1  Characteri s t i cs  of  the  s tudy cohort    
The genetic study cohort consisted of 1049 South Asians, of whom 600 (57.2%) were men mean 
age (SD) 59.0 years (11.0) and 449 (43.0%) were women, 57.3 years (9.3), p=0.047. There were 
more male smokers than females, 34.4% versus 2%, p<0.001. There were significant gender 
differences in the prevalence of hypertension, obesity, central obesity and existing CVD, all 
p<0.05. There were no significant gender differences in the prevalence of diabetes mellitus and 
mean levels of systolic blood pressure and diastolic blood pressure (Table 54).   
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Table 54 Characteristics of the study population 
Characteristics Male (n=602) Female (n=449) P value 
Age (years) 59.0 (11.0) 57.3 (9.3) 0.047 
Current smokers, n (%) 180 (34.4) 8 (2.0) <0.001 
Hypertension, n (%) 479 (80.0) 347 (77.3) 0.018 
Diabetes mellitus, n (%) 212 (35.3) 134 (30.0) 0.116 
Obesity, n (%) 287 (50.0) 292 (67.3) <0.001 
Increased waist 
circumference, n (%) 
484 (84.5) 402 (92.2) <0.001 
Systolic blood pressure (mmHg)
*
 139.4 (19.0) 142.0 (21.0) 0.60 
Diastolic blood pressure (mmHg)
*
 82.2 (11.0) 83.0 (11.2) 0.876 
Waist circumference (cm)
*
 94.2 (25.4) 93.0 (20.4) 0.312 
Body mass index (kg/m2)
* 
27.4 (4.1) 30.0 (5.3) <0.001 
Prevalent cardiovascular disease, n (%) 168 (28.0) 79 (17.6) <0.001 
*
Parametric data reported as mean (SD)-Independent sample T-test, 
+
Non-parametric data reported as median (IQR)- Mann-Whitney test 
 
In the case of lipids, lipoproteins and other biochemical measures, South Asian women showed 
higher ApoAI/ApoB ratio, higher levels of HDL-c compared to South Asian men (both p<0.001).  
Levels of triglyceride were higher in South Asian men compared to women, p=0.005. There was 
a significant gender difference in the levels of inflammatory markers with South Asian women 
showing high levels of CRP (p<0.001) and IL-6 (p=NS) compared to South Asian men. There 
were significant gender differences in the levels of liver enzymes, with South Asian men having 
high levels of ALT, AST and GGT compared to South Asian women, all p<0.001. Similarly 
South Asian men had high levels of creatinine compared to South Asian women, p<0.001.   
Distributions of all lipid measures and other biochemical measures in the study population are 
shown in Table 55. 
Table 55 Distribution of lipid measures and other biochemical measures in the study population 
Characteristics Male (n=600) Female (n=449) P value 
Apolipoprotein A (g/l)
+
 1.25 (1.10-1.44) 1.34 (1.14-1.54) 0.001 
Apolipoprotein B (g/l)
+
 0.70 (0.53 -0.86) 0.66 (0.50 -0.81) 0.005 
ApoA/ApoBratio
+ 
1.83 (1.43-2.37) 2.04 (1.63-2.54) <0.001 
Cholesterol (mmol/l)
* 
4.07 (1.6) 4.20 (1.5) 0.313 
HDL cholesterol (mmol/l)
* 
0.97 (0.33) 1.10 (0.37) <0.001 
LDL cholesterol (mmol/l)
* 
2.25 (0.93) 2.25 (0.90) 0.934 
Triglycerides (mmol/l)
+
 2.00 (1.40-2.93) 1.84 (1.33-2.66) 0.047 
Calculated triglycerides
+ 
1.87 (1.03-2.77) 1.77 (1.10-2.51) 0.194 
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Alkaline phosphatase (U/L)
+ 
70.0 (57.0-86.0) 74.0 (59.0-91.3) 0.030 
Alanine transaminase (U/L)
+ 
21.2 (16.1-30.2) 16.0 (12.2-21.0) <0.001 
Aspartate transaminase (U/L)
+ 
19.7 (17.0-25.0) 18.0 (14.4-22.0) <0.001 
Creatinine (µmol/l)
+ 
70.0 (60.0-81.0) 54.0 (45.2-64.0) <0.001 
Gamma glutamyl transpeptidase (U/L)
+ 
27.4 (18.0-46.0) 19.4 (13.0-30.0) <0.001 
C-reactive  protein  (mg/L)
+
 1.45 (0.73-3.33) 2.44 (1.10-5.00) <0.001 
Interleukin 6 (pg/ml)
+$ 
10.2 (0.00-59.0) 19.2 (0.00-81.0) 0.155 
*
Parametric data reported as mean (SD)-Independent sample T-test 
,
+
Non-parametric data reported as median (IQR)- Mann-Whitney test 
$
IL-6 levels were available only in EECHOES samples, 327 South men and 287 women, total=614)  
 
4 .2 .2 .2  Genotype  f requency  and a l l e l i c  f requency of  rs3091244 and 
rs1800795  in  South  As ians   
The allelic and genotype frequencies for rs3091244 and rs1800795 are shown in Table 56 & 57. 
For rs3091244, the minor allele frequency for T allele was 0.23 and A allele was 0.11. The carrier 
frequency for this triallelic SNP in our cohort was 55%. The minor allelic frequency for 
rs1800795 was 0.18 and the carrier frequency in our cohort was 32%.  
Table 56 Genotype and minor allelic frequencies of rs3091244 in South Asians in the UK 
rs3091244 CC 
(wild 
type) 
CT CA TA TT AA Total  Minor 
allelic 
frequency 
(95% CI) 
(T allele) 
Minor 
allelic 
frequency 
(95% CI) 
(A allele) 
Number of 
subjects (%) 
447 
(45) 
302 
(30.3) 
124 
(12.4 ) 
37 
(4) 
56  
(6) 
30 
(3) 
996 23.0 
(21.2-
25.0) 
11.0 (9.6-
12.4) 
 
 
Table 57 Genotype and minor allelic frequencies of rs1800795  in South Asians in the UK 
rs1800795 GG (wild 
type) 
GC CC Total Minor allelic 
frequency 
(95% CI) 
Number of subjects (%) 690 (68%) 284 (28%) 44 (4.3%) 1018 18.0 (16.2-
20.0) 
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4.2 .2 .3  Differences  in  cardiovascular  r i sk  factors  and serum C -
react ive  prote in leve ls  across  C -react ive  SNP rs3091244 
genotypes  
The purpose of this section was to determine whether any significant difference in demographics, 
CRP levels and CVD were evident amongst South Asians with carriers of minor allele of SNP 
rs3091244 compared to those with wild type.  
There was no significant difference in terms of demographics, lipid levels and prevalent CVD 
among the two groups divided as rs3091244 genotype CC, wild type and carriers of minor allele, 
T & A (Table 58 and Table 59). Except for the prevalence of increased waist circumference, 
where carriers of minor allele showed a higher percentage of subjects with increased central 
obesity compared to those with wild type genotype, p=0.012. A significant difference was also 
observed in the levels of CRP among the two genotype groups, with carriers of minor allele 
showing higher levels of CRP compared to wild type, p =0.003 (Table 59 & figure 36).  
Table 58 Characteristics of the study population across rs3091244 genotype  
 
 
 
CC (wild type) 
n = 447  
Carriers of minor 
alleles (alleles T & 
A) 
n = 549 
P value 
Age (years) 59.0 (10.0) 58.0 (11.0) 0.101 
Male gender, n (%) 255 (57.4) 314 (58.0) 0.659 
Current smokers, n (%) 88 (21.8) 90 (18.6) 0.230 
Hypertension, n (%) 350 (78.3) 436 (79.4) 0.667 
Diabetes mellitus, n (%) 144 (33.0) 179 (33.0) 0.958 
Obesity, n (%) 245 (57.2) 300 (58.0) 0.835 
Increased waist 
circumference, n (%) 
363 (85) 468 (90.2) 0.012 
Systolic blood pressure (mmHg)
*
 140.1 (18.3) 141.0 (21.0) 0.703 
Diastolic blood pressure (mmHg)
*
 82.1 (11.1) 82.0 (11.3) 0.920 
Waist circumference (cm)
*
 94.0 (24.0) 93.0 (24.0) 0.463 
Body mass index (kg/m2)
* 
28.1 (5.0) 28.4 (5.0) 0.393 
Prevalent cardiovascular disease, n (%) 104 (23.3) 135 (24.6) 0.627 
*
Parametric data reported as mean (SD)- Independent T-test & n(%) –chi-square test. 
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Table 59 Distribution of lipids, lipoproteins and inflammatory markers across rs3091244 genotype 
 
 
 
CC (wild type) 
n = 447 
Carriers of minor 
alleles (alleles T & 
A) 
n = 549 
P value 
Apolipoprotein A (g/l)
+
 1.27 (1.09-1.49) 1.28 (1.13-1.51) 0.350 
Apolipoprotein B (g/l)
+
 0.67 (0.53-0.84) 0.69 (0.52-0.84) 0.615 
ApoA/ApoBratio
+
 1.91 (1.50-2.41) 1.96 (1.53-2.45) 0.549 
Cholesterol (mmol/l)
* 
4.05 (1.6) 4.11 (1.7) 0.582 
HDL cholesterol (mmol/l)
* 
1.02 (0.4) 1.01 (0.32) 0.616 
LDL cholesterol (mmol/l)
* 
2.21 (0.93) 2.30 (0.91) 0.477 
Triglycerides (mmol/l)
+
 1.94 (1.35-2.69) 1.91 (1.32-2.90) 0.771 
Calculated triglycerides
+ 
1.78 (0.95-2.62) 1.87 (1.05-2.62) 0.334 
C-reactive  protein  
(mg/L)
+
 
1.50 (0.73-3.83) 2.04 (0.95-4.20) 0.003 
Interleukin 6 (pg/ml)
+$ 
13.0 (0.00-79.1) 14.0 (0.00-63.2) 0.992 
*
Parametric data reported as mean (SD)- Independent T-test. 
+ 
Non-parametric data reported as median (IQR)- 
 Mann-Whitney test 
$
IL-6 levels were available only in EECHOES samples, 327 South men and 287 women, total=614)  
 
figure 36 Levels of C-reactive protein across the genotypes 
Mann-Whitney test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
Wild type (CC), n = 447 Carriers of minor alleles (alleles T & A), n =n = 549 
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Simple linear regression was performed to determine whether SNP rs3091244 was associated 
with its phenotype, CRP levels. rs3091244 was associated with CRP levels when comparing wild 
type with carriers of minor allele (CC vs carriers of A & T), β = 0.171 (95% CI, 0.033-0.308), 
adjusted R
2
 = 0.005, p = 0.015.  
There was no significant difference in the frequency of genotypes in South Asians with prevalent 
CVD compared to South Asians without CVD (Table 60).  
Table 60 Genotype and allelic distribution in the study population 
rs3091244  South Asians without 
cardiovascular disease 
 (n=757) 
South Asians with  
cardiovascular disease 
 (n=239) 
P value 
Wild type (CC) (%) 
Heterozygous (CT/CA) (%) 
Homozygous for minor allele 
(TA/TT/AA) (%) 
343 (45.3) 
321 (42.4) 
93 (12.3) 
104 (43.5) 
105 (43.9) 
30 (12.6) 
NS 
Allelic distribution 
C  
T  
A  
 
0.67 
0.23 
0.11 
 
0.65 
0.23 
0.12 
 
NS 
 
 
4.2 .2 .4  Clinical  corre lates  of  C-  react ive  prote in  in  South Asian 
men and w omen:  mult ip le  regress ion models  
Correlation analysis was performed to identify clinical correlates of CRP in South Asian men and 
women. CRP was positively associated with waist, BMI, ApoB, alkaline phosphatase, GGT and 
negatively wth HDL-c in South Asian men. Amongst South Asian women, CRP was positively 
associated with waist, BMI, diastolic blood pressure, white blood cell count, calculated 
triglycerides, triglycerides, alkaline phosphatase, GGT and negatively with HDL-c and 
creatinine. Details are shown in Table 61.  
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Table 61 Correlation analysis for  CRP in South Asian men and women in the UK 
Variables South Asian men 
 
South Asian women 
Spearman’s 
correlation 
coefficient, r 
P value Spearman’s 
correlation 
coefficient, r 
P value 
Waist circumference (cm) 0.203 <0.001 0.241 <0.001 
Body mass index (kg/m
2
) 0.210 <0.001 0.353 <0.001 
Diastolic blood pressure 
(mmHg) 
NS  0.141 0.004 
White blood cell count NS 0.146 0.012 
Apolipoprotein B (g/l) 0.149 <0.001 NS 
HDL cholesterol -0.101 0.018 -0.130 0.008 
Calculated fasting triglycerides NS  0.104 0.020 
Triglycerides (mmol/l) NS 0.114 0.012 
Alkaline phosphatase (U/L) 0.345 <0.001 0.208 <0.001 
Creatnine (µmol/l) NS -0.137 0.007 
Gamma glutamyl  
transpeptidase (U/L) 
0.197 <0.001 0.271 <0.001 
Other variables included in the analysis were age, systolic blood pressure, glycated haemoglobin, glucose levels, 
haemoglobin, red blood cell count, ALT, AST, ApoAI, cholesterol and LDL-c. 
 
Since CRP was positively associated with both waist circumference and BMI in South Asian 
women, partial correlation analysis was performed. On partial correlation analysis, waist 
circumference was positively and independently associated with CRP after controlling for BMI in 
South Asian men, r = 0.114, p=0.007. In South Asian women, BMI was positively and 
independently associated with CRP after controlling for waist circumference, correlation 
coefficient r = 0.243, p = <0.001. Details are shown in Table 62.  
Table 62 Partial correlation for CRP and obesity in South Asian men and women   
Control variables South Asian men South Asian women 
Body mass index (kg/m
2
) Waist circumference,  
r =0.114, p=0.007 
Waist circumference,  
r= 0.000, p=0.993 
Waist circumference (cm) Body mass index, 
r= 0.075, p=0.079 
Body mass index, 
r=0.243, p=<0.001 
 
 
On multiple linear regression model 1 (developed with variables associated with CRP), alkaline 
phosphatase, BMI and -309C>T>A (CC vs. carriers of minor allele) explained 14% of the 
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interindividual variability in CRP levels in South Asian men with alkaline phosphatase 
explaining 10% of the total variance (Table 63).  
Table 63 Clinical correlates of  C-reactive protein in South Asian men: multiple linear regression model 1  
Predictor variables Beta 
coefficients 
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Alkaline phosphatase (U/L) 0.013 0.010 - 0.017 <0.001 0.100 
Body mass index (kg/m2) 0.047 0.026 - 0.069 <0.001 0.041 
-309C>T>A (CC vs. carriers of 
minor allele) 
0.235 0.055 – 0.415 0.011 0.005 
Overall adjusted R
2
 for the model 0.139, p<0.001 
Variables included in the model- BMI, HDL-c, alkaline phosphatase, GGT and -309C>T>A (CC vs. carriers of 
minor allele  
 
On multiple regression model 2, alkaline phosphatase, BMI, GGT and HDL cholesterol explained 
14.3% of the interindividual variability in CRP levels in South Asian men again with alkaline 
phosphatase explaining 10% of the total variance (Table 64).  
 
Table 64 Clinical correlates of C-reactive protein in South Asian men: multiple linear regression model 2 
Predictor variables Beta 
coefficients 
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Alkaline phosphatase (U/L) 0.013 0.010 - 0.017 <0.001 0.100 
Body mass index (kg/m2) 0.0471 0.019 - 0.0693 <0.001 0.041 
Gamma glutamyl  
transpeptidase (U/L) 
0.004 0.001 – 0.007 0.015 0.022 
HDL cholesterol (mmol/l) -0.283 -0.566 – 0.000 0.050 0.006 
Overall adjusted R
2
 for the model 0.143, p<0.001 
Variables included in the model- BMI, HDL-c, alkaline phosphatase and GGT  
 
 
In South Asian women, BMI, alkaline phosphatase, creatinine and diastolic blood pressure 
explained 17.1% of the interindividual variability in CRP levels with BMI explaining 10% of the 
total variance (Table 65).  
Table 65 Clinical correlates of  C-reactive protein in South Asian women: multiple linear regression model  
Predictor variables Beta 
coefficients 
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Body mass index (kg/m2) 0.066 0.047 - 0.085 <0.001 0.104 
Alkaline phosphatase (U/L) 0.007 0.003 - 0.011 0.001 0.030 
Creatnine (µmol/l) -0.008 -0.014 – (-0.001) 0.016 0.014 
Diastolic blood pressure (mmHg) 0.010 0.002 – 0.019 0.021 0.021 
Overall adjusted R
2
 for the model 0.171, p<0.001 
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Variables included in the model- BMI, diastolic blood pressure, HDL-c, calculated fasting triglyceride, alkaline 
phosphatase, GGT and creatnine  
 
 
In the entire cohort, BMI, alkaline phosphatase, lipid lowering therapy (yes/no), rs3091244, 
gender, HDL cholesterol and GGT explained 24% of the interindividual variability in CRP levels 
with BMI explaining 8% of the total variance. The triallelic SNP located in the promoter 
sequence explained only 0.5% of the variability in CRP levels in a model that included all clinical 
covariates (Table 66).  
Table 66 Clinical correlates of  C-reactive protein in South Asians in the UK: multiple linear regression model 
Predictor variables Beta 
coefficients 
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Body mass index (kg/m2) 0.063 0.045 - 0.080 <0.001 0.081 
Alkaline phosphatase (U/L) 0.010 0.007 - 0.014 <0.001 0.068 
Lipid lowering therapy (no/yes) -0.265 -0.433- (-0.098) 0.002 0.006 
-309C>T>A (CC vs. carriers of 
minor allele) 
0.256 0.092 - 0.420 0.002 0.005 
Gender (male/female) 0.330 0.154 - 0.505 <0.001 0.010 
HDL cholesterol (mmol/l) -0.274 -0.505 – ( -0.043) 0.020 0.003 
Gamma glutamyl  
transpeptidase (U/L) 
0.003 0.000 - 0.005 0.050 0.012 
Overall adjusted R
2
 for the model 0.235, p<0.001 
Variables included in the model- gender, BMI, diastolic blood pressure, haemoglobin, HDL-c, alkaline phosphatase, 
GGT, creatinine, lipid lowering therapy (yes/no) and -309C>T>A (CC vs. carriers of minor allele) 
 
4.2 .2 .5  The associat ion between Inter leukin -6  SNP rs1800795,  
cardiovascular  r isk  factors  and inf lammatory  markers   
There was no significant difference in terms of demographics, lipid levels, inflammatory markers 
and prevalent CVD among the two groups divided as rs1800795 genotype GG, wild type and 
carriers of minor allele, C. Characteristics of the study population and distribution of lipid and 
inflammatory markers across rs1800795 genotype are shown in Table 67 & 68. 
Table 67 Characteristics of the study population across rs1800795 genotype 
Characteristics GG (wild type) Carriers of minor alleles 
(GC & CC) 
P value 
Age (years) 57.4 (11.0) 58.0 (10.0) 0.743 
Male gender, n (%) 324 (58.0) 143 (52.0) 0.106 
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Current smokers, n (%) 101 (21.0) 36 (15.0) 0.053 
Hypertension, n (%) 442 (78.1) 226 (80.1) 0.492 
Diabetes mellitus, n (%) 173 (31.0) 82 (29.4) 0.703 
Obesity, n (%) 304 (57.0) 163 (61.0) 0.305 
Increased waist 
circumference, n (%) 
469 (88.0) 235 (88.0) 0.993 
Systolic blood pressure (mmHg)
*
 140.0 (22.0) 141.0 (20.0) 0.479 
Diastolic blood pressure (mmHg)
*
 82.0 (12.0) 83.3 (11.3) 0.071 
Waist circumference (cm)
*
 92.0 (26.4) 94.0 (25.0) 0.310 
Body mass index (kg/m2)
* 
28.3 (5.0) 29.0 (5.0) 0.319 
Prevalent cardiovascular disease, n (%) 138 (24.4) 68 (24.1) 0.932 
*
Parametric data reported as mean (SD)- Independent T-test & n(%) -chi-square test.  
 
Table 68 Distribution of lipids, lipoproteins and inflammatory markers across rs1800795  genotype 
Characteristics GG (wild type) Carriers of minor alleles 
(GC & CC) 
P value 
Apolipoprotein A (g/l)
+
 1.27 (1.12-1.51) 1.27 (1.09-1.48) 0.792 
Apolipoprotein B (g/l)
+
 0.68 (0.52-0.84) 0.70 (0.51-0.84) 0.894 
ApoAI/ApoBratio
+
 1.93 (1.51-2.41) 1.91 (1.50-2.44) 0.785 
Cholesterol (mmol/l)
* 
4.00 (1.7) 4.10 (1.7) 0.469 
HDL cholesterol (mmol/l)
* 
1.01 (0.34) 1.01 (0.40) 0.986 
LDL cholesterol (mmol/l)
* 
2.20 (0.92) 2.25 (0.91) 0.428 
Triglycerides (mmol/l)
+
 1.92 (1.31-2.90) 1.84 (1.35-2.66) 0.509 
Calculated triglycerides
+ 
1.78 (0.91-2.62) 1.78 (0.88-2.62) 0.934 
High sensitivity C-reactive 
 protein (mg/L)
+
 
1.88 (0.82-4.10) 1.83 (0.90-4.20) 0.602 
Interleukin 6 (pg/ml) 12.0 (0.00-59.0) 15.0 (0.00-105.0) 0.383 
*
Parametric data reported as mean (SD)- Independent T-test 
+ 
Non-parametric data reported as median (IQR)-Mann-Whitney test.
 
$
IL-6 levels were available only in EECHOES samples, 327 South men and 287 women, total=614)  
 
4.2.3  Discussion 
The CRP promoter polymorphism rs3091244 contributed minimally to variation in CRP levels in 
South Asians and was not associated with CVD. The triallelic SNP located in the promoter 
sequence explained only 0.5% of the variability in CRP levels. Carriers of minor alleles (CT, CA, 
TT or AA) had higher levels of CRP compared to subjects with major alleles (CC). The allelic 
frequency for CRP-390 T and A were 23% and 11% respectively similar to those reported in non-
Asian populations (Kathiresan, 2006). The IL-6 SNP, rs1800795 did not contribute to inter-
individual variability in CRP and IL-6 levels in South Asians.  
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Several studies have demonstrated the association between rs3091244 and CRP levels in non-
Asian populations. In the Framingham Heart Study, the contribution of rs3091244 was modest 
and explained only 1.4% of the variation in CRP levels. Subjects homozygous for CC genotype 
had the lowest level of CRP compared to heterozygotes (CT or CA genotypes) who had 
intermediate level of CRP and minor allele homozygotes (TT or AA) who showed the highest 
level of CRP. However, the triallelic SNP rs3091244 was not associated with prevalent CVD 
(Kathiresan, 2006). Suk Danik (2006) demonstrated that the triallelic -390C/T/A SNP was 
associated with the highest level of CRP in patients after ACS whilst Kovacs (2005) associated 
the triallelic SNP with baseline CRP levels in patients with CHD.  
With regards to association between rs3091244 and CVD, the genotypes were not associated with 
increased risk of ischemic heart disease (Zacho, 2008). Similarly, studies by Zee and Ridker 
(2002), Kardys (2006) and a meta-analysis by C Reactive Protein Coronary Heart Disease 
Genetics Collaboration (CCGC) (2011) also failed to associate CRP genotypes with the risk of 
CHD respectively, despite showing a substantial genetic influence on CRP levels. In the third 
National Health and Nutrition Examination Survey, the functional -390C/T/A SNP was 
associated with CRP levels and with prevalent CHD in the non-Hispanic population, thus 
suggesting a true causal relationship between CRP and CHD (Crawford, 2006). This was not the 
case in our cohort, this could be due to insufficient statistical power or there might be other 
multiple rare variants that could be associated with CVD in South Asians.  
The functional significance of this triallelic SNP in the promoter region of CRP gene has been 
demonstrated in vitro. Hage (2007) identified two SNPs at the promoter region of the CRP gene 
which are functional, -409G/A (rs3093062) and -390C/T/A (rs3091244). These polymorphisms 
directly contributed to the interindividual variation of blood CRP levels. Higher CRP levels were 
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observed in carriers of -409GG and -390TT. The two SNPs were reported to reside within the E 
box elements E-box 1 and E-box -2, which are functional since transcription factors bind to them 
and is altered in the presence of -409GG and -390TT SNPs. Szalai (2005) and Carlson (2005) 
demonstrated that the rs3091244 triallelic SNP in the promoter region alters the affinity for 
transcription factors and affects the transcription of the gene which results in variation of blood 
CRP levels. In vitro study using CRP promoter-firefly luciferase reporters showed that 
individuals with 409G/-390T haplotype had a highest promoter activity, with high transcription 
factor binding version of E-box 1 and E-box 2 and high levels of CRP when compared to -409A/-
390T individuals who showed weak promoter activity and hence lowest CRP levels (Szalai, 
2005). 
The study also examined the clinical correlates of CRP, which included gender, cardiovascular 
risk factors such as BMI, lipid lowering therapy (yes/no), HDL cholesterol which have been 
demonstrated in prior studies (Kathiresan, 2006). Apart from these clinical variables, liver 
function tests, alkaline phosphatase and gamma glutamyl transpeptidase levels were found to be 
correlates of CRP. In the entire cohort, BMI, alkaline phosphatase, lipid lowering therapy 
(yes/no), rs3091244 (CC vs. carriers of minor allele), gender, HDL cholesterol and GGT 
explained 24% of the interindividual variability in CRP levels with BMI explaining 8% of the 
total variance. The triallelic SNP located in the promoter sequence was independently associated 
with CRP levels and explained only 0.5% of the variability in CRP levels in a model that 
included all clinical covariates. However in South Asian men, alkaline phosphatase explained 
10% of the total variance in CRP levels while in South Asian women, BMI explained 10% of the 
total variance in CRP levels.  
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4.2 .3 .1  Conclus ion 
The CRP promoter polymorphism rs3091244 contributed minimally to variation in CRP levels in 
South Asians and were not associated with clinical CVD.  
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CHAPTER 5 RESULTS 2 
5.1  Lipids  and l ipoproteins  in  South  Asian populat ions  in  the  UK  
5.1.1  Aims and hypothesis  
Fasting triglycerides are a better discriminator of CVD risk in South Asian populations compared 
to other lipids and lipoprotein measures. Current guidelines recommend measures of triglycerides 
to be obtained in a fasting state. Due to logistical issues associated with obtaining fasted bloods, 
there are often not measured in the primary prevention setting. In this cross sectional study, the 
aim was to look at the performance of non-fasting triglycerides and calculated levels of 
triglycerides estimated by the Friedewald formula as discriminators of CVD risk in South Asians 
asymptomatic for CVD in the UK. The analysis also looked at the ethnic differences in lipids and 
lipoproteins amongst South Asians in the UK.  
5.1.2  The validity of calculated triglycerides and lipoproteins as a 
discriminator of cardiovascular disease in South Asians 
asymptomatic for cardiovascular disease 
5 .1 .2 .1  Characteri s t i cs  of  the  s tudy cohort   
The study population were recruited through the E-ECHOES study; the characteristics of the 
study population and distribution of all lipid profiles and biochemical measures are shown in 
Chapter 4 Result section 1, Table 44 & 45.  
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With regards to the characteristics amongst men by ethnic groups, more Bangladeshi men 
smoked, p<0.001. The prevalence of diabetes mellitus was highest amongst Pakistani men 22% 
compared to 7% and 9.1% in Indian and Bangladeshi men respectively, p=0.004. The prevalence 
of obesity and central obesity were also highest amongst Pakistani men p=0.010 & <0.001 
respectively. Characteristics of South Asian men by ethnic groups are shown in Table 69. 
Characteristics of South Asian women by ethnic groups are shown in Table 70. There were no 
significant differences in demographic details amongst women belonging to different ethnic 
groups. 
Table 69 Characteristics of men by  ethnic groups 
 
Characteristics 
Men by ethnic groups
^ 
( Total n=250)   
P value  Indians  
(n= 129) 
Pakistanis  
(n= 99) 
Bangladeshi  
(n= 22) 
Age (years)
* 
54.4 (7.3) 56.1 (9.5) 54.1 (10.1) 0.285 
Current smokers, n (%) 7 (5.4) 18 (18.2) 11 (50.0) <0.001 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
90 (70.0) 65 (66.0) 12 (55.0) 0.357 
Diabetes mellitus (HbA1c ≥  
6.5%), n (%)  
8 (7.0) 20 (22.0) 2 (9.1) 0.004 
Obesity (BMI≥27 kg/m2), n (%)  51 (40.0) 48 (49.0) 3 (14.0) 0.010 
Increased waist Circumference (≥ 90 
cm in men and ≥ 80 cm in women), n 
 (%)  
96 (74.4) 81 (82.0) 9 (41.0) <0.001 
Systolic blood pressure (mmHg)
*
 138.0 (16.5) 135.4 (16.2) 130.0 (12.4) 0.074 
Diastolic blood pressure (mmHg)
*
 85.0 (10.1)   82.1 (9.4) 82.5 (9.5) 0.110 
Waist circumference (cm)
*
 96.1 (12.0) 98.2 (9.3) 90.0 (7.5) 0.003 
Body mass index (kg/m2)
* 
27.0 (3.5) 27.1 (3.7) 24.1 (3.0) 0.002 
Metabolic syndrome (%)
 # 
71 (55.0) 54 (55.0) 7 (32.0) 0.118 
10 year coronary heart  
Disease risk score (%)
 + 
18 (15.3) 25 (25.3) 4 (18.2) 0.179 
*
Parametric data reported as mean (SD)- One way anova, n(%) -chi-square test.  
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones other  
Asian background, n = 4, East African Asian, n=22
 
#
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
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Table 70 Characteristics of women by  ethnic groups 
 
Characteristics 
Women by ethnic groups
^ 
( Total n=211)  
P value  Indians  
(n= 119) 
Pakistanis  
(n= 77) 
Bangladeshi  
(n= 15) 
Age (years)
* 
55.0 (8.1) 53.0 (9.0) 57.0 (8.2)  0.179 
Current smokers, n (%) 1 (1.0)  2 (2.6) 1 (7.0) 0.256 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
71 (60.0) 46 (60.0) 9 (60.0) 1.00 
Diabetes mellitus (HbA1c ≥  
6.5%), n (%)  
18 (16.2) 9 (12.3) 0 (0) 0.211 
Obesity (BMI≥27 kg/m2), n (%)  72 (61.0) 51 (68.0) 6 (40.0) 0.115 
Increased waist Circumference (≥ 90 
cm in men and ≥ 80 cm in women), n 
 (%)  
104 (87.4) 69 (91.0) 13 (87.0) 0.746 
Systolic blood pressure (mmHg)
*
 136.0 (19.4) 135.1 (20.1) 137.0 (31.0) 0.957 
Diastolic blood pressure (mmHg)
*
 81.0 (10.4) 82.0 (11.0) 83.0 (16.0) 0.729 
Waist circumference (cm)
*
 92.0 (13.0) 95.1 (12.0) 94.0 (10.2) 0.245 
Body mass index (kg/m2)
* 
28.3 (5.0) 29.0 (5.1) 27.0 (4.0) 0.288 
Metabolic syndrome (%) 49 (41.2) 37 (48.1) 6 (40.0) 0.611 
Framingham coronary heart  
Disease risk score (%)
 + 
4 (3.5) 3 (4.1) 2 (13.3) 0.220 
*
Parametric data reported as mean (SD)- One way anova, n(%) -chi-square test. 
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones East 
African Asian, n=18.  
 
Triglyceride levels were lowest amongst Bangladeshi men, p=0.027. Levels of alkaline 
phosphatase and creatinine were lowest in Indian men, p=0.001. Lipids and biochemical 
measures in South Asian men by ethnic groups are shown in Table 71. Distribution of lipids and 
biochemical measures in South Asian women by ethnic groups are shown in Table 72. There were 
no significant differences in the levels of lipids and biochemical measures in South Asian women 
belonging to different ethnic groups. 
Table 71 Distribution of lipids and biochemical measures in South Asian men by ethnic groups 
 
Characteristics 
Men by ethnic groups
^  
(Total n=250)  
P value Indians  
(n= 129) 
Pakistanis  
(n= 99) 
Bangladeshi  
(n= 22) 
Apolipoprotein AI (g/l)
+
 1.25 (1.09 – 1.39) 1.22 (1.12 – 1.35) 1.25 (1.11 – 1.39) 0.985 
Apolipoprotein B (g/l)
*
 0.79 (0.26) 0.74 (0.23) 0.75 (0.24) 0.412 
Serum cholesterol (mmol/l)
* 
4.70 (1.40) 4.64 (1.31) 4.70 (1.15) 0.946 
HDL cholesterol (mmol/l)
* 
0.99 (0.35) 0.98 (0.26) 1.03 (0.32) 0.759 
LDL cholesterol (mmol/l)
* 
2.67 (0.96) 2.60 (0.81) 2.71 (0.82) 0.786 
Triglycerides (mmol/l)
+
 2.33 (1.68 – 3.18) 2.13 (1.50 – 2.90) 1.54 (1.20 – 2.30) 0.027 
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Calculated fasting triglycerides
+ 
1.95 (1.22 – 3.02) 2.10 (1.41 – 2.80) 1.90 (1.31 – 2.50) 0.658 
Alkaline phosphatase (U/L)
+
  66.1 (54.1 – 81.0) 77.0 (62.0 – 94.0) 75.0 (59.0 – 88.4) 0.001 
Alanine transaminase (U/L)
+ 
22.1 (17.0 – 31.0) 22.0 (17.0 – 31.4) 19.5 (15.3 – 27.0) 0.370 
Aspartate transaminase (U/L)
+ 
19.1 (16.2 – 24.4) 20.7 (18.0 – 25.0) 20.0 (15.4 – 23.0) 0.162 
Creatinine (µmol/l)
+ 
66.0 (55.0 – 75.0) 73.0 (61.0 – 83.0) 74.0 (62.0 – 91.2) 0.005 
Gamma glutamyl transpeptidase  
(U/L)
+ 
23.8 ( 17.4 – 37.5) 30.0 (18.2 – 42.0) 24.3 (17.4 – 30.2) 0.111 
*
Parametric data reported as mean (SD)- One way anova,  
+ 
Non-parametric data reported as median (IQR)  
Kruskal-Wallis test 
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones other  
Asian background, n = 4, East African Asian, n=22.  
 
Table 72 Distribution of lipids and biochemical measures in South Asian women by ethnic groups 
 
Characteristics 
Women by ethnic groups
^
 (Total n=211) P value 
Indians  
(n= 119) 
Pakistani  
(n= 77) 
Bangladeshis  
(n= 15) 
Apolipoprotein AI (g/l)
+
 1.37 (1.20 – 1.54) 1.40 (1.17 – 1.60) 1.32 (1.14 – 1.52) 0.936 
Apolipoprotein B (g/l)
*
 0.72 (0.20) 0.72 (0.21) 0.75 (0.30) 0.817 
Serum cholesterol (mmol/l)
* 
4.75 (1.24) 4.80 (1.40) 4.81 (1.20) 0.973 
HDL cholesterol (mmol/l)
* 
1.20 (0.40) 1.15 (0.40) 1.15 (0.41) 0.630 
LDL cholesterol (mmol/l)
* 
2.70 (0.82) 2.60 (0.90) 2.70 (0.90) 0.691 
Triglycerides (mmol/l)
+
 1.83 (1.45 – 2.60) 2.01 (1.30 – 2.84) 2.04 (1.23 – 2.40) 0.849 
Calculated fasting triglycerides
+ 
1.76 (1.21 – 2.40) 2.10 (1.20 – 2.80) 1.91 (1.50 – 2.50) 0.347 
Alkaline phosphatase (U/L)
+
  72.0 (59.4 – 87.0) 76.0 (63.2 – 89.2) 74.0 (64.1 – 95.0) 0.716 
Alanine transaminase (U/L)
+ 
17.0 (13.0 – 20.4) 15.4 (12.1 – 21.1) 14.0 (11.3 – 21.4) 0.648 
Aspartate transaminase (U/L)
+ 
18.0 (15.0 – 22.0) 19.0 (15.4 – 25.1) 19.2 (14.0 – 23.1) 0.525 
Creatinine (µmol/l)
+ 
53.0 (47.0 – 61.0) 51.0 (45.3 – 63.0) 51.0 (48.0 – 58.0) 0.931 
Gamma glutamyl transpeptidase  
(U/L)
+ 
17.1 (12.1 – 28.0) 19.4 (13.0 – 30.0) 17.0 (13.0 – 27.4) 0.392 
*
Parametric data reported as mean (SD)- One way anova, 
+ 
Non-parametric data reported as median (IQR)- 
Kruskal-Wallis test.
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, 
excluded ones East 
African Asian, n=18.  
 
5 .1 .2 .2  Dys l ip idaemia  character i s t i cs  of  South  Asia n  men  and  w omen 
asymptomat ic  for  card iovascu lar  d i sease  in  the  UK  
The section gives an overview of the prevalence of dyslipidaemia in South Asian men and 
women asymptomatic for CVD in the UK.   
In South Asians asymptomatic for CVD, the prevalence of raised triglyceride, low HDL-c and 
combined raised triglyceride and low HDL-c were significantly more amongst South Asian men 
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compared to South Asian women, all p<0.05. Table 73 shows the dyslipidaemia characteristics of 
South Asian men and women in the UK.     
Table 73 Dyslipidaemia characteristics of South Asian men and women in the UK 
Dyslipidaemic category South Asian men South Asian women P value 
Raised serum cholesterol (>5.18 mmol/l), n (%) 89 (34.0) 80 (37.0) 0.480 
Raised serum triglyceride (>1.7 mmol/l), n (%) 178 (66.4) 127 (57.0) 0.031 
Low HDL cholesterol (<0.9 mmol/l in men & 
<1.0 mmol/l in women), n (%) 
104 (39.2) 67 (31.0) 0.050 
Isolated HDL cholesterol (<0.9 mmol/l in men 
& <1.0 mmol/l in women in the absence of 
other lipid abnormalities), n (%) 
18 (26.1) 20 (28.2) 0.782 
Raised serum triglyceride and low HDL 
cholesterol, n (%) 
81 (31.0) 45 (20.4) 0.011 
Chi-square test 
Amongst South Asian men, the prevalence of raised serum triglyceride (≥ 1.7 mmol/l) was higher 
in Indian men compared to Pakistani men and Bangladeshi men, p=0.010. Dyslipidaemia 
characteristics of South Asian men by ethnic groups in the UK are shown in Table 74. 
Dyslipidaemic characteristics of South Asian women by ethnic groups in the UK are shown in  
Table 75. There were no significant differences in the prevalence of dyslipidaemia characteristics 
amongst South Asian women belonging to different ethnic groups. 
Table 74 Dyslipidaemic characteristics of South Asian men by ethnic groups in the UK 
 
Dyslipidaemic category 
South Asian men by ethnic groups  
(Total n =250) 
P value 
Indians  
(n= 129) 
Pakistani 
(n= 99) 
Bangladeshi  
(n= 22) 
 
Raised serum cholesterol (>5.18 mmol/l), n 
(%) 
45 (37.2) 25 (25.3) 8 (36.4) 0.154 
Raised serum triglyceride (>1.7 mmol/l), n (%) 93 (73.2) 63 (64.3) 8 (40.0) 0.010 
Low HDL cholesterol (<0.9 mmol/l in men & 
<1.0 mmol/l in women), n (%) 
44 (37.0) 41 (41.4) 10 (46.0) 0.644 
Isolated HDL cholesterol (<0.9 mmol/l in men 
& <1.0 mmol/l in women in the absence of 
other lipid abnormalities), n (%) 
7 (5.4) 6 (6.1) 3 (13.6) 0.342 
Raised serum triglyceride and low HDL 
cholesterol, n (%) 
37 (30.3) 32 (32.7) 6 (27.3)  0.863 
Chi-square test 
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Table 75 Dyslipidaemic characteristics of South Asian women by ethnic groups in the UK 
 
Dyslipidaemic category 
South Asian women by ethnic groups  
(Total n =250) 
P value 
Indians  
(n= 119) 
Pakistanis  
(n= 77) 
Bangladeshi  
(n= 15) 
 
Raised serum cholesterol (>5.18 mmol/l), n 
(%) 
47 (42.0) 22 (30.0) 5 (33.3) 0.202 
Raised serum triglyceride (>1.7 mmol/l), n (%) 69 (59.0) 43 (58.1) 9 (64.3) 0.908 
Low HDL cholesterol (<0.9 mmol/l in men & 
<1.0 mmol/l in women), n (%) 
30 (27.0) 26 (34.2) 5 (33.3)  0.506 
Isolated HDL cholesterol (<0.9 mmol/l in men 
& <1.0 mmol/l in women in the absence of 
other lipid abnormalities), n (%) 
9 (8.0) 7 (9.1) 0 (0) 0.477 
Raised serum triglyceride and low HDL 
cholesterol, n (%) 
20 (17.4) 17 (23.0) 5 (33.3) 0.291 
Chi-square test 
5 .1 .2 .3  The associa t ion  betw een  l ip ids ,  l ipoprote ins  and  cardiovascu lar  
r i sk  fac tors  in  South  As ian  men  and  women  asymptomat ic  f or  
card iovascu lar  d i sease  in  the  UK 
Correlation analysis was performed to determine the clinical correlates of total cholesterol, LDL-
c, HDL-c, triglycerides and apolipoproteins.  
Total cholesterol and LDL-c levels were comparable in South Asian men and South Asian 
women; hence correlation analysis was performed for the entire cohort. Total cholesterol was 
positively associated with ApoB, HDL-c, LDL-c, diastolic blood pressure, HbA1c, ApoA, 
triglycerides measured & calculated, alkaline phosphatase, ALT, AST, creatinine, GGT and 10 
year CVD risk score, all p<0.05. LDL-c levels were positively associated with ApoB, total 
cholesterol, HDL-c, HbA1c,  ApoAI, triglycerides measured & calculated, alkaline phosphatase, 
ALT, AST, creatinine, GGT and 10 year CVD risk score, all p<0.05. Correlation analysis for total 
cholesterol and LDL-c in South Asians are shown in table 76. 
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Table 76 Correlation analysis for total cholesterol and LDL-cholesterol in South Asians asymptomatic for 
cardiovascular disease in the UK 
Variables  Cholesterol (mmol/l) LDL cholesterol (mmol/l) 
Pearson correlation coefficient, r                                                          
Apolipoprotein B (g/l) 0.772
** 
0.810
** 
Cholesterol (mmol/l) - 0.822
** 
HDL cholesterol (mmol/l) 0.352
** 
0.348
** 
LDL cholesterol (mmol/l) 0.822
** 
- 
Diastolic blood pressure (mmHg) 0.106
* 
NS 
Spearman correlation coefficient, r 
Glycated haemoglobin (HbA1c) (%) 0.101
* 
0.120
* 
Apolipoprtoein A (g/l) 0.491
** 
0.388
** 
Calculated triglyceride  0.505
** 
0.201
** 
Triglyceride (mmol/l) 0.293
** 
0.097
* 
Alkaline phosphatase (U/L) 0.224
** 
0.160
** 
Alanine transaminase (U/L)
+ 
0.192
** 
0.179
** 
Aspartate transaminase (U/L)
+ 
0.218
** 
0.195
** 
Creatnine (µmol/l)
+ 
0.160
** 
0.163
** 
Gamma glutamyl transpeptidase (U/L)
+
 0.234
**
 0.183
** 
10 year CHD risk score (%) 0.257
** 
0.225
** 
*
p<0.05, 
**
p<0.001, NS- non significant, Other variables included in the analysis were age, gender,  
BMI, waist measurement, systolic blood pressure, haemoglobin, red blood cell count and white blood  
cell count.  
 
 
Correlation analysis for HDL-c, triglycerides and calculated fasting triglycerides in South Asian 
men and women are shown in table 77 and 78. In South Asian men, HDL-c was positively 
associated with total cholesterol, LDL-c, ApoAI and AST and negatively associated with waist 
measurement, BMI, red blood cell count, triglyceride –non-fasting & calculated, and 10 year 
CHD risk score, all p<0.05. Triglyceride levels and calculated fasting triglycerides were 
positively associated with ApoB, total cholesterol, waist measurement, BMI, systolic blood 
pressure, diastolic blood pressure, alkaline phosphatase, ALT, GGT and 10 year CVD risk score 
and were negatively associated with HDL-c in South Asian men. Furthermore, calculated fasting 
triglycerides alone were positively associated red blood cell count, haemoglobin, AST and 
creatinine while triglyceride levels were negatively associated with age. 
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In South Asian women, HDL-c was positively associated with ApoB, total cholesterol, LDL-c, 
ApoA, ALT, AST and creatinine, and negatively with BMI, white blood cell, triglycerides- non-
fasting & calculated and 10 year CVD risk score. Triglyceride was positively associated with 
ApoB, total cholesterol, waist circumference, alkaline phosphatase, GGT and 10 year CVD risk 
score and negatively with HDL-c, ApoA and AST. Calculated fasting triglyceride levels were 
positively associated with ApoB, total cholesterol, LDL-c, waist measurement, alkaline 
phosphatase, GGT and 10 year CHD risk score and negatively with HDL-c.  
Table 77 Correlation analysis for lipids in South Asian men in the UK 
Variables  HDL cholesterol 
(mmol/l) 
 
Triglycerides 
(mmol/l) 
Calculated fasting 
triglycerides  
Pearson correlation coefficient, r Spearman’s correlation coefficient, r 
Age (years) NS -0.139
* 
NS 
Apolipoprotein B (g/l) NS 0.302
** 
0.431
** 
Cholesterol (mmol/l) 0.298
** 
0.320
** 
0.548
** 
HDL cholesterol (mmol/l) - -0.396
** 
-0.217
** 
LDL cholesterol (mmol/l) 0.319
** 
 NS 0.208
* 
Waist circumference (cm) -0.233
** 
0.188
* 
0.140
* 
Body mass index (kg/m
2
) -0.197
* 
0.212
** 
0.237
** 
Systolic blood pressure (mmHg) NS 0.194
* 
0.165
* 
Diastolic blood pressure (mmHg) NS 0.232
** 
0.198
* 
Red blood cell count -0.191
* 
NS 0.208
* 
Haemoglobin (g/l) NS NS 0.207
* 
Spearman’s correlation coefficient, r  
Apolipoprotein A (g/l) 0.800
** 
NS NS 
Calculated triglyceride  -0.217
** 
0.704
** 
- 
Triglyceride (mmol/l) -0.396
** 
- 0.704
** 
Alkaline phosphatase (U/L) NS 0.135
* 
0.310
** 
Alanine transaminase (U/L)
+ 
NS 0.191
* 
0.247
** 
Aspartate transaminase (U/L)
+ 
0.193
* 
NS 0.162
* 
Creatnine (µmol/l)
+ 
NS NS 0.130
* 
Gamma glutamyl transpeptidase  
(U/L)
+
 
NS 0.211
*
 0.274
** 
10 year CHD risk score (%) -0.296
** 
0.371
** 
0.462
** 
*
p<0.05, 
**
p<0.001, NS- non significant 
Other variables included in the analysis were age systolic blood pressure and white blood cell count. 
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Table 78 Correlation analysis for lipids in South Asian women in the UK 
Variables  HDL cholesterol 
(mmol/l) 
 
Triglycerides 
(mmol/l) 
Calculated fasting 
triglycerides  
Pearson correlation coefficient, r Spearman’s correlation coefficient, r 
Apolipoprotein B (g/l) 0.190
* 
0.285
** 
0.367
** 
Cholesterol (mmol/l) 0.423
** 
0.280
** 
0.461
** 
HDL cholesterol (mmol/l) - -0.400
** 
-0.223
* 
LDL cholesterol (mmol/l) 0.406
** 
NS 0.190
* 
Waist circumference (cm) NS 0.210
* 
0.230
* 
Body mass index (kg/m
2
) -0.141
* 
NS NS 
Systolic blood pressue (mmHg) NS NS NS 
Diastolic blood pressure (mmHg) NS NS NS 
White blood cell count -0.235
* 
NS NS 
Haemoglobin (g/l) NS NS NS 
Spearman’s correlation coefficient, r  
Apolipoprotein A (g/l) 0.888
** 
-0.136
* 
NS 
Calculated fasting triglyceride  -0.223
* 
0.725
** 
- 
Triglyceride (mmol/l) -0.400
** 
- 0.725
** 
Alkaline phosphatase (U/L) NS 0.185
* 
0.204
* 
Alanine transaminase (U/L)
+ 
0.188
* 
NS NS 
Aspartate transaminase (U/L)
+ 
0.401
** 
-0.145
* 
NS 
Creatinine (µmol/l)
+ 
0.271
** 
NS NS 
Gamma glutamyl transpeptidase  
(U/L)
+
 
NS 0.220
* 
0.250
** 
10 year CHD risk score (%) -0.416
** 
0.501
** 
0.425
**
 
*
p<0.05, 
**
p<0.001, NS- non significant 
Other variables included in the analysis were age and red blood cell count. 
 
 
Correlation analysis for lipoproteins in South Asian men and women are shown in table 79. 
ApoAI was positively associated with ApoB, total cholesterol, HDL-c, LDL-c, alkaline 
phosphatase, ALT, AST, creatinine and negatively with 10 year CHD risk score in South Asian 
men and women. In South Asian men only, ApoAI was positively associated with systolic blood 
pressure and GGT.  
In South Asian men and South Asian women, ApoB was positively associated with total 
cholesterol, LDL-c, ApoAI, calculated fasting triglycerides, triglycerides, alkaline phosphatase,  
AST, creatinine, and 10 year CVD risk score, all p<0.05.  In South Asian men alone, ApoB was 
negatively associated with age and positively with waist circumference, BMI, diastolic blood 
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pressure, red blood cell count, haemoglobin, ALT and gamma glutamyl transpeptidase. In South 
Asian women alone, ApoB was positively associated with HDL-c and HbA1c, p<0.05.  
Table 79 Correlation analysis for lipoproteins in South Asian men and women in the UK 
Variables South Asian 
men 
South Asian 
women 
 
South Asian 
 Men 
South Asian 
women 
Apolipoprtein AI (g/l)
 
Apolipoprotein B (g/l)
 
Correlation coefficient, r                              Spearman’s correlation 
coefficient, r 
Pearson’s correlation coefficient, r 
Age (years)
 
NS NS -0.169
* 
NS 
Apolipoprotein B (g/l) 0.290
** 
0.322
** - 
- 
Cholesterol (mmol/l) 0.463
** 
0.537
** 
0.755
** 
0.814
** 
HDL cholesterol (mmol/l) 0.800
** 
0.888
** 
NS 0.190
* 
LDL cholesterol (mmol/l) 0.350
** 
0.445
** 
0.778
** 
0.868
** 
Waist circumference (cm) NS NS 0.166
* 
NS 
Body mass index (kg/m
2
) NS NS 0.142
* 
NS 
Systolic blood pressue (mmHg) 0.140
* 
NS NS NS 
Diastolic blood pressure (mmHg) NS NS 0.139
* 
NS 
Glycated hemoglobin (%) NS NS NS 0.151
* 
Red blood cell count NS NS 0.170
* 
NS 
Hemoglobin (g/dL) NS NS 0.273
* 
NS 
 Spearman’s correlation coefficient, r 
Apolipoprtoein A (g/l)
 
- NS 0.290
** 
0.322
** 
Calculated triglyceride
 
NS NS 0.431
** 
0.367
** 
Triglyceride (mmol/l)
 
NS NS 0.302
** 
0.285
** 
Alkaline phosphatase (U/L) 0.222
** 
0.167
* 
0.183
* 
0.190
* 
Alanine transaminase (U/L)
 
0.186
* 
0.238
** 
0.258
** 
NS 
Aspartate transaminase (U/L)
 
0.276
** 
0.409
** 
0.138
* 
0.153
* 
Creatnine (µmol/l)
 
0.172
* 
0.301
** 
0.166
* 
0.190
* 
Gamma glutamyl transpeptidase  
(U/L)
 
0.200* NS 0.313
** 
NS 
10 year CHD risk score (%)
 
-0.127
* 
-0.221
** 
0.302
** 
0.344
** 
 
5.1 .2 .4  The performance of  non-fast ing  tr ig lycer ides ,  calculated 
tr ig lycer ides  and l ipoprote ins  in  the  predict ion of  
cardiovascular  r i sk  in  South Asians  asymptomatic  for 
cardiovascular  d isease:  ROC analys is  
ROC analysis was done to evaluate the performance of non-fasting triglycerides and calculated 
triglycerides in the identification of South Asians at an increased risk of CVD.  
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On ROC analysis, measured non-fasting triglycerides significantly discriminated South Asians 
with greater obesity (those with increased BMI and waist circumference), metabolic syndrome 
and raised 10 year CHD risk score from healthy South Asians, all p<0.05 whilst calculated 
triglycerides significantly discriminated South Asians with obesity, metabolic syndrome and 
raised 10 year CHD risk score from healthy South Asians, all p<0.05 (Table 80).  
Amongst apolipoproteins, ApoAI significantly discriminated South Asians with hypertension, 
metabolic syndrome and raised 10 year CHD risk score from healthy South Asians, all p<0.05.  
ApoB significantly discriminated those with metabolic syndrome and raised 10 year CHD risk 
score from healthy South Asians, p<0.001 (Table 80).  
Validity of lipids and lipoproteins were not evaluated in South Asians symptomatic for CVD risk 
factors (n=519) and CVD (n=198), this was due to the effect of lipid lowering therapy and anti-
diabetic therapy on lipids.  
Table 80 Calculated triglycerides and lipoprotein  measures as a discriminator of cardiovascular risk in South 
Asians asymptomatic for cardiovascular disease 
Triglyceride & 
lipoproteins  
Raised blood pressure (>130 mmHg or 
85 mmHg) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
 
P value  AUC 95% CI P value  AUC 95% CI 
Calculated 
triglycerides 
0.170 0.538 0.484-0.591 0.958 0.502 0.420-0.585 
Triglycerides (mmol/l) 0.080 0.548 0.494-0.602 0.790 0.489 0.408-0.570 
Apolipoprotein AI 
 (g/l) 
0.041 0.556 0.503-0.609 0.350 0.462 0.383-0.541 
Apolipoprotein B  
(g/l) 
0.939 0.498 0.444-0.552 0.604 0.521 0.434-0.608 
Triglyceride & 
lipoproteins  
Body mass index (> 27kg/m
2
) 
 
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) 
P value AUC 95% CI P value AUC 95% CI 
Calculated 
triglycerides 
0.010 0.568 0.516-0.619 0.095 0.554 0.489-0.620 
Triglycerides (mmol/l) 0.040 0.555 0.504-0.606 0.052 0.563 0.494-0.631 
Apolipoprotein A1 
 (g/l) 
0.817 0.494 0.442-0.545 0.496 0.900 0.431-0.561 
Apolipoprotein B 
 (g/l) 
0.523 0.517 0.465-0.569 0.056 0.562 0.497-0.627 
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Triglyceride & 
lipoproteins  
Metabolic syndrome
*
 (ATP III defined) 10 years CHD risk score (>20% high 
risk) 
P value AUC 95% CI P value  AUC 95% CI 
Calculated 
triglycerides 
<0.001 0.727 0.682-0.771 <0.001 0.709 0.630 – 0.788 
Triglycerides (mmol/l) <0.001 0.822 0.784-0.860 <0.001 0.665 0.588-0.743 
Apolipoprotein A1 
 (g/l) 
<0.001 0.356 0.307-0.405 <0.001 0.349 0.288-0.410 
Apolipoprotein B  
(g/l) 
0.005 0.574 0.523-0.625 0.005 0.611  0.533-0.690 
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
ROC anal;ysis in 505 South Asians aymptomatic for CVD 
 
5.1.3  Discussion 
The aim was to evaluate the diagnostic validity of calculated triglycerides and non-fasting 
triglycerides in the discrimination of CVD risk in South Asians asymptomatic for CVD in the 
UK. Both measures of triglycerides discriminated those South Asians with obesity or metabolic 
syndrome or raised 10 year CHD risk score from healthy South Asians.  
The direct pathophysiogical role of triglycerides in the development of CVD is not clear. Recent 
evidence support the hypothesis that atherosclerosis is a postprandial phenomenon. After food 
consumption, hydrolysis of triglycerides within chylomicrons generates atherogenic triglyceride-
rich remnant lipoprotein, hence greater accumulation of atherogenic particles with elevated levels 
of postprandial triglyceride. Non-fasting triglycerides have shown to be strongly correlated with 
atherogenic triglyceride-rich remnant lipoprotein and are a strong independent predictor of 
incident CVD after adjustment for traditional CVD risk factors compared to fasting levels of 
triglyceride (Jeppesen et al., 1995; Bansal et al., 2007; Nordestgaard et al., 2007).  
Amongst lipoproteins, ApoAI significantly discriminated South Asians with hypertension, 
metabolic syndrome and raised 10 year CHD risk score from healthy South Asians, all AUC 
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(0.349 – 0.556), p<0.05. ApoB significantly discriminated those with metabolic syndrome and 
raised 10 year CHD risk score from healthy South Asians, all AUC (0.574 – 0.611), p<0.001. 
The study also characterised lipid and lipoprotein measures in South Asians belonging to various 
backgrounds living in the UK. With regards to lipid and lipoprotein measures, a significant 
difference was observed only in triglyceride levels amongst South Asian men, with Indian men 
and Pakistani men having a higher triglyceride levels [2.33 mmol/l (1.68 – 3.18)] and [2.13 
mmol/l (1.50 – 2.90)] respectively compared to Bangladeshi men [1.54 mmol/l (1.20 – 2.30)], 
p=0.027.  
The prevalence of raised triglycerides was higher amongst South Asian men compared to South 
Asian women. Further analysis showed the prevalence of raised triglycerides was higher in 
Indian men compared to Pakistani and Bangladeshi men. The prevalence of low HDL-c was also 
higher amongst South Asian men but was comparable across different ethnic groups. Similarly, 
the prevalence of combined raised triglycerides and low HDL-C was significantly higher 
amongst South Asian men compared to South Asian women but was comparable across ethnic 
groups.  
5.1 .3 .1  Conclus ion 
Calculated triglycerides and non-fasting triglyceride levels discriminated South Asians with 
increased risk of CVD and hence can be used as an alternative for fasting triglyceride 
measurements in routine clinical practice.  
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5.2  Genotype-  phenotype and genotype -disease associat ion  of  
l ipids  in  South  Asians  
5.2.1  Aims and hypothesis  
Genetic association studies in non-Asian populations have identified -455T>C (rs2854116) and -
482C>T (rs2854117) within the promoter region of Apolipoprotein C3 gene on chromosome 
11q23-q24  and -1131T>C (rs662799) on Apolioprotein A5 gene on chromosome 11q23 to be 
associated with levels of triglyceride and CVD, yet genetic association studies amongst South 
Asians are scarce. The aim of this section was to determine the allelic frequency of rs2854116, 
rs2854117 and rs662799 and the contribution of these SNPs to inter-individual variability in 
blood lipids, metabolic syndrome and CVD in South Asians.   
5.2.2  Genotype-phenotype and genotype-disease association of 
l ipids in South Asians  
5 .2 .2 .1  Characteri s t i cs  of  the  s tudy cohort    
The study population were recruited through the E-ECHOES and NIASTAR study, the 
characteristics of the genetic study cohort and distribution of lipid profiles and biochemical 
measures are shown in Chapter 4 Result section 2, Table 54 & 55.  
With regards to the characteristics amongst men by ethnic groups, as seen previously, there were 
more smokers amongst Bangladeshi men. The prevalence of hypertension was higher amongst 
Indian men, and the prevalence of T2DM was highest in Bangladeshi men.  The prevalence of 
obesity and central obesity were highest amongst Pakistani men. Characteristics of South Asian 
men by ethnic groups are shown in Table 81. Characteristics of South Asian women by ethnic 
groups are shown in Table 82. Amongst women belonging to different ethnic groups, Indian 
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women were much older compared to Pakistani and Bangladeshi women, p=0.015. The 
prevalence of obesity was higher in Pakistani women. 
Table 81 Characteristics of men by  ethnic groups 
 
Characteristics 
Men by ethnic groups
^ 
( Total n=558)   
P value  Indians  
(n= 296) 
Pakistanis  
(n= 207) 
Bangladeshis  
(n= 55) 
Age (years)
* 
59.5 (10.2) 59.0 (11.0) 57.2 (12.0) 0.339 
Current smokers, n (%) 49 (20.0) 83 (44.0) 38 (73.1) <0.001 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
246 (83.1) 154 (74.4) 39 (71.0) 0.021 
Diabetes mellitus (HbA1c ≥  
6.5%), n (%)  
102 (35.0) 93 (45.4) 26 (47.3) 0.024 
Obesity (BMI≥27 kg/m2), n (%)  134 (48.0) 111 (55.0) 19 (36.0) 0.030 
Increased waist Circumference (≥ 90 
cm in men and ≥ 80 cm in women), n 
 (%)  
236 (85.0) 178 (88.0) 40 (74.1) 0.050 
Systolic blood pressure (mmHg)
*
 141.5 (18.2) 137.0 (19.5) 134.4 (18.0) 0.004 
Diastolic blood pressure (mmHg)
*
 83.0 (10.2) 82.0 (12.2) 80.2 (10.3) 0.267 
Waist circumference (cm)
*
 93.0 (28.0) 97.4 (19.4) 94.4 (8.1) 0.119 
Body mass index (kg/m2)
* 
27.4 (4.0) 28.0 (4.0) 26.0 (3.6) 0.002 
Metabolic syndrome, n (%)
 # 
169 (59.0) 119 (58.3) 26 (50.0) 0.505 
Prevalent cardiovascular disease, n 
(%) 
88 (30.0) 59 (29.0) 11 (20.0) 0.338 
*
Parametric data reported as mean (SD)- One way anova, n(%)-Chi-square test.  
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones other  
Asian background, n = 4, East African Asian, n=32.  
# #
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was 
included in the ATP III clinical identification of the metabolic syndrome 
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Table 82 Characteristics of women by  ethnic groups 
 
Characteristics 
Women by ethnic groups
^ 
( Total n= 419)  
P value  Indians  
(n= 230) 
Pakistanis  
(n= 148) 
Bangladeshis 
(n= 41) 
Age (years)
* 
58.4 (10.0) 56.0 (9.5) 57.1 (7.1) 0.015 
Current smokers, n (%) 3 (1.4) 4 (3.0) 1 (3.0) 0.629 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
182 (79.1) 108 (73.0) 33 (81.0) 0.328 
Diabetes mellitus (HbA1c ≥  
6.5%), n (%)  
74 (33.0) 53 (36.0) 13 (32.0) 0.770 
Obesity (BMI≥27 kg/m2), n (%)  139 (62.1) 115 (79.3) 21 (53.0) <0.001 
Increased waist Circumference (≥ 90 
cm in men and ≥ 80 cm in women), n 
 (%)  
203 (91.0) 140 (95.2) 38 (95.0) 0.208 
Systolic blood pressure (mmHg)
*
 143.1 (20.2) 140.4 (21.1) 139.0 (23.0) 0.277 
Diastolic blood pressure (mmHg)
*
 82.0 (11.0) 83.0 (12.0) 83.0 (12.2) 0.479 
Waist circumference (cm)
*
 90.4 (20.3) 98.1 (13.0) 95.4 (21.2) <0.001 
Body mass index (kg/m2)
* 
29.0 (5.0) 31.0 (5.3) 29.0 (6.0) 0.008 
Metabolic syndrome, n (%)
 # 
136 60.0) 90 (62.1) 26 (65.0) 0.799 
Prevalent cardiovascular disease, n 
 (%)
 
43 (19.0) 20 (14.0) 6 (15.0) 0.393 
*
Parametric data reported as mean (SD) - One way anova, n(%)-Chi-square test.  
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones East 
African Asian, n=21. Sri Lankan =1, Other Asian background=2.  
# #
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was 
included in the ATP III clinical identification of the metabolic syndrome 
 
 
With regards to lipids and biochemical measures in South Asian men by ethnic groups, levels of 
ApoAI were higher in Indian men [1.28 g/l (1.10 – 1.53)] compared to Pakistani men [1.21 g/l 
(1.10 – 1.34)] and Bangladeshi men [1.19 g/l (1.10 – 1.32)], p=0.005. Levels of total cholesterol 
were lowest in Indian men at 3.90 mmol/l (1.8), p=0.051 and levels of HDL-c were highest in 
Indian men at 1.01 mmol/l (0.4), p=0.015. Levels of alkaline phosphatase, and creatinine were 
highest amongst Bangladeshi men, p≤0.015. Distribution of lipids and biochemical measures in 
South Asian men by ethnic groups are shown in Table 83. Distribution of lipids and biochemical 
measures in South Asian women by ethnic groups are shown in Table 84. There were no 
significant differences in the levels of lipid measures in South Asian women belonging to 
different ethnic groups.  
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Table 83 Distribution of lipids and biochemical measures in South Asian men by ethnic groups 
 
Characteristics 
Men by ethnic groups
^  
(Total n=558)  
P value Indians  
(n= 296) 
Pakistanis  
(n= 207) 
Bangladeshi  
(n= 55) 
Apolipoprotein AI (g/l)
+
 1.28 (1.10 – 1.53) 1.21 (1.10 – 1.34) 1.19 (1.10 – 1.32) 0.005 
Apolipoprotein B (g/l)
+ 
0.71 (0.53 – 0.86) 0.69 (0.54 – 0.84) 0.65 (0.52 – 0.89) 0.735 
Serum cholesterol (mmol/l)
* 
3.90 (1.8) 4.24 (1.4) 4.24 (1.4) 0.051 
HDL cholesterol (mmol/l)
* 
1.01 (0.40) 0.94 (0.30) 0.90 (0.22) 0.015 
LDL cholesterol (mmol/l)
* 
2.21 (0.95) 2.24 (0.90) 2.34 (0.94) 0.627 
Triglycerides (mmol/l)
+
 1.89 (1.31 – 2.76) 2.22 (1.50 – 2.97) 1.93 (1.18 – 3.01) 0.132 
Alkaline phosphatase (U/L)
+
  68.1 (53.1 – 82.4) 71.4 (61.0 – 90.0) 73.0 (62.0 – 88.1) 0.015 
Alanine transaminase (U/L)
+ 
21.2 (16.0 – 30.0) 21.2 (16.2 – 31.2) 21.0 (17.3 – 31.0) 0.823 
Aspartate transaminase (U/L)
+ 
19.1 (16.3 – 24.3) 20.4 (17.0 – 25.0) 20.4 (17.0 – 26.2) 0.277 
Creatinine (µmol/l)
+ 
67.0 (56.0 – 77.0) 74.0 (64.0 – 84.0) 76.0 (65.0 – 90.0) <0.001 
Gamma glutamyl transpeptidase  
(U/L)
+ 
26.0 (17.0 – 46.0) 30.0 (19.0 – 44.0) 30.0 (19.1 – 45.1) 0.369 
*
Parametric data reported as mean (SD) – One way anova, + Non-parametric data reported as median (IQR) –  
Kruskal –Wallis test. 
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones other  
Asian background, n = 4, East African Asian, n=32.  
 
Table 84 Distribution of lipids and biochemical measures in South Asian women by ethnic groups 
 
Characteristics 
Women by ethnic groups
^
 (Total n = 419) P value 
Indians  
(n= 230) 
Pakistanis 
(n= 148) 
Bangladeshis 
(n= 41) 
Apolipoprotein AI (g/l)
+
 1.35(1.17 – 1.55) 1.32 (1.16 – 1.51) 1.27(1.01 – 1.54) 0.485 
Apolipoprotein B (g/l)
*
 0.66 (0.52 – 0.81) 0.66 (0.51 – 0.82) 0.58 (0.43 – 0.80) 0.186 
Serum cholesterol (mmol/l)
* 
4.20 (1.7) 4.33 (1.4) 4.00 (1.4) 0.280 
HDL cholesterol (mmol/l)
* 
1.12 (0.4) 1.10 (0.3) 1.10 (0.4) 0.588 
LDL cholesterol (mmol/l)
* 
2.28 (0.9) 2.28 (0.9) 2.04 (0.9) 0.272 
Triglycerides (mmol/l)
+
 1.81 (1.34 – 2.62) 1.92 (1.31 – 2.81) 2.03 (1.47 – 2.82) 0.531 
Alkaline phosphatase (U/L)
+
  74.0 (60.0 – 92.2) 75.0 (61.1 – 91.0) 66.1 (48.0 – 82.20 0.132 
Alanine transaminase (U/L)
+ 
16.0 (12.0 – 20.2) 16.1 (13.0 – 22.2) 16.0 (13.0 – 21.2) 0.386 
Aspartate transaminase (U/L)
+ 
17.4 (14.2 – 21.3) 18.3 (14.3 – 22.3) 19.1 (15.2 – 22.0) 0.306 
Creatinine (µmol/l)
+ 
55.0 (46.0 – 64.0) 50.5 (45.0 – 65.0) 55.0 (48.0 – 60.3) 0.836 
Gamma glutamyl transpeptidase  
(U/L)
+ 
17.7 (12.3 – 26.4) 21.1 (15.0 – 33.0) 21.2 (16.0 – 32.2) 0.002 
*
Parametric data reported as mean (SD)- One way anova, 
+ 
Non-parametric data reported as median (IQR)-  
Kruskal-Wallis test. 
^
 Included only subjects who reported their ethnicity as Indian, Pakistani or Bangladeshi, excluded ones East 
African Asian, n=21. Sri Lankan =1, Other Asian background=2.  
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5 .2 .2 .2  Genotype  f requency  and  a l l e l i c  f requency  of  rs 2854116 ,  
rs2854117  and  rs662799  in  South  As ians  in  the  UK 
For rs2854116 and rs2854117, the minor allele frequency for C allele was 0.52 and T allele was 
0.41 respectively. The carrier frequency for rs2854116 and rs2854117 in our cohort was 76% and 
64.2% respectively. The minor allelic frequency for rs662799 was 0.17 and the carrier frequency 
in our cohort was 32%. The minor allele frequency is higher than those reported in Whites, 0.17 
vs. 0.04. All the SNPs met the assumption of the Hardy Weinberg Theory. 
 The genotype frequencies for rs2854116, rs2854117 and rs662799 were comparable by ethnic 
groups. Table 85 shows the genotype frequencies and allelic frequencies of rs2854116, 
rs2854117 and rs662799 in South Asians by ethnic groups in the UK.  
Table 85 Genotype and allelic  frequencies of rs2854116, rs2854117 and  rs662799  in South Asians by ethnic 
groups in the UK 
Genotypes Indians 
n = 527 
Pakistanis 
n = 357 
Bangladeshis 
n = 97 
Total 
number of 
subjects 
(%)* 
Minor allele 
frequency,  
(95% CI) 
P 
value 
 
rs2854116 
TT (wild 
type) 
106 (21.0) 23 (25.3) 95 (28.0) 245 (24.0) 52.0 (51.0-
53.4) 
0.135 
TC 257 (51.0) 48 (53.0) 153 (45.0) 495 (48.5) 
CC 142 (28.1) 20 (22.0) 96 (28.0) 279 (27.4) 
 
rs2854117 
CC (wild 
type) 
178 (36.0) 27 (31.0) 120 (37.0) 353 (36.0) 41.3 (40.0-
43.0) 
0.726 
TC 226 (46.0) 46 (53.0) 146 (44.4) 453 (46.0) 
TT 90 (18.2) 14 (16.1) 63 (19.1) 182 (18.4) 
rs662799 TT (wild 
type) 
362 (27.0) 58 (60.4) 246 (70.0) 715 (68.4) 17.4 (16.1-
19.0) 
0.407 
TC 137 (27.0) 34 (35.4) 96 (27.3) 294 (28.2) 
CC 18 (3.5) 4 (4.2) 10 (2.8) 35 (3.4) 
*This included East African Asians, Sri Lankan, subjects from other Asian background  
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5 .2 .2 .3  The associa t ion  betw een  APOC3 promoter  po lymorphisms 
(rs2854116  & rs2854117) ,  cardiovascu lar  r i sk  fac tors  and  l ip id  
measures  in  South  As ians  in  the  UK  
There was no significant difference in terms of demographics, lipid levels and prevalent CVD 
among the two groups divided as rs2854116 genotype, wild type (TT) and carriers of minor allele 
(TC & CC) (Table 86 & 87).  
Table 86 Distribution of cardiovascular disease risk factors across rs2854116 genotypes 
 
 
 
TT (wild type) 
(n = 245) 
Carriers of minor alleles 
(TC & CC) (n = 774) 
P value 
Age (years) 58.0 (10.3) 58.0 (11.0) 0.701 
Male gender, n (%) 136 (56.0) 442 (58.0) 0.640 
Current smokers, n (%) 39 (18.0) 137 (20.3) 0.449 
Hypertension, n (%) 191 (78.0) 605 (78.2) 0.946 
Diabetes mellitus, n (%) 31 (13.0) 95 (12.3) 0.843 
Obesity, n (%) 139 (60.0) 418 (57.0) 0.508 
Increased waist 
circumference, n (%) 
213 (91.0) 640 (87.1) 0.105 
Systolic blood pressure (mmHg)
*
 140.0 (23.0) 140.4 (20.0) 0.728 
Diastolic blood pressure (mmHg)
*
 82.4 (13.0) 82.0 (11.3) 0.609 
Waist circumference (cm)
*
 95.4 (23.0) 93.0 (24.2) 0.127 
Body mass index (kg/m2)
* 
29.0 (5.0) 28.2 (5.0) 0.297 
Metabolic syndrome, n (%)
 # 
146 (61.0) 434 (60.0) 0.432 
Prevalent cardiovascular disease, n (%) 54 (22.0) 191 (25.0) 0.400 
*
Parametric data reported as mean (SD) – Independent T-test, n(%) –chi-square test. 
# #
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was 
included in the ATP III clinical identification of the metabolic syndrome 
 
 
Table 87 Lipid levels across rs2854116  genotypes 
 
 
 
TT (wild type) 
(n = 245) 
Carriers of minor alleles 
(TC & CC) (n = 774) 
P value 
Apolipoprotein A1(g/l)
+
 1.25 (1.12-1.41) 1.29 (1.11-1.51) 0.153 
Apolipoprotein B (g/l)
+
 0.67 (0.50-0.83) 0.69 (0.53-0.84) 0.138 
ApoA/ApoBratio
+
 1.90 (1.48-2.39) 1.95 (1.52-2.44) 0.807 
Cholesterol (mmol/l)
* 
4.06 (1.4) 4.10 (1.6) 0.732 
HDL cholesterol (mmol/l)
* 
0.99 (0.3) 1.03 (0.4) 0.108 
LDL cholesterol (mmol/l)
* 
2.20 (0.9) 2.25 (0.9) 0.339 
Triglycerides (mmol/l)
+
 1.94 (1.38-2.66) 1.92 (1.32-2.82) 0.654 
Calculated triglycerides
+ 
1.78 (1.10-2.54) 1.85 (1.00-2.67) 0.717 
*
Parametric data reported as mean (SD)- Independent T-test, 
+ 
Non-parametric data reported as median (IQR)-  
Mann-Whitney test. 
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There was a significant difference in the prevalence of diabetes mellitus across rs2854117 
genotype, wild type (CC) and carriers of minor allele (CT & TT), p=0.05 (Table 88). There was 
no difference in other demographic, lipid levels and prevalent CVD among the two rs2854117 
genotype group (Table 89).  
Table 88 Distribution of cardiovascular disease risk factors across rs2854117 genotypes 
 
 
 
CC (wild type) 
(n = 307) 
Carriers of minor alleles 
(CT & TT) (n = 516) 
P value 
Age (years) 58.0 (9.3) 58.0 (11.0) 0.741 
Male gender, n (%) 164 (54.0) 291 (57.0)  0.479 
Current smokers, n (%) 40 (15.4) 90 (20.3) 0.109 
Hypertension, n (%) 243 (79.2) 411 (80.0) 0.864 
Diabetes mellitus, n (%) 80 (26.4) 169 (33.0) 0.054 
Obesity, n (%) 176 (60.1) 278 (57.3) 0.451 
Increased waist 
circumference, n (%) 
265 (90.4) 421 (90.0) 0.128 
Systolic blood pressure (mmHg)
*
 141.0 (21.0) 140.4 (20.0) 0.915 
Diastolic blood pressure (mmHg)
*
 83.0 (11.2) 82.0 (11.4) 0.233 
Waist circumference (cm)
*
 94.0 (25.0) 92.0 (26.0) 0.331 
Body mass index (kg/m2)
* 
29.0 (5.0) 28.2 (5.0) 0.219 
Metabolic syndrome (%)
 # 
181 (60.0) 301 (60.0) 0.926 
Prevalent cardiovascular disease, n (%) 74 (24.1) 124 (24.0) 0.981 
*
Parametric data reported as mean (SD)- Independent T-test, n(%)- chi-square test. 
# #
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was 
included in the ATP III clinical identification of the metabolic syndrome 
 
Table 89 Lipid levels across rs2854117  genotypes 
 
 
 
CC (wild type) 
(n = 307) 
Carriers of minor alleles 
(CT & TT) (n = 516) 
P value 
Apolipoprotein A (g/l)
+
 1.25 (1.11-1.50) 1.28 (1.11-1.52) 0.354 
Apolipoprotein B (g/l)
+
 0.67 (0.52-0.82) 0.70 (0.52-0.84) 0.299 
ApoA/ApoB ratio
+
 1.92 (1.50 -2.50) 1.94 (1.52-2.40) 0.597 
Cholesterol (mmol/l)
* 
4.00 (1.6) 4.05 (1.7) 0.371 
HDL cholesterol (mmol/l)
* 
1.00 (0.3) 1.01 (0.4) 0.258 
LDL cholesterol (mmol/l)
* 
2.20 (0.9) 2.22 (0.94) 0.692 
Triglycerides (mmol/l)
+
 1.90 (1.39-2.67) 1.91 (1.30-2.90) 0.601 
Calculated triglycerides
+ 
1.74 (0.94-2.46) 1.83 (0.86-2.71) 0.325 
*
Parametric data reported as mean (SD)- Independent T-test, 
+ 
Non-parametric data reported as median (IQR)-  
Mann-Whitney test
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5 .2 .2 .4  The associa t ion  betw een  APOA5 promoter  polymorphi sm 
rs662799,  cardiovascular  r i sk  f ac tors  and  l ip id  measures  in  
South  Asians  in  the  UK  
The section shows the significant difference in demographics and lipid levels in South Asians 
with carriers of minor allele of rs662799 compared to those with wild type.  
The prevalence of metabolic syndrome was significantly higher in carriers of minor allele, C 
allele of rs662799 compared to those with wild type, p = 0.030 (Table 90).  
Table 90 Distribution of CVD risk factors across rs662799 genotypes 
 
 
 
TT (wild type) 
(n = 715) 
Carriers of minor alleles 
(TC & CC) (n =329) 
P value 
Age (years) 58.0 (10.1) 59.0 (11.0) 0.168 
Current smokers, n (%) 121 (19.1) 66 (23.0) 0.168 
Hypertension, n (%) 551 (77.1) 262 (80.0) 0.352 
T2DM, n (%) 236 (33.2) 102 (31.1) 0.503 
Obesity, n (%) 403 (59.0) 171 (55.2) 0.267 
Increased waist 
circumference, n (%) 
607 (88.4) 267 (86.4) 0.386 
Systolic blood pressure (mmHg)
*
 140.0 (20.3) 141.0 (19.3) 0.344 
Diastolic blood pressure (mmHg)
*
 82.3 (12.0) 82.0 (11.0) 0.452 
Waist circumference (cm)
*
 95.0 (22.3) 92.0 (25.1) 0.060 
Body mass index (kg/m2)
* 
28.4 (5.0) 28.2 (5.0) 0.616 
High sensitivity C-reactive 
 protein (mg/L)
+
 
1.86 (0.80-4.12) 1.68 (1.00-4.00) 0.949 
Metabolic syndrome (%)
 #
 391 (56.3) 204 (64.0) 0.030 
Prevalent cardiovascular disease, n (%) 162 (23.0) 81 (25.0) 0.486 
*
Parametric data reported as mean (SD)- Independent T-test, n(%)- chi-square test. 
# 
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
With regards to lipid measures, carriers of minor allele, C allele of rs662799 had significantly 
higher levels of ApoB, total cholesterol and triglyceride compared to those with wild type, all p 
<0.05 (Table 91, figure 37 & 38).   
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Table 91 Lipid levels across rs662799  genotypes 
 
 
 
TT (wild type) 
(n = 715) 
Carriers of minor alleles 
(TC & CC) (n =329) 
P value 
Apolipoprotein A (g/l)
+
 1.30 (1.11-1.48) 1.30 (1.11-1.52) 0.243 
Apolipoprotein B (g/l)
+
 0.67 (0.52-0.83) 0.71 (0.54-0.90) 0.004 
ApoA/ApoBratio
+
 1.94 (1.53-2.45) 1.92 (1.50-2.40) 0.102 
Cholesterol (mmol/l)
* 
4.04 (1.62) 4.30 (1.53) 0.030 
HDL cholesterol (mmol/l)
* 
1.03 (0.40) 1.02 (0.40) 0.736 
LDL cholesterol (mmol/l)
* 
2.22 (0.88) 2.33 (1.00) 0.066 
Triglycerides (mmol/l)
+
 1.84 (1.30-2.66) 2.20 (1.50-3.10) <0.001 
Calculated triglycerides
+ 
1.83 (1.00 -3.00) 1.90 (1.21-2.90) 0.114 
*
Parametric data reported as mean (SD)- Independent T-test, 
+ 
Non-parametric data reported as median (IQR)-  
Mann-Whitney test
 
 
 
figure 37 Levels of total cholesterol across rs662799genotypes 
 
                                                                                                                                              Independent T-test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
 
 
 
 
 
 
 
 218 
figure 38  Levels of triglyceride across rs662799  genotype 
                                                                                                                                  Kruskal-Wallis test 
 
 
 
 
 
 
 
 
 
 
 
 
Boxes represent interquartile range and medians are shown as solid lines 
Linear regression was performed to determine whether lipid measures were associated with SNP 
rs662799 (for categorical variables, the regression coefficient indicates the average difference in the 
dependent variable between the two groups). SNP rs662799 was associated with levels of 
triglyceride (β= 0.341 (95% CI 0.144-0.537), r2=0.011, P=0.001), total cholesterol (β= 0.241 
(95% CI 0.028-0.454), r
2
=0.004, P=0.030) and Apo B (β = 0.090 (95% CI 0.024-0.156), 
r
2
=0.006, P=0.08) when comparing wild type (TT) with carriers of minor allele (TC & CC).  
5 .2 .2 .5  The associa t ion  betw een  APOA5 promoter  polymorphi sm 
rs662799  wi th  tr ig lyceride  l eve ls  and  metabol i c  syndrome in  
South  Asians  in  the  UK  
Logistic regression was performed to determine the odds of having raised triglycerides and 
metabolic syndrome in carriers of -1131 C allele compared to non-carriers.  
 
P=0.001 
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The odds ratio for raised plasma triglyceride in carriers of -1131 C allele compared to non-
carriers was 1.21, 95% CI 1.10 -1.35, P>0.001. The odds ratio for metabolic syndrome in carriers 
of -1131 C allele compared to non-carriers was 0.738, (95% CI, 0.562 – 0.968). 
5 .2 .2 .6  Cl in ica l  correla tes  o f  t r ig lycer ides  in  South  Asian  men  and 
w omen:  mul t ip l e  regress ion  models  
Multiple regression models were developed with variables associated with triglycerides in 
correlation analysis and was performed to determine clinical correlates that independently 
explained variation in triglyceride levels in South Asians.  
On correlation analysis, triglyceride was positively associated with waist circumference, BMI, 
red blood cell count, white blood cell count, ApoB, cholesterol, ALT and GGT and was 
negatively associated with ApoAI, ApoAI/Bratio and HDL-c in South Asian men and women, all 
p<0.05. In South Asian men alone, triglyceride was positively associated with diastolic blood 
pressure, haemoglobin and LDL-c and negatively with age, all p<0.05. In South Asian women 
alone, triglyceride was positively associated with HbA1c, p<0.05. Correlation analysis for 
triglycerides in South Asians is shown in table 92.    
Table 92 Correlation analysis for triglycerides in South Asian men and women in the UK 
Variables South Asian men 
 
South Asian women 
Spearman’s 
correlation 
coefficient, r 
P value Spearman’s 
correlation 
coefficient, r 
P value 
Age (years) -0.187 <0.001 NS 
Waist circumference (cm) 0.130 0.002 0.187 <0.001 
Body mass index (kg/m
2
) 0.133 0.002 0.127 0.010 
Diastolic blood pressure 
(mmHg) 
0.156 <0.001 NS 
Glycated haemoglobin  (%) NS NS 0.152 0.003 
Haemoglobin (g/l) 0.268 <0.001 NS 
Red blood cells  0.247 <0.001 0.135 0.022 
White blood cells 0.156 0.002 0.300 <0.001 
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Apolipoprotein AI (g/l) -0.153 <0.001 -0.117 0.020 
Apolipoprotein B (g/l) 0.285 <0.001 0.197 <0.001 
ApoAIBratio -0.409 <0.001 -0.296 <0.001 
Cholesterol (mmol/l) 0.359 <0.001 0.203 <0.001 
HDL cholesterol (mmol/l) -0.315 <0.001 -0.336 <0.001 
LDL cholesterol (mmol/l) 0.167 <0.001 NS 
Alanine transaminase (U/L)
+ 
0.205 <0.001 0.130 0.012 
Gamma glutamyl  
transpeptidase (U/L)
+ 
0.263 <0.001 0.251 <0.001 
+
Measured only in E-ECHOES samples  
On multiple linear regression models, total cholesterol, HDL-c, ApoB, GGT and rs662799 
explained 40% of the variability in triglyceride levels in South Asian men with total cholesterol 
explaining 12% of the total variance (Table 93).  
Table 93 Clinical correlates of triglyceride  in South Asian men: multiple linear regression model 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Total cholesterol (mmol/l) 
HDL cholesterol (mmol/l) 
Apolipoprotein B (g/l) 
Gamma glutamyl transpeptidase  
(U/L) 
rs662799 (TT vs. TC & CC) 
1.038 
-2.775 
-2.814 
0.010 
 
0.392 
0.781 – 1.296 
-3.275 – (-2.276) 
-4.140 – (-1.488) 
0.004 – 0.015 
 
0.076 – 0.707 
<0.001 
<0.001 
<0.001 
0.001 
 
0.015 
0.115 
0.080 
0.019 
0.014 
 
0.006 
Overall adjusted R
2
 for the model 0.389, p<0.001 
Variables included in the model- Age, waist, diastolic blood pressure,  HbA1c, haemoglobin, ApoB, total cholesterol, 
 HDL cholesterol,ALT,GGT and rs662799 genotype (TT vs. TC & CC) 
 
In South Asian women, HDL-c, total cholesterol, GGT, rs662799 and HbA1c explained 31% of 
the variability in triglyceride levels with HDL cholesterol explaining 10% of the total variance 
(Table 94).  
Table 94 Clinical correlates of triglyceride  in South Asian women: multiple linear regression model 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
HDL cholesterol (mmol/l) 
Total cholesterol (mmol/l) 
Gamma glutamyl transpeptidase  
(U/L) 
rs662799 (TT vs. TC & CC) 
Glycated haemoglobin (%) 
-1.647 
0.398 
0.005 
 
0.302 
0.125 
-1.971 – (-1.323) 
0.306 – 0.490 
0.002 – 0.009 
 
0.068 – 0.536 
0.027 – 0.224 
<0.001 
<0.001 
0.001 
 
0.012 
0.013 
0.090 
0.052 
0.036 
 
0.017 
0.030 
Overall adjusted R
2
 for the model 0.307, p<0.001 
Variables included in the model- Age, waist, diastolic blood pressure,  HbA1c, haemoglobin, ApoB, total cholesterol, 
HDL cholesterol, ALT, GGT and rs662799 genotype (TT vs. TC & CC) 
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5.2.3  Discussion 
The APOA5 -1131C>T (rs662799) is a determinant of plasma triglyceride levels in the South 
Asian population. The odds ratio for raised plasma triglyceride in carriers of -1131 C allele was 
1.21 compared to non-carriers, p>0.001. Carriers of the minor allele -1131 C had higher levels of 
triglycerides, total cholesterol and more metabolic syndrome compared to wild type 
homozygotes. APOC3 promoter polymorphisms rs2854116 and rs2854117 did not contribute to 
any variations in blood lipid levels and metabolic syndrome. None of the polymorphisms were 
associated with CVD in this cohort.  
The minor allele frequency of rs662799 observed in our cohort was similar to those reported in 
Asian Indians and was higher in South Asians compared to those in Whites, 17% versus 4% 
(Chandak, 2006). The minor allele frequencies of rs2854116 and rs2854117 were higher than 
those reported in Whites but similar to those in South Asian populations (Pollex, 2007). There 
was no significant difference in the genotype frequencies for APOC3 promoter polymorphisms 
and APOA5 -1131T>C in subjects belonging to Indian, Pakistani and Bangladeshi origin.  
The APOA5 gene is located 27kb distal to apoA-IV in apoA1/C3/A4/A5 gene cluster on 
chromosome 11q23. The functionality of APOA5 gene was demonstrated in gene knockout 
studies, where the human APOA5 transgenic mice had low levels of plasma triglyceride (0.32 ± 
(SD) 0.11 mg/ml) compared to APOA5 knockout mice (1.53 ± 0.77 mg/ml). Our findings were 
consistent with prior studies that have associated APOA5 -1131C allele with elevated levels of 
triglycerides in Europeans (Aouizerat, 2003; Dorfmeister, 2007; De Caterina, 2011; Evans et al., 
2011) and Asian Indians (Chandak, 2006). The APOA5 -1131T>C polymorphism has also been 
associated with increased risk of CVD (De Caterina, 2011; Evans, 2011). 
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APOC3 codes for a 79-residue glycoprotein and is synthesised in the liver and is a protein 
component of triglyceride rich lipoprotein particles. Over expression of ApoCIII delays the 
catabolism of triglycerides by down regulating LPL and impairs the apoE mediated clearance of 
triglyceride-rich lipoprotein by the liver, resulting in hypertriglyceridemia (Ito et al., 1990; Li, 
1995). The expression of ApoCIII is down regulated by insulin, transcriptional activity of 
promoter constructs containing the mutant alleles of the APOC3 promoter polymorphisms 
located within an insulin-responsive element (-490 to -449) is compromised and fails to respond 
effectively to insulin-mediated down-regulation hence remains active constantly (Li, 1995; 
Waterworth, 2003).  
APOC3 promoter polymorphisms have been associated with variations in triglyceride levels 
(Hegele et al., 1997; Waterworth, 2000), increased risk of metabolic syndrome (Miller et al., 
2007; Pollex, 2007) and CHD in multi ethnic groups (Olivieri et al., 2002). In our cohort, levels 
of triglyceride were comparable in South Asians with minor alleles of APOC3 promoter 
polymorphisms and in those with wild type homozygotes. The prevalence of metabolic syndrome 
was also comparable in those with minor allele of APOC3 promoter polymorphisms and wild 
type homozygotes. APOC3 promoter polymorphisms are the most studied SNPs in lipid 
metabolism and have mostly generated positive associations with lipids in multi ethnic groups. 
However, along with the present study, there are studies that have failed to confirm this 
association (Dallongeville et al., 2006; Sentinelli, 2011).   
Finally, the strongest evidence for the association of triglycerides and CVD has been observed in 
subjects with low HDL-C (Criqui et al., 1993) and diabetes mellitus (Laakso et al., 1993); such 
an effect could blank out a modest effect (Emerging Risk Factors Collaboration, 2009). The 
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increased risk of CVD attributed to hypertriglyceridemia could be due to dysfunctional HDL and 
small dense LDL particles that are more prone to oxidative modification (Miller et al, 2011). 
5.2 .3 .1  Conclus ion 
APOA5 -1131T>C is a determinant of plasma triglyceride levels in the South Asian population; 
however this polymorphism was not associated with CVD. Prior studies have confirmed the role 
of APOC3 promoter polymorphisms on serum triglyceride levels and CVD, but these findings 
were not replicated in our South Asian cohort.   
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CHAPTER 6 RESULTS 3 
6.1  The val idi ty  of  biomarkers  of  thrombosis ,  haemostasis ,  and 
endothel ial  dysfunct ion as discriminators  of  cardiovascular  
disease r isk in South  Asia ns  in  the  UK 
6.1.1  Aims and hypothesis  
South Asians have an increased risk of CVD compared to the general population in the UK. 
However, there is no substantial population based evidence for the performance of D-dimer, P- 
selectin and vWF as discriminators of CVD risk in South Asians. The aim of this section was to 
evaluate the performance of these biomarkers in the identification of South Asians at an increased 
risk of CVD initially in South Asians asymptomatic for CVD and then to validate the findings in 
a group of South Asians with CVD risk factors (on medication for anti-hypertensive, anti –
diabetic or lipid lowering therapy) and existing CVD events.  
6.1.2  The validity of biomarkers of thrombosis, haemostasis and 
endothelial dysfunction as discriminators of cardiovascular 
disease in South Asians asymptomatic for cardiovascular 
disease 
6.1 .2 .1  Character is t ics  of  the  s tudy  cohort   
The characteristics of the study population (E-ECHOES) and distribution of all lipid profiles and 
biochemical measures are shown in Chapter 4 Result section 1, Table 44 & 45. There was no 
significant gender difference in the levels of P-selectin in South Asians. The levels of D-dimer 
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were higher in South Asian women compared to South Asian men, p <0.001. The levels of vWF 
were higher amongst South Asian men compared to South Asian women, p=0.04. Table 95 
shows the distribution of plasma biomarkers in the study population. 
Table 95 Distribution of plasma biomarkers in the study population  
Characteristics Men (n=276) Women (n=229) P value 
D-dimer (µg/ml)
+ 
0.21 (0.12-0.33) 0.29 (0.19-0.44) <0.001 
P-selectin (ng/ml)
+
 32.0 (24.4-40.0) 30.5 (23.3-39.3) 0.442 
Von willebrand factor (IU/dL)* 79.4 (15.4) 77.0 (15.0) 0.04 
+
Reported as median and interquartile range -Mann-Whitney test 
*Reported as mean (SD) –Independent T-test 
 
6.1 .2 .2  Levels  of  D-dimer ,  P  se lect in ,  von wil lebrand factor and 
cardiovascular  r isk  factors  in  South Asians  asymptomatic  
for  cardiovascular  d isea se 
The section shows the levels of D-dimer, P selectin and vWF across each CVD risk factor in 
South Asians asymptomatic for CVD.  
In the entire cohort of South Asians asymptomatic for CVD, levels of D-dimer were higher in 
those with greater central obesity compared to non-obese subjects, p =0.002. Levels of D-dimer 
were comparable in those with other CVD risk factors such as hypertension, obesity, diabetes 
mellitus, low HDL-c, raised triglycerides, metabolic syndrome, 10 year CVD risk score and 
healthy South Asians (table 96).  
Table 96 Difference in the levels of D-dimer across cardiovascular risk factors in South Asians asymptomatic for 
cardiovascular disease 
Risk factors D-dimer (µg/ml) P value (Mann-Whitney test) 
Hypertensive (>130 mmHg or 85 mmHg) 
Not hypertensive 
0.23 (0.13 – 0.39) 
0.24 (0.15 – 0.40) 
0.397 
Obesity (BMI≥27 kg/m2) 
Not obese 
0.24 (0.15 – 0.41) 
0.23 (0.14 - 0.38) 
0.323 
Central obesity (≥ 90 cm in men and ≥ 80 cm in 
women) 
Not obese 
0.25 (0.15 – 0.40)  
 
0.20 (0.12 – 0.31) 
0.002 
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With diabetes mellitus (HbA1c ≥ 6.5%) 
Without diabetes mellitus 
0.27 (0.18– .39)  
0.23 (0.14 – 0.39) 
0.252 
Low HDL cholesterol (<0.9 mmol/l in men & <1.0 
mmol/l in women) 
Normal HDL Cholesterol  
0.23 (0.12 – 0.38)  
 
0.24 (0.15 – 0.40) 
0.419 
Elevated triglycerides (≥ 1.7 mmol/l) 
Normal triglycerides 
0.23 (0.14 – 0.40) 
0.24 (0.20 – 0.40) 
0.349 
With metabolic syndrome
* 
Without metabolic syndrome 
0.24 (0.14–0.38)  
0.23 (0.14 – 0.40) 
0.617 
10 year CHD risk score (>20%) 
10 year CHD risk score (<20%) 
0.31 (0.12 – 0.48) 
0.23 (0.14 – 0.38) 
0.187 
Reported as median and interquartile range 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
Levels of P-selectin were higher in those with elevated triglycerides compared to those with 
normal triglycerides, p=0.050. Levels of P-selectin were comparable in those with CVD risk 
factors such as hypertension, greater obesity, diabetes mellitus, low HDL-c, metabolic syndrome 
and 10 year CVD risk score and healthy South Asians (Table 97).  
Table 97 Difference in the levels of P selectin across cardiovascular risk factors in South Asians asymptomatic for 
cardiovascular disease  
Risk factors P selectin (ng/ml) P value (Mann-Whitney test) 
Hypertensive (>130 mmHg or 85 mmHg) 
Not hypertensive 
31.3 (24.0 – 40.0) 
31.0 (24.0 – 38.3) 
0.705 
Obesity (BMI≥27 kg/m2) 
Not obese 
31.0 (24.0–39.0)  
32.0 (24.0 – 40.0) 
0.605 
Central obesity (≥ 90 cm in men and ≥ 80 cm in 
women) 
Not obese 
31.4 (24.0 – 40.0) 
 
31.0 (24.0 – 39.2) 
0.696 
With diabetes mellitus (HbA1c ≥ 6.5%) 
Without diabetes mellitus 
31.1 (24.4–41.0)  
31.2 (24.0 – 39.0) 
0.646 
Low HDL cholesterol (<0.9 mmol/l in men & <1.0 
mmol/l in women) 
Normal HDL Cholesterol  
32.1 (24.5 – 40.1) 
 
31.0 (24.0 – 39.1) 
0.342 
Elevated triglycerides (≥ 1.7 mmol/l) 
Normal triglycerides 
32.0 (25.0 – 40.0) 
31.0 (23.0 – 37.4) 
0.050 
With metabolic syndrome
* 
Without metabolic syndrome 
32.1 (25.0 – 40.1) 
31.0 (23.0 – 38.0) 
0.071 
10 year CHD risk score (>20%) 
10 year CHD risk score (<20%) 
34.0 (24.0 – 40.2) 
31.0 (24.2 – 39.5) 
0.413 
Reported as median and interquartile range 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
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Levels of vWF were higher in South Asians with obesity compared to non-obese subjects, p 
=0.022 and in those with higher 10 year CVD risk score compared to those with lower 10 year 
CVD risk score, p=0.002 (Table 98). 
Table 98 Difference in the levels of  von willebrand factor across  cardiovascular risk factors in South Asians 
asymptomatic for cardiovascular disease  
Risk factors Von willebrand factor  
(IU/dL) 
P value  
(Independent sample T test) 
Hypertensive (>130 mmHg or 85 mmHg) 
Not hypertensive 
77.0 (14.3) 
79.0 (16.0) 
0.174 
Obesity (BMI≥27 kg/m2) 
Not obese 
80.0 (15.2) 
77.0 (15.0) 
0.022 
Central obesity (≥ 90 cm in men and ≥ 80 cm in 
women) 
Not obese 
79.0 (15.0) 
 
76.2 (16.0) 
0.146 
With diabetes mellitus (HbA1c ≥ 6.5%) 
Without diabetes mellitus 
80.5 (14.3) 
78.0 (16.1) 
0.516 
Low HDL cholesterol (<0.9 mmol/l in men & <1.0 
mmol/l in women) 
Normal HDL Cholesterol  
79.0 (14.0) 
 
78.0 (16.1) 
0.516 
Elevated triglycerides (≥ 1.7 mmol/l) 
Normal triglycerides 
79.0 (16.0) 
78.0 (15.0) 
0.540 
With metabolic syndrome
* 
Without metabolic syndrome 
79.3 (14.0) 
77.0 (16.1) 
0.074 
10 year CHD risk score (>20%) 
10 year CHD risk score (<20%) 
84.0 (16.3) 
77.2 (15.0) 
0.002 
Reported as mean and standard deviation 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
6.1 .2 .3  The assoc iat ion between D-dimer ,  P-se lect in ,  von 
wil lebrand factor and cardiovascular  r i sk factors  in  South 
Asian men and women  
Correlation analysis were performed to identify clinical correlates of D-dimer, P selectin and Vwf 
in South Asians. 
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D-dimer was positively associated with age, HbA1c, and CRP, p<0.05 in South Asian men. D-
dimer levels were negatively associated with triglycerides only (correlation coefficient, r=-0.151, 
p=0.030) in South Asian women. In the entire cohort of South Asians asymptomatic for CVD, D- 
dimer was positively associated with age, gender, CRP and was negatively associated with red 
blood cell count, haemoglobin, ALT and triglyceride, p<0.05. Correlation analyses for D-dimer 
are shown in table 99 & 100.  
Table 99 Correlation analysis for D-dimer  in South Asian men and women asymptomatic for cardiovascular 
disease 
Variables South Asian men 
 
South Asian women 
Speraman’s correlation 
coefficient, r 
P value Speraman’s correlation 
coefficient, r 
P value 
Age (years) 0.179 0.003 NS 
Glycosylated hemoglobin 
(%) 
0.123 0.050 NS 
High sensitivity C-
reactive protein (mg/L) 
0.204 0.001 NS 
Triglycerides (mmol/l) NS -0.151 0.025 
Variables included in the analysis were age, waist circumference, BMI, systolic blood pressure,  
diastolic blood pressure, white blood cell count, red blood cell count, hemoglobin, HbA1c, alkaline  
phosphatase, ALT, AST, GGT, creatnine, ApoAI, ApoB, total cholesterol, LDL-c,  
HDL-c, triglycerides, 10 year CHD risk score,  vWF , CRP and P selectin.   
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Table 100  Correlation analysis for D-dimer  in the entire cohort  
 
Variables included in the analysis were  waist circumference, BMI, systolic blood pressure,  
diastolic blood pressure, white blood cell count, HbA1c, alkaline phosphatase, AST, GGT,  creatnine, ApoAI, ApoB, 
 total cholesterol, LDL-c, HDL-c, triglycerides, 10 year CHD risk score,  vWF , CRP and P selectin.   
 
In the entire cohort, levels of P-selectin were positively associated with white blood cell count, 
alkaline phosphatase, ApoB, total cholesterol, GGT, LDL-c, triglycerides and 10 year CHD risk 
score, all p<0.05 . Correlation analyses for P selectin are shown in table 101.  
Table 101 Correlation analysis for P-selectin  in South Asians asymptomatic for cardiovascular disease  
Variables Speraman’s correlation coefficient, r P value 
 
White blood cell count 0.199 0.001 
Alkaline phosphatase (U/L)  0.135 0.003 
Apolipoprotein B (g/l) 0.135 0.003 
Total cholesterol (mmol/l) 0.140 0.002 
Gamma glutamyl transpeptidase  
(U/L)
 
0.125 0.007 
LDL cholesterol (mmol/l) 0.107 0.020 
Triglycerides (mmol/l) 0.117 0.010 
10 year CHD risk score (%) 0.115 0.012 
Variables included in the analysis were age, waist circumference, BMI, systolic blood pressure,  
diastolic blood pressure,  red blood cell count, hemoglobin, HbA1c, ALT, AST, GGT,  creatnine, ApoAI, ApoB, total 
 cholesterol, HDL-c,10 year CHD risk score  vWF , CRP and P selectin.  
 
Levels of vWF were positively associated with age, waist measurement, BMI, systolic blood 
pressure, CRP, white blood cell count, alkaline phosphatase, AST, creatinine, GGT and 10 year 
CHD risk score, all p<0.05 in South Asian men. In South Asian women, levels of vWF were 
Variables South Asians asymptomatic for CVD    
Speraman’s correlation 
coefficient, r 
P value 
Age (years) 0.096 0.032 
Gender  0.227 <0.001 
High sensitivity C-reactive 
protein (mg/L) 
0.161 <0.001 
Red blood cell count -0.166 0.006    
Haemoglobin (g/dL) -0.155 0.010               
Alanine transaminase (U/L) -0.119 0.010 
Triglycerides (mmol/l) -0.109 0.017 
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negatively correlated with ApoB and ApoAI, p<0.05 and positively with red blood cell count. 
Correlation analyses for vWF are shown in table 102.  
Table 102 Correlation analysis for von willebrand factor in South Asian men and women asymptomatic for 
cardiovascular disease 
Variables South Asian men 
 
South Asian women 
Pearson’s correlation 
coefficient, r 
P value Pearson’s correlation 
coefficient, r 
P value 
Age (years) 0.153 0.011 NS 
Waist measurement (cm) 0.181 0.003 NS  
Body mass index (kg/m
2
) 0.154 0.011 NS 
Systolic blood pressure 
(mmHg) 
0.156 0.010 NS  
Apolipoprotein B (g/L) NS -0.148 0.031 
 Speraman’s 
correlation 
coefficient, r 
P value Speraman’s correlation 
coefficient, r 
P value 
Red blood cell count NS 0.185 0.040 
White blood cell count  0.192 0.020 NS  
Apolipoprotein AI (g/L) NS -0.135 0.050 
High sensitivity C-reactive 
protein (mg./L) 
0.207 0.001 NS  
Alkaline phosphatase (U/L)  0.150 0.015 NS  
Aspartate transaminase 
(U/L) 
0.126 0.042 NS  
Creatinine (µmol/l)
 
0.147 0.017 NS  
Gamma glutamyl  
transpeptidase  (U/L)
 
0.169 0.006 NS  
10 year coronary heart  
Disease risk score (%) 
0.227 <0.001 NS  
Variables included in the analysis were diastolic blood pressure, white blood cell count,  hemoglobin, HbA1c,  
 ApoAI, ApoB, total cholesterol, LDL-c,HDL-c, triglycerides, vWF , CRP and P selectin.   
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6.1 .2 .4  Clinical  corre lates  of  D-dimer,  P  se lect in  and von 
wil lebrand factor  in  South Asian men and women:  mult ip le  
regression models  
Multiple regression models were developed with variables associated with D-dimer, P selectin 
and vWF and was performed to identify clinical correlates that independently explained variation 
in the above mentioned plasma biomarkers in South Asians. 
On multiple regression models, red blood cell count alone explained 7% of the variation in D-
dimer levels. GGT explained 2% of the variation in P selectin levels. Table 103 & 104 shows the 
clinical correlates of D-dimer and P selectin in South Asians asymptomatic for CVD. 
Table 103 Clinical correlates of D-dimer in South Asians: multiple linear regression model  
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Red blood cell count -0.109 -0.169 - -0.050 <0.001 0.068 
Variables included in the model- age, gender, CRP, haemoglobin, ALT,  BNP and triglycerides 
 
Table 104 Clinical correlates of P-selectin  in South Asians: multiple linear regression model  
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Gamma glutamyl transpeptidase 
(U/L) 
0.156 0.044 – 0.268 0.007 0.024 
Variables included in the model- white blood cell count, alkaline phosphatase, GGT, triglycerides and 10 year CVD 
risk score 
  
 
Table 105 & 106 shows the clinical correlates of vWF in South Asians, model 1 & 2. In model 1, 
creatinine, white blood cell count, age and BMI explained 7% of the variation in vWF levels. In 
model 2, creatinine, white blood cell count and waist circumference explained 6% of the 
variation in vWF levels.  
 
Table 105 Clinical correlates of  von willebrand factor  in South Asians: multiple linear regression model 1 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
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Creatinine (µmol/l) 0.157 0.051 – 0.263 0.004 0.020 
White blood cell count 1.104 0.180 – 2.028 0.019 0.020 
Age (years) 0.285 0.061 – 0.509 0.013 0.013 
Body mass index (kg/m
2
) 0.430 0.029 – 0.831 0.040 0.006 
Overall adjusted R
2
 for the model- 0.07 
Variables included in the model- age, gender, red blood cell count, white blood cell count, ApoAI,  CRP, alkaline 
phosphatase, ALT, creatinine, GGT  
 
Table 106 Clinical correlates of von Will brand factor  in South Asians: multiple linear regression model 2 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Creatinine (µmol/l) 0.159 0.053 – 0.266 0.003 0.020 
White blood cell count 1.019 0.093 – 1.946 0.031 0.020 
Waist circumference (cm) 0.174 0.004 – 0.343 0.050 0.007 
Overall adjusted R
2
 for the model- 0.060 
Variables included in the model- waist circumference, red blood cell count, white blood cell count, CRP, alkaline 
phosphatase, ALT, creatinine, GGT and 10 year CVD risk score 
 
 
6.1 .2 .5  The performance  of  D-dimer ,  P  select in  and von wil lebrand 
factor  in  the  predict ion of  car diovascular  r i sk  in  South 
Asians  asymptomatic  for  cardiovascular  d isease:  ROC 
analys is  
The performance of D-dimer, P selectin and vWF as discriminators of CVD risk in South Asians 
was evaluated using ROC analysis. On ROC analysis, D-dimer significantly discriminated those 
with greater central obesity from non-obese South Asians, AUC- 0.601 (95% CI 0.542 – 0.659), 
p=0.002. P selectin significantly discriminated South Asians with elevated triglycerides from 
South Asians with normal triglycerides, AUC-0.553 (95% CI 0.501 – 0.606), p=0.050. Levels of 
vWF significantly discriminated subjects with greater obesity, metabolic syndrome and higher 10 
year CVD risk score from healthy South Asians, all AUC 0.551 -0.642, p<0.05. Plasma 
biomarkers as discriminators of metabolic and cardiovascular disease risk in South Asians 
asymptomatic for cardiovascular disease are shown in Table 107 -109.  
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Table 107  D-dimer as a discriminator of metabolic and cardiovascular disease risk amongst South Asian men and 
women asymptomatic for cardiovascular disease 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
 
Table 108  P–selectin as a discriminator of metabolic and cardiovascular disease risk amongst South Asian men and 
women asymptomatic for cardiovascular disease 
 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
D-dimer (mg/L) 
 
Raised blood pressure (>130 mmHg or 
85 mmHg) 
Body mass index (> 27kg/m
2
) 
 
P value  AUC 95% CI P value  AUC 95% CI 
0.397 0.477 0.424 - 0.530 0.323 0.526 0.475 - 0.577 
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
P value AUC 95% CI P value AUC 95% CI 
0.002 0.601 0.542 – 0.659 0.253 0.547 0.469 – 0.625 
Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Low HDL cholesterol (<0.9 mmol/l 
in men & <1.0 mmol/l in women, 
non-smokers) 
P value AUC 95% CI P value AUC 95% CI 
0.346 0.474 0.422 – 0.527 0.419 0.478 0.422 – 0.533 
Metabolic syndrome
*
 (ATP III defined) 10 years CHD risk score (>20%) 
P value AUC 95% CI P value AUC 95% CI 
0.617 0.487 0.436 – 0.538 0.187 0.553 0.467 – 0.639 
 
 
 
 
 
 
 
P selectin (ng/ml) 
 
 
Raised blood pressure (>130 mmHg or 
85 mmHg) 
Body mass index (> 27kg/m
2
) 
 
P value  AUC 95% CI P value  AUC 95% CI 
0.705 0.510 0.457 – 0.564 0.605 0.487 0.435 – 0.538 
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
P value AUC 95% CI P value AUC 95% CI 
0.696 0.512 0.451 – 0.573 0.646 0.519 0.441 – 0.596 
Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Low HDL cholesterol (<0.9 mmol/l 
in men & <1.0 mmol/l in women, 
non-smokers) 
P value AUC 95% CI P value AUC 95% CI 
0..050 0.553 0.501 – 0.606 0.342 0.526 0.472 – 0.581 
Metabolic syndrome
*
 (ATP III defined) 10 years CHD risk score (>20%) 
P value AUC 95% CI P value AUC 95% CI 
0.071 0.547 0.496 – 0.598 0.413 0.533 0.454 – 0.612 
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Table 109  Von willebrand factor as a discriminator of metabolic and cardiovascular disease risk amongst South 
Asian men and women asymptomatic for cardiovascular disease 
 
*
Metabolic syndrome –fasting glucose was not measured in E-ECHOES samples instead T2DM status was included 
in the ATP III clinical identification of the metabolic syndrome 
 
6.1.3  The validity of biomarkers  of thrombosis, haemostasis and 
endothelial dysfunction as discriminators of cardiovascular 
disease in South Asians with cardiovascular disease risk 
factors and existing cardiovascular disease  
The performance of plasma biomarkers were then analysed in a larger cohort which consisted of 
South Asians with CVD risk factors and existing CVD along with South Asians asymptomatic 
for CVD. The characteristic of South Asian men and women are shown separately in Table 110 
& Table 111.  
A significant age difference was observed in South Asian men and women with subjects with 
CVD being older compared to subjects with CVD risk factors and subjects asymptomatic for 
CVD, both p<0.001. The prevalence of hypertension, diabetes mellitus, obesity and central 
obesity were higher amongst South Asian men and women with CVD risk factors and lowest 
 
 
 
 
 
 
vWF  (IU/dL) 
 
 
Raised blood pressure (>130 mmHg or 
85 mmHg) 
Body mass index (> 27kg/m
2
) 
 
P value  AUC 95% CI P value  AUC 95% CI 
0.174 0.537 0.484 – 0.590 0.040 0.555 0.504 – 0.605 
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) 
Diabetes mellitus (HbA1c ≥ 6.5%) 
P value AUC 95% CI P value AUC 95% CI 
0.335 0.531 0.467 – 0.594 0.165 0.557 0.481 – 0.632 
Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Low HDL cholesterol (<0.9 mmol/l 
in men & <1.0 mmol/l in women, 
non-smokers) 
P value AUC 95% CI P value AUC 95% CI 
0.807 0.493 0.440 – 0.547 0.389 0.524 0.471 – 0.577 
Metabolic syndrome
*
 (ATP III defined) 10 years CHD risk score (>20%) 
P value AUC 95% CI P value AUC 95% CI 
0.050 0.551 0.500 – 0.602 <0.001 0.642 0.567 – 0.716 
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amongst subject with CVD compared to those asymptomatic for CVD, all p<0.05. The use of 
CVD medications were higher amongst South Asian men and women with CVD compared to 
those with CVD risk factors, all p<0.001.  
Table 110 Characteristics of South Asian men 
Characteristics South Asians  
asymptomatic for  
CVD, n=276 
South Asians with  
CVD risk factors, 
n = 294 
Subjects with  
CVD, n = 132 
P value 
Age (years)
* 
55.0 (8.3) 59.0 (10.0) 65.0 (10.1) <0.001 
Current smokers, n (%) 39 (14.1) 52 (17.7) 25 (18.9) 0.369 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
190 (69.0) 265 (90.1) 126 (96.0) <0.001 
Diabetes mellitus (HbA1c ≥ 6.5%), 
n (%)  
33 (12.0) 181 (62.0) 64 (49.0) <0.001 
Obesity (BMI≥27 kg/m2), n (%)  117(42.4) 169 (58.0) 67(51.0) 0.002 
Increased waist  
Circumference (≥ 90 cm in men 
and ≥ 80 cm in women), n (%)  
201 (73.0) 256 (87.1) 109 (83.0) <0.001 
Systolic blood pressure (mmHg)
*
 137.0 (16.1) 143.0 (19.0) 139.1 (20.3) 0.001 
Diastolic blood pressure (mmHg)
*
 85.0 (21.0) 84.2 (21.0) 78.0 (11.3) 0.001 
Waist circumference (cm)
*
 96.2 (11.1) 100.1 (12.0) 101.0 (13.0) <0.001 
Body mass index (kg/m2)
* 
27.0 (4.0) 28.1 (4.3) 28.0 (4.4) <0.001 
Past medical history 
     Previous HF (%) 
     Previous MI (%) 
     Angina (%) 
 
0 
0 
0 
 
 
0 
0 
0 
 
 
6 (4.5) 
67 (51.0) 
79 (60.0) 
 
 
 
 
 
Drug therapy (%) 
     ACE inhibitors 
     Beta-blockers 
     Calcium blockers 
     Diuretics 
     Anti-platelet therapy     
 
0 
0 
0 
0 
0 
 
118 (40.1) 
38 (13.0) 
82 (28.0) 
62 (21.1) 
64 (22.0) 
 
62 (47.0) 
57 (43.2) 
37 (28.0) 
32 (24.2) 
54 (41.0) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
*
Parametric data reported as mean (SD), Statistical tests - One-way anova & n (%)- chi square test.  
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Table 111 Characteristics of South Asian women 
Characteristics South Asians  
asymptomatic for  
CVD,  n =229 
South Asians  
with CVD risk  
factors, n ==225 
Subjects with  
CVD, n=66 
P value 
Age (years)
* 
54.3  (7.5)  
 
58.2 (8.8) 62.0 (9.0) <0.001 
Current smokers, n (%) 4 (1.7) 3 (1.3) 1 (1.5) 0.938 
Hypertension (>130 mmHg  
or 85 mmHg), n (%)  
139 (61.0) 201 (89.3) 61 (92.4) <0.001 
Diabetes mellitus (HbA1c ≥ 
6.5%), n (%)  
30 (13.1) 103 (46.0) 37 (56.1) <0.001 
Obesity (BMI≥27 kg/m2), n (%)  139 (61.0) 159 (71.0) 49 (74.2) 0.040 
Increased waist  
Circumference (≥ 90 cm in men 
and ≥ 80 cm in women), n (%)  
199 (87.3) 213 (95.0) 64 (99.0) 0.002 
Systolic blood pressure (mmHg)
*
 135.4 (20.1) 144.0 (19.0) 140.1 (23.0) <0.001 
Diastolic blood pressure  
(mmHg)
*
 
83.0 (23.0) 83.0 (11.0) 77.3 (10.2) 0.061 
Waist circumference (cm)
*
 93.0 (12.3) 97.0 (14.0) 100.2 (14.1) <0.001 
Body mass index (kg/m2)
* 
29.0 (6.5) 30.1 (5.4) 30.3 (5.3) 0.042 
Past medical history 
     Previous HF (%) 
     Previous MI (%) 
     Angina (%) 
 
0 
0 
0 
 
0 
0 
0 
 
 
6 (9.1) 
24 (36.4) 
36 (56.1) 
 
Drug therapy (%) 
     ACE inhibitors 
     Beta-blockers 
     Calcium blockers 
     Diuretics 
     Anti-platelet therapy     
 
0 
0 
0 
0 
0 
 
61 (27.1) 
35 (16.0) 
45 (20.0) 
67 (30.0) 
28 (12.4) 
 
24 (36.4) 
25 (38.0) 
19 (29.0) 
18 (27.3) 
25 (38.0) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
*
Parametric data reported as mean (SD), Statistical tests - One-way anova & n (%)- chi square test.  
 
The distribution of lipids, biochemical measures and plasma biomarkers are shown in Table 112 
& 113. Levels of ApoB, total cholesterol and LDL-c were higher in South Asian men and women 
asymptomatic for CVD compared to those with modifiable CVD risk factors and existing CVD, 
all p<0.05. In women alone, HDL-c was significantly higher in subjects asymptomatic for CVD 
compared to those with CVD risk factors and existing CVD, p =0.012. Levels of liver enzymes, 
ALT and GGT were significantly higher in South Asian men with CVD risk factors compared to 
those asymptomatic for CVD and existing CVD, both p<0.05. Creatinine levels were higher in 
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South Asian men with CVD compared to those asymptomatic for CVD and with CVD risk 
factors, p<0.001.  
With regards to plasma biomarkers, levels of D-dimer were significantly higher in South Asian 
men with existing CVD compared to those asymptomatic for CVD and those with CVD risk 
factors, both p<0.05. In South Asian women, all plasma biomarkers were comparable in subjects 
asymptomatic for CVD, those with CVD risk factors and those with existing CVD.   
Table 112 Distribution of lipids,  biochemical measures and plasma biomarkers in South Asian men 
Characteristics South Asians  
asymptomatic for  
CVD, n=276 
South Asians with  
CVD risk factors,  
n = 294 
Subjects with  
CVD, n = 132 
P value 
Apolipoprotein AI (g/l)
+
 1.24 (1.21 – 1.28) 1.25 (1.22 – 1.29) 1.20 (1.14 -  1.30) 0.070 
Apolipoprotein B (g/l)
*
 0.80 (0.3) 0.70 (0.3) 0.60 (0.2) <0.001 
Serum cholesterol (mmol/l)
* 
4.70 (1.3) 4.20 (1.3) 3.71 (1.20) <0.001 
HDL cholesterol (mmol/l)
* 
0.99 (0.3) 0.99 (0.3) 0.97 (0.3) 0.706 
LDL cholesterol (mmol/l)
* 
2.70 (0.9) 2.20 (0.9)  1.84 (0.7) <0.001 
Triglycerides (mmol/l)
+
 2.50 (2.28 – 2.71) 2.44 (2.27-2.62) 2.30 (2.02 – 2.58) 0.196 
Alkaline phosphatase (U/L)
+
  73.5 (71.0 – 76.4) 71.4 (69.0 – 74.3) 70.0 (65.3 – 74.0) 0.126 
Alanine transaminase (U/L)
+ 
25.0 (23.2 – 26.3) 27.0 (25.0-29.0) 23.0 (20.0-25.1) 0.003 
Aspartate transaminase (U/L)
+ 
22.0 (20.4-23.0) 23.0 (21.4-24.1) 22.0 (20.0 -24.0) 0.299 
Creatinine (µmol/l)
+ 
69.4 (57.1 – 78.0) 69.0 (59.0 -79.0) 76.0 (63.0 – 90.0)  <0.001 
Gamma glutamyl  
transpeptidase (U/L)
+ 
32.2 (30.0 -35.0) 42.2 (38.0-47.0) 40.0 (29.0-45.0) 0.002 
D-dimer (µg/ml) 0.23 (0.21 -0.26) 0.33 (0.26 -0.40) 0.40 (0.30 -0.52) 0.006 
P-selectin (ng/ml) 34.0 (32.0 -36.1) 34.0 (31.2-36.1) 32.0 (29.3 -35.0) 0.825 
Von willebrand factor (IU/dL) 79.4 (15.4) 79.0 (21.4) 81.2 (15.3) 0.409 
*
Parametric data reported as mean (SD) – One way anova, + Non-parametric data reported as median (IQR)-  
Kruskal-Wallis test 
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Table 113 Distribution of lipids,  biochemical measures and plasma biomarkers in South Asian women 
Characteristics South Asians  
asymptomatic 
 for CVD,  
 n =229 
South Asians  
with CVD risk  
factors, n ==225 
Subjects with  
CVD, n=66 
P value 
Apolipoprotein AI (g/l)
+
 1.34 (1.30-1.40) 1.30 (1.25-1.40) 1.30 (1.20 - 1.34) 0.060 
Apolipoprotein B (g/l)
*
 0.76 (0.25) 0.67 (0.25) 0.60 (0.22) <0.001 
Serum cholesterol (mmol/l)
* 
4.80 (1.30) 4.10 (1.23) 4.00 (1.30) <0.001 
HDL cholesterol (mmol/l)
* 
1.20 (0.40) 1.10 (0.40) 1.04 (0.40) 0.012 
LDL cholesterol (mmol/l)
*
 2.70 (0.90) 2.14 (0.82) 1.95 (0.80) <0.001 
Triglycerides (mmol/l)
+
 2.13 (1.98 -2.2.9) 2.22 (2.04-2.41) 2.34 (1.98-2.70) 0.511 
Alkaline phosphatase (U/L)
+
  77.0 (73.2 -80.2) 78.0 (74.2 -81.3) 78.0 (70.0 -85.3) 0.875 
Alanine transaminase (U/L)
+ 
19.0 (17.2 -20.3) 18.0 (17.0 -19.0) 21.0 (17.2 -25.0) 0.868 
Aspartate transaminase (U/L)
+ 
20.0 (19.0 -21.0) 19.0 (17.5 -20.0) 21.0 (18.0 -24.2) 0.139 
Creatinine (µmol/l)
+ 
52.0 (46.0 -61.0) 53.0 (43.0 -63.0) 55.0 (48.3 -70.0) 0.125 
Gamma glutamyl  
transpeptidase (U/L)
+ 
25.2 (22.0 -29.0) 25.0 (22.0 -28.0) 37.1 (22.1 -52.3) 0.243 
D-dimer (µg/ml) 0.40 (0.33 – 0.50) 0.40 (0.30 – 0.44) 0.40 (0.26 -0.55) 0.815 
P-selectin (ng/ml) 34.0 (32.0 – 36.4) 33.0 (31.0 -35.0) 31.0 (28.0 -34.3) 0.716 
Von willebrand factor (IU/dL) 77.0 (15.0) 80.0 (22.0) 80.0 (16.2) 0.138 
*
Parametric data reported as mean (SD) – One way anova, + Non-parametric data reported as median (IQR)-  
Kruskal-Wallis test 
 
6.1 .3 .1  The assoc iat ion between D-dimer ,  P-se lect in ,  von 
wil lebrand factor and cardiovascular  r i sk factors  in  South 
Asians 
Correlation analysis was performed to determine the clinical correlates of D-dimer, P selectin and 
vWF in South Asians. 
On correlation analysis, D-dimer was positively associated with age, gender, CRP,  vWF and 
negatively with red blood cell count, haemoglobin, ALT, GGT and triglycerides, all p<0.05. 
Correlation analysis for D-dimer in South Asians is shown in table 114.  
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Table 114 Correlation analysis for D-dimer in South Asians  
Variables South Asians , total n =1222 (South Asians asymptomatic for CVD =505, 
South Asians with modifiable CVD risk factors =519, South Asians with 
existing CVD =198    
Spearman’s correlation 
coefficient, r 
P value 
Age (years) 0.159 <0.001 
Gender  0.162 <0.001 
High sensitivity C-reactive 
protein (mg/L) 
0.142 <0.001 
Red blood cell count -0.173 <0.001 
Haemoglobin (g/dL) -0.168 <0.001 
Alanine transaminase (U/L) -0.159 <0.001 
Gamma glutamyl  
transpeptidase  (U/L) 
-0.084 0.005 
Triglycerides (mmol/l) -0.113 <0.001 
Von willebrand factor (IU/dL) 0.090 0.002 
Variables included in the analysis were waist circumference, BMI, systolic blood pressure,  
diastolic blood pressure, white blood cell count, HbA1c, alkaline phosphatase,  AST, gamma glutamyl 
 transpeptidase, creatnine, ApoAI, ApoB, total cholesterol, LDL-c, HDL-c, triglycerides and P selectin 
 
P-selectin was positively associated with waist circumference, diastolic blood pressure, CRP, 
white blood cell count, red blood cell count, haemoglobin, alkaline phosphatase, ALT, ApoB, 
AST, total cholesterol, GGT, creatinine, LDL-c and triglycerides, all p<0.05. Correlation analysis 
for P-selectin in South Asians is shown in table 115.  
Table 115 Correlation analysis for P selectin  in South Asians  
Variables South Asians , total n =1222 (South Asians asymptomatic for CVD =505, 
South Asians with modifiable CVD risk factors =519, South Asians with 
existing CVD =198    
Spearman’s correlation 
coefficient, r 
P value 
Waist circumference (cm) 0.060 0.040 
Diastolic blood pressure 
(mmHg) 
0.086 0.003 
High sensitivity C-reactive 
protein (mg/L) 
0.082 0.005 
White blood cell count 0.145 <0.001 
Red blood cell count 0.080 0.035 
Haemoglobin (g/dL) 0.094 0.012 
Alkaline phosphatase (U/L) 0.155 <0.001 
Alanine transaminase (U/L) 0.078 0.009 
Apolipoprotein B (g/dL) 0.111 <0.001 
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Aspartate transaminase (U/L) 0.087 0.003 
Total cholesterol (mmol/l) 0.117 <0.001 
Gamma glutamyl  
transpeptidase  (U/L) 
0.106 <0.001 
Creatnine 0.072 0.015 
LDL cholesterol (mmol/l) 0.085 0.004 
Triglycerides (mmol/l) 0.138 <0.001 
Variables included in the analysis were age, gender,BMI, systolic blood pressure, HbA1c, ApoAI, ApoB, 
 HDL-c  and vWF.   
 
 
vWF levels were positively associated with age, systolic blood pressure, CRP, alkaline 
phosphatase, creatinine and D-dimer, all p<0.05. Correlation analysis for vWF in South Asians is 
shown in table 116.  
Table 116 Correlation analysis for von willebrand factor  in South Asians  
Variables South Asians , total n =1222 (South Asians asymptomatic for CVD 
=505, South Asians with modifiable CVD risk factors =519, South 
Asians with existing CVD =198    
Pearson’s correlation coefficient, r P value 
Age (years) 0.210 <0.001 
Systolic blood pressure (mmHg) 0.062 0.033 
 Spearman’s correlation coefficient, 
r 
P value 
High sensitivity C-reactive protein 
(mg/L) 
0.097 0.001 
Alkaline phosphatase (U/L) 0.078 0.009 
Creatnine (µmol/l) 0.163 <0.001 
D-dimer (µg/ml) 0.090 0.002 
Variables included in the analysis were  gender, waist circumference, BMI, diastolic blood pressure, 
Red blood cell count, white blood cell count, HbA1c, hemoglobin, ALT, AST, GGT,  ApoAI, ApoB, total cholesterol,  
LDL-c, HDL-c, triglycerides and  P selectin 
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6.1 .3 .2  Clinical  corre lates  of  D-dimer,  P  se lect in  and von 
wil lebrand factor  in  South Asians:  mult ip le  regress ion 
models  
Multiple regression models were developed with variables associated with D-dimer, P selectin 
and vWF respectively. The models enabled to determine clinical correlates that independently 
contributed to the variation in the above mentioned plasma biomarkers.  
On multiple regression models, red blood cell count, CRP, age and triglycerides explained 7% of 
the variation in D-dimer levels in South Asians. Table 117 shows the clinical correlates of D-
dimer in South Asians. 
Table 117 Clinical correlates of D-dimer in South Asians: multiple linear regression model  
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Red blood cell count -0.084 -0.128 - -0.040 <0.001 0.020 
CRP (mg/L) 0.011 0.002 – 0.019 0.012 0.003 
Age (years) 0.003 0.001 – 0.006 0.020 0.023 
Triglycerides (mmol/l) -0.018 -0.035 - -0.001 0.043 0.003 
Overall adjusted R
2
 for the model -0.072 
Variables included in the model- age, gender, CRP, red blood cell count, haemoglobin, alanine transaminase, GGT, 
BNP, vWF and triglycerides 
 
Total cholesterol, white blood cell count, creatinine and BNP explained 6% of the variations in P-
selectin in South Asians. Table 118 shows the clinical correlates of P- selectin in South Asians.  
Table 118 Clinical correlates of P-selectin  in South Asians: multiple linear regression model  
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Total cholesterol (mmol/l) 1.763 0.545 – 2.981 0.005 0.011 
White blood cell count 1.277 0.350 – 2.205 0.007 0.009 
Creatinine (µmol/l) 0.116 0.033 – 0.199 0.006 0.006 
BNP (pmol/L) -0.115 -0.226 - -0.004 0.042 0.003 
Overall adjusted R
2
 for the model -0.056 
Variables included in the model- age, gender, waist circumference, diastolic blood pressure, CRP, white blood cell 
count, red blood cell count, haemoglobin, alkaline phosphatase, ALT, AST, ApoB, total cholesterol, creatinine, GGT, 
LDL-c BNP and triglycerides 
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Age, alkaline phosphatase and creatinine explained 7% of the variation in vWF levels in South 
Asians. Table 119 shows the clinical correlates of von willebrand factor in South Asians. 
Table 119 Clinical correlates of  von willebrand factor  in South Asians: multiple linear regression model  
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Age (years) 0.365 0.221 – 0.508 <0.001 0.043 
Alkaline phosphatase (U/L) 0.111 0.059 – 0.163 <0.001 0.013 
Creatinine (µmol/l) 0.073 0.016 – 0.129 0.012 0.015 
Overall adjusted R
2
 for the model -0.065 
Variables included in the model- age, systolic blood pressure, CRP or alkaline phosphatase, creatinine, BNP and D-
dimer 
6.1 .3 .3  The performance  of  D-dimer ,  P  select in  and von wil lebrand 
factor  in  the  predict ion of  cardiovascular  r i sk  in  South 
Asians 
ROC analysis was done to evaluate the performance of D-dimer, P selectin and vWF as 
discriminators of CVD risk in South Asians i) South Asians asymptomatic for CVD ii) South 
Asians with CVD risk factors and iii) South Asians with existing CVD. 
On ROC analysis, vWF significantly discriminated South Asians with existing CVD from South 
Asians asymptomatic for CVD, AUC 0.555 (95% CI, 0.507 – 0.603), p =0.030. D-dimer and P-
selectin did not discriminate South Asians with CVD from those asymptomatic for CVD. Table 
120 shows plasma markers as discriminators of CVD in a cohort which consisted of South Asians 
with existing CVD (n=198) versus South Asians asymptomatic for CVD, (n=506).  
Table 120 Plasma biomarkers as discriminators of CVD in a cohort which consisted of South Asians with existing 
CVD (n=198) versus South Asians asymptomatic for CVD, (n=506)  
Biomarkers P value  AUC 95% CI 
vWF (IU/dL) 0.030 0.555 0.507-0.603 
D-dimer (µg/ml) 0.066 0.545 0.498-0.592 
P-selectin (ng/ml) 0.854 0.495 0.447-0.544 
 
vWF, D-dimer and P-selectin did not discriminate South Asians with existing CVD and CVD 
risk factors (combined n=198 & n=519 respectively) from those asymptomatic for CVD, n =506. 
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Table 121 shows plasma markers as discriminators of CVD in a cohort which consisted of South 
Asians with existing CVD (n=198) & CVD risk factors (n=519) versus South Asians 
asymptomatic for CVD, (n=506).  
Table 121 Plasma markers as discriminators of CVD in a cohort which consisted of South Asians with existing CVD 
(n=198) & CVD risk factors (n=519) versus South Asians asymptomatic for CVD, (n=506). 
Biomarkers P value  AUC 95% CI 
vWF (IU/dL) 0.483 0.512 0.478 - 0.545 
D-dimer (µg/ml) 0.199 0.522 0.489 -0.555 
P-selectin (ng/ml) 0.689 0.507 0.474 -0.540 
 
vWF, D-dimer and P-selectin did not discriminate South Asians with CVD risk factors, n=519 
from those asymptomatic for CVD, n =506. Table 122 shows plasma markers as discriminators 
of CVD in a cohort which consisted of South Asians with CVD risk factors (n=519) versus South 
Asians asymptomatic for CVD, (n=506).  
Table 122 Plasma markers as discriminators of CVD in a cohort which consisted of South Asians with CVD risk 
factors (n=519) versus South Asians asymptomatic for CVD, (n=506).  
Biomarkers P value  AUC 95% CI 
vWF (IU/dL) 0.782 0.495 0.459 - 0.531 
D-dimer (µg/ml) 0.483 0.513 0.477 -0.549 
P-selecting 
(mg/ml) 
0.559 0.511 0.475 -0.547 
6.1.4  Discussion 
In South Asians asymptomatic for CVD, D-dimer and vWF significantly discriminated South 
Asians with central obesity from healthy South Asians. Moreover, vWF discriminated South 
Asians with increased CVD risk from healthy South Asians. 
Elevated levels of D-dimer reflect increased fibrinolytic activity and have been associated with 
varying degrees of atherosclerosis (Panchenko et al., 1995; Tataru et al., 1999). Previous studies 
have associated D-dimer and vWF with obesity. Ferguson et al., (1998) reported elevated levels 
of D-dimer in obese Black children whereby D-dimer was positively associated with percentage 
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body fat, subcutaneous abdominal adipose tissue and BMI. In the Framingham offspring study, 
BMI and waist-to-hip ratio were associated with haemostatic factors -fibrinogen, factor VII, 
plasminogen activator inhibitor antigen, tissue plasminogen activator and vWF (Rosito et al., 
2004). Mills et al., (2008) reported in healthy young adults of diverse ethnic background that 
elevated levels of D-dimer were associated with higher BMI irrespective of ethnicity.  
Pomp et al., (2007) reported a 2.4 fold increase in the risk of venous thrombosis in subjects with 
BMI >30 kg/m
2
 compared to non-obese subjects. Obesity is an established risk factor for CVD 
(Hubert et al., 1983) and its effect is mediated through enhanced inflammation (Visser et al., 
1999), platelet activation (Anfossi et al., 2009; Anfossi et al., 2010), increased levels of 
coagulation factors (Rosito, 2004), impaired fibrinolysis (Lijnen, 2009) and endothelial 
dysfunction (Perticone et al., 2001). In our cohort, the high prevalence of obesity (51.0%) and 
increased waist circumference (79.4%) amongst South Asians asymptomatic for CVD along with 
elevated levels of D-dimer and vWF reflect the adverse risk profile associated with body fat in 
South Asians.  
Adhesion molecule, P-selectin significantly discriminated South Asians with elevated 
triglycerides from healthy subjects. Kavazarakis et al., (2002) demonstrated in healthy children 
that elevated levels of triglycerides increased the risk of endothelial dysfunction and reported an 
association between triglycerides and P-selectin levels. Broijersen et al., (1998) demonstrated in 
normolipidemic subjects after a fatty meal, postprandial increase in triglycerides sensitized 
platelets resulting in enhanced platelet P-selectin expression.      
Adhesion molecules are involved in the early stages of atherosclerosis and up regulation of these 
molecules in the endothelium reflect platelet activation and endothelial dysfunction (Varughese et 
al., 2007). Elevated levels of P-selectin have been associated with worse CVD outcomes and 
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recurrent CV events in subjects with MI (Blann et al., 1997; Ridker, 2001b). In the ASCOT trial, 
P-selectin was a significant predictor of MI in hypertensive subjects (Varughese, 2007). In our 
cohort elevated levels of P-selectin in asymptomatic South Asians with abnormal triglycerides 
suggest an adverse risk for the development of CVD.  
Of all the plasma biomarkers measured in this cohort, vWF alone significantly discriminated 
South Asians with existing CVD from those asymptomatic for CVD. Elevated levels of vWF 
have been associated with incident CVD (Wennberg, 2011).   
The main limitations of the study are the cross sectional study design, generalization of the South 
Asian ethnic groups and inclusion of subjects above the age of 45 years. Hence our finding might 
not be applicable to individual ethnic groups and to young South Asians. Bloods were obtained 
for the measurement of plasma biomarkers at a single point of time and hence the diurnal 
variability of plasma biomarkers was not addressed. The strength of the study was the ability to 
determine the performance of plasma biomarkers of CVD in South Asians asymptomatic for 
CVD who were not under the influence of any medication for modifiable CVD risk factors.  
6.1 .4 .1  Conclus ion 
The performance of D-dimer, P-selectin and vWF as biomarkers of CVD risk in South Asians 
was modest, with only vWF discriminating South Asians with increased risk of CVD and 
existing CVD.  
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6.2  The performance of  brain  natriuret ic peptide as  a  
discriminator  of  lef t  ventricular  systol ic  dysfunct ion  in  South  
Asians  in  the  UK 
6.2.1  Aims and hypothesis  
Left ventricular systolic dysfunction if left untreated can lead to chronic heart failure which has 
poor outcomes. Early identification of asymptomatic LVSD enables clinicians in the prevention 
and better management of heart failure. BNP has shown to be a useful marker for the screening of 
LVSD in the general population. South Asians have an increased risk of CVD which might 
predispose this ethnic group to LVSD but the performance of BNP as a discriminator of LVSD 
has not been explored in this ethnic group. The aim of this study was to evaluate the 
discriminative value for BNP in the identification of South Asians with LVSD defined as LVEF 
<50%.  
6.2.2  The performance of brain natriuretic peptide as a 
discriminator of left ventricular systolic dysfunction is 
South Asians in the UK 
6.2 .2 .1  Character is t ics  of  the  s tudy  populat ion  
Of 638 South Asian subjects, 629 subjects had normal LV function and 9 had LVSD defined as 
LVEF <50%. The prevalence of LVSD defined as LVEF < 50% in our study cohort was 1.4%. 
South Asian patients with LVSD were much older compared to those with normal LV function, 
68 years vs. 57.4 years, p=0.001. BMI, waist circumference, hypertension were comparable in 
South Asians with normal LV function and in those with LVSD. Pulse pressure were higher in 
South Asian patients with LVSD compared to those with normal LV function, p=0.007. The 
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prevalence of HF, MI, angina and diabetes were higher amongst South Asian patients with LVSD 
compared to those with normal LV function, all p<0.05. Compared to South Asians with normal 
LV function, those with LVSD were significantly on ACE inhibitors, 19.1% vs. 68.0%, p=0.003. 
Differences in demographic details between South Asians with normal LV function and those 
with LVSD are shown in Table 123.  
Table 123 Differences in demographic details between South Asians with normal LV function and those with LVSD 
Characteristics  South Asians with 
normal LV function 
(LVEF >50%) n=629 
South Asians with 
LVSD (defined as LVEF 
<50%) n =9 
P value 
Mean age (years) 57.4 (9.2) 68.0 (11.0) 0.001 
Male (%) 350 (56.0) 6 (67.0) 0.379 
Current smokers (%) 52 (8.3) 0 (0.0) 0.463 
Body mass index (kg/m
2
) 28.1 (5.0) 26.2 (3.2) 0.246 
Waist circumference (cm) 97.0 (12.0) 97.0 (7.0) 0.965 
Systolic blood pressure (mmHg) 140.0 (19.1) 150.1 (38.2) 0.125 
Diastolic blood pressure (mmHg) 82.1 (11.1) 78.2 (14.0) 0.311 
Pulse pressure (mmHg) 58.0 (15.0) 72.0 (33.0) 0.007 
Obesity (kg/m
2
), (%) 357 (57.0) 3 (33.3) 0.143 
Increased waist circumference (cm) (%) 539 (86.0) 9 (100) 0.252 
Past medical history 
    Previous HF (%) 
     Previous MI (%) 
     Angina (%) 
     Hypertension (%) 
     Diabetes (%)      
 
3 (0.5) 
41 (6.5) 
48 (8.0) 
491 (78.1) 
216 (34.3) 
 
1 (11.1) 
3 (33.3) 
4 (44.4) 
9 (100) 
6 (67.0) 
 
0.055 
0.019 
0.004 
0.110 
0.051 
Drug therapy (%) 
     ACE inhibitors 
     Beta-blockers 
     Calcium blockers 
     Diuretics 
     Anti-platelet therapy     
 
120 (19.1) 
73 (12.0) 
85 (14.0) 
84 (13.4) 
56 (10.0) 
 
 
6 (68.0) 
3 (33.3) 
2 (22.2) 
2 (22.2) 
2 (22.2) 
 
0.003 
0.080 
0.353 
0.348 
0.193 
*
Parametric data reported as mean (SD) – Independent T-test & n (%)-chi-square test.  
 
Differences in haematological and lipid profiles between South Asians with normal LV function 
and those with LVSD are shown in Table 124. Levels of ApoAI, ApoB, total cholesterol, LDL-c, 
HDL-c, triglycerides, haemoglobin, MCV and creatinine were comparable in both groups.  
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Table 124 Differences in haematological and lipid profiles between South Asians with normal LV function and those 
with LVSD 
Characteristics  South Asians with normal 
LV function (LVEF 
>50%) n=601 
South Asians with LVSD 
(defined as LVEF <50%)  
n =9 
P value 
Apolipoprotein AI (g/dL)
+ 
1.27 (1.11 – 1.46) 1.30 (1.20 – 1.34) 0.858 
Apolipoprotein B (g/dL)
* 
0.70 (0.2) 0.65 (0.2) 0.653 
Total cholesterol (mmol/l)
* 
4.40 (1.4) 4.00 (0.7) 0.333 
LDL cholesterol (mmol/l)
* 
2.34 (1.0) 2.01 (0.5) 0.303 
HDL cholesterol (mmol/l)
* 
1.04 (0.4) 1.10 (0.3) 0.729 
Triglycerides (mmol/l)
+ 
1.98 (1.46 – 2.94) 1.90 (1.25 – 2.61) 0.525 
Haemoglobin (g/dL)
* 
14.0 (2.0) 14.3 (1.0) 0.617 
Mean corpuscular volume (fL)
* 
87.4 (6.5) 83.3 (2.3) 0.275 
Creatinine (µmol/l)
* 
65.2 (25.0) 68.2 (19.0) 0.715 
*
Parametric data reported as mean (SD) –Independent T-test, + Non-parametric data reported as median (IQR)- 
Mann-Whitney test 
Haematological factors were available only for 380 subjects (Subjects with LVSD=3, without LVSD=377) 
 
6.2 .2 .2  Brain  natr iuret ic  pept ide  and le f t  ventr icular systo l ic  
dysfunction  
BNP levels were determined in South Asians with LVSD and in those with normal LV function.  
Levels of BNP were significantly higher in South Asian patients with LVSD compared to those 
with normal LV function, median (IQR), 3.93 pmol/l (2.00 -8.12) vs. 28.30 pmol/l (9.30 -45.10), 
p<0.001. Figure 39 shows levels of BNP in South Asians with normal LV function and those 
with LVSD. 
Table 125 Levels of brain natriuretic peptide in South Asians with and without left  ventricular systolic dysfunction  
in  South Asians 
 South Asians without LVSD 
 (defined as LVEF >50%),  n=629 
South Asians with LVSD (LVEF < 
50%),  n=9 
P value 
Brain natriuretic 
peptides (pmol/l) 
3.93 (2.00 – 8.12) 28.30 (9.30 – 45.10)  <0.001 
Reported as median (IQR) –Mann-Whitney test 
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figure 39 Levels of brain natriuretic peptides in South Asians with normal LV function and those with 
left ventricular systolic dysfunction 
 
            Mann Whitney test 
             
 
 
 
 
 
 
 
 
6.2 .2 .3  Correlat ion and mult ip le  regress ion analys is  for  brain  
natr iuret ic  pept ide  in  South Asians  
Correlation analysis was performed to determine clinical correlates of BNP in South Asians. 
Multiple regression models were then developed with variables associated with BNP in order to 
determine independent predictors of BNP levels in South Asians.  
BNP was positively associated with age (r=0.308), pulse pressure (r=0.218), HbA1c (r=0.115), 
vWF (r=0.122), D-dimer (r=0.138), and negatively associated with diastolic blood pressure (r=-
0.161), red blood cell count (r=-0.275), haemoglobin (r=-0.317), ApoB (r=-0.105), cholesterol 
(r=-0.123), LDL-c (r=-0.101),  triglycerides (r=-0.162) and P-selectin (r=-0.119). Correlation 
analyses for BNP in South Asians are shown in table 126. 
P<0.001 
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Table 126 Correlation analyses for  brain natriuretic peptides in South Asians  
Variables South Asian men 
 
Spearman’s correlation 
coefficient, r 
P value 
Age (years) 0.308 <0.001 
Diastolic blood pressure (mmHg) -0.161 <0.001 
Pulse pressure (mmHg) 0.218 <0.001 
HbA1c (%) 0.115 0.005 
Red blood cell count  -0.275 <0.001 
Haemoglobin (g/dL) -0.317 <0.001 
Apolipoprotein B (g/dL) -0.105 0.009 
Total Cholesterol (mmol/l) -0.123 0.002 
LDL cholesterol (mmol/l) -0.101 0.012 
Triglycerides (mmol/l) -0.162 <0.001 
vWF  (IU/dL) 0.122 0.002 
D-dimer (µg/ml) 0.138 0.001 
P selectin (ng/ml) -0.119 0.003 
Other variables in the analysis- waist circumference, BMI, systolic blood pressure, CRP, white blood cell count, 
MCV, ApoAI, HDL-c, creatnine, LVEF 
 
On multiple linear regression, age, haemoglobin, pulse pressure, D-dimer and triglycerides 
explained 14.5% of the variations in BNP levels in South Asians. Table 127 shows the clinical 
correlates of brain natriuretic peptides in South Asians. 
Table 127 Clinical correlates of brain natriuretic peptides in South Asians: multiple regression model 
Predictor variables Beta 
coefficients  
95% Confidence 
Interval 
P value Adjusted R
2
 (simple 
linear regression)  
Age (years) 
Haemoglobin (g/dL) 
Pulse pressure (mmHg) 
D-dimer (µg/ml) 
Triglycerides (mmol/l) 
0.146 
-0.802 
0.112 
4.103 
-0.765 
0.031 -0.261 
-1.346 - -0.257 
0.047 – 0.177 
0.831 – 7.376 
-1.378 - -0.153 
0.013 
0.004 
0.001 
0.014 
0.014 
0.093 
0.050 
0.070 
0.020 
0.030 
Overall adjusted R
2
= 0.145 
Variables included in the model-gender, diastolic blood pressure, HbA1c, Red blood cell count, ApoB/total 
cholesterol/ LDL cholesterol, P-selectin 
 
BNP were not associated with LVEF (r=-0.072, p=0.068) but was associated with pulse pressure 
(r = 0.281, p<0.001). Relationship between BNP and ejection fractions is shown in figure 40. 
Figure 41 shows the relationship between BNP and pulse pressure. 
 
 
 251 
figure 40 Relationship  between brain natriuretic peptide and left ventricular ejection fraction in South 
Asians 
                                                                                                                                    Simple linear regression                                                                                                                                     
        
 
 
 
 
 
 
 
 
 
 
figure 41 Relationship  between brain natriuretic peptide and pulse pressure in South Asians  
 
                                                                                                                                                   Simple linear regression 
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6.2 .2 .4  Brain  natr iuret ic  pept ide and haemoglobin  levels  
On correlation analysis, BNP were negatively associated with haemoglobin levels (r=-0.317, 
p<0.001). Figure 42 shows the relationship between natriuretic peptide and haemoglobin levels. 
Levels of BNP were highest in subjects with lowest haemoglobin levels and vice versa. Levels of 
brain natriuretic peptide across haemoglobin quartiles are shown in Table 128.  
figure 42 Relationship  between brain natriuretic peptide and haemoglobin levels 
                                                                                                                                    Simple linear regression 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 128 Levels of brain natriuretic peptide across haemoglobin quartiles  
Haemoglobin 
quartiles 
Haemoglobin levels  
<12.57g/Dl 
(n=94) 
12.58 – 13.63 g/dL 
(n=97) 
13.64 -14.92 g/dL 
(n=96) 
>14.93 g/dL 
(n=93) 
BNP (pmol/l) 8.40 (3.80-17.42) 5.02 (2.60-8.34) 3.10 (1.30-6.80) 2.99 (1.06-6.29) 
Kruskal-wallis test, p value <0.001 
Haemoglobin levels were available only 380 subjects 
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6.2 .2 .5  The performance  of  brain natriuret ic  pept ide  as  a  
d iscr iminator of  le f t  ventr icular  dysfunct ion in  South 
Asians  in the UK 
The purpose of this section was to evaluate the performance of BNP as a discriminator of LVSD 
in South Asians. The discriminative measure was assessed by sensitivity and specificity and the 
area under the ROC curves.  
On ROC analysis, BNP significantly discriminated South Asians with LVSD from those with 
normal LV function, AUC -0.876 (95% CI, 0.777 – 0.976), p<0.001. Table 129 shows brain 
natriuretic peptide as a discriminator of left ventricular systolic dysfunction in South Asians.  
Table 129 Brain natriuretic peptide as a discriminator of left ventricular systolic dysfunction  in  South Asians  
 Left ventricular systolic dysfunction  
(defined as LVEF < 50%), Positive n=9, negative =629 
Brain natriuretic peptide (pmol/l) P value AUC 95% CI 
<0.001 0.876 0.777 – 0.976 
Cut off value  8.865 pmol/l or 30.8 pg/ml 
BNP concentrations were expressed in pmol/l, to convert to pg/ml levels were multiplied by 3.47 
 
Since there were only 9 subjects with LVEF <50% in our study cohort which did not give us 
enough power for ROC analysis, 46 South Asian HF subjects from a previous study conducted at 
the Centre for Cardiovascular Sciences, City Hospital were added and the ROC analysis for BNP 
was repeated. These South Asian HF patients were recruited from the specialist heart failure 
clinics at City and Sandwell Hospitals. HF was defined as those with typical HF symptoms 
associated with LVSD (ejection fraction <40%) documented by echocardiography. The study was 
approved by the West Midlands research ethics committee and all patients gave written informed 
consent prior to participation (Sosin et al., 2008). The characteristics of these 46 South Asian HF 
patients are shown in Table 130. 
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Table 130 Characteristics of South Asian heart failure patients  
Characteristics  South Asian heart failure patients (defined as LVEF 
<40%)  
n =46 
Mean age (years) 62.0 (13.2) 
Male (%) 31 (67.4) 
Current smokers (%) 3 (6.5) 
Systolic blood pressure (mmHg) 138.4 (26.0) 
Diastolic blood pressure (mmHg) 82.4 (13.0) 
Past medical history 
     Previous MI (%) 
     Angina (%) 
     Hypertension (%) 
     Diabetes (%)      
 
31 (67.4) 
25 (54.3) 
21 (45.7) 
21 (45.7) 
Drug therapy (%) 
     ACE inhibitors 
     Beta-blockers 
     Diuretics 
      
 
39 (85.0) 
24 (52.2) 
29 (63.0) 
Total cholesterol (mmol/l)
* 
4.60 (1.1) 
HDL cholesterol (mmol/l)
* 
1.30 (0.3) 
Triglycerides (mmol/l)
+ 
1.53 (1.20 – 2.24) 
Brain natriurectic peptide (pmol/l) 4.50 (2.14 – 10.0) 
*
Parametric data reported as mean (SD) – One sample T-test & n (%)-chi-square test.  
 
On ROC analysis, BNP significantly discriminated South Asians with LVSD from those without, 
AUC -0.896 (95% CI, 0.852 – 0.940), p<0.001. Table 131 shows brain natriuretic peptide as a 
discriminator of left ventricular systolic dysfunction in South Asians. Table 132 shows the 
performance of BNP in identifying LVSD in South Asians.  
Table 131 Brain natriuretic peptide as a discriminator of left ventricular systolic dysfunction  in  South Asians 
 Left ventricular systolic dysfunction  
(defined as LVEF < 50%) Positive n= 55, negative = 629 
Brain natriuretic peptide (pmol/l) P value AUC 95% CI 
<0.001 0.896 0.852 – 0.940 
Cut off value  10.5 pmol/l or 36.4 pg/ml 
BNP concentrations were expressed in pmol/l, to convert to pg/ml levels were multiplied by 3.47 
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Table 132 Performance of BNP in identifying LVSD in South Asians 
Characteristics  South Asians with LVSD <50% 
Sensitivity  80.0% 
Specificity 82.8% 
Positive predictive value 28.9% 
Negative predictive value 97.9% 
True positive=44, false positive=108 
True negative=521, false negative=11 
 
6.2.3  Discussion 
The main finding of this study was that BNP significantly discriminated South Asians with 
LVSD from those with normal LV function with a discriminative value of 36.4 pg/ml in 
combined community based population and HF patients from a clinic setting with a high negative 
predictive value of 97.9%. Our findings add to the already existing evidence of high predictive 
value for natriuretic peptide in HF settings. There is no clear consensus on the best discriminative 
value for BNP in the identification of LVSD or assay method (Thygesen, 2011).The performance 
of Bayer ADVIA Centaur BNP assay used in this study is equivalent to other methods for 
determining BNP such as Triage BNP and ShionoRIA assay (Wu et al., 2004). 
In the Framingham Heart study, BNP values of 45 pg/ml in men and 50 pg/ml in women) showed 
95% specificity for LVSD (Vasan et al., 2002). While values of 100 pg/ml has shown to increase 
the diagnostic accuracy of BNP in the emergency diagnosis of HF (Maisel, 2002; Mueller et al., 
2004). McDonagh (1998) reported BNP concentration of 17.9 pg/ml or more in the identification 
of LVSD in the general population. Our discriminative values were closer to the ones reported in 
the Framingham heart study.   
The prevalence of LVSD in South Asians in our study cohort was 1.4% The prevalence rate for 
LVSD was similar to those reported in non-Asian populations, in the Echocardiographic Heart of 
England Screening study, the prevalence rate for LVSD was 1.8% (Davies, 2001), in the 
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Rotterdam study the prevalence for LVSD was 3.7% (Mosterd et al., 1999) and McDonagh et al., 
(1997) reported a prevalence rate of 2.9% for LVSD in an Urban UK population. In this cohort 
the prevalence of LVSD was mainly in those with concomitant diabetes or MI and this finding 
has been reported in previous studies (Lip, 1997; Galasko, 2005). 
Even though there was a significant difference in the levels of BNP between South Asian with 
LVSD and those with normal LV function, BNP levels did overlap in both groups. This could be 
due to concomitant diuretics and angiotensin-converting enzyme inhibitor therapy which can 
lower BNP levels (Bhatia et al., 2006). This limits the usefulness of BNP as a screening 
biomarker for LVSD in South Asians already on cardiovascular medications.  
In our South Asian cohort, BNP was associated with pulse pressure and not with LVEF. This 
suggests the classic pathway where BNP is secreted in response to volume and pressure overload 
in HF patients (Maisel, 2002). Pulse pressure was significantly higher in South Asians with 
LVSD compared to those with normal LV function. The visual assessment of LVSD provides 
valuable diagnostic and prognostic information to clinicians (Devereux et al., 1986; Watanabe et 
al., 2001). The lack of association between BNP and LVSD could be due to skewed distribution.  
BNP was also shown to be associated with haemoglobin levels in South Asians. Anemia in HF 
patients is associated with poor outcomes and increased risk of mortality (Horwich et al., 2002; 
Ezekowitz et al., 2003). The relationship between anemia, HF and poor outcomes is not well 
understood but several mechanisms have been proposed. Enhanced inflammation in HF can 
affect bone marrow function and predispose HF patients to anemia (Levine et al., 1990; Iversen et 
al., 2002). The presence of anemia and reduced kidney function itself can predispose HF patients 
to worse outcomes (Al-Ahmad et al., 2001; Horwich, 2002)  
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Ralli et al., (2005) demonstrated an increased risk of mortality in HF when elevated levels of 
BNP were accompanied by anemia. Reduced hemoglobin levels suggest an increase in cardiac 
output secondary to a higher myocardial oxygen demand and this can lead to ventricular dilation 
and left ventricular hypertrophy (Ueno et al., 2008). In our cohort, hemoglobin levels were 
similar in South Asians with LVSD and in those with normal LV function but levels of BNP 
were highest in subjects with lowest hemoglobin levels and vice versa. 
Possible mechanisms for the link between BNP and hemoglobin levels in South Asians could be 
independent of hemodynamic parameters and due to endothelin-1; a direct stimulator of BNP in 
HF. Elevated levels of endothelin-1 has been linked to anemia and hypoxia (Helfman and 
Falanga, 1993). Over expression of endothelin-1 in cardiocytes and smooth muscle cells lead to 
myocardial hypertrophy and cardiotoxicity (Sakai et al., 1996) and BNP can be an indicator of 
endothelin-1 induced myocardial injury (Nakagawa et al., 1995; Ralli, 2005). South Asian 
patients with LVSD had a higher prevalence of prior MI and diabetes mellitus which could lead 
to ischemia induced endothelin-1.  
Another possible reason for the release of endothelin-1 in migrant South Asians could be the 
migration from low altitudes within the Indian sub-continent to high altitudes in the UK which 
could have resulted in high altitude induced hypoxia. Prior studies have shown that subjects who 
live permanently in a high altitude might have adapted to high altitude hypoxia and hence have 
lower pulmonary pressure, higher plasma concentration of nitric oxide compared to migrants 
(Erzurum et al., 2007). Elevated levels of endothelin-1 have also been reported in infectious 
diseases such as malaria (Basilico et al., 2002; Dietmann et al., 2008). Further studies are 
warranted to prove this relationship between anaemia and secretion of BNP in South Asians.  
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The limitations are the cross sectional design and relatively small numbers due to the lower 
prevalence of LVSD in South Asian community population. South Asians are a heterogeneous 
group and our study has reported Indians, Pakistanis and Bangladeshi as a combined group. Even 
though the study population was community based and was expected to have only asymptomatic 
subjects for LVSD, 4 subjects were known to have HF and only one subjects had LVEF less than 
50%. In order to confirm the discriminative value obtained for BNP in the South Asian 
community samples we combined South Asian HF patients recruited from a clinical setting with 
South Asian recruited from General Practices who might be asymptomatic or have less severe 
disease. However the discriminative values for BNP in the identification of LVSD in the 
community population was close to the combined clinic and community populations.  
6.2 .3 .1   Conclusion  
BNP significantly discriminated South Asians with LVSD from those with normal LV function 
with a high negative predictive value.  
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CHAPTER 7 RESULTS 4 
7 .1  Haemoglobin  a bnormal i t i e s  and the  r i sk  o f  card iovascu lar  d i sease  in  
South  As ians  
7.1.1  Aims and hypothesis  
Haemoglobinopathies such as beta thalassemia are blood born disorders that are particularly 
prevalent amongst populations originating from the Indian subcontinent. It is estimated that the 
carrier rate for beta thalassemia amongst South Asians are 1 in 20 (Lahiry et al., 2008). Bartels et 
al., (2006) demonstrated that there is accelerated erythropoiesis in subjects with beta thalassemia 
trait, evidence to support ‘intravascular haemolysis – an increased release of iron from these red 
blood cells, which is implicated in the progression of CHD (Rother et al., 2005; Levy et al., 
2007). However studies in non-Asian populations have shown beta thalassemia trait to confer a 
protective role against CVD (Crowley, 1987; Wang and Schilling, 1995). This is mainly 
considered due to its favourable impact on cholesterol metabolism (Shalev et al., 2007) whereby 
there is an increased uptake of LDL by the bone marrow to provide cholesterol for the production 
of red blood cells (Calandra et al., 2004). Less is known about the cardiovascular implications of 
haemoglobin abnormalities in South Asian populations. The aim of this case control study was to 
analyse haemoglobin abnormalities by ESI-MS and determine whether they were more common 
amongst South Asians with CVD than those without CVD.   
7.1 .1 .1  Study  populat ion  
The study population were from two main studies involving South Asian population in the 
department, namely E-ECHOES and NIASTAR trial.  
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7.1 .1 .2  Power ca lculat ion  
The pilot study was designed to use groups of n=100 of controls and patients, where 67 subjects 
were needed for 80% power to be able to detect a 5% difference in rates of haemoglobin 
disorders at 5% alpha.   
7.1.2  Haemoglobin abnormalities  and the risk of cardiovascular 
disease in South Asians in the UK 
7.1 .2 .1  Character is t ics  of  the  s tudy  cohort   
A total of 156 South Asians were included in this pilot study, of whom 84 were control subjects 
(without any documented evidence of CVD) and 72 were CVD patients. The characteristics of 
South Asian cardiovascular patients and control subjects are shown in Table 133.  The CVD 
patients were older, and comparable with control subjects for gender, BMI and blood pressure. 
Lipid lowering therapy was mainly statin therapy in controls, all CVD patients were on statin and 
anti-platelet therapy.  
Table 133 Characteristics of South Asian cardiovascular disease patients and control subjects 
Characteristics Subjects without  
CVD (n= 84) 
Subjects with CVD 
(n = 72) 
P value 
Age (years)
* 
55.5 (7.9) 62.6 (13.1) <0.001 
Male gender, n (%) 47 (60.3) 51 (71.8) 0.14 
Body mass index (kg/m2)
*
 28.7 (7.1) 27.5 (4.4) 0.28 
Ischaemic stroke, n (%) 0 72 (100) - 
Coronary heart disease, n (%) 0 18 (25.0) - 
Peripheral vascular disease, n (%) 0 2 (2.7) - 
Hypertension, n (%) 44 (52.4) 65 (90.1) <0.05 
Diabetes mellitus, n (%) 25 (29.8) 33 (45.8) 0.08 
Systolic blood pressure (mmHg)
*
 140 (15) 145 (22) 0.09 
Diastolic blood pressure (mmHg)
*
 91.0 (48.9) 81.0 (12.3) 0.10 
Anti-platelet therapy, n (%) 14 (16.7) 72 (100) <0.001 
Lipid lowering therapy, n (%) 29 (34.5) 72 (100) <0.001 
Ever smoked, n (%) 84 (28.6) 19 (26.4) 0.55 
*
Parametric data reported as mean (SD)  
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With regards to lipids and lipoproteins, CVD patients had lower apolipoproteins and LDL-c 
compared to control subjects, all p<0.001 except HDL-c (NS). Table 134 shows the distribution 
of lipids and lipoproteins in South Asian cardiovascular disease patients and control subjects.  
Table 134 Distribution of lipids and lipoproteins in South Asian cardiovascular disease patients and control subjects  
Characteristics Subjects without  
CVD (n= 84) 
Subjects with CVD 
(n = 72) 
P value 
Apolipoprotein AI (g/l)
*
 1.44 (0.29) 1.20 (0.41) <0.001 
Apolipoprotein B (g/l)
*
 0.73 (0.22) 0.47 (0.16) <0.001 
Serum cholesterol (mmol/l)
* 
4.80 (1.08) 2.52 (3.08) <0.001 
HDL cholesterol (mmol/l)
* 
1.20 (0.40) 1.06 (0.49) 0.07 
LDL cholesterol (mmol/l)
* 
2.56 (0.93) 1.58 (0.75) <0.001 
*
Parametric data reported as mean (SD)  
 
7.1 .2 .2  Haemoglobin  abnormal i t ies  in  South Asian cardiovascular 
d isease pat ients  and controls  
On comparison of haematological factors, haemoglobin levels, red blood cell counts and MCV 
were comparable between CVD patients and control subjects. Haemoglobin abnormalities were 
significantly more common in CVD patients compared to control subjects, p=0.002. Elevation of 
delta chains within the haemoglobin was significantly more common amongst CVD patients 
compared to control subjects, p=0.005. Lipoprotein subfraction concentration of iron were 
significantly higher amongst CVD patients compared to control subjects, all p<0.05. 
Haematological factors and abnormalities of the haemoglobin in South Asian cardiovascular 
patients and controls are shown in Table 135.  
Table 135 Haematological factors and abnormalities of the haemoglobin in South Asian cardiovascular disease 
patients and controls 
 Without CVD (n=84) With CVD (n=72) P value 
Haemoglobin (g/dL)
+ 
13.6 (12.5-14.6) 13.7 (12.6-14.7) 0.72 
Red blood cell count (×1000,000  
cells/µl)
+ 
5.01 (4.68-5.31) 4.93 (4.53-5.30) 0.40 
Mean corpuscular volume (fL)
+ 
86.8 (83.2-90.1) 87.1 (84.0-89.6) 0.85 
Platelet count (×1000 cells/µl)
+ 
292 (238-348) 256 (220-294) 0.009 
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All haemoglobin disorders, n (%) 12  (14.3) 25 (34.7) 0.002 
Elevated delta chain level, n (%) 4 (4.8) 14 (19.4) 0.005 
High levels of alpha/beta chain  
Glycation, n (%) 
6 (7.1) 12 (16.7) 0.08 
Beta chain variants, n (%) 2 (2.4) 0 - 
VLDL iron 0.30 (0.00-0.90) 0.60 (0.20-1.10) 0.031 
LDL iron 0.30 (0.00-0.80) 0.70 (0.30- 1.30) 0.01 
HDL3 iron 0.70 (0.00 – 1.10) 1.90 (1.25-2.80) <0.001 
HDL2 iron 0.30 (0.00 – 1.00) 0.60 (0.35-1.15) 0.01 
Data reported as median (IQR) –Mann-Whitney test,  number (%)- chi-square test 
 
Amongst CVD patients, carotid intima media thickness (CIMT) was higher and HDL c lower in 
those with elevated delta chain levels compared to CVD patients with no anomaly detected, p 
<0.05.  
Differences in lipids, lipoproteins and carotid intima media thickness in South Asian 
cardiovascular disease patients by elevated delta chain levels are shown in Table 136. 
Table 136 Differences in lipids, lipoproteins and carotid intima media thickness in South Asian cardiovascular 
disease patients by  elevated delta chain levels 
 Patient with no anomaly 
detected (n=47) 
Patient with elevated delta 
chain levels (n=14) 
P value 
Age (years)
* 
60.7 63.9 0.46 
Apolipoprotein AI (g/l)
* 
1.22 (0.42) 1.12 (0.44) 0.71 
Apolipoprotein B (g/l)
* 
0.47 (0.15) 0.44 (0.21) 0.67 
Serum cholesterol (mmol/l)
* 
2.41 (3.22) 3.21 (1.37) 0.21 
HDL cholesterol (mmol/l)
* 
1.03 (0.37) 0.78 (0.23) 0.003 
LDL cholesterol (mmol/l)
* 
1.61 (0.82) 1.51 (0.65) 0.66 
Carotid intima media thickness 
(mm)* 
0.65 (0.17) 0.75 (0.22) 0.008 
*
Parametric data reported as mean (SD)- Independent T-test, available only in CVD patients  
 
On logistic regression across patients and controls combined, the presence of any 
Haemoglobin anomalies were independently associated with control vs. patient status (β = - 
1.7, p = 0.002) in a model that included age, gender, diabetes, haemoglobin concentration  
and LDL c.  
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7.1.3  Discussion 
The main finding of this pilot study was that haemoglobin disorders are more common amongst 
South Asians with CVD and that this is associated with low levels of HDL-C. Of all the 
haemoglobin abnormalities, elevated delta chain appeared to be more common amongst South 
Asian CVD patients. Moreover, patients with elevated delta chain levels had greater vascular 
damage reflected by greater CIMT and lower HDL-c than those with normal haemoglobin. These 
preliminary findings, taken together with the observation of higher levels of iron measured within 
sub fractions of lipids amongst South Asian CVD patients suggest an interaction between 
haemoglobin disorders and lipid metabolism in South Asians that may contribute to a higher risk 
of CVD (Patel et al., 2012).  
Despite lower levels of LDL and HDL particles amongst CVD patients, levels of iron in the lipid 
sub fractions of these patients were much higher than in controls. Camejo (1998) suggested a 
model for the interaction between hemin and apolipoproteins. There is a  high affinity between 
the carboxylic groups of the hemin and positively charged segments of ApoB rich in lysine and 
arginine on the surface of LDL monolayer whereby the porphyrin ring is interacting with fatty 
acid chains of phospholipids and free cholesterol and the tetrapyrrole ring is embedded in the 
hydrophobic core of LDL. The alteration in the charge and structure of the LDL particle after 
hemin oxidation leads to increase uptake and degradation of oxidised LDL by macrophages, thus 
indicating a pathological significance. Similar interaction have been reported for HDL whereby 
proteins within its structure interact with iron binding protein such as hemopexin in sequestrating 
excess free heme in the circulation (Vaisar et al., 2007). In CVD patients, high levels of iron 
were observed in HDL sub fractions, it is still unclear whether this interaction is of physiological 
or pathological nature.  
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‘The majority of patients identified with abnormal haemoglobin in this study had normal blood 
profiles, and whilst low levels of mean corpuscular volume are reported amongst patients with 
elevated delta chain haemoglobin, such abnormalities were not observed here. The older age of 
our CVD patients could explain the higher levels of iron measured within lipoprotein sub 
fractions. Moreover, while a positive association between carotid intima media thickness (CIMT) 
with HDL cholesterol, and a negative association between HDL cholesterol with iron measured 
within HDL subfractions were observed amongst those with haemoglobin abnormalities, the 
study is underpowered to confirm such observations. Further research is needed amongst large 
cohorts assessing the cardiovascular impact of haemoglobin disorders in this and other 
populations’(Patel et al., 2012b).  
7.1 .3 .1  Conclus ion 
Haemoglobin disorders particularly elevation of delta chain levels were more common amongst 
South Asians with CVD and was associated with greater vascular damage and lower levels of 
HDL-c. Furthermore, the higher levels of iron on sub fractions of lipids amongst South Asian 
CVD patients suggest an interaction between haemoglobin disorders and lipid metabolism which 
might contribute to a higher risk of CVD, further research is needed.  
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CHAPTER 8 GENERAL DISCUSSION 
 
South Asians have an increased risk of CVD compared to the general population in the UK; the 
underlying pathophysiology for this is unclear. Traditional risk factors such as diabetes mellitus 
and triglycerides do reflect an increased risk of CVD in South Asians. CVD events in South 
Asians occur much earlier in life and are often accompanied by normal serum lipids and blood 
pressure measurements (Patel, 2012). Hence, the focus of this thesis was to meet the need to 
establish biomarkers that can identify South Asians at increased risk of CVD early.  
To do this properly, a large prospective study of South Asians without CVD is required to look at 
how well various biomarkers predict incident disease. However the logistics for setting up such a 
study is difficult, for instance, the cost involved, the duration of such a study, the selection of 
biomarkers of interest, the constantly changing primary prevention strategies which might 
introduce confounding factors such as effect of intervention on biomarkers.  
The study design for this thesis was cross-sectional and subjects were randomly selected from a 
large community based sample of South Asians recruited through population and hospital based 
studies. The limitations of the study are its cross-sectional nature and the generalization with the 
wider South Asian diaspora. Subjects were recruited for the E-ECHOES study on a consecutive 
basis, and as such were not age-gender matched nor case-control matched. The main findings of 
this thesis were as follows. 
Performance of circulating biomarkers in South Asians  
This thesis looked at cardiovascular biomarkers that have been extensively studied in European 
population but not in South Asian population and found that these biomarkers do operate in 
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South Asians, but maybe at a lower discriminative range for instance in the performance of CRP 
as a discriminator of CVD risk in South Asians. High levels of CRP are not fully explained by 
traditional CVD risk factors, suggesting the involvement of environmental or genetic factors 
(Albert, 2004). This could also be consistent with the hypothesis that people with 
ancestral
 
origins in hostile tropical environments exhibit increased pro-inflammatory responses 
compared to those living in a temperate environment. This genetic selection is important for their 
defence mechanisms and survival in a pathogenic tropical environment. However, when 
migrating to temperate environment the balance between the benefit and the risk of these 
increased pro inflammatory responses is altered, resulting in an increased incidence of 
inflammatory related diseases (Le Souef et al., 2000).  
Of all the biomarkers, CRP was a comprehensive marker of CVD risk where a range of 1.43-2.30 
mg/L maximised sensitivity and specificity. This level is lower than that seen in White 
populations. This was established in South Asian cohorts asymptomatic for CVD, not on any 
prior medications such as statin therapy which can have an impact on CRP levels. Our findings 
were replicated in further two South Asian cohorts i) a homogeneous Indian community in the 
UK ii) a homogeneous Indian community in India. However, atherosclerosis is an inflammatory 
disease with a prolonged asymptomatic phase, and subjects in this study were not screened for 
the presence of subclinical atherosclerosis using imaging techniques. Another limitation is it has 
already been established that traditional CVD risk assessment underestimate CVD risk in South 
Asians but Framingham risk score was used to establish 10-year CVD risk in this study. Hence in 
order to validate the performance of all the blood biomarkers studied in this thesis in the 
prediction of incident disease in South Asians, a prospective longitudinal study needs to be 
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conducted. Again a major issue will be statin therapy as it is widely used both in primary and 
secondary settings in the management of abnormal lipid levels and prevention of CVD.   
Non-fasting triglycerides was another marker that discriminated South Asians at increased risk of 
CVD in this thesis and can be used as an alternative for fasting triglyceride measurements in 
routine clinical practice. Fasting triglycerides are better discriminator of CVD risk in South Asian 
population compared to other lipid and lipoprotein measures (Patel, 2010). Due to the logistic 
issue in obtaining bloods in fasting state, fasting triglycerides are not often measured in primary 
settings. Recent studies have shown non-fasting triglycerides as an independent predictor of 
incident CVD compared to fasting levels of triglyceride (Jeppesen et al., 1995; Bansal et al., 2007; 
Nordestgaard et al., 2007). Our findings support the hypothesis that atherosclerosis is a 
postprandial phenomenon and this needs to be validated in a larger South Asian population.  
The performance of D-dimer, P-selectin and vWF as biomarkers of CVD risk in South Asians 
was modest in comparison to CRP and non-fasting triglycerides. But before ruling them out as 
poor markers, a prospective follow up study needs to be conducted to associate these markers 
with incident CVD in South Asians.  
BNP, an established marker of LVSD was also studied in this thesis mainly because the increased 
risk of CHD observed in South Asians might predispose them to higher prevalence of LVSD and HF 
(Blackledge, 2003; Patel, 2008a). BNP significantly discriminated South Asians with LVSD from 
those with normal LV function with a discriminative value of 36.4 pg/ml and high negative 
predictive value. The findings were similar to the ESC guidelines which recommend a cut off 
value of 35 pg/mL for BNP for ruling out HF in patients in non-acute setting. Since the study 
population was community based, the prevalence of LVSD in this study cohort was only 1.4%. 
To determine the performance of BNP as a marker of LVSD in South Asians, the community 
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based samples were combined with South Asian heart failure patients recruited from  heart failure 
clinics who might have be more symptomatic. In order to confirm the discriminative value of 
BNP in the identification of LVSD in South Asians, our finding needs to be replicated in a larger 
South Asian population. 
Genetic-association studies in South Asians 
The thesis also looked at candidate gene approach and SNPs that have been extensively studied in 
European population. The aim was to dissect the underlying pathophysiology for increased CVD 
risk observed amongst the South Asian population by studying SNPs that contribute to the 
variation in inflammatory and metabolic phenotypes involved in the development of CVD. Even 
though the SNPs of interest were associated with their phenotypes, their lack of association with 
CVD makes them unlikely to have any clinical implications.  
The CRP promoter polymorphism rs3091244 contributed minimally to variation in CRP levels in 
South Asians and were not associated with clinical CVD. Genetic studies so far argue against a 
causal relationship between CRP and CVD and show this marker as a mere bystander with no active 
role in the development of CVD (Kardys, 2006; Elliot et al., 2009). Again APOA5 -1131T>C was an 
independent determinant of plasma triglyceride levels in the South Asian population and was not 
associated with CVD. Prior studies have associated APOC3 promoter polymorphisms with serum 
triglyceride levels and CVD, but these findings were not replicated in our South Asian cohort.   
There can be a number of reasons for the lack of association between the polymorphisms and 
CVD in our cohort. One of the major limitations was that the study subjects were recruited 
randomly through a population based study in the UK. The overall prevalence of CVD was only 
24.0% and the low numbers may have failed to detect a significant association. Apart from this, 
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CVD is a multi-factorial disease with other multiple rare variants that could be associated with 
CVD. Clinical correlates can also influence the relationship between genetic variants and CVD. 
Novel biomarkers in South Asians 
This thesis explored novel biomarkers in South Asians targeting putative mechanisms of disease. 
In a pilot case-control study, haemoglobinopathies were linked to CVD in South Asians which 
requires further exploration using a larger cohort. Aberrant erythropoiesis is associated with 
haemolytic diseases and this could increase iron availability in the circulation (Rother, 2005: 
Levy, 2006) and potentially lead to iron transport on lipoproteins but this concept needs further 
investigation.  
Increased body iron stores have been implicated in the pathogenesis of CVD and diabetes 
mellitus (Sullivan, 1981; Jiang, 2004). A novel in-house ELISA for ferritin bound to 
apolipoprotein B was developed which showed elevated levels of ferritin bound to ApoB in non-
diabetic South Asians compared to non-diabetic Caucasians. Whether this interaction is of 
pathological significance needs to be further investigated (Main findings of this thesis are shown 
in table 137). 
Diversity in the South Asian population 
 
In our study population, 49% of South Asians were of Indian descent, 35% of Pakistani origin 
and hence the observation may not be applicable to other ethnic groups among whom the CVD 
risk profile varies. Smoking was significantly higher amongst Bangladeshi men compared to 
Pakistani and Indian men. This is consistent with the findings from Bush (2003) community 
based study in New Castle. The prevalence of diabetes mellitus was higher in Pakistani men 
compared to Bangladeshi and Indian men. The prevalence of obesity and central obesity was also 
higher in Pakistani men compared to Bangladeshi and Indian men. In our cohort, the higher rates 
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of diabetes mellitus observed among Pakistani men could be attributed to their higher prevalence 
of central obesity. Bhopal (1999) demonstrated in a cross sectional study in Newcastle upon Tyne 
that the prevalence of diabetes mellitus was significantly higher among Pakistani and 
Bangladeshi men compared to Indian men. There were no significant differences in the 
demographic details for women belonging to Indian, Pakistani and Bangladeshi origin. The rates 
of diabetes and hypertension in this study cohort were similar to those rates reported from South 
Asian community groups living in the Birmingham area (Patel, 2007).  
 
This thesis provides a platform for future studies  
i. The population based study, E-ECHOES enables to establish screening biomarkers in 
South Asians for example in this thesis the performance of CRP as a discriminator of 
CVD and BNP as a discriminator of LVSD in South Asians was evaluated.   
ii. Prospective longitudinal study - The performance of CRP, calculated & non-fasting 
triglycerides, vWF and BNP needs to validate in prospective longitudinal studies in 
order to look at hard outcomes such as acute coronary syndromes, LVSD or heart 
failure. 
iii. Exploring novel biomarkers in South Asians- a novel ELISA was developed for 
ferritin bound to apolipoprotein B. There is a need to further explore the association 
between ferritin bound to apolipoprotein B and the disease of interest i.e. diabetes 
mellitus and also establish reference limits in a cross-sectional study. The structural 
interaction between ferritin and apolipoprotein B needs to be explored by proteomic 
techniques.   
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iv. Haemoglobinopathies were linked to CVD in South Asians, potentially through iron 
transportation on lipoproteins but this link needs to be further investigated in a larger 
cohort.  
Table 137  Main findings of this thesis 
Performance of 
circulating biomarkers in 
South Asians  
 CRP levels in the range of 1.43-2.30 mg/L discriminated South Asians 
at increased risk of CVD. This level is lower than that seen in white 
populations. IL-6 levels did not discriminate South Asians at increased 
risk of CVD. 
 
 Calculated triglycerides and non-fasting triglycerides discriminated 
South Asians with increased risk of CVD and hence can be used as an 
alternative for fasting triglyceride measurements in routine clinical 
practice.  
 
 The performance of D-dimer, P-selectin and vWF as biomarkers of 
CVD risk in South Asians was modest, with only vWF discriminating 
South Asians with increased risk of CVD and existing CVD.  
 
 BNP significantly discriminated South Asians with LVSD from those 
with normal LV function with a discriminative value of 36.4 pg/ml and 
high negative predictive value. 
 
 
Genetic-association studies 
in South Asians  
 The CRP promoter polymorphism rs3091244 contributed minimally to 
variation in CRP levels in South Asians and were not associated with 
clinical CVD. 
 
 APOA5 -1131T>C is a determinant of plasma triglyceride levels in the 
South Asian population; however this polymorphism was not associated 
with CVD. APOC3 promoter polymorphisms are associated with serum 
triglyceride levels and CVD, but these findings were not replicated in 
our South Asian cohort.   
 
Novel biomarkers in South 
Asians  
 Haemoglobin disorders are common amongst South Asians with CVD 
and were associated with greater vascular damage and lower levels of 
HDL-c (Pilot study).  
 
 Development of a novel enzyme linked immunoassay-Ferritin bound to 
Apolipoprotein B 
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APPENDICES 
9.1  Appendix  A 
9.1.1  Ethnic proportion of the UK  
Table 138 Proportion of ethnic minority population in the West Midlands   
 
 
 
 
 
 
 
 
 
 
Table 139  Ethnic minority population in Birmingham  
 
 
 
 
 
 
 
 
 
Reproduced from Race for opportunity, regional factsheet, 2010 
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9.2  Appendix  B  
9.2.1  Isolation of deoxyribonucleic acid from human blood and 
Taqman single nucleotide polymorphism genotyping  
9.2 .1 .1  Iso lat ion  of  deoxyribonucle ic  ac id  from human w hole  b lood 
us ing  Taqman sample  to  SNP kit   
Taqman sample to SNP kit was also used to isolate DNA from whole blood. The kit is composed 
of two reagents, lysis solution and DNA stabilizing solution. Preparation of sample lysate was 
performed according to table 140. The lysates were then stored at -20
0
C. When performing 
genotying assay on lysates, taqman GTXpress master mix was used, reaction mix and cycling 
stage for the PCR are shown in table 141 & 142 respectively.  
Table 140  Preparation of sample lysate  
Sample type Sample input Volume of lysis 
solution (µl) 
Incubation 
temperature for 3 
minutes (
0
C) 
Volume of DNA stabilizing 
solution (µl) 
Blood 2µl 20 Room temperature 20 
 
 
Table 141 Reaction mix for lysate 
Reagents Volume (µl/well) 
Taqman GTXpress Master mix 
Taqman genotyping assay mix 
DNase-free water 
DNA 
Total  
5.0 
0.5 
2.5 
2.0 
10.0 
 
Table 142 Cycling stage for the PCR 
 Thermal cycling 
Stage Holding stage Cycling (40 cycles)  
Denature Anneal/ extend 
Temperature 95
0
C 95
0
C 60
0
C 
Time (mm:ss) (StepOne Plus) 00.20 00:03 00:20 
Time (mm:ss) (Fast 7500) 00.20 00.03 00.30 
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9.2 .1 .2  Custom des igned taqman s ingle  nucleot ide  polymorphism 
assays  
figure 43 Overview of the custom designed taqman SNP for rs1800795 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target sequence was obtained from the dbSNP database  
at http://www.ncbi.nlm.nih.gov/SNP 
dbSNP-rs1800795 
ACTCAGTTCAGAACATCTTTGGTTTTTACAAATACAAATTAACTGGAACGCTAAATTCTA 
 GCCTGTTAATCTGGTCACTGAAAAAAAATTTTTTTTTTTTCAAAAAACATAGCTTTAGCT 
 TATTTTTTTTCTCTTTGTAAAACTTCGTGCATGACTTCAGCTTTACTCTTTGTCAAGACA 
 TGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAGAAAGTAAAGGAAGAGTGGTTCT 
GC TTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTCCCCCTAGTTGTGTCTTGC 
[G/C]ATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAGCCCCACCCGC 
TCTGGCCCCACCCTCACCCTCCAACAAAGATTTATCAAATGTGGGATTTTCCCATGAGTCTC 
 AATATTAGAGTCTCAACCCCCAATAAATATAGGACTGGAGATGTCTGAGGCTCATTCTGC 
 CCTCGAGCCCACCGGGAACGAAAGAGAAGCTCTATCTCCCCTCCAGGAGCCCAGCTATGA 
 ACTCCTTCTCCACAAGTAAGTGCAGGAAATCCTTAGCCCTGGAACTGCCAGCGGCGGTCG 
Assessing the quality of the sequence 
1) The uniqueness of the sequences was established by BLAST (Basic Local Alignment Search Tool) at 
http://www.ncbi.nlm.nih.gov/BLAST  assessed on 08.02.2010 
Sequence producing significant alignment; Locus- NT 007819.17-Homo sapiens chromosome 7 genomic 
contig, score -588, E-value = 1e-165 
2) There were no repetitive elements detected in this sequence after analysing the sequence through the 
program Repeat masker (http://repeatmasker.genome.washington.edu) 
3) Specialized BLAST was performed to identify SNPs not of interest and was masked with a N. 
 
 
ACTCAGTTCAGAACATCTTTGGTTTTTACAAATACAAATTAACTGGAACGCTAAATTCTA 
 GCCTGTTAATCTGGTCACTNAAAAAAAANTTNTTTTTTTNCAAAAANCATAGCTTTAGCT 
 TATTTTTTTTCTCTTTGTAAAACTTCGTGCATGACTTCAGCTTTACTCTTTGTCAAGACA 
 TGCCAAAGTGCTGAGTCACTAATAAAAGAAAAAAAGAANGTAAAGGAAGAGTGGTTCTGC 
 TTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTTNCCCNCTAGTTGTGTCTTGC 
[G/C]ATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTTCCAATCAGCCCCACCCGCTC 
 TGNCCCCACCCTCACCCTCCAACAAAGATTTATCAAATGTGGGATTTTCCNATGAGTCTC 
 AATATTAGAGTCTCAACCCCCAATAAATATAGGACTGGAGATGTCTGAGGCTCATTCTGC 
 CCTCGANCNCACCGGGAACGAAANAGAAGCTCTATCTCCCCTCCAGGAGCCCAGCTATGA 
 ACTCCTTCTCCACAAGTAAGTGCAGGAAATCCTTAGCCCTGGAACTGCCAGCGGCGGTCG   
 
 
4) The masked sequence with SNP of our interest was then submitted to Applied Biosytems for taqman 
SNP genotyping assay 
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figure 44 Overview of the custom designed taqman SNP for rs2854116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target sequence was obtained from the dbSNP database at 
http://www.ncbi.nlm.nih.gov/SNP  
 
dbSNP-rs2854116 
ATCCCTAGGAGACTGAGTCCACGCTGCTGTCCCGCCAGCCCTGCAGCCCAGATGAGCTCA 
GGAACTGGGGGTGGGCCTGGGGAGCCCTCATTCCTTCCTAGCTGACTGGCTCCCCAGGGA 
GAGGCTGGTGAGAGGGGAAATGGCTTGGACATAGGCCAGGGGCCTCGGGCCCATCTCAG 
C CTTTCACACTGGAATTTCAGGCCCCTCCCTCCACCAGCCCCAAGCCCTGAACACAGCCTG 
GAGTAGAGGGGTGAGGGGCTTCTTCAGACTTGAGAACAAGTGGGTGGCTTGGGCTGGGGG 
[A/G]TGTTTGGAGTAAAGGCACAGAAGACCAGGCATCAGTGGCTCCGGCAAGGCCTGGTTA 
CAGGGCTGAGCTCTCACAGCCCCTCCCAGCACCTCCATCTCTGGGTTTCAATCCAGGCAGGC 
GAGTGCTGCTCACCCAGCAGCCCCCCACCCGCCCCCACCCTGTGTGCCCCCCGCTGCCTCC 
CCCTTAGTGTAGGGCAGGGGTTGGTGGAGAAGGGCCAAGGCCGCTCAGAGCCCGAGGCCT 
TTGCCCCTCCCTCCACCAGGCTCCCTATTTTGCCCTCTGGACCCACTGATAACATCCCCT 
 
 
Assessing the quality of the sequence 
1) The uniqueness of the sequences was established by BLAST (Basic Local Alignment Search Tool) 
at http://www.ncbi.nlm.nih.gov/BLAST  assessed on 20.02.2010 
 
Sequence producing significant alignment; Locus- NT 033899.8 -Homo sapiens chromosome 11 genomic 
contig, score – 1105, E value = 0.0 
 
 
2) There were no repetitive elements detected in this sequence after analysing the sequence through the 
program Repeat masker (http://repeatmasker.genome.washington.edu) 
 
3) Specialized BLAST was performed to identify SNPs not of interest and was masked with a N. 
 
ATCCCTAGGAGACTGAGTCCACGCTGCTGTCCCGCCAGCCCTGCAGCCCAGATGAGCTCAG 
GAACTNGGGGTGGGCCTGGGGAGCCCTCATTCCTTCCTAGCTGACTGGCTCCCCAGGGAGA 
GGCTGGTGAGAGGGGAAATGGCTTGGACATAGGCCAGGNGCCTCGGGCCCATCTCAGCCTT 
TCACACTGGAATTTCAGGCCCCTCCCTCCACCAGCCCCAAGCCCTGAACACAGCCTGGAGTA 
GAGGGGTGAGGGGCTTCTTCAGACTTGAGANCAAGTGGGTGGCTTGGGCTGGGGG[A/G]TGT 
TTGGAGTAAAGGCACAGAAGACCNGGCATCAGTGGCTCCGGCAAGGCCTGGTTACAGGGCTG 
AGCTCTCACAGCCCCTCCCAGCACCTCCATCTCTGGGTTTCAATCCAGGCAGGCGAGTGCTGC 
TCACCCAGCAGCCCCCCACCCGCCCCCACCCTGTGTGCCCCNCGCNGCCTCCCCCTNAGTGTA 
GGGCAGGGGTTGGTGGAGAAGGGCCAAGGCCGCTCAGAGCCCGAGGCCTTTGCCCCTCCCTC 
CACCAGGCTCCCTATTTTGCCCTCTGGACCCACTGATAACATCCCCT 
 
 
4) The masked sequence with SNP of our interest was then submitted to Applied Biosytems for taqman 
SNP genotyping assay 
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figure 45 Overview of the custom designed taqman SNP for rs2854117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target sequence was obtained from the dbSNP database at 
http://www.ncbi.nlm.nih.gov/SNP  
 
dbSNP-rs2854117 
TGTCCCGCCAGCCCTGCAGCCCAGATGAGCTCAGGAACTGGGGGTGGGCCTGGGGAGCCC 
TCATTCCTTCCTAGCTGACTGGCTCCCCAGGGAGAGGCTGGTGAGAGGGGAAATGGCTTG 
GACATAGGCCAGGGGCCTCGGGCCCATCTCAGCCTTTCACACTGGAATTTCAGGCCCCTC 
CCTCCACCAGCCCCAAGCCCTGAACACAGCCTGGAGTAGAGGGGTGAGGGGCTTCTTCAG 
ACTTGAGAACAAGTGGGTGGCTTGGGCTGGGGGGTGTTTGGAGTAAAGGCACAGAAGACC 
[G/A]GGCATCAGTGGCTCCGGCAAGGCCTGGTTACAGGGCTGAGCTCTCACAGCCCCTCCC 
AGCACCTCCATCTCTGGGTTTCAATCCAGGCAGGCGAGTGCTGCTCACCCAGCAGCCCCCC 
AC CCGCCCCCACCCTGTGTGCCCCCCGCTGCCTCCCCCTTAGTGTAGGGCAGGGGTTGGTGG 
AGAAGGGCCAAGGCCGCTCAGAGCCCGAGGCCTTTGCCCCTCCCTCCACCAGGCTCCCTA 
 TTTTGCCCTCTGGACCCACTGATAACATCCCCTGGGGGAGGAGCTGGTCTCATGTCTGGG 
 
Assessing the quality of the sequence 
1) The uniqueness of the sequences was established by BLAST (Basic Local Alignment Search Tool) at 
http://www.ncbi.nlm.nih.gov/BLAST  assessed on 19.03.2010 
 
 
Sequence producing significant alignment; Locus- NT 033899.8 -Homo sapiens chromosome 11 genomic 
contig, score – 1105, E value = 0.0 
 
 
 
2) There were no repetitive elements detected in this sequence after analysing the sequence through the 
program Repeat masker. (http://repeatmasker.genome.washington.edu) 
 
3) Specialized BLAST was performed to identify SNPs not of interest and was masked with a N. 
 
TGTCCCGCCAGCCCTGCAGCCCAGATGAGCTCAGGAACTNGGGGTGGGCCTGGGGAGCCC 
TCATTCCTTCCTAGCTGACTGGCTCCCCAGGGAGAGGCTGGTGAGAGGGGAAATGGCTTG 
GACATAGGCCAGGNGCCTCGGGCCCATCTCAGCCTTTCACACTGGAATTTCAGGCCCCTC 
CCTCCACCAGCCCCAAGCCCTGAACACAGCCTGGAGTAGAGGGGTGAGGGGCTTCTTCAG 
ACTTGAGANCAAGTGGGTGGCTTGGGCTGGGGGNTGTTTGGAGTAAAGGCACAGAAGACC 
 [G/A]GGCATCAGTGGCTCCGGCAAGGCCTGGTTACAGGGCTGAGCTCTCACAGCCCCTCCC 
AGCACCTCCATCTCTGGGTTTCAATCCAGGCAGGCGAGTGCTGCTCACCCAGCAGCCCCCC 
AC CCGCCCCCACCCTGTGTGCCCCNCGCNGCCTCCCCCTNAGTGTAGGGCAGGGGTTGGTG 
GAGAAGGGCCAAGGCCGCTCAGAGCCCGAGGCCTTTGCCCCTCCCTCCACCAGGCTCCCTA 
TTTTGCCCTCTGGACCCACTGATAACATCCCCTGGGGGAGGAGCTGGTCTCATGTCTGGG 
 
 
    
4) The masked sequence with SNP of our interest was then submitted to Applied Biosytems for taqman 
SNP genotyping assay 
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Genomic wet DNA was used for genotyping experiments. Negative controls (sterile water) and 
two positive controls for the SNPs rs1800795, rs2854116, rs2854117 were analysed on all plates 
to ensure there was no contamination. The reaction volume for each well was set to 20 µl (Table 
143) and number of cycles to 50 (Table 144). 
Table 143  Reaction mix 
Reagents  Volume (µl/ 96 reactions) 
2 × Taqman SNP genotyping mastermix  
20 × Taqman SNP genotyping assay 
DNAse-free water 
Genomic DNA template 
Total volume  
1008.00 
50.40 
756  
2 µl /well 
20.00/ well 
 
 
Table 144 Cycling stage for the PCR  
 Pre-PCR read Thermal cycling Post-PCR read 
Stage Holding stage Holding stage Cycling (50 cycles)  Holding stage 
Denature Anneal/ extend 
Temperature 60
0
C 95
0
C 92
0
C 60
0
C 60
0
C 
Time (mm:ss) 00:30 10:00 00:15 01:00 00:30 
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9.2.2  Allele, genotype frequencies and hardy Weinberg 
equilibrium  
The following equations were used for calculating allele, genotype frequencies and to 
determine whether the study population met Hardy Weinberg’s theory (Hardy-Weinberg and 
population genetics calculation, online resource).  
Allele frequencies were calculated using the following equations; 
For example major allele is depicted as A and minor allele as a.  
The frequency of the major allele = (total number of major alleles in the population/ total 
number of alleles in population for locus), where total number of major alleles in the 
population = no of homozygotes for A allele (AA*2) + no of heterozygotes (Aa) & total 
number of alleles in population for locus in diploid individuals = total number of 
individuals*2 (2 alleles at locus per individual) 
The frequency of the minor allele = (total number of minor allele in the population/ total 
number of alleles in population for locus), where total number of minor allele in the 
population = no of homozygotes for minor allele, a (aa*2) + no of heterozygotes (Aa).  
Genotype frequencies were calculated as follows;  
Frequency of AA genotype (homozygotes for major allele) = number of AA individuals / 
population size 
Frequency of Aa genotype (heterozygotes) = number of Aa individuals / population size  
Frequency of aa genotype (homozygotes for mutant allele = number of aa individuals / 
population size  
For the population to meet the assumptions of the Hardys Weinberg, the observed genotype 
frequencies calculated from the real population should agree with the expected frequencies 
 279 
predicted by the Hardy-Weinberg Theory, the following equation derived from Hardy-
Weinberg Equilibrium Theory was used;  
 p2 + 2pq + q2 = 1, where p
2
 = Frequency of genotype A/A, 2pq = Frequency of genotype 
A/a., q = Frequency of genotype a/a   
9.2.3  Zonal density gradient ultracentrifugation  
EDTA treated blood samples were used to separate very low density lipoprotein (VLDL), LDL, 
HDL2 and HDL3 sub fractions using the Optima TLX Ultracentrifuge (Beckman Coulter, High 
Wycombe UK). Plasma from these samples were analysed within 4 days of collection. A sodium 
chloride/potassium bromide (NaCl/KBr) density gradient solution (density 1.30g/ml) was used to 
adjust the density of the plasma (density 1.006g/ml) to 1.063g/ml (density of LDL). The 
following equation was used to calculate the volume of density gradient solution to be added to 
plasma.  
 Volume of density gradient solution to be added = 2.1 ml (volume of plasma) × (1.063 – 1.006) / 
(1.30 -1.063) 
The same equation was used to calculate the volume of density gradient solution to be added to 
prepare different density salt solutions. 
The Beckman tubes were layered as follows; 1ml of 1.21 of density salt solution was added using 
a syringe to the bottom of the tube, followed by 1ml of 1.125 density salt solution using a 
dispenser pump (pump flow rate:0.17ml/min, volume:1ml), then 2.1ml of 1.063g/ml of plasma 
was applied using the dispenser pump (pump flow rate: 0.15ml/min, volume flow:2.1ml) and 
finally 1ml of saline (density 1.006g/ml) was added over the plasma layer using the dispenser 
pump (flow rate:0.17 ml/min, volume:1ml). The dispenser pump controls the flow rate of liquid 
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accurately and can minimise the mixing of the different layers when preparing the tubes. The 
prepared tubes were then sealed with a heat sealer and immediately placed in vertical rotors in the 
Optima TLX Ultracentrifuge at 4
0
C and spun at 110,000 rpm for 7.38 hours. 
At the end of each run, lipoprotein fractions were collected using a fractional recovery system 
and dispenser pump. Before cutting the top of the Beckman tube, approximately 0.1ml of VLDL 
layer was collected using a syringe and needle. The tubes were then placed into the fractional 
recovery system which is connected to the dispenser pump. The layers were then collected as 
follows, 1ml of VLDL (density 1.006g/ml) from the top of Beckman tube was transferred to 
VLDL tube and made up to 2ml using saline, followed by 2.1 ml of LDL (density 1.006-1.063 
g/ml) in the upper middle into LDL tube, then 1ml of HDL2 (density 1.063 -1.125 g/ml) layer in 
the lower upper middle into the HDL2 tube and finally HDL3 (density 1.125 – 1.21 g/ml) in the 
bottom portion of the Beckman tube into HDL3 tube (Winocour et al, 1991). Levels of iron were 
measured on separated lipoprotein sub fractions on the Cobas Integra 400 (Roche Diagnostics, 
UK).  
9.2.4  Mass spectrometry for identification of hemoglobin 
variants by ESI-MS 
The objective of this experiment was to assess the presence of single-point mutation haemoglobin 
variants, high δ-chain and high glycation levels without knowledge of their disease status in 174 
South Asian samples by ESI-MS. Analysis was performed on a Xevo Triple Quandrupole 
(Waters Corporationm Milford, MA, USA) equipped with a TriVersa NanoMate (Advion 
Biosciences Ltd, Ithaca, NY, USA).  
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Blood samples were prepared for analysis by diluting 0.5 µl of blood in 250 µl of 50% 
acetonitrile 0.2% HCOOH within a 96-well plate, compatible with the TriVersa NanoMate. All 
samples were analysed twice and for each sample a three minute acquisition was performed in 
multi-channel acquisition (MCA) mode at a scan speed of two spectra/sec. BioPharmaLynx 
software was used for data processing. The software allows to deconvolute multiple spectral 
outputs and compares the results (Wild et al, 2001).  
The analysis identified the masses and intensities of all peaks present within the deconvoluted 
spectrum. The masses for the α, β, δ and glycated globin chains were pre-defined within the 
software and automatically detected within each sample. All data files obtained were analysed by 
the BioPharmaLynx method. The mass and intensity derived for alpha, beta ,delta chains and 
glycated alpha and beta chains and any peaks observed in the spectrum at greater than 20% 
intensity was imported into Excel. Excel was then used to compare the results for α-chain 
measurement, δ-chain intensity and glycated α- and β-chain intensity between samples. The error 
in α- and β-chain measurement was used to indicate whether a α- or β-chain variant with a mass 
shift of 6 Dalton (Da) or less was present. The presence of any additional peaks within the spectra 
at greater than 20% intensity suggested the presence of a structural variant resulting from a mass 
shift of more than 6 Da.  
The percentage of glycated haemoglobin (HbA1c) was calculated as described by Roberts et al 
(2001) from intensity information obtained for the α- and β-chain and singly glycosylated α- and 
β-chain species from the deconcoluted spectrum for each sample. The principle behind this 
approach being that the measurement of glucose addition on the β chain can be quantified by a 
mass increase of 162 Da to the native protein chain where a mass of 180 Da is attributed to the 
addition of glucose through the elimination of water (-18 Da).  
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The following equation was used to calculated % glycosylated haemoglobin;  
% glycosylated haemoglobin = 50[αg/(α+αg) + βg/(β + βg)] where α and β represent the intensities 
of the α- and β-chains, and αg and βg represent the intensities of the glycated α- and β-chains 
respectively. The measurement of glycosylated haemoglobin level is based on several 
assumptions such as there is no significant contribution to glycosylated haemoglobin from other 
globin chains, that all α-chain species and β-chain species have the same sensitivity.  
The estimation of δ-chain levels was achieved by performing a ratio calculation of δ-chain 
intensity to β-chain intensity. The assumption being that the β- and δ-chains have similar 
sensitivities. This approach uses a δ: β ratio of the intact chains to provide a surrogate marker of 
HbA2 levels.  
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9.3  Appendix  C 
9.3.1  The performance of C-reactive protein as a 
discriminator of cardiovascular risk in  a 
homogeneous Indian community in India and a 
homogeneous Indian community in  the UK 
Table 145 C-reactive protein as a discriminator of metabolic and cardiovascular disease risk amongst non- migrant 
Gujarati Indians   
 
 
 
 
 
C-reactive protein 
(mg/L) 
Raised blood pressure  
(>130 mmHg or 85 mmHg) 
(84, 28.4% were hypertensive) 
 
Body mass index (> 27kg/m
2
) 
(29, 9.8% were obese) 
P value  AUC 95% CI P value  AUC 95% CI 
<0.001 0.664 0.600– 0.729 <0.001 0.786 0.716-0.856 
Cut-off value for  
CRP (mg/L)  
1.09 mg/L 1.68 mg/L 
 
C-reactive protein 
(mg/L)  
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) (63, 23.0% were 
obese) 
Diabetes mellitus  
(Oral glucose tolerance test)  
(73, 27.1% had either T2DM/ glucose 
tolerance)
 
P value AUC 95% CI P value AUC 95% CI 
<0.001 0.745 0.681-0.809 0.003 0.617 0.539-0.694 
Cut-off value for  
CRP (mg/L)  
1.31 mg/L 1.05 mg/L 
 
  
C-reactive protein (mg/L 
Low HDL cholesterol (<0.9 mmol/l in 
men &<1.0 mmol/l in women) (78, 
27.0% had low-HDL-c) 
Elevated triglycerides (≥ 1.7 mmol/l) 
(21, 7.1% had raised triglycerides) 
P value AUC 95% CI P value AUC 95% CI 
<0.001 0.641 0.571-0.711 <0.001 0.729 0.621-0.837 
Cut-off value for  
CRP (mg/L) 
1.16 mg/L 1.43 mg/L 
 
C-reactive protein 
(mg/L)  
Metabolic syndrome
*
 (ATP III defined) 
(27, 9.5% had metabolic syndrome) 
10 years CHD risk score (>20%)  
(26, 10.3% had high CVD risk) 
P value  AUC 95% CI P value AUC 95% CI 
<0.001 0.758 0.680-0.837 0.001 0.691 0.603-0.779 
Cut-off value for  
CRP (mg/L)  
1.57 mg/L 1.43 mg/L 
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Table 146 C-reactive protein as a discriminator of metabolic and cardiovascular disease risk amongst migrant 
Gujarati Indians in the UK 
NS- non significant 
 
 
 
 
 
C-reactive protein 
(mg/L) 
Raised blood pressure  
(>130 mmHg or 85 mmHg) 
(116, 49.1% were hypertensive) 
 
Body mass index (> 27kg/m
2
) 
(89, 38.2% were obese) 
P value  AUC 95% CI P value  AUC 95% CI 
0.001 0.628 0.557-0.698 <0.001 0.691 0.622-0.759 
Cut-off value for  
CRP (mg/L)  
1.32 mg/L 1.44 mg/L 
  
C-reactive protein 
(mg/L)  
Central obesity (≥ 90 cm in men and ≥ 
80 cm in women) (112, 52.0% were 
obese) 
Diabetes mellitus  
(Oral glucose tolerance test)  
(27, 14.0% had either T2DM/ glucose 
tolerance)
 
P value AUC 95% CI P value AUC 95% CI 
0.001 0.637 0.563-0.710 0.001 0.701 0.584-0.818 
Cut-off value for  
CRP (mg/L)  
1.30 mg/L 1.91 mg/L 
 
 
C-reactive protein (mg/L 
Low HDL cholesterol (<0.9 mmol/l in 
men &<1.0 mmol/l in women) 
(30,13.0% had low-HDL-c) 
Elevated triglycerides (≥ 1.7 mmol/l) 
(35, 15.0% had raised triglycerides) 
P value AUC 95% CI P value AUC 95% CI 
0.286 0.560 0.452-0.669 0.099 0.413 0.307–0.518 
Cut-off value for  
CRP (mg/L) 
NS NS 
 
C-reactive protein 
(mg/L)  
Metabolic syndrome
*
 (ATP III defined) 
(43,19.0% had metabolic syndrome) 
10 years CHD risk         score (>20%) 
(20, 9.2% had high CVD risk) 
P value  AUC 95% CI P value AUC 95% CI 
<0.001 0.720 0.631-0.810 0.006 0.686 0.568-0.803 
Cut-off value for  
CRP (mg/L)  
1.89 mg/L 2.19 mg/L 
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9.3.2  The performance of obesity and central obesity as 
discriminators of metabolic and Cardiovascular 
disease risk in South Asians asymptomatic for 
cardiovascular disease   
BMI significantly discriminated those with diabetes mellitus, [AUC 0.579 (95% CI, 0.502 – 
0.65), p=0.050], raised triglycerides [AUC 0.581 (95% CI 0.528 – 0.634), p=0.003] and 
metabolic syndrome [AUC 0.623 (95% CI 0.574 -0.671), p<0.001] from healthy South Asians. 
Waist circumference significantly discriminated those with raised blood pressure [AUC 0.555 
(95% CI 0.502 -0.608), p=0.041], T2DM [AUC 0.618 (95% CI .543 – 0.693), p=0.003], raised 
triglycerides [AUC 0.626 (95% CI 0.575 – 0.677), p<0.001], metabolic syndrome [AUC 0.677 
(0.631 – 0.724), p<0.001] and 10 year CVD risk score [AUC 0.582 (0.508 – 0.655), p=0.040].  
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Table 147 Obesity and central obesity as discriminators of metabolic and cardiovascular disease risk amongst South 
Asian men and women asymptomatic for cardiovascular disease 
 
 
 
 
 
 
 
 
 
 
 
Obesity 
 Diabetes mellitus (HbA1c ≥ 6.5%) 
 
Elevated measured triglycerides (≥ 
1.7 mmol/l) 
P value  AUC 95% CI P value  AUC 95% CI 
Body mass index 
(kg/m
2
) 
0.050 0.579 0.502-0.650 0.003 0.581 0.528-0.634 
 Metabolic syndrome
*
 (ATP III defined) 
(243, 48.1% had metabolic syndrome) 
 
P value AUC 95% CI 
Body mass index 
(kg/m
2
) 
<0.001 0.623 0.574-0.671 
Central obesity 
 Raised blood pressure (>130 mmHg or 
85 mmHg)  
 
 
Diabetes mellitus (HbA1c ≥ 6.5%) 
 
P value AUC 95% CI P value AUC 95% CI 
Waist circumference 
(cm)  
0.041 0.555 0.502-0.608 0.003 0.618 0.543-0.693 
 Elevated measured triglycerides (≥ 1.7 
mmol/l) 
Metabolic syndrome
*
 (ATP III 
defined) 
 
P value AUC 95% CI P value AUC 95% CI 
Waist circumference 
(cm)  
<0.001 0.626 0.575-0.677 <0.001 0.677 0.631-0.724 
 10 years CHD risk score (>20%) 
 
 
 P value AUC 95% CI 
Waist circumference 
(cm)  
0.040 0.582 0.508–0.655 
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